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Abstract 
 
Brachyspira are the causative agent of avian intestinal spirochaetosis, a gastrointestinal 
disease common in layer hens and broiler breeders. This disease costs the UK laying industry 
approximately £18 million per annum, resulting from reduced egg production and poor egg 
quality. Prevalence of Brachyspira is increasing, and due to the poor understanding of this 
pathogen, mitigation strategies have been largely unsuccessful. Therefore, preventative 
measures are essential. 
These studies aimed to improve the understanding of Brachyspira pathobiology and 
investigate Lactobacillus probiotics as a suitable mitigation strategy. Brachyspira and 
Lactobacillus species were characterised using phenotypic and genotypic methods. Four 
Lactobacillus isolates were selected for their inhibition of Brachyspira in vitro and 
demonstrated inhibition by a number of mechanisms.  
Secreted metabolites in Lactobacillus cell free supernatant inhibited Brachyspira (p value £ 
0.05) and metabolomic studies identified the production of organic acids to be a major 
contributor to inhibition. Protein denaturation in cell free supernatants significantly reduced 
Brachyspira inhibition (p value £ 0.05), suggesting the role of bacteriocins in inhibition. 
Furthermore, L. reuteri isolates co-aggregated with Brachyspira in vitro, reducing pathogen 
viability (p value £ 0.05). 
Pro-inflammatory responses to Brachyspira in HD11 avian macrophages were dominated by 
upregulation of IFNg (p value £ 0.01) and pre-treatment of cells with Lactobacillus significantly 
reduced this response (p value £ 0.0001), demonstrating the ability of probiotics to alter 
immune responses to Brachyspira. Galleria mellonella were utilised to study Brachyspira 
virulence and probiotic intervention. G. mellonella exhibited a varied response to Brachyspira 
 v 
infection and Lactobacillus isolates were able to protect against the mortality associated with 
Brachyspira isolates (p value £ 0.05). 
The studies here demonstrated that Lactobacillus probiotics are a suitable mitigation strategy 
against Brachyspira. A number of mechanisms were identified, however future studies are 
required to explore these mechanisms in a more relevant in vivo chicken model.  
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Chapter 1: Introduction 
 
1.1 Brachyspira  
 
1.1.1 History of Brachyspira Taxonomy 
 
Brachyspira are the sole genus assigned to the Brachyspiraceae family in the order 
Spirocheateales (Paster and Dewhirst, 2000). The order Spirocheateales contains all 
spirochaetes, including Borrelia, Leptospira and Treponema (Stanton, 2006) and there are 
several common properties shared by these spirochaetes. These include their helical 
morphology, periplasmic flagella and natural resistance to rifampicin (Paster and Dewhirst, 
2000). 
In the last forty years, the genus Brachyspira has undergone several taxonomic 
reclassifications. These organisms were originally known as Treponema, where the name T. 
hyodysenteriae was originally applied to both pathogenic, strongly haemolytic isolates and 
non-pathogenic, weakly haemolytic organisms isolated from swine. In 1978, Miao et al. 
(1978) discovered that human treponemes were genetically distinct from swine treponemes 
and that the pathogenic and non-pathogenic T. hyodysenteriae only shared 28% sequence 
homology. This subsequently led to the classification of T. hyodysenteriae as the aetiological 
agent of swine dysentery and T. innocens as non-pathogenic a year later (Kinyon and Harris, 
1979). In 1991, Stanton et al. (1991) proposed the reclassification of T. hyodysenteriae and T. 
innocens to a new genus known as Serpula, when studies showed that these organisms were 
only distantly related to other Treponema species. However, the name Serpula was changed 
again in 1992, to Serpulina, as Serpula had already been used to name a genus of fungi 
(Stanton, 1992). Finally, Ochiai et al. (1997) proposed the unification of the genera Serpulina 
and Brachyspira owing to the similarities discovered between S. hyodysenteriae, S. innocens, 
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S. pilosicoli and B. aalborgi. The genus Brachyspira was used instead of Serpulina since B. 
aalborgi was proposed as a new genus is 1982 (Hovind-Hougen et al., 1982), before the 
reclassification of T. hyodysenteriae to Serpulina in 1991.  
 
1.1.2 The genus Brachyspira 
 
Brachyspira (brachy “short” and spira “coli”) are Gram negative, oxygen tolerant, anaerobic 
spirochetes that have been isolated from the gastrointestinal tracts of both mammals and 
birds, including humans, chickens, pigs, dogs and horses. These organisms have also been 
cultured from the faeces and blood of infected hosts, demonstrating that these bacteria have 
a wide host range and have the potential to cause both enteric and systemic infections.  
The genus consists of seven confirmed species of Brachyspira as seen in Table 1.1. These 
include B. aalborgi, B. alvinipulli, B. hyodysenteriae, B. innocens, B. intermedia, B. murdochii 
and B. pilosicoli. There are an additional seven proposed species, including B. canis, B. 
christiani, B. corvi, B. hampsonii, B. ibaraki, B. puli and B. suanatina. B. pilosicoli is the only 
species to our knowledge that can infect both human and non-primate animal hosts and thus 
may pose a zoonotic threat. 
B. alvinipulli, B. intermedia and B. pilosicoli are the species that are considered to be the 
causative agent of avian intestinal spirochaetosis. B. hyodysenteriae causes swine dysentery 
in pigs and B. intermedia causes the less severe gastrointestinal disease, porcine intestinal 
spirochaetosis. B. innocens is proposed to be non-pathogenic in both the avian and porcine 
hosts although it has been previously associated with reduced productivity in laying hens 
(Burch et al., 2006). Humans of any age can be infected with B. pilosicoli and B. aalborgi, 
resulting in human intestinal spirochaetosis but this is frequently associated with poorly 
developed countries (Mikosza et al., 2001).   
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Species Host Range Associated Disease Reference  
B. aalborgi Human, primate Intestinal Spirochaetosis  Hovind-Hougen et al., 1982 
B. alvinipulli Chicken, domestic goose, dog Intestinal Spirochaetosis  Stanton et al.,1998 
B. hyodysenteriae  Pig, rat, mouse, chicken, goose Swine dysentery (pigs) Harris et al., 1972 
B. innocens Pig, dog, horse, chicken Avirulent Kinyon and Harris, 1979 
B. intermedia Pig, chicken Intestinal Spirochaetosis  Stanton et al., 1997 
B. murdochii  Pig, rat, chicken Avirulent Stanton et al., 1997 
B. pilosicoli Pig, dog, horse, human, primate, 
chicken 
Intestinal Spirochaetosis  Trott et al., 1996 
Proposed Species    
B. canis Dog  Duhamel et al., 1998 
B. christiani Human  Jensen et al., 2001 
B. corvi Jackdaw, crow  Jansson et al., 2008 
B. hampsonii Pig  Chander et al., 2012 
B. ibaraki Human  Tachibana et al., 2002 
B. puli Chicken, dog  Stephens and Hampson, 1999 
B. suanatina Pig, mallard  Råsbäck et al., 2007 
(Adapted from Mappley et al., 2014). 
 
 
(Harris et al., 1972a; KINYON and HARRIS, 1979b; Hovind-Hougen et al., 1982; TROTT et al., 1996; Stanton et al., 1997a; G E Duhamel et al., 
1998; Stanton, Postic and Jensen, 1998; Stephens and Hampson, 1999; Jensen et al., 2001; Tachibana, H., Nakamura, S., Hampson, D. J. & 
Adachi, 2002; Råsbäck et al., 2007; Jansson, Fellström and Johansson, 2008; Chander et al., 2012) 
 
  
 
Table 1. 1 Confirmed and proposed species of Brachyspira and their host range 
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1.1.3 Phenotypic characteristics of Brachyspira 
 
1.1.3.1 Cell morphology and cultural characteristics  
 
Brachyspira are Gram negative, long, helical shaped bacteria, depicted in Figure 1.1 (Mirajkar 
et al., 2016). Cells range in length from 2.0-11.0 µm, width from 0.20- 0.45 µm and number 
of flagella from 8-30 per cell as shown in Table 1.2. Additionally, the cell end can be blunt, 
pointed or tapered, depending on the Brachyspira species.  
Spirochaetes possess periplasmic flagella (Figure 1.2) and the number of flagella varies 
between the species of Brachyspira, as shown in Table 1.2. The different numbers of flagella 
can prove useful in differential diagnosis of an isolate, using electron microscopy. Brachyspira 
species responsible for avian intestinal spirochaetosis typically have an end:middle:end 
flagella ratio of 8:16:8 or 5:10:5 owing to the fact that individual flagellum originate from the 
poles of the cell and overlap in the middle (Fellström et al., 1997).  
Brachyspira are slow growing, fastidious organisms that typically take 3-5 days to form a thin, 
flat film of growth on agar. Species that are implicated in poultry disease were weakly 
haemolytic, characterised by a halo of weak haemolysis around areas of growth on blood 
agar. Other Brachyspira species such as B. hyodysenteriae are strongly haemolytic on blood 
agar and therefore can be distinguished from poultry isolates. Spirochaetes stain poorly with 
Gram stains and therefore the Warthin-Starry stain is the most appropriate method to 
visualise Brachyspira cells following culture. Additionally, cells can be visualised using dark-
field microscopy, whereby the spirochaete morphology and motility are most clearly 
visualised. Growth of Brachyspira in vitro can be carried out on solid or liquid media, 
supplemented with blood or serum.  Selective agar such as Brachyspira selective agar which 
contains 5% sheep blood, spectinomycin at a concentration of  800µg/ml and colistin and 
vancomycin each at a concentration of 25µg/ml supports Brachyspira growth (Råsbäck et al., 
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2005). Selective media is important to inhibit growth of other organisms that could inhibit or 
out-grow Brachyspira. Cultures of Brachyspira can be grown more rapidly on fastidious 
anaerobic agar containing 10% sheep blood, but this is only recommended for pure isolates. 
Brachyspira can be grown in a number of different liquid broth media including, brain heart 
infusion broth (BHI) and Brachyspira enrichment broth, containing tryptone soya broth, 10% 
cysteine hydrochloride, 10% glucose and 10% serum (Råsbäck et al., 2005). 
Brachyspira culture is carried out under anaerobic conditions, preferably in an anaerobic 
cabinet containing a gas composition of 10% hydrogen, 10% carbon dioxide and 80% nitrogen 
and growth can be observed after 3- 5 days of culture, but culture can take up to two weeks 
(Hampson, personal communication). Colonies appear as a dull flat sheet that grows over the 
surface of an agar plate, which is why it is difficult to isolate individual Brachyspira colonies. 
Surface growth of the species implicated in avian intestinal spirochaetosis is surrounded by 
weak b- haemolysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. 1 Phase- contrast microscopy of B. hampsonii NSH-24 cells imaged at x100 showing the long spiral morphology of Brachyspira (Mirajkar et al., 
2016). 
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Brachyspira species  Length (µm) Width (µm) Number of flagella 
B. aalborgi  2-6  0.2 8 
B. alvinipulli 8-11 0.2-0.35 22-30 
B. hyodysenteriae 7-9 0.3 -0.4 22-28 
B. innocens 7-9 0.3 -0.4 20-26 
B. intermedia 8-10 0.35-0.45 24-28 
B. murdochii 5-7 0.23-0.3 22-26 
B. pilosicoli  5-7 0.2-0.4 8-12 
 
 
Figure 1. 2 Diagram of a spirochaete indicating that the flagella are inserted at the termini 
of the spirochaete cell. These bundles of flagella wind around the protoplasmic cylinder and 
overlap in the middle. The outer membrane ensure that the flagella remain in the periplasm. 
The flagella are inserted into the cytoplasmic membrane of the cell and extend into the 
periplasm. Spirochaete movement is facilitated by the co-ordinated rotation of the flagella. 
Adapted from (Rosa et al., 2005). 
 
Table 1. 2 Size and number of flagella associated with the seven validated species of Brachyspira. 
Different species of Brachyspira can be distinguished using scanning electron microscopy (SEM) 
due to the varying lengths, widths and number of flagella possessed by each species.  
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1.1.3.2 Biochemical properties of Brachyspira 
 
Brachyspira produce several enzymes that can be utilised to determine the biochemical 
profile of each isolate in order to determine the species. Biochemical tests for Brachyspira 
include colorimetric assays for indole production, hippurate hydrolysis and the activity of a-
galactosidase, a-glucosidase and b- glucosidase (Fellström & Gunnarsson, 1995; Fellström et 
al., 1999). The typical biochemical results for Brachyspira species are detailed in Table 1.3 
whereby Brachyspira species are assigned groups based on their phenotypic profiles. A major 
drawback of these biochemical tests is that the results were initially determined using 
Brachyspira isolated from pigs, which are known to differ from avian isolates. Due to these 
inaccuracies, molecular methods are being used in conjunction with phenotypic methods for 
a more accurate identification. Additionally, as whole genome sequencing becomes more 
readily available, sequencing may be the gold standard for Brachyspira identification as PCR 
based methods have drawbacks that will later be discussed.  
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Group Haemolysis α-
galactosidase 
α-
glucosidase 
β-
glucosidase 
Indole 
production 
Hippurate 
hydrolysis 
Species indicated 
I Strong - ± + ± - B. hyodysenteriae  
II Weak − + + + − B. intermedia 
IIIa Weak − − + − − B. murdochii 
IIIb Weak ± − + − − B. innocens 
IIIc Weak ± + + − − B. innocens 
IV Weak ± ± − − + B. pilosicoli 
ND Weak − − + − + B. alvinipulli 
Table 1. 3 Grouping of Brachyspira species according to their biochemical properties (Fellström et al., 1999). 
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1.1.3.3 Metabolic properties of Brachyspira  
 
There is a significant lack of understanding of the metabolic pathways present within 
Brachyspira, however recent genome sequencing and high-throughput phenotypic testing 
have begun to improve the understanding of the metabolic capabilities of this organism 
(Mappley et al., 2012). 
 Genome sequencing has revealed that the central metabolic pathways for energy production 
in Brachyspira species include glycolysis, gluconeogenesis and the non-oxidative pentose 
phosphate pathway (Bellgard et al., 2009; Wanchanthuek et al., 2010). The end products of 
these metabolic pathways include acetate, butyrate, ethanol, hydrogen and carbon dioxide 
(Stanton and Lebo, 1988; Trott et al., 1996; Stanton et al., 1997; Stanton et al., 1998). 
Brachyspira species have an incomplete set of genes coding for the TCA cycle, as observed 
with other spirochaetes such as Borrelia burgdorferi and Treponema pallidum. (Bellgard et al., 
2009). This therefore suggests that Brachyspira generate adenosine triphosphate (ATP) 
through the fermentation of sugars. To date, the ability of B. pilosicoli and B. murdochii to 
utilise the enzymes of the incomplete TCA cycle to synthesis glutamate have been noted, a 
metabolic pathway not shared by B. hyodysenteriae.  
High-throughput testing of carbon metabolism for Brachyspira species has highlighted that 
many metabolic pathways are shared by B. pilosicoli and B. hyodysenteriae, but that there are 
key differences both between species of Brachyspira and within the same species (Mappley 
et al., 2012). Of 178 carbon sources tested, the utilisation of only seven were found to differ 
between B. pilosicoli and B. hyodysenteriae (Mappley et al., 2012). However, of these seven, 
the ability of B. pilosicoli to metabolise four carbon sources differed; to fully explain this, 
further research is required.  
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1.1.3.4 Genotypic characteristics of Brachyspira 
 
Brachyspira have a circular genome with an approximate size of between 2.43- 3.49Mbp, with 
B. pilosicoli generally having the smallest genome. The Brachyspira genome has a low GC 
content of between 24-28%. There is a paucity of public genome sequences data for 
Brachyspira species implicated in poultry disease with only one genome sequence available 
for B. alvinipulli, B. intermedia (Håfström et al., 2011) and B. innocens and four available 
sequences for B. pilosicoli (Lin et al., 2013; Mappley et al., 2012; Wanchanthuek et al., 2010). 
B. hyodysenteriae is responsible for swine dysentery and therefore results in a much more 
severe disease than observed in poultry which may account for why twenty-five genome 
sequences are available (Bellgard et al., 2009; Black et al., 2015; La et al., 2016). Additionally, 
one B. murdochii (Pati et al., 2010) and five B. hampsonii sequences are available (Genbank, 
NCBI). 
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Table 1. 4 Summary of the Brachyspira genome sequences and their genome size and GC content (%) 
available on Genbank. 
 
(Adapted from Hampson and Wang, 2017). 
 
 
 
As mentioned, B. pilosicoli have one of the smallest genomes of all Brachyspira species, 
however the size of these genomes can vary from between 2.43 and 2.88Mbp indicating 
genome plasticity: B. pilosicoli genomes have been shown to have major genome 
rearrangements that coincide primarily with mobile genetic elements. Despite this variability, 
there were many core genome features shared with other species, such as their core 
metabolic pathways (Mappley et al., 2012; Wanchanthuek et al., 2010). Despite its small 
genome size, B. pilosicoli isolates encode more proteins than B. hyodysenteriae, this may have 
resulted in B. pilosicoli having the ability to colonise a wider host range than B. hyodysenteriae 
(Hampson & Wang, 2017).  
Brachyspira 
species  
Number of 
genomes 
Genome size 
(Mbp) 
GC content 
(%) 
Reference  
B. aalborgi 1 2.5 27.0 (Mappley et al., 2012) 
B. alvinipulli 1 3.42 26.8 (Stanton et al., 1998), 
DOE Joint Genome 
Institute 
B. hampsonii 5 2.93- 3.18 27.4 (Mirajkar et al., 2016) 
B. hyodysenteriae 25 2.99-3.19 27.1 (Bellgard et al., 2009; 
Black et al., 2015; La et 
al., 2016) 
B. innocens 1 3.28 27.22 DOE Joint Genome 
Institute 
B. intermedia 1 3.30 27.7 (Håfström et al., 2011) 
B. murdochii 1 3.24 27.75 (Pati et al., 2010) 
B. pilosicoli 4 2.56–2.89 27.44–
27.90 
 
(Lin et al., 2013; 
Mappley et al., 2012; 
Wanchanthuek et al., 
2010) 
B. suanatina  2 3.26 27.0 (Mushtaq et al., 2015) 
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Due to the lack of genome data for other Brachyspira species implicated in avian disease, 
further comparative genomics has not been undertaken, however, as more sequences 
become available, species level comparison and pangenome analysis of avian isolates will 
improve the understanding of Brachyspira and avian intestinal spirochaetosis. Furthermore, 
methods of genetic manipulation are required to confirm the functions of genes highlighted 
in bioinformatic analysis. Although research has been conducted with Brachyspira isolates 
with specific gene mutations, further tools to manipulate the genome are needed (Rosey et 
al., 1995; Stanton et al., 1999).  
 
1.1.4 Virulence characteristics of Brachyspira  
 
Brachyspira have a number of virulence factors which allow it to survive and navigate the 
gastrointestinal tract of the host in order to cause disease. Disease relies upon these bacteria 
gaining close proximity to the intestinal mucosa where they can adhere to the cells. In order 
to do this, Brachyspira must first move through the viscous mucus of the caeca and/or colon. 
Virulence mechanisms of Brachyspira are overall, poorly understood and severity of disease 
is dependent on several factors, including isolate of Brachyspira, health of the host, diet and 
resident intestinal microbiota.  
 
1.1.4.1 Motility  
 
Brachyspira are motile by periplasmic flagella and movement is facilitated by the co-ordinated 
rotation of the flagella which are inserted into the poles of the bacterial cell and overlap in 
the middle. Motility is an important virulence factor for Brachyspira as it is essential for host 
colonisation and gaining close proximity to the intestinal mucosa for attachment and invasion 
of enterocytes (Naresh and Hampson, 2010). Furthermore, strong motility enables 
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Brachyspira to evade the physical effects of mucus, which is designed to remove unattached 
bacteria from the gastrointestinal tract (Nakamura et al., 2006; Witters & Duhamel, 1999) . 
Whole genome sequencing has identified the presence of flaA and flaB genes in Brachyspira 
species and disruption of these genes in B. hyodysenteriae has been shown to be associated 
with an inability to colonise mice in a murine infection model (Kennedy et al., 1997). These 
genes have been identified in B. hyodysenteriae, B. murdochii and B. pilosicoli (Bellgard et al., 
2009; Wanchanthuek et al., 2010), furthermore, Mappley et al. (2012) identified several types 
of flagella associated proteins present in B. pilosicoli isolates, including but not limited to 
inner, outer and periplasmic proteins.  
Periplasmic flagellar consist of three major components: the basal body, the hook and the 
filament, as illustrated in Figure 1.3. The basal body is comprised primarily of export proteins, 
the MS ring that attaches the rod assembly to the cell membrane, the C ring, the collar 
structure within the peptidoglycan, FilL and the motor components: MotA and MotB. The 
hook is primarily comprised of FlaE and the filament is composed of FlaA, the major flagellin 
protein and FlaB, the minor flagellin protein (Motaleb et al., 2015). 
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1.1.4.2 Chemotaxis 
 
Chemotaxis is the movement of an organism in response to an extracellular stimulus, allowing 
bacteria to move towards chemoattractants. Potent chemoattractants for Brachyspira are 
mucin, fructose and L-serine and cells mediate the movement towards these chemicals using 
rotation of the periplasmic flagella (Kennedy and Yancey, 1996; Naresh and Hampson, 2010). 
The chemotaxis mechanisms have been studied extensively in E. coli (Parkinson, 2003), 
however it is proposed that similar mechanisms are utilised by Brachyspira as genome 
sequencing has revealed the presence of similar chemotaxis proteins (Che) and methyl-
accepting chemotaxis proteins (MCPs) (Bellgard et al., 2009; Wanchanthuek et al., 2010). 
Chemotaxis uses a two-component histidine protein kinase dependent signal transduction 
pathway, comprising of both MCPs and Che proteins as illustrated in Figure 1.4. MCPs are 
Figure 1. 3 Main components of the periplasmic flagella structure in spirochaetes. (a) Schematic of 
a spirochaete cells showing the periplasmic flagellar filaments originating from the poles of each 
cell, between the outer membrane (OM) and inner membrane (IM). The filaments overlap in the 
middle of the cell and result in the strong motility associated with spirochaetes. (b) Schematic of 
the periplasmic flagellar motor, illustrating various interacting proteins responsible for flagellar 
movement. PG- peptidoglycan layer, EXP- export apparatus. (Motaleb et al., 2015).  
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chemoreceptors which bind signals in the periplasmic domain. This signalling cascade begins 
with the histidine kinase CheA and the coupling factor CheW; CheA autophosphorylates and 
the phosphate group is transferred to CheY, thus activating this protein. The phosphorylated 
CheY proteins then binds to the FliM protein in the flagellar motors to facilitate rotation. 
Although the exact pathways involved in Brachyspira chemotaxis are yet to be elucidated, 
bioinformatics has identified MCP proteins and Che proteins present in B. hyodysenteriae and 
B. pilosicoli. Genes for the MCP proteins, including aer, tsr, tar, tgr and tap have been 
identified in B. hyodysenteriae and genes for the Che proteins, including cheA, cheB, cheD, 
cheR, cheV, cheX, cheY and cheZ have been identified in B. hyodysenteriae and/or B. pilosicoli. 
(Bellgard et al., 2009; Mappley et al., 2012; Wanchanthuek et al., 2010). 
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1.1.4.3 Adhesion and invasion 
 
The mechanisms of adhesion and invasion by Brachyspira are poorly understood, however B. 
pilosicoli has been observed forming end on attachments to enterocytes to form a pseudo-
brush border. B. pilosicoli can also invade the crypts, epithelium and the lamina propria. Thus 
far, it appears that only B. aalborgi and B. pilosicoli can adhere to healthy epithelial cells, 
whereas evidence suggests that other Brachyspira species adhere and invade disrupted cells 
(Mappley et al., 2014). The attachments formed by Brachyspira may be responsible for 
disruption of the intestinal mucosa, thus resulting in poor fluid and nutrient absorption, 
leading to diarrhoea and poor growth performance in infected animals. 
Figure 1. 4 Main components of key chemotaxis pathways in spirochaetes (Xu et al., 2017). Responses to 
chemotactic signals in the gastrointestinal tract results in a signalling cascade from the methyl-accepting 
chemotaxis protein (MCP), which detects the signal, which for Brachyspira species may be mucin. This signal 
is transduced through CheW and CheA, where CheA autophosphorylates and the phosphate group is 
transferred to CheY. The phosphorylated CheY binds to flagellar motor proteins to initiate the movement of 
the periplasmic flagellar. 
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Invasion of enterocytes and between epithelial tight junctions is depicted in Figure 1.5. As 
with other virulence factors, this mechanism has not been well characterised, however 
translocation of Brachyspira to the blood has been noted and systemic infection in multiple 
organs have been observed in experimental infections of chickens with B. pilosicoli (Mappley 
et al., 2013; Woodward et al., 2015). In cases of human spirochaetemia, only elderly and 
critically ill patients have been diagnosed with Brachyspira in the bloodstream, therefore it 
may be associated with impaired immune function (Bait-Merabet et al., 2008; Fournié-
Amazouz et al., 1995). 
 
1.1.4.4 Haemolysis 
 
The production of haemolysins is considered a major virulence factor, particularly for B. 
hyodysenteriae. Brachyspira species known to infect poultry are weakly b- haemolytic, 
whereas B. hyodysenteriae is known to be strongly b- haemolytic. Haemolysins cause lysis of 
red blood cells by destroying their cell membrane and it could be suggested that they may be 
involved in the damage to the mucosa of the large intestine during swine dysentery. Whole 
genome analysis of B. hyodysenteriae and B. pilosicoli has identified eight putative haemolysin 
genes (Wanchanthuek et al., 2010).  
 
1.1.4.5 NADH oxidase activity  
 
Despite their anaerobic nature, all Brachyspira species can tolerate oxygen due to their NADH 
oxidase activity. This enzyme protects the bacterial cells from oxygen toxicity and studies have 
shown that an inactivated nox gene reduces the colonisation and virulence of B. 
hyodysenteriae, but does not render them avirulent (Stanton et al., 1999).  
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1.1.4.6 Lipooligosaccharide  
 
Lipooligosaccharides are complex carbohydrates associated with the surface of the bacterial 
cell wall. They are known to activate the host immune response via toll-like receptor 4 (TLR4) 
which is expressed on a number of immune cells, which may result in the mucosal 
inflammation observed during infection (John et al., 2017). Furthermore, LOS forms the basis 
of serological testing for B. hyodysenteriae isolates implicated in swine dysentery and reacts 
strongly with the sera of infected pigs (Hampson et al., 1990), suggesting that it is a prime 
target for the host immune response (Trott et al., 2001). 
A number of LOS have been described in Brachyspira, however, the exact mechanisms of LOS 
in disease is unknown. B. pilosicoli LOS has been shown to be serologically distinct between 
isolates of this species and shows no cross-reactivity with other Brachyspira species, which 
may explain why hosts may suffer from repeated infections with Brachyspira, and why 
vaccines have not been hugely successful (Lee & Hampson, 1999; Trott et al., 2001). 
 
1.2 Avian Intestinal Spirochaetosis (AIS) 
 
1.2.1 What is avian intestinal spirochaetosis? 
 
Avian intestinal spirochaetosis is an enteric disease resulting from the colonisation of the 
caeca and/or colo-rectum of poultry with spirochaetes such as Brachyspira. This disease 
primarily infects layer hens and broiler breeders over the age of 20 weeks and can range in 
severity of symptoms, but typically presents as a delayed onset of lay, watery brown to grey 
diarrhoea, a 6-10% reduction in egg production, faecally stained eggs and a reduced growth 
rate (Burch et al., 2006). More severe clinical manifestations can include typhlitis and 
increased mortality rates within flocks. Avian intestinal spirochaetosis has a significant impact 
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on the UK laying industry, exacerbated by the removal of antibiotic growth promoters from 
livestock feed in 2006.  
The Brachyspira species primarily reported to cause avian intestinal spirochaetosis are B. 
pilosicoli, B. intermedia and B. alvinipulli; B. innocens is proposed to be non-pathogenic, and 
is often isolated alongside these pathogenic species (Burch et al., 2006). 
 
1.2.2 What is the significance of avian intestinal spirochaetosis? 
 
Since the ban of antibiotic growth promoters from livestock feed in 2006, the incidence of 
avian intestinal spirochaetosis has increased significantly and is becoming a growing concern 
(Medhanie et al., 2013). This disease has a significant economic burden on the UK laying 
industry, with the most recent estimation stating that it costs the industry £18 million per 
annum. This figure was based on a national flock size of 30 millions laying hens, with 30 eggs 
lost per hen at a cost of 5p per egg (Mappley et al., 2014). These losses estimated in the UK 
are likely to be similar worldwide, with studies in Australian, Italy and Iran showing similar 
prevalence to that observed in the UK (McLaren et al., 1996; Bano et al., 2008; Bassami et al., 
2012).  
 
1.2.3 Epidemiology of avian intestinal spirochaetosis 
 
1.2.3.1 Host Range 
 
Brachyspira can colonise the caeca and colo-rectum of many avian species, both domestic 
and wild. Of the domestic poultry, known hosts include: layer hens (Davelaar et al., 1986; 
Dwars  et al., 1989; Griffiths et al., 1987; Myers et al., 2009; Swayne et al., 1992), broiler hens 
(Dwars et al., 1990), broiler breeder hens (Stephens and Hampson, 2002) and turkeys 
(Mathey and Zander, 1955). Of the wild bird species, known hosts include: flamingos, rheas, 
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ducks, swans, (Trott et al., 1996) grouse (Fantham, 1910), ducks (Råsbäck et al., 2007), 
ostriches (Stoutenburg and Swayne, 1992)  and pheasants (Webb et al., 1997).  
 
1.2.3.2 Transmission and Infection 
 
Brachyspira are transmitted through flocks via the faecal-oral route. Transmission begins 
when birds come into contact with vectors, such as wild birds, rodents or environmental 
reservoirs (Oxberry et al., 1998; Boye et al., 2001; Backhans et al., 2010), Brachyspira are then 
shed in the faeces of infected birds and rapidly spread throughout a flock as shown in Figure 
1.5 (Le Roy et al., 2015). Farming practices can facilitate the spread of infection through poor 
biosecurity and rodent control. Furthermore, intensification of farming has led to the close 
proximity of poultry, facilitating the rapid spread of disease. Wet litter conditions can also 
promote the proliferation of bacteria and the coprophagic behaviour of chickens in these 
conditions can result in rapid spread of Brachyspira.  
The infection process begins when the spirochaetes reach the caeca and colo-rectum of the 
bird. Once these pathogens reach the lower gastrointestinal tract, chemotaxis towards mucin 
and the strong motility through the mucus enables Brachyspira to gain close proximity to the 
intestinal epithelium. B. pilosicoli, in particular can form end on attachments to cells to form 
a pseudo-brush border. Brachyspira can also invade enterocytes and disturb tight junctions, 
therefore increasing the chances of translocation to the bloodstream and subsequently a 
systemic infection (Le Roy et al., 2015). Systemic infections were reported by Mappley et al. 
(2013), whereby Brachyspira were isolated from the liver, spleen and reproductive tracts of 
experimentally infected hens. 
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1.2.3.3 Prevalence  
 
Avian intestinal spirochaetosis has been well documented in Europe, North American and 
Australia, but is thought to be endemic worldwide (Pattinson, 2007). The prevalence of 
Brachyspira in UK laying flocks has been estimated to be as high as 100% in barn flocks,  91% 
in free range flocks, 86% in organic free-range flocks and up to 76% in caged flocks (Burch, et 
al., 2009). In the study presented by Burch et al. (2009), Brachyspira infection in free-range 
hens was seen to occur by the age of 22 weeks, shortly after they have access to the outside. 
Figure 1. 5 The proposed transmission and infection process of B. pilosicoli. The numbers in the grey circles 
represent the transmission process: 1. Infection vectors such as wild bird or rodents spread Brachyspira to 
poultry, which become infected by the faecal-oral route; 2. Brachyspira is excreted in the faeces of infected 
birds which is then spread throughout the rest of the flock; 3. Persistence of infection within the flock. The 
numbers in white circles represent the infection process of B. pilosicoli once it has reached the lower 
gastrointestinal tract of the birds: 1. Virulence factors such as motility and chemotaxis facilitate the 
movement of Brachyspira to the mucus and subsequently the intestinal epithelium; 2. B. pilosicoli attach to 
enterocytes can form a ‘false brush border’; 3. Brachyspira can invade the epithelial cells and disrupt the 
epithelial tight junctions; 4. Thus resulting in the translocation of Brachyspira to the blood stream; 5. 
Systemic infection can occur (Le Roy et al., 2015).  
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By comparison, caged hens did not test positive for Brachyspira until 36 weeks of age. The 
infection of free-range hens at a young age is likely to be as a result of exposure to 
environmental reservoirs of Brachyspira more frequently than caged hens. Brachyspira have 
been shown to survive in soil and contaminated water supplies. At 10°C it has been shown 
that B. hyodysenteriae and B. pilosicoli have the potential to survive in soil for up to 210 days, 
this therefore makes infection control difficult in free-range flocks as Brachyspira infection 
would occur naturally from eating and scratching behaviour (Boye et al., 2001). Furthermore, 
Brachyspira have also demonstrated the ability to survive for up to 66 days in contaminated 
water supplies (Oxberry et al., 1998). The abundance of the bacteria in the environment not 
only means that infection spreads by direct ingestion of bacteria from the environment but 
can also be rapidly spread on farms by vectors such as humans, dogs, rodents and wild birds. 
In barn and caged systems, the spread of Brachyspira by rodent vectors is of increasing 
concern. A survey in Sweden identified rodents, in particular rats, to be major carriers of 
Brachyspira on poultry farms, with 83% of rats and 33% of mice carrying the bacteria 
(Backhans et al., 2010). Wild birds are also known to harbour intestinal spirochaetes 
asymptomatically, therefore the spread of pathogenic Brachyspira species to commercial 
flocks is possible. Thus, in barn and caged systems biosecurity is essential to limit the 
prevalence of avian intestinal spirochaetosis.  
Epidemiological studies have shown that commercial poultry are most frequently infected 
with B. intermedia followed by B. pilosicoli, however the prevalence of B. innocens is much 
higher than the pathogenic species (Bano et al., 2008; Burch et al., 2009). B. alvinipulli has 
been rarely isolated from commercial poultry in the UK but has been isolated in poultry in the 
USA (Swayne et al., 1992), The Netherlands (Feberwee, et al., 2008) and Sweden (Jansson and 
Pringle, 2011). 
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1.2.3.4 Disease incubation period and persistence  
 
The incubation period and persistence of avian intestinal spirochaetosis can be dependent on 
the dose and species of Brachyspira ingested and also the environment of the poultry 
infected, as previously discussed. Clinical symptoms can occur in experimentally infected 
birds as soon as five days post infection (Mappley et al., 2014) but colonisation is most 
commonly observed after seven days post infection (Hampson et al., 2002; Mappley et al., 
2013). However, significant colonisation and disease symptoms can persist several weeks 
following experimental infection, although this is not true for all experimental infections 
(Hampson and Jamshidi, 2002; Hampson et al., 2002; Stephens and Hampson, 2002). 
Persistence of infection in naturally infected flocks is likely due to the close proximity of barn 
or caged hens and/or contact with environmental reservoirs by free-range hens (Le Roy et al., 
2015). 
 
1.2.3.5 Possible zoonoses 
 
Brachyspira species, in particular B. pilosicoli are of potential zoonotic concern. Although 
human intestinal spirochaetosis in relatively rare, it mostly occurs in immunocompromised 
patients and those with poor living standards (Korner and Gebbers, 2003). Epidemiological 
studies in humans have not been undertaken and publications are often formed of case 
studies where human infection has been determined by colo-rectal biopsy. These biopsies 
show the attachment of spirochaetes to the intestinal epithelium, noted as a false brush 
border (Hampson, 2018; Ngwa et al., 2016). In rare cases, B. pilosicoli has been shown to 
cause bacteraemia in the elderly and immunocompromised patients (Prim et al., 2011; Trott 
et al., 1997).  
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Despite intestinal spirochaetosis being rarely observed in humans, B. pilosicoli has a wide host 
range and has been documented to infect humans, poultry and pigs. B. pilosicoli from these 
three hosts have been shown to have genetic similarity, suggesting that infected animal hosts 
may potentially serve as a reservoir for human disease (Hampson et al., 2006; Mappley et al., 
2012). Furthermore, it has been shown that B. pilosicoli can contaminate meat of infected 
poultry, which may pose as a zoonotic threat to humans (Verlinden et al., 2012).  It is 
important to note, however, that broiler hens are rarely infected with Brachyspira and thus 
the infection risk comes from the meat of spent laying hens.  
 
1.2.4 Clinical symptoms and pathology  
 
The understanding of the clinical symptoms and pathology associated with avian intestinal 
spirochaetosis has developed as a results of experimental challenge of Brachyspira in chicks 
and adult hens and also from the observation of natural occurrence of disease. Although 
experimental challenge with Brachyspira does not mimic the natural environment in which 
commercial flocks may acquire these bacteria, in a commercial environment, milder 
symptoms such as diarrhoea may be undetected and thus avian intestinal spirochaetosis is 
often not recognised in flocks.  
 
1.2.4.1 Sub-clinical colonisation  
 
Colonisation with intestinal spirochaetes in the absence of clinical disease is most common in 
wild birds and water birds, where they are considered as commensal bacteria. Studies have 
shown that these birds and their habitats can be reservoirs of infection for both humans and 
other animals as infection with both pathogenic and non-pathogenic Brachyspira results in 
sub-clinical colonisation in these wild hosts (Oxberry et al., 1998; Jansson et al., 2004). Sub-
clinical colonisation of commercial laying hens and broiler breeders is associated with 
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infection with B. innocens or B. murdochii (Stephens and Hampson, 1999, Stephens and 
Hampson, 2002). 
 
1.2.4.2 Mild to moderate clinical disease  
 
Mild to moderate clinical disease is associated with colonisation by B. alvinipulli, B. intermedia 
and B. pilosicoli, particularly in laying hens and broiler breeders over the age of 20 weeks. 
Typically, infection is associated with symptoms such as diarrhoea, increased fat content in 
the faeces, a 6-10% reduction in egg production, reduced growth rates and a delayed onset 
of lay (Davelaar et al., 1986; Griffiths et al., 1987;  Burch et al., 2006). Furthermore, eggs may 
have decreased nutritional value and infected broiler breeders produce weak chicks with 
retarded growth rates (Dwars et al., 1993). Moreover, a comprehensive study carried out in 
the Netherlands found that broiler flocks derived from breeders infected with Brachyspira 
had poorer feed conversion and slower growth rates than the offspring of flocks where 
Brachyspira was not present. It is important to note that the broilers themselves were not 
colonised with spirochaetes (Smit et al., 1998). 
 
1.2.4.3 Severe clinical disease 
 
Severe clinical symptoms are infrequently observed in commercial chicken flocks but may be 
exacerbated by stress (Stephens and Hampson, 2001). Severe clinical symptoms have been 
observed in chickens infected with B. intermedia and B. pilosicoli whereby spirochaetes have 
penetrated between or below caecal epithelial cells, resulting in erosion or necrosis of the 
mucosa (Davelaar et al., 1986; Dwars et al., 1990). Furthermore, the presence of spirochaetes 
between epithelial cells poses a risk of systemic infection as noted in studies which suggest 
B. pilosicoli can infect multiple organs in laying hens (Mappley et al., 2013). Histological 
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examination of caeca from naturally infected birds has revealed that invasive spirochaetes 
and typhlitis were associated with B. intermedia infections (Stephens and Hampson, 2001). 
 
1.2.4.4 Experimental infection models of avian intestinal spirochaetosis 
 
To improve the understanding of Brachyspira infection and the clinical symptoms associated 
with each of the species implicated in poultry disease, experimental infections have been 
conducted. Infection with B. alvinipulli resulted in a dilated caeca with foamy, pale-yellow 
contents in both one-day old chicks and adult hens  Histopathology also showed that infected 
birds had severe symptoms including, mild to moderately severe typhlitis, caecal villus 
hyperplasia and inflammation as a result of lymphocyte and/or heterophil infiltration (Swayne 
et al., 1995). Birds naturally infected with B. alvinipulli also displayed the mild symptoms 
associated with avian intestinal spirochaetosis, in addition to some of the more severe clinical 
symptoms such as typhlitis and tissue necrosis (Feberwee et al., 2008). 
Symptoms of experimental infection with B. intermedia included, diarrhoea, reduced growth 
rates, reduced egg production and egg weights (Hampson and McLaren, 1999; Phillips et al., 
2004). Histopathology confirmed the presence of B. intermedia in the caeca and scanning 
electron microscopy confirmed the presence of spirochaetes in the caecal epithelium, 
however no associated pathology was observed. Infected birds had less fat than control birds 
and the caeca were more gassy and contained a higher water content (Hampson and 
McLaren, 1999). 
Experimental challenge with B. pilosicoli in chicks and adult hens caused symptoms such as 
diarrhoea and decreased growth rates. Adult hens had increased faecal staining of egg shells 
and reduced egg production, in addition to foamy caecal contents. Mild pathology is often 
associated with experimental infection in hens including vacuolation in enterocyte cytoplasm 
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and crypt elongation (Dwars et al., 1992; Trott et al., 1995; Stephens and Hampson, 2002; 
Hampson and Jamshidi, 2002).  
B. pilosicoli has shown a unique ability to form pseudo brush borders by forming end on 
attachments to enterocytes in the gastrointestinal tract of infected hosts, which can damage 
the microvilli and impair gastrointestinal function (Trampel et al., 1994; Muniappa et al., 
1996).  This has also been noted in human and porcine infections with B. pilosicoli (Mathan 
and Mathan, 1985; Girard et al., 1995; Brito et al., 1996). 
 
1.2.5 Host immunity 
 
The host immune mechanisms directed against Brachyspira are poorly understood. The 
innate immune response is the first line of defence against Brachyspira and infection has been 
associated with the infiltration of immune cells such as macrophages in to the lamina propria 
(Antonakopoulos et al, 1982; Padmanabhan et al., 1996; Duhamel, 2001). Moreover, 
experimentally infected pigs and mice have been shown to develop serum antibody 
responses to Brachyspira isolates, although these adaptive immune responses have been 
shown to vary (Sacco et al., 1997; Jamshidian et al., 2004; Hampson, 2018). 
Brachyspira infection can remain persistent in poultry flocks, which may be attributed to the 
ability of these bacteria to adhere to the intestinal epithelium which may aid in subverting 
the immune system or evading an immune response, but these mechanism have yet to be 
elucidated (Hampson, 2018). Different Brachyspira isolates show considerable antigenic 
variability in their surface lipooligosaccharide (LOS), however more work is needed to define 
their role in disease, including whether they may be involved in attachment or protective 
immunity for example.  
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1.2.6 Diagnosis of avian intestinal spirochaetosis 
 
Avian intestinal spirochaetosis requires a definitive diagnosis consisting of a number of 
phenotypic and molecular techniques, as clinical symptoms alone are non-specific and 
insufficient. 
 Culture followed by light, phase-contrast or dark-field microscopy to confirm cell morphology 
and motility, can be used as a preliminary screen for Brachyspira. In addition, biochemical 
testing, can be employed to speciate isolates (Fellström and Gunnarsson, 1995), although as 
discussed previously the biochemical profiling of avian isolates can be unreliable (Atyeo et al., 
1999). Therefore, phenotypic tests that are time consuming and inconsistent, especially with 
mixed species infections, need to be routinely supported by molecular methods.  
PCR primer sequences to identify Brachyspira have been designed to target either the 16S 
ribosomal ribonucleic acid (rRNA) gene or the NADH oxidase (nox) gene (Mikosza et al., 2001; 
Phillips et al., 2005; 2006). Primers were designed to identify isolates from the Brachyspira 
genus, B. pilosicoli primers were designed using the 16S rRNA gene and B. intermedia primers 
were designed using the nox gene (Mikosza et al., 2001; Phillips et al., 2005, 2006). A major 
drawback of the current molecular methods for Brachyspira identification for avian intestinal 
spirochaetosis is that there are no current PCR primers to identify B. alvinipulli or B. innocens. 
However, with the increased availability of whole genome sequencing, designing PCR assays 
for less common or non-pathogenic Brachyspira strains will become increasingly feasible. 
Other molecular methods utilised to identify Brachyspira include restriction digestion of 
specific PCR products that result in species-specific banding patterns using gel electrophoresis 
(Barcellos et al., 2000; Rohde et al., 2002). 
Histological samples can be used to confirm the attachment of Brachyspira to the intestinal 
mucosa using the both haematoxylin and eosin staining and Warthin-Starry staining. 
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However, attachment of Brachyspira is not observed in all clinical cases, which is why 
combinations of diagnostic methods must be utilised. Fixed tissue can also be visualised using 
electron microscopy, although this is an expensive and time-consuming method of 
visualisation. Fluorescence in situ hybridisation can also be used as to support diagnosis of 
intestinal spirochaetosis. This method uses fluorescent oligonucleotide probes to visualise 
and localise Brachyspira associated with the intestinal mucosa in fixed tissue. This technique 
has been utilised in both animal and human samples and is advantageous in that it confirms 
the presence of Brachyspira and also shows where they are localised in the gastrointestinal 
tract (Boye et al., 1998; Jensen et al., 2000; Jensen et al., 2001).  
Finally, as whole genome sequencing techniques become more readily available, sequencing 
isolates will become more commonplace. This will not only improve the accuracy of 
Brachyspira diagnosis, but also aid with improving the understanding of these organisms.  
 
1.2.7 Treatment of avian intestinal spirochaetosis 
 
Brachyspira are susceptible to a range of antibiotics, however there are a limited number of 
antibiotics licensed for use in animal medicine and different countries have different 
legislation surrounding their use. Some of the most common antimicrobials used in the 
livestock industry to treat avian intestinal spirochaetosis are tiamulin, tylosin, 
chlortetracycline and lincomycin, with tiamulin and tylosin the only licensed antibiotics for 
use in the UK (Burch, 2011). Bacteriostatic antibiotics such as tiamulin and tylosin are the 
most effective against Brachyspira and target bacterial protein synthesis, although 
antimicrobial resistance to tylosin is increasing due to its previous use as an antibiotic growth 
promoter in swine feed (Hampson et al., 2006; Kim et al., 2016). Resistance to tylosin has 
been associated with mutations in the peptidyl transferase region of the 23S rRNA gene which 
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prevents tylosin binding (Karlsson et al., 2004). Tiamulin has been used in veterinary medicine 
for a considerable period of time, primarily in the swine industry (Taylor, 1980). Denagardâ 
Tiamulin (Novartis) is currently available for use in pigs and has more recently become 
available for use in the poultry industry for the treatment of avian intestinal spirochaetosis 
(Woodward et al., 2015). Another benefit of tiamulin is that it has a zero-day egg withdrawal 
period, and therefore treatment of avian intestinal spirochaetosis does not impact adversely 
on the egg industry. Tiamulin resistance is also associated with point mutations in the V 
domain of the 23S rRNA gene and in the L3 gene. These genes are within close proximity of 
the peptidyl transferase binding site of tiamulin and thus mutations in these genes may affect 
the efficacy of tiamulin (Pringle et al., 2004; Hidalgo et al., 2011). 
 
1.2.8 Interventions and prevention against avian intestinal spirochaetosis 
 
Interventions are required to control the spread of Brachyspira, especially as incidence of this 
organism can be up to 90% in flocks and disease is hard to diagnose, as previously discussed. 
Despite avian intestinal spirochaetosis being easily treated with antibiotics, antimicrobial 
resistance is emerging and there is an increased consumer demand for antibiotic free animal 
products. Therefore, it is essential to implement measures to prevent disease, not only to 
protect animal welfare, but also address consumer demands. 
 
1.2.8.1 Biosecurity  
 
Efficient biosecurity on farms is essential for controlling the introduction and spread of avian 
intestinal spirochaetosis. Wild birds and rodent reservoirs  require effective controls usually 
by  physical containment including security fencing, bird-proof netting around openings and 
rodent traps (Oxberry et al.,  1998; Backhans et al., 2010; Mappley et al., 2014). Disinfectant 
foot-dips are utilised to prevent transmission especially as Brachyspira have been shown to 
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have a wide host range (Hampson and Jamshidi, 2002). Furthermore, chickens have been 
shown to be infected with B. hyodysenteriae, which is not known to typically infect poultry, 
therefore biosecurity on multi-species farms is of paramount importance (Feberwee et al., 
2008). Other disinfectants such as iodine, chlorine, hydrogen peroxide and quaternary 
ammonium disinfectants have shown efficacy against Brachyspira in organic matter (Phillips 
et al., 2003; Corona-Barrera et al., 2004).  
 
1.2.8.2 Vaccines 
 
Vaccine development against intestinal spirochaetosis has been primarily focussed to 
alleviate swine dysentery, however vaccines have elicited varied responses (Hampson et al., 
1993). Autogenous vaccines for B. pilosicoli and B. intermedia have been tested in pigs and 
chickens and have demonstrated the ability to elicit antibody responses, although there are 
no commercially available vaccines. Despite primary and secondary antibody responses, 
these vaccines have not been able to reduce the intestinal colonisation Brachyspira (Hampson 
et al., 2000). Experimental vaccines in mice generated systemic and colonic IgG antibodies 
and after vaccination, mice were colonised for significantly fewer days compared to non-
vaccinated controls (Movahedi and Hampson, 2010). These studies suggested the potential 
for oligopeptide-binding proteins as constituents for vaccines, however, further testing would 
be required in experimental chicken studies.  
 
1.2.8.3 Essential oils and phytochemicals  
 
More recently the efficacy of essential oils and phytochemicals has been assessed for 
inhibitory capabilities against Brachyspira species. Phytochemicals have a long history of use 
in animal nutrition as an alternative to antibiotic growth promoters; their use is generally 
associated with decreased bacterial load (Franz et al., 2010; Grilli et al., 2015). Studies have 
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revealed that essential oils such as thymol and cinnamaldehyde were inhibitory against B. 
intermedia in vitro and in vivo and that their inhibitory effects were comparable to that of 
other Gram negative, enteric pathogens such as E. coli, Salmonella and Campylobacter 
(Verlinden et al., 2013). This study also demonstrated the potential of essential oils as an 
intervention for B. intermedia infection, with the bacterial numbers being significantly 
reduced compared to experimentally infected controls. Efficacy of compounds against B. 
hyodysenteriae was correlated to the carbon chain length (Maele et al., 2016). Short-chain 
fatty acids such as lactic and formic acid were associated with high MIC values and medium 
chain fatty acids such as thymol and carvacrol were associated with lower MIC values (Maele 
et al., 2016). Additionally, citrus fruit extracts such as BIOCITRO have demonstrated 
bactericidal and bacteriostatic activity against B. hyodysenteriae by damage of the cell 
membrane and induction of the formation of spherical bodies (de Nova et al., 2017).  
 
1.2.8.4 The introduction of probiotics to prevent avian intestinal spirochaetosis 
 
Probiotics have been shown to be effective against Brachyspira both in vitro and in vivo. L. 
rhamnosus and L. farciminis have shown the ability to antagonise the motility of Brachyspira 
through co-aggregation. SEM analysis demonstrated that Brachyspira are trapped in a 
physical network with the Lactobacillus (Bernardeau et al., 2009). Furthermore, the 
production of organic acids such as lactic acids have been shown to elicit stress responses in 
these pathogens (Bernardeau et al., 2009). Cell free supernatant has been shown to have a 
lethal effect on Brachyspira cells which was characterised by the perforation of the bacterial 
cell wall. Other stress responses, such as the formation of spherical bodies form in response 
to toxic chemicals and changes in environmental conditions as a result of lactic acid 
production (Bernardeau et al., 2009). It is proposed that this spherical body formation is an 
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important survival mechanism to protect the cells from adverse conditions, and cells have 
been shown to return to normal morphology when conditions improve (Wood et al., 2006). 
Additionally, homofermentative lactic acid bacteria such as L. salivarius, L. amylovorus, B. 
thermophilum and B. faecium have shown inhibitory abilities against both B. hyodysenteriae 
and B. pilosicoli. Both live cells and cell free supernatant have elicited inhibitory effects, 
however heterofermentative lactic acid bacteria such as L. reuteri have not shown inhibitory 
potential against Brachyspira (Klose et al., 2009; 2010). This is contrary to more recent 
research that has demonstrated inhibition of B. pilosicoli and B. innocens by L. reuteri and L. 
salivarius cells and their cell free supernatant in vitro (Mappley et al., 2011). Thus, 
demonstrating that probiotics are isolate specific, not species specific. Inhibition of 
Brachyspira was pH dependent and low pH cell free supernatant from Lactobacillus resulted 
in significant inhibition of Brachyspira. Additionally, in concurrence with the studies 
conducted by Bernadeau et al (2009), the motility of Brachyspira was shown to be inhibited 
by both viable and heat-inactivated Lactobacillus after four and twenty-four hours of contact 
time. L. reuteri and L. salivarius isolates were also able to significantly reduce the adherence 
of Brachyspira to intestinal epithelium cells in vitro and ex vivo (Mappley et al., 2011). In 
addition to these in vitro studies, further in vivo studies aimed to determine if the L. reuteri 
isolate used in Mappley et al (2011) would improve hen health following experimental 
infection with B. pilosicoli. The results showed decreased faecal moisture, decreased faecal 
staining on eggs, decreased Brachyspira colonisation and decreased pathology associated 
with disease, in addition to increased egg weights in birds pre-treated with L. reuteri (Mappley 
et al., 2013).  
Whilst there have been several reports of the efficacy of probiotics against Brachyspira and 
avian intestinal spirochaetosis specifically, there is a clear need to generate a greater 
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understanding of lactic acid bacteria such as Lactobacillus and their interaction with 
Brachyspira if we are to fully exploit their potential to contribute to control measures.  
 
1.3 Lactobacilli and their potential as probiotics 
 
1.3.1 The genus Lactobacillus  
 
The Lactobacillus (lac “milk” and bacillum “small rod”) genus is assigned to the 
Lactobacillaceae family, in the order Lactobacillales and class Bacilli, which belongs to the 
Firmicutes phylum. Lactobacillus species are Gram positive, rod-shaped, non- spore forming, 
non-motile, fermentative, facultative anaerobes. Lactobacilli can be either hetero- or 
homofermenters, depending on their species. Heterofermenters such as Lactobacillus reuteri 
ferment sugars such as glucose to produce lactic acid in addition to carbon dioxide, ethanol 
and acetic acid via the pentose phosphate pathway, whereas homofermenters such as 
Lactobacillus crispatus and Lactobacillus salivarius ferment glucose to produce lactic acid via 
the glycolysis pathway (Caplice and Fitzgerald, 1999). 
These bacteria are abundant commensals in the gastrointestinal tracts of bird and mammals, 
in addition to being exploited for the production of fermented food products such as cheese 
and yogurt. Lactobacillus species are widely used as probiotics in human and veterinary 
medicine to promote good gastrointestinal health and have many known benefits.  
 
1.3.2 What are probiotics and why are they important? 
 
Probiotics (pro “for” and biotic “life”) are defined as “live microorganisms that confer health 
benefits on the host when administered in adequate quantities” (FAO/WHO, 2002). Probiotic 
bacteria such as Lactobacillus are natural colonisers of both mammalian and avian 
gastrointestinal tracts and are generally recognised as safe (GRAS) for consumption. 
Probiotics work on the assumption that a healthy gastrointestinal microbiota can confer 
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health benefits. They are an important alternative to the use of antimicrobials, especially in 
livestock and have the potential to aid in the protection of the gastrointestinal tract, not only 
from pathogens, but also from stress related disease. It is important to note that probiotics 
are notoriously strain specific, thus, extensive research into specific probiotic strains against 
specific pathogens is required to provide sufficient evidence for their efficacy. 
 
1.3.3 Probiotic use in poultry  
 
Probiotics have been used extensively in the poultry industry since the 1970s. The research 
conducted by Rantala and Nurmi (1973) first described the use of probiotic bacteria to protect 
chicks from infection with Salmonella Infantis. This study introduced the concept of 
competitive exclusion, whereby two-day old chicks were pre-treated with the gastrointestinal 
contents from healthy, mature chickens, to protect from challenge with Salmonella (Rantala 
and Nurmi, 1973). There are also numerous studies that have demonstrated the competitive 
exclusion effects of probiotics against avian pathogens such as Campylobacter jejuni, 
Salmonella Typhimurium and E. coli (Weinack et al., 1981; Schoeni and Wong, 1994; 
Revolledo et al., 2006; Zhang et al., 2007). 
The use of probiotics in poultry aims to restore or beneficially alter the microbiota in animals, 
particularly those that are young, stressed or have been treated with antibiotics (Collins et 
al., 2009). The microbiota of conventionally reared birds does not stabilise until 4-6 weeks of 
age (Mead, 1989) and studies have suggested that the timing of probiotic administration can 
be essential to their protective effects. For example, L. reuteri administration in the first week 
of life may be able to impact the abundance of Lactobacillus in the avian gastrointestinal tract, 
in addition to protecting against pathogens after 6 weeks of age (Nakphaichit et al., 2011). 
Furthermore, intensification of poultry farming can induce stress in animals which can have a 
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direct effect on the gastrointestinal tract, reducing productivity and growth rates. 
Lactobacillus probiotics have demonstrated the ability to increase and diversify the intestinal 
microbiota following heat stress, which may contribute to promoting a healthy intestinal flora 
and reducing the effects of stress in poultry flocks (Lan et al., 2004). 
There are a number of probiotics available, some of which are well defined in terms of the 
probiotic strains used, and others which are undefined. Products such as Protexin Pro- 
Solubleâ are well defined and consist of Enterococcus faecium NCIMB 10415, which has been 
shown to increase the feed conversion, growth and concentration of lactic acid bacteria in 
the gastrointestinal tract of birds (Samli et al., 2007). Whereas products such as Aviguardâ 
contain undefined organisms from the gastrointestinal tracts of healthy, pathogen free birds. 
Despite being undefined, there is sufficient evidence to suggest that this product can reduce 
the colonisation of pathogens such as E. coli and Salmonella through competitive exclusion 
(Nakamura et al., 2002; Hofacre et al., 2009). Typically, probiotics for use in animals are 
Enterococcus, Bacillus or Saccharomyces species, whereas Lactobacillus and Bifidobacterium 
species are typically consumed by humans, but are gaining more interest in the poultry 
industry (Simon et al., 2001). 
 
1.3.4 Lactobacillus probiotics in poultry 
 
Lactobacillus are present throughout the chicken gastrointestinal tract and are often the 
dominant genus isolated (Stanley et al., 2014). Within this genus, the most abundant species 
of Lactobacillus are L. crispatus, L. reuteri and L. salivarius (Hilmi et al., 2007).  
Research regarding the efficacy of Lactobacillus probiotics for the prevention of Brachyspira 
is still very much in its infancy. However, the use of probiotics in poultry production to 
mitigate common pathogens such as E. coli, Salmonella and Campylobacter is well 
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established. Therefore, there is potential to develop suitable probiotics to prevent 
Brachyspira. 
 
1.3.5 Guidelines for the characterisation of bacteria intended for probiotic use 
 
There are clear guidelines set out by the European Union for the characterisation of 
microorganisms intended for use as animal feed additives (EFSA et al., 2017). These support 
the use of whole genome sequencing as the gold standard for the “unambiguous” 
identification of organisms, in addition to screening for antimicrobial resistance, toxin and 
virulence factor genes.  
To be considered as a suitable probiotic for animal feed supplementation, a microorganism 
needs to be on the qualified presumption of safety (QPS) list, which stipulates the species of 
microorganisms that are considered to be safe for use as animal feed additives (EFSA, 2013). 
Furthermore, phenotypic antimicrobial sensitivities must be determined, in addition to 
screening for the presence of AMR genes to ensure that isolates do not possess genes that 
could be transferrable to other bacteria in the gastrointestinal tract. The break-points for 
Gram positive bacteria are transparent and well defined in this legislation, thus ensuring the 
robust characterisation of bacterial isolates for use as potential feed additives. It is also 
recommended that the ability of isolates to produce antimicrobial metabolites is determined. 
This can be achieved using cell free supernatant (CFS) studies to investigate whether there 
are any inhibitory affects against a pathogen. If inhibition is observed, the inhibitory 
metabolite(s) should be identified where possible. In addition to the in vitro and in silico 
interrogation of bacterial isolates and their genome sequences, it is recommended that in 
vivo studies are carried out to determine the impact on the gut microbiota in the desired host 
and to ensure any additional additives are compatible with other additives already 
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administered in animal feed. The EFSA guidelines were established to provide standardised 
guidelines to ensure the safety of microbial products that are fed to livestock and may 
ultimately enter the human food chain. Furthermore, these guidelines work towards ensuring 
the safety of bacterial products before they are widely distributed in feed (EFSA et al., 2017). 
 
1.3.6 Proposed mechanisms of probiotic action  
 
1.3.6.1 Competitive exclusion  
 
Competitive exclusion is described as the exclusion of a pathogen from an ecological niche by 
out competition by a probiotic (Callaway et al., 2008; Collins et al., 2009). The term 
competitive exclusion was first demonstrated in 1973 (Rantala and Nurmi, 1973). Since then, 
probiotic bacteria have been well researched as competitive exclusion products against many 
common poultry pathogens such as E. coli, Salmonella and Campylobacter (Weinack et al., 
1981; Schoeni and Wong, 1994; Mead, 2000; Revolledo et al., 2006; Zhang et al., 2007). 
Additionally, recent studies have shown promise for probiotics as potential competitive 
exclusion products for Brachyspira (Mappley et al., 2013). 
In studies to investigate the potential for Lactobacillus probiotics to antagonise Brachyspira, 
potential Lactobacillus probiotics demonstrated the ability to co-aggregate with Brachyspira 
(Bernardeau et al., 2009; Mappley et al., 2011). This physical interaction between bacteria is 
proposed to antagonise the growth, motility and adherence capabilities of Brachyspira, thus 
impairing its ability to colonise the caeca and/ or large intestine, in addition to having a direct 
effect on motility and chemotaxis (Mappley et al., 2011). Following on from this research, 
Mappley et al. (2013) were the first to demonstrate that Lactobacillus, namely L. reuteri LM1, 
had the ability to antagonise B. pilosicoli in vivo. Competitive exclusion was proposed as a 
mechanism of Brachyspira inhibition as L. reuteri reduced the colonisation of B. pilosicoli and 
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the associated pathology. However, it is also important to consider other inhibitory 
mechanisms such as production of acids and antimicrobial compounds, discussed in this 
chapter.  
 
1.3.6.2 Production of organic acids 
 
Lactobacillus produce organic acids that have been shown to induce stress responses in 
pathogenic bacteria and have a direct inhibitory effect. Both homo- and heterofermentative 
Lactobacillus species produce organic acids as a result of glucose fermentation and can 
mediate the pH of the gastrointestinal tract, in additional to having direct effects on the 
intestinal mucous and bacterial numbers (Skrivanová and Marounek, 2007).  
Organic acids have been utilised as poultry feed and water additives for many years, as an 
alternative to antibiotic growth promoters (Khan and Iqbal, 2016). In the UK, formic, propionic 
and lactic acid are regularly used to acidify feed (Collins et al., 2009) and the primary objective 
of this acidification is to reduce the numbers of pathogenic bacteria in the gastrointestinal 
tract. The addition of organic acids to poultry feed is generally considered as safe (GRAS) by 
the European Union and studies have suggested that this supplementation has beneficial 
effects directly on the host. For example, histological analysis of the small intestine has 
suggested that organic acids can significantly increase villus height, subsequently facilitating 
nutrient absorption and therefore the performance of chickens (Adil et al., 2010). These 
histological alterations are proposed to be as a result of reducing the numbers of intestinal 
bacteria, thus decreasing the inflammatory responses in the intestinal mucosa, which 
promotes increased villus height.  
Additionally, organic acids are commonly used to directly inhibit pathogenic bacteria such as 
E. coli, Salmonella and Campylobacter (Van Immerseel et al., 2006; Naseri et al., 2012). At a 
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low pH, organic acids will be undissociated and therefore lipophilic and can diffuse across the 
bacterial cell membrane, reducing the pH of the cell, resulting in cell death (Skrivanová and 
Marounek, 2007). Furthermore, organic acids have been shown to cause stress responses in 
Brachyspira species, resulting in the formation of spherical bodies and damage to the cell 
membrane (Bernardeau et al., 2009). Lactic acid is the major metabolite produced by 
Lactobacillus isolates and has been shown to be a potent membrane permeabiliser, causing 
sub-lethal damage to bacterial cells (Alakomi et al., 2000; Fayol-Messaoudi et al., 2005). 
 
1.3.6.3 Production of antimicrobial metabolites 
 
In addition to pH dependent inhibition of bacteria in the gastrointestinal tract, pH 
independent mechanisms are proposed to effectively inhibit pathogenic bacteria. 
Mechanisms of inhibition include the production of bacteriocins, the production of hydrogen 
peroxide and the production of other secondary metabolites such as reuterin. 
Bacteriocins are ribosomally synthesised, antimicrobial peptides produced by Lactobacillus 
species that were initially believed to be inhibitory against other closely related Gram positive 
organisms. However, there is also evidence to suggest that they are capable of inhibiting 
Gram negative bacteria (Cotter et al., 2005; Messaoudi et al., 2013). Many Lactobacillus 
isolates produce different bacteriocins, which are separated in to three main groups: Class I 
lantibiotics, Class II bacteriocins and Class III bacteriocins, which are now known as 
bacteriolysins. Class I lantibiotics contain the unusual amino acids, lanthionine and b- 
methyllanthionine and these proteins undergo posttranslational modification during 
maturation. These bacteriocins exhibit antimicrobial activity against closely related Gram 
positive bacteria, and rarely inhibit Gram negative bacteria (Lee and Kim, 2011). Nisin is a 
common Class I bacteriocin used in food preservation and forms pores in bacterial cell 
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membranes, resulting in cell death (Garg et al., 2014). Class II bacteriocins are non- 
lanthionine containing bacteriocins and are more commonly produced than Class I 
bacteriocins. Class II bacteriocins are small (< 10KDa), heat-stable proteins that do not 
undergo extensive posttranslational modification (Yang et al., 2014). The mechanism of 
action of Class II bacteriocins is similar to that of Class I, in that they permeabilise the cell 
membrane of the target bacterial cell, resulting in the efflux of metabolites from the target 
cell and subsequent cell death (Ennahar et al., 2000). The final class of bacteriocins are the 
bacteriolysins, these are high molecular weight, heat-labile proteins which are sub-divided 
into two distinct groups: group A and group B. Group A are bacteriolytic proteins such as 
Enterolysin A, which kill the target cell through lysis of the bacterial cell wall of sensitive cells 
(Khan et al., 2013). Group B are non-bacteriolytic proteins such as Helveticin J, that have a 
bactericidal effect on target cells (Joerger and Klaenhammer, 1986).  
Other inhibitory metabolites produced by Lactobacillus species include reuterin, from some 
L. reuteri isolates and hydrogen peroxide production. Reuterin is a broad-spectrum 
antimicrobial produced by some isolates of L. reuteri and is an example of a secondary 
metabolite produced by L. reuteri in the absence of glucose, the preferred energy source. 
Reuterin is produced when cells metabolise glycerol as the primary carbon source and has 
exhibited a range of inhibitory activity against foodborne pathogens such as E. coli and L. 
monocytogenes (Rodríguez et al., 2003). Hydrogen peroxide can be produced by some 
Lactobacillus species, namely L. acidophilus, L. gasseri, L. johnsonii and L. reuteri and is 
cytotoxic to a range of pathogens including S. Typhimurium and E. coli in vitro (ÜNlütürk and 
Turantasl, 1987; Asad et al., 2004). The antimicrobial effect has been attributed to the 
production of reactive oxygen species from its dissociation and subsequent damage to 
bacterial DNA (Halliwell, 1978).  
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1.3.6.4 Promotion of intestinal health and immunomodulation  
 
The gastrointestinal tract and the immune system form a complex, integrated structure that 
has evolved to not only digest food, but also as the first line of defence against ingested 
pathogenic bacteria. The natural microbiota of the gastrointestinal tract is important in 
forming both a physical and immunological barrier between the host and its environment, to 
maintain good intestinal health (Delcenserie et al., 2008). A healthy gastrointestinal tract is 
essential for preventing disease and improving the welfare of livestock. 
Due to the interactions between the gastrointestinal tract and the immune system, the 
immunomodulatory properties of probiotic bacteria have been proposed. Probiotic bacteria 
are known to influence the production of cytokines from intestinal epithelial cells and innate 
immune cells in vitro (Haller et al., 2000; Zhang et al., 2005; Ma et al., 2011). This can be 
achieved through a number of mechanisms. Firstly, probiotic isolates have demonstrated the 
ability to activate macrophages and lymphocytes and influence phagocytosis by macrophages 
in a strain dependent manner, in a murine model (Perdigón et al., 1988). This has the potential 
to improve the immune response to pathogenic bacteria by priming the immune system. 
Secondly, probiotic bacteria have been shown to modulate immune responses of the innate 
immune system by acting on pathways such as the Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) and NFkB pathways. Lactobacillus isolates have 
demonstrated the ability to inactivate these pathways, resulting in the downregulation of 
important pro-inflammatory cytokines such as IFNg and IL6 (Lee et al., 2010; Llewellyn and 
Foey, 2017). Probiotics are also known to produce suppressor of cytokine signalling (SOCS) 
proteins.  These proteins also inhibit the JAK/STAT pathway, in addition to TLR4 mediated 
cytokine responses (Dimitriou et al., 2008), subsequently resulting in the downregulation of 
pro-inflammatory cytokines.  
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1.4 Project Rationale  
 
The understanding of Brachyspira pathogenesis and disease may have been hampered by the 
absence of suitable infection models and mutagenesis strategies. While there have been a 
number of experimental infections using chicken models, resultant disease and pathology 
have been varied and do not provide sufficient data on the mechanisms of disease or the 
virulence of specific isolates. Furthermore, there are a number of ethical and scientific 
limitations of this model. For example, animal experimental models are tightly regulated and 
require specialist staff and research facilities which are often unavailable. Therefore, 
alternative models of infection need to be considered to allow for more detailed mechanistic 
studies, such as those presented in this thesis. Moreover, the paucity of knowledge of the 
Brachyspira genome has also resulted in the relatively poor understanding of these organisms 
and their pathobiology. 
 
1.4.1 Tissue culture models 
 
Immortalised cell lines are frequently utilised to study enteric bacterial pathogens such as E. 
coli, Salmonella and Campylobacter (Finlay and Falkow, 1990; Everest et al., 1992; Jung et al., 
1994). The use of the HT29-16E colonic cell line has recently been developed for the study of 
Brachyspira adhesion and invasion and to determine the efficacy of probiotic interventions 
(Mappley et al., 2011). In addition to the availability of human intestinal cells lines, avian cell 
lines are becoming more readily available, although to date a widely available commercial 
avian intestinal cell line is not available. However, the availability of the HD11 avian 
macrophage cell line has allowed the study of immune interactions with organisms such as 
Salmonella and Campylobacter to be investigated (Withanage et al., 2004; Smith et al., 2005; 
Chiang et al., 2009). This cell line was derived from chicken haematopoietic cells which were 
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infected with avian leukaemia virus. These cells have macrophage-like properties; they 
express Fc receptors, are capable of phagocytosis and express macrophage cell surface 
antigen (Beug et al., 1979). 
 
1.4.2 Galleria mellonella infection model 
 
Brachyspira virulence has not been extensively investigated due to the lack of and poor 
accessibility to suitable in vivo models and the restrictions surrounding them, as previously 
discussed. In order to attempt to develop a suitable in vivo model, the G. mellonella model 
was explored to assess the suitability for use as a model for Brachyspira infection. This model 
has been shown to be powerful and reliable for the study of bacterial virulence and treatment 
of a range of pathogens in the context of a functional immune system (Desbois and Coote, 
2012; Betts et al., 2017; Jønsson et al., 2017; Mehat et al., 2018). Additionally, it has received 
considerable interest due to its simplicity, availability and few ethical issues surrounding its 
use (Desbois and Coote, 2012) (Figure 1.6).  
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G. mellonella are capable of a cellular immune response, mediated by haemocytes in the 
haemolymph of the larvae. These cells are phagocytic in nature and have a number of 
functional similarities to mammalian neutrophils, which are analogous with avian heterophils 
(Brooks et al., 1996). This is important for Brachyspira infection models as this pathogen can 
infect both mammalian and avian hosts. Haemocytes primarily kill pathogens through 
respiratory burst and the production of superoxide, in addition to the production of 
antimicrobial peptides (Kavanagh and Reeves, 2004). An advantage of this model is that the 
immune response can be measured; the response to LPS and peptidoglycan activates the 
phenoloxidase cascade, which leads to the production of melanin. The extent of melanin 
production is often directly associated with bacterial load and results in a colour change in 
the larvae (Desbois and Coote, 2012), whereby a cream colour indicates no melanin 
production and dark brown indicates production, as shown in Figure 1.7. Melanin 
Figure 1. 6 (A) Healthy G. mellonella larvae at the instar larval stage. (B) Larvae are typically injected 
into the prolegs. For single injections, they are typically injected with a pathogen in the right proleg, 
for multiple injections used in these studies, one injection was into the right proleg and one into 
the left. (C) Larvae are typically injected with a Hamilton syringe in to the proleg.   
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encapsulates the invading pathogen and prevents proliferation (Söderhäll and Cerenius, 
1998).  
 
 
 
 
 
 
 
 
 
 
In these studies, this model represented a systemic infection and not a model of 
gastrointestinal infection. Brachyspira has been shown to cause systemic infection in both 
humans and in experimentally infected chickens, and therefore this is a relevant model to 
begin to elucidate the virulence of Brachyspira species in vivo. Although, there is an 
understanding that results need to be supported by follow up in vivo studies with a more 
relevant host.  
 
1.4.3 A Metabolomics Approach 
 
The use of nuclear magnetic resonance spectroscopy (NMR) to identify small metabolites in 
the cell free supernatants of Lactobacillus has been described in previous studies (Parolin et 
al., 2015; Nardini et al., 2016). These studies have begun to elucidate the metabolites that 
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Figure 1. 7 Images of G. mellonella larvae showing different degrees of melanisation. A score of 0 
indicates no melanisation, a score of 1 indicates melanisation at down the tail line, a score of 2 
indicates spots of melanisation through the body and a score of 4 indicates complete melanisation 
and death. Melanisation is the synthesis and deposition of melanin to encapsulate pathogens 
during infection. Adapted from Tsai et al. (2016) 
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may be contributing to pathogen inhibition. In the studies presented in this thesis, the 
metabolites produced by Lactobacillus were investigated in order to explore the mechanisms 
of Brachyspira inhibition that were originally identified by Mappley et al. (2011). 
Proton NMR (1H- NMR) analyses the different types of hydrogen present in a molecule and 
how these hydrogen atoms relate to other atoms in the molecule. It exploits the magnetic 
properties of atomic nuclei and works on the principle that nuclei with an odd atomic number, 
such as those in hydrogen, have nuclear spin. In the absence of a magnetic field, the nuclear 
spins of hydrogen are randomly orientated. However, when NMR applies an electromagnetic 
field, the nuclear spin either aligns with or against the magnetic field. The more highly 
populated alignment is known as the lower energy state. Electromagnetic radiation is used 
the ‘flip’ this alignment from the low energy state, to the high energy state. Removing the 
electromagnetic radiation allows the nuclei to return to their normal energy state, emitting a 
small magnetic field. This signal is collected and converted to peaks on the NMR spectrum. 
The basic arrangement of the NMR spectrometer is illustrated in Figure 1.8: the sample for 
analysis is positioned in a magnetic field and excited with radio frequency. The aligned 
hydrogen atoms produce a radio frequency which is used to generate an output signal, and 
this signal is then converted into an NMR spectra (as presented in Chapter 6). The spectra 
generated is a plot of the radio frequency or chemical shift against the absorption the energy 
applied.  
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Figure 1. 8 The basic arrangement on an NMR spectrometer. The sample is placed 
in a magnetic field and excited with radio frequency. The alignment of hydrogen 
atoms with the atomic field produces a radio frequency output signal which is 
translated into the NMR spectra presented in Chapter 6. 
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1.5 Project aims and hypothesis  
 
As discussed throughout this chapter, Brachyspira infection and avian intestinal 
spirochaetosis have a significant impact on the welfare of animals and cost the UK laying 
industry in excess of £18 million each year. Since the ban of antibiotic growth promoters in 
the EU in 2006 the prevalence of Brachyspira has increased and there are only limited licenced 
antibiotics for treatment. Therefore, it is essential that preventative measures are employed 
to improve animal health and reduce incidence of disease, in addition to protecting the 
antibiotics available to treat infection. Probiotics have demonstrated suitability as potential 
interventions against Brachyspira, however mechanisms of action have yet to be fully 
elucidated. Moreover, there is a paucity of knowledge surrounding the pathobiology of 
Brachyspira. Therefore, a more comprehensive understanding of the genetic and phenotypic 
capabilities of Brachyspira may be able to identify novel probiotic interventions to reduce the 
incidence of avian intestinal spirochaetosis.  
The hypothesis of this project was that Lactobacillus probiotics would be a suitable mitigation 
strategy for avian intestinal spirochaetosis caused by Brachyspira species. 
The main aims of this project were therefore to investigate Lactobacillus probiotics as an 
intervention against Brachyspira infection and to elucidate these mechanisms of inhibition. 
This was achieved through the following objectives: 
• To characterise phenotypically and genotypically a panel of Brachyspira isolates, 
including all species involved in avian intestinal spirochaetosis (discussed in chapters 
3 and 4). 
• To isolate and characterise a panel of Lactobacillus probiotic candidates from healthy 
chickens in accordance with the European guidelines and determine their inhibitory 
capabilities against Brachyspira isolates (discussed in chapter 5). 
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• To elucidate the mechanisms attributed to the inhibition of Brachyspira by way of 
analysing the Lactobacillus cell free supernatant for inhibitory metabolites and 
investigating the effects of co-aggregation of the two bacteria in co-culture (discussed 
in chapter 6) 
• To develop an in vitro tissue culture model to investigate the avian macrophage 
immune responses to Brachyspira species (discussed in chapter 7) 
o To investigate how a probiotic intervention may impact these responses.  
• To develop an in vivo Galleria mellonella model to study the virulence of Brachyspira 
species (discussed in chapter 7). 
o To investigate how a probiotic intervention may be able to protect the G. 
mellonella following Brachyspira infection.  
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Chapter 2: Materials and Methods 
 
2.1 Bacteriological Methodology  
 
2.1.1 Brachyspira bacterial isolates and culture conditions 
 
A panel of thirteen UK poultry Brachyspira isolates were assembled for use in the studies 
presented here. All strains were isolated from clinical cases of avian intestinal spirochaetosis 
(AIS). These isolates represented the four species implicated in poultry disease and are 
detailed in Table 2.1. For all studies, the Brachyspira isolates were cultured on fastidious 
anaerobic blood agar (FABA) (LAB M) supplemented with 5% sheep blood or Brachyspira 
selective agar (BSA), consisting of blood base agar number 2 (Oxoid), supplemented with 5% 
sheep blood, spectinomycin (800µg/ml), colistin (25µg/ml) and vancomycin (25µg/ml) 
(Sigma-Aldrich) (Råsbäck et al., 2005). Where broth cultures were required Brachyspira were 
transferred from the surface of an agar plate into brain heart infusion broth (BHI), 
supplemented with 10% (v/v) foetal bovine serum (FBS) (Sigma- Aldrich). Brachyspira were 
cultured anaerobically in an anaerobic cabinet (Don Whitley Scientific) (10% hydrogen, 10% 
carbon dioxide and 80% nitrogen) at 37°C for 3-5 days.  
Brachyspira stock cultures were stored at -80°C in FBS supplemented with 30% Brachyspira 
enrichment broth (BEB), consisting of tryptone soya broth (Oxoid), supplemented with 10% 
DL-cysteine hydrochloride (Sigma- Aldrich), 10% glucose and 10% FBS.  
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Table 2. 1 Brachyspira isolates used in this project 
Brachyspira Species Isolate Name Species of Isolation Source1 
B. alvinipulli* ATCC 51933 Chicken ATCC Collection (Swayne 
et al., 1995) 
B. alvinipulli SAP 945 Chicken  University of Surrey 
B. innocens* SAP 927 Chicken  University of Surrey 
B. innocens* SAP 924 Chicken University of Surrey 
B. innocens* SAP 943 Chicken  University of Surrey 
B. intermedia SAP 891 Chicken  University of Surrey 
B. intermedia*  SAP 919 Chicken  University of Surrey 
B. intermedia SAP 866 Chicken  University of Surrey 
B. pilosicoli* B2904 Chicken APHA (Mappley et al., 
2012) 
B. pilosicoli* SAP 865 Chicken  University of Surrey 
B. pilosicoli*  SAP 859 Chicken  University of Surrey 
B. pilosicoli  SAP 903 Chicken  University of Surrey 
B. pilosicoli SAP 868 Chicken  University of Surrey 
1 Source: American Type Culture Collections, Virginia, University of Surrey, Guildford, United Kingdom, 
APHA, Animal and Plant Health Agency, Addlestone, United Kingdom. 
* Brachyspira isolates fully characterised and used throughout the project. 
 
 
2.1.2 Lactobacillus bacterial isolates and culture conditions 
 
A panel of seventeen poultry derived Lactobacillus isolates were assembled for the studies 
presented here. The isolates are detailed in Table 2.2. All isolates were isolated from the 
faeces of healthy chickens at the start of the project. Lactobacillus isolates were grown on 
Man-Rogosa-Sharpe (MRS) agar and in MRS broth (Oxoid) anaerobically in an anaerobic 
cabinet at 37°C for 18 hours.  
Lactobacillus stock cultures were stored in MRS broth supplemented with 30% (v/v) glycerol 
at -80°C.  
Heat-inactivated Lactobacillus were prepared by resuspending each Lactobacillus isolate in 
0.1M sterile phosphate buffered saline (PBS) at the required cell density, determined by 
optical density (OD) and heating aliquots at 95°C for 20 minutes. 
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Lactobacillus cell free supernatants (CFS) were prepared by centrifuging 18-hour broth 
cultures of each Lactobacillus isolate (109 CFU/ml) at 3000 x g for 10 minutes at ambient 
temperature, followed by filter-sterilisation through a 0.2µm filter (Fisher-Scientific) yielding 
CFS. The pH of each CFS ranged from 3.8-4.5, depending on the isolate, therefore the pH was 
adjusted to 3.8, 4.5 and 7.2 for inhibition assays using 1M sodium hydroxide or 1M 
hydrochloric acid (Sigma-Aldrich) to investigate both pH dependent and independent 
mechanisms of inhibition.  
To further investigate the pH independent mechanism is inhibition, Lactobacillus CFS samples 
were incubated with 200µg trypsin for one hour at 37°C to denature heat-stable proteins. 
Additionally, CFS samples were heat treated at 120°C for 20 minutes to denature heat-labile 
proteins in the CFS.  
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Table 2. 2 Lactobacillus isolates presented in this project 
Lactobacillus Species 
 
Isolate Name Species of Isolation 
L. agilis SAP 2104 Chicken 
L. crispatus* SAP 2105 Chicken 
L. crispatus* SAP 2106 Chicken 
L. crispatus* SAP 2107 Chicken 
L. crispatus SAP 2109 Chicken 
L. crispatus SAP 2110 Chicken 
L. crispatus SAP 2111 Chicken 
L. mucosae SAP 2102 Chicken 
L. reuteri* SAP 2108 Chicken 
L. reuteri** SAP 2114 Chicken 
L. reuteri** SAP 2115 Chicken 
L. salivarius* SAP 2103 Chicken 
L. salivarius SAP 2112 Chicken 
L. salivarius* SAP 2113 Chicken 
L. salivarius** SAP 2116 Chicken 
L. salivarius** SAP 2117 Chicken 
L. salivarius* SAP 2118 Chicken 
* Lactobacillus isolates sent for whole genome sequencing.  
** Lactobacillus isolates identified and characterised as potential probiotics.  
 
 
2.1.3 Other bacterial isolates and culture conditions 
 
E. coli K12, avian pathogenic E. coli isolates A1, B1 and B3 (APEC), Salmonella Typhimurium 
SAP 16 and Enterococcus faecalis ATCC 29212 were obtained from the Surrey Animal 
Pathogen (SAP) collection. Isolates were cultured on nutrient agar (NA) or nutrient broth 
aerobically at 37°C for 18 hours. 
Stock cultures were stored in nutrient broth supplemented with 30% (v/v) glycerol at -80°C. 
 
2.1.4 Isolation of Lactobacillus from chicken faeces 
 
All Lactobacillus isolates were isolated from the faeces of healthy free-range laying hens in 
the UK. Faeces was enriched in MRS broth for 4 hours, anaerobically at 37°C, followed by 
culture on MRS agar in an anaerobic cabinet at 37°C for 48 hours. Single colonies of differing 
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morphology were selected and sub-cultured on three separate occasions on to MRS agar to 
ensure purity for further characterisation.  
2.1.5 Identification and Characterisation of Brachyspira  
 
2.1.5.1  Gram stain 
 
A suspension of Brachyspira in 0.1M sterile PBS was prepared and a smear was made on a 
glass slide, which was then heat-fixed and 1% (w/v) crystal violet added at ambient 
temperature for 30 seconds. The slide was washed with water and Lugol’s iodine solution 
added for 30 seconds, after which IMS was added for 3 seconds. The counterstain, safranin 
was added for 60 seconds and then the slide was washed with water and air-dried.  Slides 
were examined under oil immersion light microscopy, where the pink Gram stain and 
spirochaete morphology of Brachyspira were determined.  
 
2.1.5.2 Warthin- Starry silver stain 
 
A suspension of Brachyspira in 0.1M sterile PBS was prepared and a smear was made onto a 
glass slide and heat-fixed. Slides were placed in 1% silver nitrate and incubated for one hour 
in a water bath at 56°C. Slides were placed in a solution of 2% silver nitrate, gelatin and 
hydroquinone until staining appeared golden brown (1-3 minutes). Slides rinsed with warm 
water and dehydrated using 100% ethanol before coverslips were mounted.  
Slides were examined under light microscopy to determine spirochaete morphology.  
 
2.1.5.3 α-Glucosidase, β-glucosidase and α-galactosidase activity tests 
 
A suspension of Brachyspira in 0.1M sterile PBS (≥ McFarland 4.0) was prepared by 
transferring surface growth from FABA agar using a sterile swab. Three aliquots of the 
suspension were transferred into separate universal tubes and an α- glucosidase (p-
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nitrophenyl-α-D-glucopyranoside), β-glucosidase (p-nitrophenyl-β-Dglucopyranoside) or α-
galactosidase (p-nitrophenyl-α-D-galactopyranoside) diatab (Rosco Diagnostics) was added to 
each. The suspensions were incubated anaerobically at 37˚C for 16 hours. Results were 
recorded whereby a yellow colour change was regarded as positive and no colour change as 
negative for the respective enzyme activity. 
 
2.1.5.4 Hippurate test 
 
A suspension of Brachyspira in 1% (w/v) sodium hippurate solution (Sigma-Aldrich) (≥ 
McFarland 2.0) was prepared by transferring surface growth from FABA agar using a sterile 
swab. The suspensions were incubated anaerobically at 37˚C for 24 hours, after which 150 µl 
API NIN (ninhydrin) reagent (BioMérieux) was added. Following 10-minute incubation at 
ambient temperature, results were recorded whereby a blue-purple colour change was 
regarded as positive and a clear-orange colour change as negative for the ability to hydrolyse 
sodium hippurate to glycine and sodium benzoate. 
 
2.1.5.5 Indole test 
 
A suspension of Brachyspira in BHI + 10% FBS (≥ McFarland 4.0) was prepared by transferring 
surface growth from FABA agar using a sterile swab. The inoculated BHI broth was incubated 
anaerobically, at 37˚C for 24 hours, after which 150 µl API JAMES (Kovac’s) reagent 
(BioMérieux) was added. Following a 10-minute incubation at ambient temperature, results 
were recorded whereby the formation of a pink-red pellicle was regarded as positive and a 
yellow pellicle as negative for the ability to cleave indole from tryptophan. 
 
2.1.5.6 Antimicrobial sensitivity testing of Brachyspira isolates  
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Antimicrobial sensitivity testing of all Brachyspira isolates were performed using the broth 
microdilution method.  
An antimicrobial doubling series for gentamicin, tylosin and chlortetracycline (Sigma-Aldrich) 
ranged from 0.125- 128 µg/ml, for lincomycin (Sigma-Aldrich) 0.0625- 64 µg/ml and for 
tiamulin (Sigma-Aldrich) 0.008- 0.25 µg/ml. Antimicrobial 10× stock solutions were prepared 
in accordance to the manufacturer’s instructions and diluted to double the desired working 
concentration for each antimicrobial, these were filter sterilised using a 0.2µm filter. 
Antimicrobials were double diluted into BHI broth + 10% FBS (Karlsson et al., 1999) to support 
the growth of Brachyspira, 100µl of Brachyspira cell suspension at a concentration of 106 
CFU/ml was added to each well of a 96 well plate and incubated anaerobically at 37°C for 3-
4 days. The MIC was recorded as the lowest antimicrobial concentration to inhibit the growth 
of Brachyspira. Each assay was repeated in triplicate with three biological repeats. 
 
2.1.5.7 Brachyspira growth curves 
 
Brain heart infusion (BHI) broth supplemented with 10% FBS was prepared by transferring 
surface growth from FABA agar using a sterile swab to yield a concentration of 106 CFU/ml. 
100µl of each broth was transferred into a 96 well plate. Plates were incubated in an 
anaerobic cabinet for 5 days at 37°C. Optical density (OD620) readings were taken every 10 
hours for the duration of experiment using a Tecan Spark 10 plate reader (Tecan). Bacteria 
were enumerated using a Helber counting chamber under dark field microscopy (x40) every 
24 hours. Each assay was repeated in triplicate with five biological repeats. 
 
2.1.5.8 Biolog Phenotypic MicroarrayTM 
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The metabolic capabilities of Brachyspira were analysed using Biolog Phenotypic 
MicroarrayTM (PM) technology which screened for the utilisation of 190 carbon sources (PM1 
and PM2) by each isolate. All PM1 and PM2 plates and reagents were supplied by Biolog and 
experiments were conducted according to the manufacturer’s instructions. In brief, all plates 
and reagents were pre-incubated in an anaerobic cabinet 24 hours before use. Using a sterile 
swab, the surface growth of Brachyspira from FABA was inoculated in to 7 ml of Biolog 
inoculating fluid (IF-0 x1) to achieve a transmittance of 40% using a Biolog turbidimeter. 6ml 
of this inoculum was diluted into 18 ml of inoculating fluid containing Dye mix D (Biolog), 
potassium ferricyanide (Sigma-Aldrich) and menadione sodium bisulfite (Sigma- Aldrich). 
Bacterial suspensions were pipetted into the PM1 and PM2 96 well plates at a volume of 
100µl/ well and incubated in an anaerobic cabinet at 37°C for 72 hours.  
A major modification was made to the way the PM1 and PM2 plates were read due to 
technical issues with the OmniLog plate reader. All plates were read using a Tecan Spark 10 
plate reader (Tecan) at 540nm wavelength to measure the reduction of the tetrazolium dye 
(yellow) to formazan (purple), indicative of Brachyspira respiration at 37°C, every 24 hours 
for 72 hours. It is important to note that the dye reduction is indicative to cellular respiration, 
which occurs independent of cell growth. Each experiment was conducted with three 
biological repeats. 
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Figure 2. 1 Plate layout for PM1 Biolog plate. Each of the 96-wells contains a different carbon 
source available to determine bacterial respiration capabilities. Well A1 does not contain a 
carbon sources and is therefore a negative control for growth.  
Figure 2. 2 Plate layout for PM2 Biolog plate. Each of the 96-wells contains a different carbon 
source available to determine bacterial respiration capabilities. Well A1 does not contain a carbon 
sources and is therefore a negative control for growth. 
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2.1.6 Identification and Characterisation of Lactobacillus as Potential Probiotics  
 
2.1.6.1 Gram stain 
 
Details of the Gram stain protocol are provided in section 2.1.5.1, where Lactobacillus were 
determined by the purple Gram Stain and bacillus morphology.  
 
2.1.6.2 Catalase test 
 
A drop of 3% (w/v) hydrogen peroxide solution (Sigma-Aldrich) was placed on to a glass slide 
and a small amount of Lactobacillus, transferred from MRS agar was added. Results were 
recorded immediately with the production of gaseous bubbles regarded as catalase positive 
and the absence of gaseous bubbles as catalase negative. Catalase-positive E. coli K12 was 
used as a positive control. 
 
2.1.6.3 Growth curves 
 
Lactobacillus isolates were inoculated into MRS broth from the surface growth on MRS agar 
at a concentration of 105 CFU/ml. Isolates were grown anaerobically at 37°C on a shaking 
platform for 24 hours, optical density (OD) readings were taken at an absorbance of 600nm 
every 2 hours for 10 hours and again at 24 hours. Isolates were plated onto MRS agar, using 
the Miles-Misra technique every 2 hours to enumerate the bacteria.  Assays were performed 
with three technical and three biological repeats. 
 
2.1.6.4 Antimicrobial sensitivity testing of Lactobacillus 
 
Antimicrobial sensitivity testing of all Lactobacillus isolates was performed using the broth 
microdilution method. This method is recommended in the EFSA guidelines which outline the 
guidelines for antimicrobial resistance testing in potential animal feed additives (European 
Food Safety Authority, 2012).  
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The antimicrobial doubling series for ampicillin, chloramphenicol, clindamycin, erythromycin 
and gentamicin (Fisher Scientific) ranged from 0.06-128 µg/ml and for kanamycin, 
streptomycin, tetracycline and vancomycin (Fisher Scientific) ranged from 1-256 µg/ml. 
Antimicrobial 10x stock solutions were prepared in accordance to the manufacturer’s 
instructions and diluted to double the desired working concentration for each antimicrobial, 
these were filter sterilised using a 0.2µm filter. Antimicrobials were double diluted into Lactic 
acid bacteria susceptibility medium (LSM), this medium is composed of 90% iso-sensitest 
broth and 10% MRS broth which supports the growth of Lactobacillus and has no effect on 
the potency of the antimicrobials tested (Klare et al., 2005). 100µl of each cell suspension at 
a concentration of 105 CFU/ml was added and the 96 well plates were incubated anaerobically 
at 37°C for 24 hours. The MIC was recorded as the lowest antimicrobial concentration to 
inhibit the growth of Lactobacillus. Each assay was repeated in triplicate with three biological 
repeats. 
Enterococcus faecalis ATCC 2912 was used as a control strain and results were compared to 
published break-points to confirm the accuracy of the MIC results. 
 
2.1.6.5 Acid tolerance assay 
 
The four selected Lactobacillus isolates, L. reuteri SAP 2114 and 2115 and L. salivarius SAP 
2116 and 2117 were tested for tolerance to low pH. 0.1M sterile PBS was adjusted to pH 1.9 
using 1M hydrochloric acid (Sigma-Aldrich). Lactobacillus isolates (108 CFU/ml) were 
resuspended in PBS at pH 1.9 and pH 7.2 and incubated anaerobically at 37°C for 3 hours. 
Lactobacillus were plated on to MRS agar using the Miles-Misra technique at 0 hours and 
again after 3 hours of incubation under both pH conditions. MRS plates were incubated 
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anaerobically at 37°C for 18 hours, after which lactobacilli were enumerated. Assays were 
performed with three technical and three biological repeats. 
 
2.1.6.6 Bile salt tolerance assay 
 
The tolerance of Lactobacillus to oxgall (containing bovine bile salts) and two poultry bile salts 
taurocholic acid and sodium taurochenodeoycholate (Sigma-Aldrich) was determined for the 
four selected potential probiotic candidates L. reuteri SAP 2114 and SAP 2115 and L. salivarius 
SAP 2116 and SAP 2117. Lactobacillus isolates (105 CFU/ml) were inoculated into MRS broth 
containing 1% or 0.3% (w/v) oxgall, taurocholic acid and sodium taurochenodeoycholate, 
control broths contained MRS alone. A concentration of 0.3% bile salts was considered by 
Gilliland et al. (1984) to be the critical concentration, high enough to screen for resistant 
isolates. For each condition, 200µl of broth mixture was transferred into a 96 well plate and 
incubated anaerobically at 37°C in a Tecan Spark 10 plate reader (Tecan). Optical density (OD) 
readings were taken at an absorbance of 600nm, every 15 minutes for 24 hours. After 24 
hours, each condition was plated on to MRS agar using the Miles-Misra technique to 
enumerate the bacteria following exposure to bile salts and subsequently compared to 
control broths. Assays were performed with three technical and three biological repeats.  
Isolates were initially classified in accordance to previously published methods (Chateau et 
al., 1994) whereby Lactobacillus growth in the presence of bile salts was compared to the 
control broth which contained no bile salts. The difference in the time taken for the 
absorbance to increase by an OD600 of 0.3 was used to determine tolerance to bile salts. A 
delay in growth of less than 15 minutes between the test and control determined an isolate 
to be resistant to bile salts, between 15 and 40 minutes determined an isolate to be tolerant, 
between 40 and minutes determined an isolate to be weakly tolerant and greater than 60 
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minutes determined an isolate to be sensitive to bile salts. However, this method only 
accounted for the lag phase of growth and it could be observed that some of the bile salts 
impacted the log growth phase, therefore this was considered when analysing the data. 
 
2.1.6.7 Growth and inhibition assay of Brachyspira 
 
In a 96 well plate, Lactobacillus CFS adjusted to pH 3.8, pH 4.5 and pH 7.2 at 10% (v/v) was 
added to Brachyspira culture in BHI + 10% FBS (106 CFU/ml) and incubated anaerobically at 
37°C for 120 hours.  Optical density (OD 620) readings were taken at 10-hour intervals for the 
duration of the experiment. BHI + 10% FBS without Brachyspira was added to the 96 well 
plate to standardise the OD readings. Control broths were prepared by adjusting MRS to pH 
3.8, pH 4.5 and pH 7.2. All assays were performed with five biological repeats each with three 
technical repeats.  
To establish if the Brachyspira inhibitory components were proteinaceous in nature, the 
effect of the proteolytic enzyme trypsin on the CFS inhibition of Brachyspira was investigated. 
Treated CFSs were added to Brachyspira cultures in BHI at 10% (v/v) and incubated 
anaerobically at 37°C. Optical density readings were taken as detailed about. Control broths 
were prepared by trypsin or heat-treating MRS broth. All assays were performed with five 
biological repeats each with three technical repeats. 
 
2.1.6.8 Nuclear magnetic resonance of Lactobacillus CFS 
 
Cell free supernatants from all Lactobacillus isolates were prepared by combining 400µl of 
CFS with 200µl of phosphate buffer. The samples were vortexed and centrifuged at 10,000x 
g for 10 minutes at ambient temperature. 550µl of each supernatant was transferred into a 
5mm NMR tube. For each sample a 1H NMR spectra was acquired using a Bruker 800 
spectrometer. Each experiment was repeated in triplicate. Spectra were digitised and 
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analysed using MatLab 2017 and metabolite analysis was performed using Chenomx 
software.  
 
2.1.6.8.1 Phosphate buffer recipe 
 
28.86 g sodium phosphate dibasic (Na2HPO4) 
5.25 g sodium phosphate monobasic (NaH2PO4) 
0.172 g (Sodium 3(Trimethylsilyl) propionate-d4) TSP (1 mM) 
0.193 g sodium azide (NaN3) 
1L D2O 
 
2.1.6.9 Agar viability assay of Brachyspira 
 
Agar viability assays were performed using the ‘spot test’ as previously described (Bernadeau 
et al., 2009). L. reuteri SAP 2114 and SAP 2115 and L. salivarius SAP 2116 and SAP 2117, viable 
and heat-inactivated, were resuspended in 0.1M sterile PBS (109 CFU/ml) and incubated with 
Brachyspira cell suspensions in 0.1M sterile PBS (109 CFU/ml) in a 96 well plate at 37°C, 
anaerobically for 4 hours. Following incubation, 5µl of each cell suspension was spotted onto 
Brachyspira selective agar and incubated at 37°C, anaerobically for 5 days. The extent of 
viability and presence of haemolysis were quantified on the 5th day by measuring the zone of 
Brachyspira growth and compared to control suspension of Brachyspira incubated with PBS 
alone.  Assays were performed in triplicate with three biological repeats.  
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2.2 Molecular Methodology  
 
2.2.1 Identifying Brachyspira using PCR 
 
Established Brachyspira genus and species-specific PCRs were used for the initial 
identification of Brachyspira isolates. Primer sequences and PCR product sizes are presented 
in Table 2.3. The genus specific PCRs were based on the 16S rRNA gene and used to confirm 
that all the isolates were from the Brachyspira genus (Phillips et al., 2005). PCRs designed for 
the identification of B. intermedia and B. pilosicoli were based on two well conserved genes 
in the genus, the NADH oxidase (nox) and 16S rRNA genes, respectively  (Mikosza et al., 2001; 
Phillips et al, 2006). 
PCR was used to amplify target DNA sequences detailed in Table 2.3. A 20µl reaction mixture 
was prepared consisting of GoTaq®MasterMix (Promega), the forward and reverse primers 
(20pmol/µl) (Sigma-Aldrich), DNA template (20-50ng/µl) and DNAse free water.  
PCR amplifications were performed using a Techne thermocycler as follows: 95°C for 5 
minutes to denature the DNA, followed by 30 cycles of denaturation at 95°C for 60 seconds, 
annealing at 55°C for 60 seconds and extension at 72°C for 60 seconds, followed by a final 
DNA extension at 72°C for 7 minutes. Samples were then cooled to 4°C. 
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Table 2. 3 Primer sequences for Brachyspira genus and species-specific PCRs. Target gene, primer 
name, primer sequence and PCR product size are detailed below. 
Target 
species 
Target 
gene 
Primer 
name 
 Primer sequence (5’-3’) Size Reference 
Brachyspira 
genus 
16S rRNA Br16S-F 
Br16S- R 
 TGAGTAACACGTAGGTAATC  
GCTAACGACTTCAGGTAAAAC  
1309 (Phillips et 
al., 2005) 
Brachyspira 
intermedia 
nox Int1-F 
Int1-R 
 AGAGTTTGATGATAATTATGAC  
ATAAACATCAGGATCTTTGC  
567 (Phillips et 
al., 2006) 
Brachyspira 
pilosicoli 
16S rRNA Acoli-F 
Acoli-R 
 AGAGGAAAGTTTTTTCGCTT  
CCCCTACAATATCCAAGACT  
439 (Mikosza et 
al., 2001) 
 
 
Brachyspira genus-specific primers targeted the amplification of the 16S rRNA gene which 
produced an amplicon of 1309 bp (Phillips et al., 2005). B. pilosicoli species- specific primers 
targeted the 16S rRNA gene in B. pilosicoli which produced an amplicon of 439 bp and B. 
intermedia species-specific primers targeted the NADH oxidase (nox) gene in B. intermedia 
which produced an amplicon of 567 bp (Mikosza et al., 2001; Phillips et al., 2006).  Gel 
electrophoresis of the PCR products was performed, and the species of each isolate was 
inferred using the amplicon sizes stated above and summarised in Table 3.1.  
 
2.2.2 Gel electrophoresis 
 
Agarose (Sigma- Aldrich) was melted in 1x Tris-Borate- EDTA (TBE) (Sigma-Aldrich) at 1% 
(w/v), SYBR™ safe gel stain was added to the agarose (1: 10,000) (Fisher Scientific) and set 
into a gel casting tray using a comb to form the loading wells. The gel was placed in Sub- Cell 
tank (Bio-Rad) and submerged in 1x TBE buffer. 5µl of each PCR product was loaded alongside 
a 1 Kb molecular marker ladder (Promega). Gels were electrophoresed at 100 volts (V) for 
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approximately 45-minutes. Following this, the gels were visualised using the Odysseyâ FC 
imaging system. 
 
2.2.3 Identifying Brachyspira using whole genome sequencing  
 
2.2.3.1 Genomic DNA extraction 
 
DNA was extracted using the GenElute™ bacterial genomic DNA kit (Sigma-Aldrich) as per the 
manufacturer’s instructions. Briefly, a heavy suspension of Brachyspira in sterile water was 
prepared and centrifuged at 16,000 x g for 2 minutes at ambient temperature. Pelleted cells 
were resuspended in 180µl of lysis solution and 20µl of RNase A and incubated at ambient 
temperature for 2 minutes. 20µl of Proteinase K was added to the sample and incubated at 
55°C for 60 minutes, following this 200µl of lysis solution C was added to the sample and 
vortexed for 15 seconds and then incubated at 55°C for a further 60 minutes.  
500µl of column preparation solution was added to each GenElute Miniprep binding column 
to maximise the binding of DNA to the membrane and centrifuged at 12,000 x g or 1 minute.  
200µl of ethanol (95-100%) was added to the lysate and vortexed for 5-10 seconds, the lysate 
was transferred to the binding column and centrifuged at ≥ 6500 x g at ambient temperature 
for 1 minute. Columns were washed twice with 500µl of wash solution 1 and centrifuged at ≥ 
6500 x g at ambient temperature for 1 minute. DNA was eluted in 70µl DNase free water, 
incubated at ambient temperature for 5 minutes and then centrifuged at ≥ 6500 x g at 
ambient temperature for 1 minute.  
The concentration and purity of the DNA was assessed using a BioDrop spectrophotometer. 
DNA was then stored at -20°C before being sent for whole genome sequencing.  
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2.2.3.2 Whole genome sequencing 
 
Isolates selected for whole genome sequencing are detailed in Table 2.1. Isolates were 
cultured from -80°C stocks and sub-cultured for 48-72 hours. DNA was extracted from these 
isolates and quantified as detailed in section 2.2.3.1. DNA samples were sequenced on an 
Illumina MiSeq platform conducted at the APHA, Weybridge, UK. 2x 150bp paired end 
sequence reads were processed and assembled into contiguous sequences using the Shovill 
pipeline (https://github.com/tseemann/shovill). This pipeline uses SPAdes, however is a more 
rapid genome assembler. SPAdes is a de novo genome assembler for Illumina whole genome 
sequences data for bacteria and is a major improvement on previous assemblers such as 
Velvet (Bankevich et al., 2012) 
 
2.2.3.2.1 Illumina sequencing  
 
Illumina sequencing is split in to four key parts: the sample preparation, cluster generation, 
sequencing and data analysis. In brief, the sample preparation involves breaking the DNA into 
fragments, adapters are added to the ends of the DNA fragments and through reduced cycle 
amplification additional motifs are introduced to the fragments, including the sequencing 
binding site and regions complimentary to the flow cell oligonucleotides. Cluster generation 
occurs on the flow cell, which is a glass slide containing different lanes. Each lane is coated 
with oligonucleotides. Each fragment of DNA is isothermally amplified on the flow cell. Firstly, 
the DNA fragment hybridised to the oligonucleotide that is complementary to the adapter 
region on the fragment. Once hybridised, a DNA polymerase creates a complementary strand 
to create a double stranded molecule. This molecule is then denatured, and the original 
template is washed away. Stands are then clonally amplified by bridge amplification whereby 
the remaining single strand folds over and the adapter region on the other end of the DNA 
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fragment hybridised to a commentary oligonucleotide on the flow cell surface. DNA 
polymerase then creates a complementary strand, forming a double stranded bridge. This 
bridge is denatured, resulting in two single stranded copies of the molecule bound to the flow 
cell. This process is repeated, resulting in clonal replication of all of the DNA fragments in the 
sample. After clonal amplification, the reverse strands are cleaved and washed away, leaving 
only the forward strands. The 3’ ends of these strands are blocked to prevent any unwanted 
priming. Sequencing beings with the extension of the first sequencing primer to produce the 
first read and then with each subsequent cycle, additional fluorescently tagged nucleotides 
are added the nucleotide chain based on the sequences of the template. Each nucleotide 
emits a fluorescent signal and the wavelength and signal intensity determines the base added 
to the DNA strand. The number of cycles determines the length of the read. This process is 
repeated for the forward and reverse strands of DNA and continues for all DNA fragments, 
thus producing millions of reads. The final step is the data analysis. The described process 
produces millions of reads which represent all of the fragments of DNA initially created. Reads 
with similar sequences are clustered together, with forward and reverse reads being paired, 
thus creating contiguous sequencings which can be aligned to a reference genome.  
 
2.2.3.3 Sequence analysis  
 
Bioinformatic analysis was performed on all Brachyspira isolates with the help from Dr 
Arnoud van Vliet, University of Surrey. The total dataset contained the 8 Brachyspira genomes 
sequences in this project, 13 B. pilosicoli genomes that were sequenced for a collaborative 
project and all of the publicly available genomes downloaded from Genbank. The assembly 
statistics (number of contigs, genome size) were obtained by using Quast v2 (Gurevich et al., 
2013). Genome sequences were annotated using Prokka v1.12 (Seemann, 2014). 
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Brachyspira genomes, were phylogenetically clustered using core genome single nucleotide 
polymorphisms (SNPs) using parSNP (Treangen et al., 2014) using the "-x" switch, which uses 
PhiPack to remove regions of recombination, and the "-a 13" switch to increase sensitivity 
(van Vliet, 2017). Figtree was used for the visualisation of phylogenetic tree 
(http://tree.bio.ed.ac.uk/software/figtree/). 
Pan-genome analysis of all Brachyspira  isolates was carried out using Roary v.3.12.0 with an 
80% minimum percentage identity for BLASTP (Page et al., 2015). Roary outputs gave a matrix 
of presence/absence of genes, enabling comparisons between isolates or species to be 
inferred. The Roary_plots.py script (Sanger Centre) was used to visualise the pangenome with 
the phylogenetic trees. Additionally, an ABRicate database was created with the methyl-
accepting chemotaxis protein gene sequences of interest, which allowed for the screen of all 
Brachyspira genomes for the presence of these genes, with a 75% percentage identity 
(https://github.com/tseemann/abricate).  
 
2.2.4 Identifying Lactobacillus 
 
Lactobacillus isolates were identified using 16S rRNA sequencing for a rapid identification in 
the initial characterisation of a panel of 60 isolates. After further characterisation and 
determination of Brachyspira inhibition, 11 isolates were sent for whole genome sequencing 
by Illumina sequencing as described in section 2.2.3.2.1.  
 
2.2.5 Identifying Lactobacillus with 16S rRNA sequencing  
 
The 16S rRNA gene was amplified by PCR from the Lactobacillus DNA template using the 
primers 8F (5´-AGT TTG ATC CTG GCT CAG-3´) and 1492R (5´-ACG GCT ACC TTG TTA CGA CTT 
-3´). The 1537bp PCR product was confirmed by gel electrophoresis as described in section 
2.2.2 and purified prior to sequencing. Sequencing was performed by Sanger sequencing. 
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Homology searches to determine the species of each isolate were performed using Basic Local 
Alignment Search Tool (BLAST) to compare sequences to the GenBank, NCBI online database.  
 
2.2.5.1 Purification of PCR products 
 
PCR products were purified before being sent for sequencing using the QIAquick® PCR 
purification kit (Qiagen) as per the manufacturer’s instructions. Briefly, five volumes of buffer 
PB were added to one volume of the PCR product and transferred into a QIAquick spin 
column. The column was centrifuged at 17,900 x g for 1 minute at ambient temperature, the 
flow-through was discarded. The column was washed with buffer PE and centrifuged at 
17,900 x g for 1 minute, an additional centrifugation step was performed to remove residual 
buffer. The DNA was eluted in 30µl of DNase free water and incubated for 5 minutes at 
ambient temperature and centrifuged at 17,900 x g for 1 minute. DNA was analysed for 
concentration and purity on a NanoDrop™ spectrophotometer and stored at -20°C.  
 
2.2.6 Identifying Lactobacillus with whole genome sequencing 
 
2.2.6.1 Genomic DNA extraction  
 
Genomic DNA was extracted from Lactobacillus as described in section 2.2.3.1, with the 
addition of steps at the start of the protocol for complete lysis of Gram positive cells. 
A heavy suspension of Lactobacillus was prepared in sterile water and centrifuged at 16,000 
x g for 2 minutes at ambient temperature, the water was removed, and the cell pellet was 
resuspended in 200µl of lysozyme solution (prepared according the manufacturer’s 
instructions) and incubated at 37°C for 1 hour. Following incubation, 20µl of RNase A was 
added to the sample and incubated at ambient temperature for 2 minutes. 20µl of proteinase 
K was added to the sample, followed by 200µl of lysis solution C and vortexed for 15 seconds. 
The sample was incubated at 55°C for 20 minutes to ensure cell lysis. 
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The remainder of the protocol is described in section 2.2.3.1. 
 
2.2.6.2 Whole genome sequencing 
 
Isolates selected for whole genome sequencing are detailed in Table 2.2. Isolates were 
cultured from -80°C stocks and sub-cultured for 18 hours. DNA was extracted from these 
isolates and quantified as detailed in section 2.2.3.1 DNA samples were sequenced on an 
Illumina MiSeq or HiSeq 2500 platform conducted at the Microbes NG, University of 
Birmingham, UK. 2x250bp paired end sequence reads were processed and assembled into 
contiguous sequences using the SPAdes 3.10 genome assembler (Bankevich et al., 2012).  
 
2.2.6.3 Sequence analysis 
 
Bioinformatic analysis was performed on all Lactobacillus isolates, the total dataset contained 
ten Lactobacillus genomes. The assembly statistics (number of contigs, genome size) were 
obtained by using Quast v2 (Gurevich et al., 2013). Genome sequences were annotated using 
Prokka v1.11b (Seemann, 2014). 
Lactobacillus genomes, were phylogenetically clustered using core genome single nucleotide 
polymorphisms (SNPs) using parSNP (Treangen et al., 2014) and Figtree  was used for the 
visualisation of phylogenetic tree (http://tree.bio.ed.ac.uk/software/figtree/). 
The genome sequences of all Lactobacillus isolates were screened for the presence of 
antimicrobial resistance genes using ABRicate (https://github.com/tseemann/abricate), this 
allowed for mass screening of contigs for antimicrobial resistance genes using several 
available databases, Resfinder, the comprehensive antibiotic resistance database (CARD) and 
Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT). 
Lactobacillus genome sequences were also screened for the presence of bacteriocin and 
secondary metabolite gene clusters. Bacteriocin mining using BAGEL4  was used to identify 
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potential genes involved in bacteriocin production (http://bagel.molgenrug.nl) (de Jong et al., 
2006; van Heel et al., 2013). Potential secondary metabolite gene clusters were identified 
using anti-SMASH (https://antismash.secondarymetabolites.org/#!/start) (Blin et al., 2017). 
 
2.2.7 RNA preparation for HD11 avian macrophages 
 
2.2.7.1 RNA extraction 
 
RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) as per the manufacturer’s 
instructions. Briefly, samples were thawed on ice, the lysate was transferred to a gDNA 
eliminator column and centrifuged at 10,000 x g for 30 seconds at ambient temperature. 
350µl of 70% ethanol was added to the lysate and mixed before it was transferred to an 
RNeasy spin column and centrifuged at 10,000 x g for 15 seconds at ambient temperature. All 
flow-through was discarded and 700µl of Buffer RW1 was added to the spin column and 
centrifuged at 10,000 x g for 15 seconds at ambient temperature. The column was washed 
twice with 500µl of Buffer RPE and centrifuged at 10,000 x g for 2 minutes to dry the column 
and remove all ethanol contamination. RNA was then eluted in 30µl of RNase free water and 
the concentration and purity of the RNA was assessed using a BioDrop spectrophotometer. 
RNA was stored at -80°C prior to RT-PCR.  
 
2.2.7.2 DNase treatment and cDNA synthesis 
 
The RNA was treated with DNase to remove any contaminating DNA. The DNA-free Kit 
(Ambion) was used according to the manufacture’s guidelines. In brief, 3µl of DNase I buffer 
and 1µl of rDNase I were added to 30µl of RNA and incubated at 37°C for 30 minutes. 3µl of 
DNase inactivation reagent was subsequently added to the RNA and incubated at room 
temperature for 2 minutes, mixing occasionally. The RNA mix was centrifuged at 10,000 x g 
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at room temperature for 2 minutes and the RNA transferred into a clean, nuclease-free tube 
for subsequent reverse transcription.  
cDNA synthesis was carried out using the High-Capacity cDNA reverse transcription kit 
(Applied Biosystems) in accordance to the manufacturer’s guidelines. In brief, a reverse 
transcription mastermix was made, consisting of RT buffer, dNTP mix, RT random primers, 
reverse transcriptase and nuclease-free water. 10µl of mastermix was combined with 10µl of 
each RNA sample and sealed in a 96-well plate.  cDNA synthesis was performed using the 
BioRad CFX96 Touch system with the following thermal cycler conditions: 25°C for 10 minutes, 
37°C for 120 minutes to enable reverse transcription and 85°C to denature the reverse 
transcriptase. Samples were then cooled to 4°C and stored at -20°C before use.  
 
2.2.7.3 Quantitative RT-PCR 
 
RNA expression was determined by RT-PCR using a BioRad CFX96 Touch system. Primers and 
probes for 28S, IL1β, IL6, IL8, IL10 and IFNγ are described in Table 2.4. RT-PCR was performed 
with SsoAdvanced universal probes supermix (BioRad) with the following cycles: 95°C for 2 
minutes, then 50 cycles of 95°C for 10 seconds and 60°C for 1 minute. Data were visualised 
and analysed using the BioRad CFX Manager 3.1. All RT-PCR experiments were repeated in 
triplicate with three biological repeats. 
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a. Primer sequences obtained from (Kaiser et al., 2000). 
b. Primer sequences obtained from (Smith et al., 2005). 
 
 
 
Target Probe Sequence Forward Primer Sequence Reverse Primer Sequence  
28S a 5ʹ-(FAM)-AGGACCGCTACGGACCTCCACCA-
(TAMRA)-3ʹ 
5ʹ-GGCGAAGCCAGAGGAAACT-3ʹ 5ʹ-GACGACCGATTTGCACGTC-3ʹ 
IL-1β a 
 
5ʹ-(FAM)-CCACACTGCAGCTGGAGGAAGCC-
(TAMRA)-3 
5ʹ-GCTCTACATGTCGTGTGTGATGAG-3’ 5ʹ-TGTCGATGTCCCGCATGA-3ʹ 
IL- 6 a 5ʹ-(FAM)-
AGGAGAAATGCCTGACGAAGCTCTCCA-
(TAMRA)-3ʹ 
5ʹ-GCTCGCCGGCTTCGA-3ʹ 5ʹ-GGTAGGCTGAAAGGCGAACAG-3’ 
IL-8 b 5_-(FAM)-GCCCTCCTCCTGGTTTCAG-(TAMRA)-
3_ 
5’-TGGCACCGCAGCTCATT-3 5’-TCTTTACCAGCGTCCTACCTTGCGACA-3’ 
IFN- γ a 
 
5’-(FAM)-TGGCCAAGCTCCCGATGAACGA-
(TAMRA)-3’ 
5’-GTGAAGAAGGTGAAAGATATCATGGA-3’ 5’-GCTTTGCGCTGGATTCTCA-3’ 
IL-10 b 5ʹ-(FAM)-CGACGATGCGGCGCTGTCA-(TAMRA)-
3ʹ 
5ʹ-CATGCTGCTGGGCCTGAA-3ʹ 5ʹ-CGTCTCCTTGATCTGCTTGATG-3ʹ 
Table 2. 4 Cytokine primer and probe sequences used for RT-PCR 
 76 
2.3 In vitro Phenotypic Methodology 
 
2.3.1 Culture of HD11 avian macrophage cells 
 
HD11 avian macrophage cells (Beug et al., 1979) were selected to investigate the immune 
responses elicited by Brachyspira on avian innate immune cells in vitro.  
HD11 stock cultures were thawed from liquid nitrogen (-196°C) at 37°C in a water bath and 
were reconstituted in RPMI 1640 supplemented with L- glutamine 1x and sodium bicarbonate 
(Sigma-Aldrich). The media was further supplemented with 2.5% chicken serum (Sigma-
Aldrich), 2.5% FBS (Sigma-Aldrich), 10% tryptose phosphate broth (Sigma-Aldrich) and 1% 
penicillin-streptomycin (Sigma-Aldrich). Initially, HD11 cells were seeded into a T25 tissue 
culture flask and incubated at 37°C in the presence of 5% carbon dioxide, until a 80% 
confluent monolayer was present. To propagate the HD11 cells, they were trypsinised with 
0.5% trypsin-EDTA (Sigma-Aldrich) and resuspended in supplemented RPMI and seeded into 
T75 tissue culture flasks. Prior to experiments, HD11 cells were trypsinised, resuspended in 
the supplemented RPMI and seeded into 24-well plates at a concentration of 1x105 cells/ml 
and grown to confluency for 48 hours.  
HD11 stock cultures were stored in the supplemented RPMI plus 10% DMSO and 70% FBS and 
placed liquid nitrogen (-196°C). 
 
2.3.2 HD11 cytokine release in response to Brachyspira infection 
 
HD11 cytokine responses have been previously characterised for other pathogenic 
gastrointestinal bacteria such as Salmonella and Campylobacter. Therefore, cytokine 
response assays were performed as previously described (Kaiser et al., 2000; Smith et al., 
2005). Briefly, Brachyspira inocula were prepared by transferring the surface growth from a 
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FABA plate into 0.1M sterile PBS to yield a concentration of 5 x 108 CFU/ml, which was 
resuspended in tissue culture media to a concentration of approximately 5 x 107 CFU/ml.  
Confluent HD11 cells in 24 well plates were in washed twice with pre-warmed 0.1M sterile 
PBS to remove media containing antibiotics. Antibiotic-free media was added to each well 
and designated wells were infected with either B. pilosicoli SAP 859, B. alvinipulli ATCC 51933, 
B. intermedia SAP 919 or B. innocens SAP 924 and incubated at 37°C in the presence of 5% 
carbon dioxide for 3 hours. 
HD11 cells were lysed using 350µl buffer RTL + β- mercaptoethanol and the lysates were 
frozen at -80°C prior to RNA extraction.  All assays were repeated in duplicate with three 
biological repeats. Salmonella Typhimurium SL1344 (SAP 16) was used as a positive control 
and PBS was used as a negative control.  
 
2.3.3 HD11 Cytokine release in response to Brachyspira infection following Lactobacillus 
pre-exposure  
 
To investigate the possible immunomodulatory properties of Lactobacillus, HD11 cells were 
infected with Lactobacillus prior to infection with Brachyspira.  
Lactobacillus inocula were prepared by transferring the surface growth from an MRS plate 
into 0.1M sterile PBS to yield a concentration of 5 x 108 CFU/ml, which was resuspended in 
tissue culture media to a concentration of approximately 5 x 107 CFU/ml. Confluent HD11 cells 
in 24 well plates were in washed twice with 0.1M sterile PBS to remove media containing 
antibiotics. Antibiotic-free media was added to each well and designated wells were infected 
with either L. reuteri SAP 2115 or L. salivarius SAP 2117 and incubated at 37°C in the presence 
of 5% carbon dioxide for 30 minutes prior to Brachyspira infection. The remaining 
methodology is detailed in section 2.3.2. All assays were repeated in duplicated with three 
biological repeats.  
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2.3.4 Survival of Brachyspira in the HD11 infection model 
 
2.3.4.1 Gentamicin protection assay 
 
The gentamicin protection assay was performed in order to determine if Brachyspira survived 
intracellularly. After 4-hours of incubation the media was removed and the HD11 cells were 
washed three times with PBS. 100µl of this spent media was plated on to FABA to determine 
whether Brachyspira would survive for the duration of the experiment in sub-optimal 
conditions.  
HD11 cells were resuspended in media supplemented with gentamicin at a concentration of 
100µg/ml and incubated at 37°C with an atmosphere of 5% CO2 for 2 hours to kill any extra-
cellular bacteria. Media was removed, and cells were washed 3 times with PBS before being 
lysed with 1% Triton X-100. The lysate was plated on to FABA and incubated anaerobically at 
37°C for 5 days. These assay were repeated in triplicate with three biological repeats. 
 
2.4 In vivo Methodology  
 
2.4.1 Development of a Galleria mellonella virulence assay for Brachyspira 
 
Galleria mellonella larvae were purchased from Wiggly Wigglers, larvae were stored on wood 
chips in the dark at 17°C to prevent pupation. All larvae were inspected prior to use in 
experiments to ensure they were healthy, indicated by a pale-yellow colour. Experiments with 
G. mellonella were performed as described by Ramarao et al. (2012), with some 
modifications. 
 
2.4.1.1 Determining a suitable Brachyspira concentration for G. mellonella infection 
 
The optimal Brachyspira inoculum for use in the G. mellonella virulence assay was initially 
determined to inform subsequent experiments. Brachyspira inocula were prepared by 
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transferring the surface growth from a FABA to 0.1M sterile PBS to yield concentrations of 
107, 106, and 105 CFU/larvae. G. mellonella were injected into the front left proleg with 10µl 
of each concentration of Brachyspira inoculum. Control larvae were injected with PBS to 
control for any lethal effects from the injection process. The injections were performed with 
a Hamilton 1705 syringe (Fisher-Scientific) with 10 larvae infected per experimental condition, 
repeated in triplicate.  
Larvae were incubated for 120 hours at 37°C in Petri dishes lined with Whatmanä filter paper 
(Fisher Scientific) with mortality scores recorded every 24 hours.  
 
2.4.1.2 Infection of G. mellonella with Brachyspira 
 
The optimal inocula for all Brachyspira isolates, 107 CFU/ larvae was prepared in 0.1M sterile 
PBS as described above in section 2.4.1.1. G. mellonella larvae were injected with 10µl of 
these inocula into the top left proleg. Control larvae were injected with PBS to control for any 
lethal effects of the injection process and non-injected controls were used to monitor the 
pupation of the larvae. Ten larvae were infected with each isolate of Brachyspira with five 
biological repeats. Larvae were incubated for 120 hours at 37°C in Petri dishes lined with 
Whatmanä filter paper (Fisher Scientific) with mortality and morbidity scores taken every 24 
hours. 
The mortality scores scored each larvae as either being dead or alive. The morbidity scoring 
system scored each larvae depending on the degree of melanisation with a score of 0 
indicating no melanisation, a score of 1 indicating melanisation down the tail line, a score of 
2 indicating spotting and dark pigment across the body and a score of 4 indicating complete 
melanisation and death. Examples can be seen in Figure 1.7 (Tsai et al., 2016). 
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2.4.1.3 G. mellonella histopathology 
 
G. mellonella were fixed in 10% (v/v) neutral buffered formalin for 14 days. For light 
microscopy, both transverse and longitudinal sections were cut and stained with several 
different staining methods. Haematoxylin and eosin (H&E) staining was used to observe 
pathology associated with Brachyspira infection, silver staining was used to specifically 
visualise Brachyspira bacteria in the G. mellonella and Gram staining was used to stain for any 
other bacteria that may have been present within the G. mellonella. Three larvae were fixed 
per timepoint and three sections in each orientation were mounted on to each slide. 
 
 
 
Score
Bacteria in gut 
(cocci)
Melanin/inflammatory 
nodules Clusters of haemocytes 
Morphological 
descriptor
0 negligible none none Normal
1
very small colonies 
within the layers 
close to the gut 
lumen
presence of few very small 
melanocytic bodies
very few groups of up to 3 
hemocytes under the cuticle Minimal
2A
small number of 
colonies, small to 
medium size  within 
the layers close to 
the gut lumen and 
minimally invading 
the intestinal wall
presence of small numbers 
of  small to medium size 
inflammatory 
nodules/melanocytic bodies 
normally within the adipose 
bodies or the hemolymph
small number of clusters of 
hemocytes composed of 3-10 
cells under the cuticle Mild
2B
moderate number of 
colonies, small to 
medium size  within 
the layers close to 
the gut lumen and 
minimally invading 
the intestinal wall
presence of moderate 
numbers of small to medium 
size inflammatory 
nodules/melanocytic bodies 
(generally more pigmented) 
normally within the adipose 
bodies or the hemolymph
moderate numbers of clusters of 
hemocytes composed of 3-10 
cells under the cuticle Moderate
3
abundant large 
colonies, transmural
abundant melanocytic 
bodies throught the body, 
normally colaescing within 
different adipose bodies and 
hemolypmh
abundant clusters of hemocytes 
composed of 3-10 melanocyetic 
cells under the cuticle or larger 
than 10 cells Severe
Table 2. 5 The criteria used for Galleria mellonella histopathology scoring. 
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2.4.1.4 Giemsa staining of G. mellonella haemocytes 
 
Giemsa stain is a differential stain that can be used to differentiate bacterial cells from 
haemocytes. In this study, the Giemsa stain was used to differentiate Brachyspira cells from 
G. mellonella haemocytes. G. mellonella tails were cut and the haemolymph was collected 
into a sterile tube. 10µl was smeared in to a glass slide and fixed in pure methanol for 5-7 
minutes. The slides were air dried and then immersed in Giemsa stain (Sigma-Aldrich) for 60 
minutes. The slides were rinsed with deionised water, air dried and evaluated using light 
microscopy (x40). Haemocytes stain blue/purple and bacterial cells stain pink and thus can be 
differentiated.  
 
2.4.1.5 Culture of Brachyspira from G. mellonella haemolymph  
 
G. mellonella tails were cut with sterile scalpels and the haemolymph from three larvae was 
pooled into a sterile tube at 0, 2, 4, 6, 24, 48, 72, 96 and 120 hours post infection with 
Brachyspira. 50µl of haemolymph was plated in to Brachyspira selective agar (BSA) and 
incubated anaerobically at 37°C for 5-7 days to assess the survival of Brachyspira in vivo.  
 
2.4.2 Development of a G. mellonella model to assess the protective activity of Lactobacillus 
against Brachyspira 
 
2.4.2.1 Determining suitable Lactobacillus cell and CFS concentrations for G. mellonella 
infection 
 
The virulence of four probiotic candidates, L. reuteri SAP 2114, L. reuteri SAP 2115, L. salivarius 
SAP 2116 and L. salivarius SAP 2117 were predetermined by injecting larvae with 10µl of each 
isolate at concentrations of 102, 103, 104 and 105 CFU/ larvae into the top left proleg. 
Lactobacillus inocula were prepared by transferring the surface growth of each isolate from 
MRS agar into 0.1M sterile PBS to achieve the above concentrations. Control larvae were 
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injected with PBS to control for any lethal effects from the injection process. Ten larvae were 
infected with each Lactobacillus isolate, repeated in triplicate. 
Larvae were incubated for 120 hours at 37°C in Petri dishes lined with Whatmanä filter paper 
(Fisher Scientific) with mortality and morbidity scores were taken every 24 hours as detailed 
in section 2.4.1.2. 
The effect of the Lactobacillus CFS from L. reuteri SAP 2114, L. reuteri SAP 2115, L. salivarius 
SAP 2116 and L. salivarius SAP 2117 was also predetermined by injecting larvae with 10µl of 
neat CFS and a 1:10 dilution of the CFS into the top left proleg. Control larvae were injected 
with MRS broth to control for any lethal effects cause by the broth. Ten larvae were infected 
with each Lactobacillus CFS, repeated in triplicate. 
Larvae were incubated for 120 hours at 37°C in Petri dishes lined with Whatmanä filter paper 
(Fisher Scientific) with mortality and morbidity scores taken every 24 hours as detailed in 
section 2.4.1.2. 
 
2.4.2.2 G. mellonella probiotic protection model 
 
To assess the ability of the four probiotic candidates to protect against Brachyspira, separate 
groups of G. mellonella were injected with 10µl of each Lactobacillus isolate at a 
concentration of 104 CFU/larvae or the 1:10 dilution of Lactobacillus CFS into the top left 
proleg and incubated for one hour at 37°C in petri dishes lined with Whatmann filter paper. 
After incubation, pre-treated G. mellonella groups were injected with 10µl of each 
Brachyspira isolate at a concentration of 107 CFU/ larvae into the top right proleg. Control 
larvae were injected with PBS or MRS as non-pre-treated controls. Sixteen larvae were pre-
treated with Lactobacillus and infected with Brachyspira, repeated five times. 
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Larvae were incubated for a further 120 hours at 37°C in petri dishes lined with Whatmanä 
filter paper with mortality and morbidity scored taken every 24 hours as detailed in section 
2.4.1.2. 
 
2.5 Data analysis and statistics 
 
Data from all experiments presented were tabulated using either Microsoft Excel 2017 or 
Graphpad Prism 7, the means, standard deviations and standard errors were calculated in 
these programs.  
The data for experiments presented in sections 2.1.6.5, 2.1.6.6 and 2.1.6.7 were analysed for 
statistical significance using a one-way ANOVA with either a Sidak’s or Dunnett’s multiple 
comparisons post-test with a 95% confidence interval. A one-way ANOVA was used as each 
experiment consisted of three or more experimental groups, including controls. The Sidak’s 
test was used when comparing selected sets of means and the Dunnett’s test was used to 
compare every mean to the mean of a control.  
Data for experiments presented in section 2.1.6.8 were visualised and analysed using MatLab 
2017 and scripts provided by Dr Caroline Le Roy (Korrigan Sciences Limited., 2010-2011). 
Principle component analysis (PCA) was employed to investigate the variation between the 
NMR data collected from multiple isolates of Lactobacillus. PCA transforms a large number of 
possibly correlated variables into a smaller number of uncorrected variables called principle 
components in order to simplify complex data and investigate the variability in the dataset. 
PCA is an unsupervised analysis and therefore finds patterns in data without knowing the 
samples used (Lever et al., 2017). Colourplots were generated from the principle components 
in order to identify the metabolites responsible for the variance.  
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Gene expression studies with HD11 avian macrophages presented in section 2.3 were initially 
analysed using BioRad CFX Manager 3.1. This software normalised the gene expression to the 
28S house-keeping gene (D Cq) and calculated the relative fold gene expression (DD Cq) for 
all of the samples. These calculations are as follows:  
DCq = Cq (gene of interest) - Cq (housekeeping gene) 
DD Cq = DCq (treated sample) - DCq (control sample) 
These values were then collated in Graphpad Prism 7 to generate graphs of relative 
expression. Statistical significance was determined using a one-way ANOVA with a Tukey 
post-test to compare all means with one another to fully investigate how gene expression 
differed between cells treated with multiple isolates of both Brachyspira and Lactobacillus in 
multiple combinations.  
Galleria mellonella survival assays were analysed using Graphpad Prism 7 which generated 
Kaplan-Meier survival curves. Analysis of survival curves was performed using the log rank 
test. 
In all experiments a p value of ≤ 0.05 indicated statistical significance. Where further 
categorisation of p values was required asterisks (*) were noted as follows: p value ≤ 0.05 *, 
p value ≤ 0.005 **, p value ≤ 0.0050 *** and p value ≤ 0.0001 ****.  
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Chapter 3: The characterisation of Brachyspira species implicated in 
avian intestinal spirochaetosis  
 
3.1 Introduction 
 
Brachyspira species are the causative agent of avian intestinal spirochaetosis (AIS) which 
causes disease in laying hens and broiler breeders. The species primarily considered to be 
pathogenic to poultry are Brachyspira alvinipulli (Stanton et al., 1998), Brachyspira intermedia 
(Stanton et al., 1997) and Brachyspira pilosicoli (Stephens and Hampson, 2001) with 
Brachyspira innocens (Stanton et al., 1997) considered to be non-pathogenic in the avian host 
(Stephens and Hampson, 2001). Brachyspira infections in poultry commonly manifest as 
diarrhoeal disease and result in reduced egg production (Davelaar et al., 1986; Dwars et al, 
1993).  
Since the ban of antibiotic growth promoters as feed supplements in 2006, (European 
Commission, 2005) the incidence of Brachyspira has increased and is estimated to infect up 
to 90% of free range hens and 76% of caged hens (Burch, 2010), costing the UK laying industry 
an estimated £18 million per annum (Mappley et al., 2014). Despite a number of attempts to 
mitigate the disease,  including creation of autogenous vaccines and improving biosecurity 
(Phillips et al., 2003; Corona-Barrera et al., 2004; Amin et al., 2009), the incidence of 
Brachyspira continues to rise. Therefore, suggesting that an improved understanding of this 
organism is required to ensure adequate control strategies can be implemented.  
Until recently, identification of Brachyspira species has been heavily reliant on the 
biochemical properties of each species. However, the metabolic capabilities of Brachyspira 
are poorly understood and previous development of confirmatory biochemical tests utilised 
porcine isolates, which were later shown to be somewhat distinct from poultry isolates (Atyeo 
et al., 1999). In recent years, molecular techniques, such as PCR have resulted in improved 
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detection and identification of Brachyspira isolates (Mikosza et al., 2001; Phillips et al., 2005, 
2006). Furthermore, whole genome sequencing is not only becoming increasingly important 
for the improved understanding of Brachyspira and its pathobiology, but also proves useful 
as a diagnostic tool for confirming species identification.  
Therefore, this chapter focused on techniques including, biochemical testing, antimicrobial 
resistance testing, PCR and whole genome sequencing to phenotypically and genotypically 
characterise Brachyspira isolates from chickens with avian intestinal spirochaetosis. This 
enabled the assembly of a collection of well characterised Brachyspira isolates that could be 
studied in experimental models to investigate the pathobiology of this organism and elucidate 
the mechanisms by which control strategies, such as the use of probiotics may mitigate 
disease caused by this organism.  
Therefore, the aims and objectives of this chapter were: 
• To use a combination of phenotypic and genotypic characterisation techniques to 
identify Brachyspira isolates from species implicated in poultry disease, namely B. 
alvinipulli, B. intermedia, B. innocens and B. pilosicoli. 
• To investigate the metabolic diversity of avian Brachyspira isolates using Biolog PMTM 
technology. 
• To determine the growth kinetics of a panel of avian Brachyspira isolates. 
• To determine the antimicrobial resistance profiles of the panel of avian Brachyspira 
isolates in light of emerging resistance to commonly used antibiotics.  
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3.2 Results 
 
3.2.1 Phenotypic characterisation of avian Brachyspira isolates  
 
3.2.1.1 Brachyspira staining and biochemistry 
 
All Brachyspira isolates described here were isolated previously at the APHA from the faeces 
of poultry with suspected avian intestinal spirochaetosis in the United Kingdom. A control 
strain of B. alvinipulli, isolated from chicken caeca in Ohio, USA, was purchased from the 
American Type Culture Collection (ATCC) to ensure all species implicated in poultry disease 
were utilised in these studies. 
Gram stains and Warthin-Starry stains were performed on each isolate of Brachyspira, 
followed by examination using light microscopy to determine the morphology of the cells. 
The Gram stain revealed Gram negative, helical spirochaetes and the Warthin-Starry stain, 
which was specific for spirochaetes, revealed a positive brown stain with spirochaete 
morphology, as shown in Figure 3.1. Dark-field microscopy was employed as a further 
confirmatory test for Brachyspira species, whereby the cells were observed for their ‘cork-
screw like” motility, an important characteristic for spirochaetes. 
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Biochemical tests were employed to preliminarily speciate all Brachyspira isolates (Table 3.1). 
It was evident from the data presented in Table 3.1, that phenotypic characterisation by 
means of biochemical testing was insufficient for the identification of all Brachyspira isolates 
as approximately 40% (5/13) of the isolates were unable to be identified (expected results are 
shown in Table 1.3). Therefore, genotypic methods of characterisation by means of PCR and 
whole genome sequencing were employed to accurately identify all Brachyspira isolates. 
These additional tests highlighted that biochemical testing alone, was only correct for only 
46% (6/13) of the isolates. 
The isolates selected for further phenotypic study were as follows: B. pilosicoli B2904, B. 
pilosicoli SAP 858, B. pilosicoli SAP 865, B. intermedia SAP 919, B. innocens SAP 924, B. 
innocens SAP 927, B. innocens SAP 943 and the B. alvinipulli ATCC 51933 type strain. These 
isolates were selected because they could be definitively identified using a combination of 
phenotypic and genotypic tests.  The Brachyspira isolates that could not be identified using a 
A 
 
B 
 
x 40  
 
x 40  
x 40  
 
x 40  
Figure 3. 1  Gram and Warthin- Starry stained images of Brachyspira pilosicoli SAP 865. These 
staining techniques were carried out to ensure that each isolate was Brachyspira. (A) The Gram 
stain illustrates Gram negative spirochaetes (scale bar 5µm). (B) The Warthin-Starry stain illustrates 
spirochaetes strained brown (scale bar 5µm). These images are characteristic of Brachyspira 
species.  
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combination of biochemistry and PCR were not sent for whole genome sequencing because 
they were likely to be mixed species and the aim of this work was to characterise at least one 
isolate of each species implicated in avian intestinal spirochaetosis.
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Table 3. 1 A summary of the PCR, biochemistry and whole-genome sequencing results for all Brachyspira isolates used in these studies. Both phenotypic and genotypic 
methods of characterisation are shown here to illustrate the difficulties when trying to identify the species of each isolate of Brachyspira. These data show the preliminary 
identification of each isolate before the start of the project and the series of PCRs and biochemical tests carried out in order to identify each isolate. Ultimately, whole genome 
sequencing was used to ensure the correct identification of several isolates due to the varied PCR and biochemistry results. The isolates marked with an asterisk (*) were 
genome sequenced and were used in future studies. 
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3.2.1.2 Growth kinetics of Brachyspira 
 
Using the Brachyspira isolates detailed in the section 3.2.1.1, a growth curve protocol was 
developed to characterise the growth kinetics of the eight chosen isolates to inform future 
studies presented in Chapters 5, 6 and 7.  
Brachyspira isolates were slow growing as illustrated in Figure 3.2. The log phase of growth 
began after approximately 25 hours of anaerobic culture at 37°C and the stationary phase 
was reached between 80-100 hours of culture for the all isolates except B. pilosicoli SAP 865 
and B. innocens SAP 927. These isolates demonstrated overall poor growth in broth as seen 
in Figures 3.2 C and H. The ability of Brachyspira to grow in brain heart infusion (BHI) broth 
under the given conditions varied not only between species, but also within a species, which 
demonstrated the varying growth patterns between all isolates tested. B. intermedia SAP 919 
grew the most successfully in broth, whereas B. alvinipulli ATCC 51933 had relatively poor 
growth. The three isolates of both B. pilosicoli and B. innocens showed a range of growth 
phenotypes in broth. B. pilosicoli B2904 and B. innocens SAP 924 exhibited high growth in 
broth, indicated by an optical density (OD600) that exceeded 0.3 at the end of the exponential 
growth phase. B. pilosicoli SAP 859 and B. innocens SAP 943 exhibited intermediate growth in 
broth, indicated by an OD600 between 0.25 and 0.3 at the end of the exponential growth 
phase. B. pilosicoli SAP 865 and B. innocens SAP 927 exhibited poor growth in broth, indicated 
by an OD600 of less than 0.2 at the end of the exponential growth phase. Overall, each isolate 
exhibited variability in growth independent of species.  
The results from these growth curves informed the selection of B. pilosicoli and B. innocens 
isolates for experiments in Chapters 5, 6 and 7. B. pilosicoli SAP 859 and B. innocens SAP 924 
were selected because these isolates could be grown successfully in broth, ensuring sufficient 
bacterial numbers could be achieved for subsequent assays. Additionally, B. intermedia SAP 
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919 and B. alvinipulli ATCC 51933 were selected to ensure that all of the Brachyspira species 
implicated in poultry disease were utilised in these studies. B. pilosicoli B2904 was used as a 
control due to its known ability to grow under laboratory conditions (Mappley et al., 2011, 
Mappley et al., 2013). 
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Figure 3. 2 Brachyspira growth curves A: B. pilosicoli B2904 B: B. pilosicoli SAP 859 C: B. pilosicoli SAP 
865 D: B. intermedia SAP 919 E: B. alvinipulli   ATCC 51933 F: B. innocens SAP 943 G: B. innocens SAP 
924 H: B. innocens SAP 927 in BHI broth + 10% serum. Growth was monitored over 120 hours of 
anaerobic incubation at 37°C. Optical density readings were taken at 620nm wavelength every ˜10 
hours.These data were averages of five biological replicates, each with three technical replicates. The 
standard error of the mean is also shown.  
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3.2.1.3 Antimicrobial sensitivity testing of Brachyspira isolates 
 
The antimicrobial resistance profiles of the Brachyspira isolates against four clinically relevant 
antibiotics (tylosin, chlortetracycline, lincomycin and tiamulin) were conducted (Table 3.3).  
Seven of the eight of Brachyspira isolates tested were susceptible to chlortetracycline, 
lincomycin, tiamulin and tylosin, with B. alvinipulli ATCC 51933 showing decreased sensitivity 
to chlortetracycline. There is an absence of recognised clinical breakpoints for Brachyspira, 
thus breakpoints used in these studies were inferred from previous studies (Duhamel et al., 
1998; Brooke et al., 2003; Burch, 2005; Hampson et al., 2006; Pringle et al., 2012; Hellman et 
al., 2014). Sensitivity to each antibiotic was therefore determined by an MIC of < 4 mg/L for 
chlortetracycline, < 50 mg/L for lincomycin <  0.25 mg/L of tiamulin and < 16 mg/L for tylosin.  
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Table 3. 2 Minimum inhibitory concentrations (MICs) of the antibiotics chlortetracycline, gentamicin, 
lincomycin, tiamulin and tylosin determined by broth microdilution against eight Brachyspira isolates. 
The experiment was performed with three biological replicates, each with three technical replicates.  
 
 
 
 
3.2.1.4 Metabolic profiling of Brachyspira isolates using Biolog Phenotype MircoArrayä 
technology 
 
Biolog Phenotypic MicroarrayTM (PM) technology was implemented to further phenotypically 
characterise the panel of eight Brachyspira isolates used in these studies, furthermore it 
allowed metabolic comparisons to be made between avian Brachyspira isolates. The use of 
the Biolog technology determined the ability of each Brachyspira isolate to metabolise 190 
different carbon sources on PM1 and PM2 plates (Figures 2.1 and 2.2).  
The heat maps in Figures 3.3 and 3.4 illustrated the utilisation of different carbon sources on 
PM1 and PM2 plates. The data presented were the means of three biological repeats.  
Furthermore, all data were normalised to the A1 well on each PM plate, which contained no 
carbon source, to assess the baseline respiration of the cells in the absence of a carbon 
Brachyspira 
Species 
Isolate 
Name 
MIC µg/ml  
Chlortetracycline 
 
Lincomycin  
 
Tiamulin 
 
Tylosin 
B. alvinipulli ATCC 
51933 
4 0.5 0.0625 4 
B. innocens SAP 927 0.125 < 0.0625 < 0.016 0.5 
B. innocens SAP 924 0.125 < 0.0625 < 0.016 1 
B. innocens SAP 943 0.125 < 0.0625 < 0.016 0.5 
B. intermedia SAP 919 1 < 0.0625 < 0.016 1 
B. pilosicoli B2904 0.25 
 
0.125 0.125 2 
B. pilosicoli SAP 865 2 0.5 0.0625 4 
B. pilosicoli SAP 859            0.125         32 0.125 < 0.016 
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source. Isolates that exhibited high utilisation of carbon sources were shown in dark purple 
(Figures 3.3 and 3.4), corresponding to an optical density at 540nm of greater than 0.4, 
isolates that exhibited moderate utilisation of carbon sources are shown in purple, 
corresponding to an OD540 of between 0.2-0.39, isolates that exhibited low utilisation of 
carbon sources are shown in pale purple, corresponding to an OD540 of between 0.1-0.2 and 
isolates that were unable to utilise carbon sources are shown in white, corresponding to an 
OD540 of less than 0.1. 
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Carbon Source PM1
Neg control
L- Arabinose 
N-Acetyl-D-glucosamine
D- Saccharic Acid
Succinic Acid
D- Galactose
L- Aspartic Acid
L- Proline
D- Alanine
D- Trehalose
D- Mannose
Dulcitol
D-Serine
D- Sorbitol
Glycerol
L- Fuctose
D- Glucuromic Acid
D- Gluconic Acid
D,L-a-Glycerol-Phosphate
D-Xylose
L- Lactic Acid
Formic Acid
D-Mannitol
D- Gluamic Acid
D- Glucose-6-Phosphate
D- Galactonic Acid-y-Lactone
D, L-Malic Acid
D-Ribose
Tween 20
L- Rhamnose
D- Fructose
Acetic Acid
a-D-Glucose
Maltose
D- Melibiose
Thymidine
L- Asparagine
D-Aspartic Acid
D- Glucosaminic Acid
1,2- Propanediol
Tween 40
a-Keto-Glutaric Acid
a-Keto- Butyric Acid
a-Methyl-D0 Galactoside
a-D-Lactose
Lactoulose
Sucrose
Uridine
L- Glutamine
m-Tartaric Acid
D-Glucose-1-Phosphate
D- Fructose-6-Phosphate
Tween 80
a-Hydroxy Glutatic Acid-y-
Lactone
a-Hydroxy Butyric Acid
B-Methyl-D-Glucoside
Adinitol
Maltotriose
2- Deoxy Adenosine
Adenosine
Glycyl-:-Aspartic Acid
Citric Acid
m-Inositol
D- Threonine
Fumaric Acid
Bromo Succinic Acid
Propionic Acid
Mucic Acid
Glycolic Acid
Glyoxylic Acid
D- Cellobiose
Inosine
Glycyl- Glutamic Acid
Tricarballylic Acid
L- Serine
L- Threonine
L- Alanine
L- Alanyl-Glycine
Acetoacetic Acid
N- Acetyl-B-D-Mannosamine
Mono Methly Succinate
Methyl Pyruvate
D- Malic Acid
L- Malic Acid
Glycy- L -Proline
p-Hydroxy Phenyl Acetic Acid
m-HydroyPhenyl Acetic Acid
Tyramine
D- Psicose
L- Lyxose
Glucuronamide
Pyruvic Acid
L- Galactonic Acid-y- Lactone
D- Galacturonic Acid
Phenylethyl-amine
2- Aminoethanol 
B. innocens 
SAP 924
B. innocens 
SAP 927
B. innocens 
SAP 943
B. alvinipulli 
ATCC 51933
B. pilosicoli 
B2904
B. pilosicoli 
SAP 859
B. pilosicoli 
SAP 865
B. 
intermedia 
SAP 919
Figure 3.  3 Heatmap of the differences 
in the utilisation of carbon sources for 
8 isolates of Brachyspira using the 
Biolog Phenotypic MicroarrayTM (PM) 
technology. This figure summarises the 
respiration of all 8 isolates: B alvinipulli 
ATCC 51933, B. pilosicoli B2904, B. 
pilosicoli SAP 859, B. pilosicoli SAP 865, 
B. intermedia SAP 919, B. innocens SAP 
924, B. innocens 927 and B. innocens 
SAP 943, on the carbon sources on 
PM1 plates. Plates were incubated 
anaerobically for 48 hours, after which 
the optical density readings were taken 
at 540nm wavelength. The levels of 
respiration are colour-coded whereby 
dark purple indicates high levels of 
respiration on a carbon source, purple 
indicates moderate levels of 
respiration on a carbon source, pale 
purple indicates low levels of 
respiration on a carbon source and 
white indicates no respiration on a 
carbon source. Assays were performed 
with three biological replicates and the 
mean values    are presented in this 
figure. 
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 Carbon Source PM2
Neg Control
Chondrionitin Sulfate C
a-Cyclodextrin
B- Cyclodextrin
y- Cyclodextrin
Dextrin
Gelatin
Glycogen
Inulin
Laminarin
Mannan
Pectin
N- Acetyl-D-Galactosamine
A-Acetly-Neuraminic Acid
B-D-Allose
Amygdalin
D-Arabinose
D-Arabitol
L- Arabitol
Arbutin
2- Deoxy-D- Ribose
i- Erythritol 
D-Fucose
3-0-B-D-Galacto-pyranosyl-D-
Arabinose
Gentiobiose
L- Glucose
Lactitol
D- Melezitose
Maltitol
a-Methyl-D-Glucoside
B-Methyl-D-Galactoside
3- Methyl Glucose
B-Methyl-D- Glucuronic Acid
a-Methyl-D-Mannoside
B-Methyl-D-Xyloside
Palatinose
D-Raffinose
Salicin
Sedoheptulosan
L-Sorbose
Stachyose
D- Tagatose
Turanose
Xylitol
N-Acetyl-D-Glucosaminitol 
y-Amino Butyric Acid
B- Amini Valeric Acid
Butyric Acid
Capric Acid
Caproic Acid
Citraconic Acid
Citramalic Acid
D- Glucosamine
2-Hydroxy Benzoic Acid
4- Hydroxy Benzoic Acid
B- Hydroxy Butyric Acid
y-Hydroxy Butyric Acid
a-Keto-Valeric Acid
Itaconic Acid
5-Keto-D-Gluconic Acid
D-Lactic Acid Methly Ester
Malonic Acid
Melibionic Acid
Oxaclic Acid
Oxalomalic Acid
Quinic Acid
D-Ribono-1,4-Lactone
Sebacic Acid
Sorbic Acid
Succinamic Acid
D-Tartaric Acid
L- Tartaric Acid
Acetamide
L-Alaninamide
N-Acetyl-L-Glutamic Acid
L- Arginine
Glycine
L- Histidine
L. Homoserine
Hydroxy-L-Proline
L- Isoleucine
L- Leucine
L- Lysine
L- Methionine
L- Ornithine
L- Phenylalanine
L- Pyroglutamic Acid
L- Valine
D,L- Carnitine
Sec-Butylamine
D,L- Octopamine
Putrescine
Dihydroxy Acetone
2,3- Butanediol
2,3- Butone
3-Hydroxy-2- Butanone
B. alvinipulli 
ATCC 51933
B. pilosicoli 
B2904
B. pilosicoli 
SAP 859
B. pilosicoli 
SAP 865
B. 
intermedia 
SAP 919
B. innocens 
SAP 924
B. innocens 
SAP 927
B. innocens 
SAP 943 Figure 3. 4 Heatmap of the differences 
in the utilisation of carbon sources for 
8 isolates of Brachyspira using the 
Biolog Phenotypic MicroarrayTM (PM) 
technology. This figure summarises the 
respiration of all 8 isolates: B alvinipulli 
ATCC 51933, B. pilosicoli B2904, B. 
pilosicoli SAP 859, B. pilosicoli SAP 865, 
B. intermedia SAP 919, B. innocens SAP 
924, B. innocens 927 and B. innocens 
SAP 943, on the carbon sources on 
PM2 plates. Plates were incubated 
anaerobically for 48 hours, after which 
the optical density readings were taken 
at 540nm wavelength. The levels of 
respiration are colour-coded whereby 
dark purple indicates high levels of 
respiration on a carbon source, purple 
indicates moderate levels of 
respiration on a carbon source, pale 
purple indicates low levels of 
respiration on a carbon source and 
white indicates no respiration on a 
carbon source. Assays were performed 
with three biological replicates and the 
mean values    are presented in this 
figure. 
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Approximately 20% (39/190) of the carbon source utilisation was shared by all eight 
Brachyspira isolates and approximately 56% (107/190) of the carbon sources were not used 
by any isolate, as shown in Table 3.4 and Appendix I. Therefore, thirty-nine carbon sources 
featured in the core Brachyspira metabolic pathways, these included carbon sources such as 
glucose, glucose-6-phosphate, fructose-6-phosphate, fructose and galactose.  
The Brachyspira isolates utilised an extensive number of sugars for the generation of energy 
but did not utilise amino acids such as L- proline, D-serine and L- glutamine and short chain 
fatty acids such as formic and propionic acids. L- lactic acid was, however, solely metabolised 
by B. alvinipulli ATCC 51933.  
Each species utilised between 57-66 different carbon sources. B. pilosicoli demonstrated the 
ability to respire on the most carbon sources, 35% (66/190), whereas B. alvinipulli utilised 
31% (59/190) of the total carbon sources available and B. intermedia and B. innocens utilised 
30% (57/190). Notably, the metabolic data collected from B. alvinipulli ATCC 51933 and B. 
pilosicoli B2904 in these studies largely matched that of a previous studies (Stanton et al., 
1998; Mappley et al., 2012).  
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The ability to utilise, and the extent of utilisation of different carbon sources differed both 
between different species and between isolates within the same species. It is important to 
note that only one B. alvinipulli and one B. intermedia isolate were used in these studies and 
therefore these data may not be representative of these species.  
These data have identified potential metabolic targets that could be incorporated in to 
differential biochemical tests to improve the accuracy of the biochemical tests developed by 
Fellström and Gunnarsson (1995). For example, b- glucosidase activity has previously been 
used as the only biochemical method to differentiate B. alvinipulli and B. pilosicoli, using this 
Biolog data it was evident that B. alvinipulli uniquely utilised glycerol, lactic acid, D-glutamic 
acid, 1,2- propanediol,  a-keto-glutaric acid, Tween 80, glycolic acid and thymidine (Table 3.5), 
potentially identifying carbon sources unique to B. alvinipulli which could be implemented to 
improve the differentiation from B. pilosicoli, although further validation would be required. 
Biochemical testing was unable to correctly identify any B. alvinipulli isolates (Table 3.1) and 
therefore improvements to these techniques are required.  
 
Total carbon sources utilised by Brachyspira species (%) 
 
Total used Total not used Shared 
by all 
B. alvinipulli B. innocens B. intermedia B. pilosicoli 
 
44% 56% 20% 31% 30% 30% 35% 
(83/190) (107/190) (39/190) (59/190) (57/190) (57/190) (66/190) 
Table 3. 3 Carbon sources utilised by eight Brachyspira isolates. This table shows the total number of carbon 
sources utilised by all eight isolates, the total number of carbon sources not used by these isolates, the number 
of carbon sources common to all isolates and the number of carbon sources utilised by each of the four species 
of Brachyspira, B. alvinipulli, B. innocens, B. intermedia and B. pilosicoli. These data represent the utilisation 
of each carbon source after 48 hours of anaerobic culture at 37°C using optical density at 540nm wavelength 
to capture the reduction of the tetrazolium dye and subsequent colour change, indicative of cellular 
respiration.  
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Metabolic variation was observed between different isolates within the B. pilosicoli species. 
Although in total, B. pilosicoli isolates metabolised sixty-six carbon sources, twenty of these 
differed between the three isolates tested, with SAP 865 able to respire on ten different 
carbon sources compared to that of SAP 859 and B2904, as shown in Table 3.5. B. pilosicoli 
B2904 and SAP 859 were more phenotypically alike and shared the ability to respire on a- 
acetyl neuraminic acid, b- methyl-D- galactoside and butyric acid and only differed in the 
ability to respire on adenosine, inosine, 2-aminoethanol, laminarin, a-keto-butyric acid and 
cellobiose. Therefore, it was not possible to attribute specific carbon source utilisation to B. 
pilosicoli to inform metabolic targets for species identification.  This metabolic variation was 
also noted by Mappley et al. (2012) and emphasised the need to test more Brachyspira 
Number of carbon sources unique to each Brachyspira species 
 
B. alvinipulli a B. innocens B. intermedia a B. pilosicoli 
8 2 2 5 
Glycerol a- methyl-D- mannoside b Amygdalin Inosine c 
Lactic acid  b- methyl-D- xyloside b b-hydroxy butyric acid L- alanine d 
D- glutamic acid    2-aminoethanol e 
1,2-propanediol   Inulin d 
a-keto-glutaric acid   Mannan d 
Tween 80    
Glycolic acid    
Thymidine    
Table 3. 4 Differential carbon source utilisation for each species of Brachyspira. This table shows the 
number of unique carbon sources utilised by the different species of Brachyspira. These data represent the 
utilisation of each carbon source after 48 hours of anaerobic culture at 37°C using optical density at 540nm 
wavelength to capture the reduction of the tetrazolium dye and subsequent colour change, indicative of 
cellular respiration. 
a There was only one isolate per species and thus this may not be representative of the species 
b Carbon sources utilised by only SAP 924  
c Carbon source utilised by only B2904  
d Carbon sources utilised by only SAP 865  
e Carbon source utilised by only SAP 859  
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isolates to build comprehensive biochemical profiles of each species, with the intention of 
improving the differential diagnosis of Brachyspira isolates. 
 
 
 
 
 
 
3.2.2 Genotypic characterisation and identification of Brachyspira isolates 
 
3.2.2.1 PCR 
As previously demonstrated, phenotypic characterisation of Brachyspira was insufficient for 
the identification all isolates, therefore genotypic characterisation methods were also 
employed. PCR was performed as a preliminary screen to confirm isolates were of the 
Brachyspira genus and to identify isolates belonging to either the B. pilosicoli or B. intermedia 
species. 
PCR correctly identified 3 of the 13 isolates that formed the original panel of Brachyspira 
isolates (Table 3.1). A major drawback of this characterisation method was that it was only 
Carbon sources variation in B. pilosicoli isolates  
B2904 only SAP 859 only SAP 865 only B2904 and SAP 
859 only 
SAP 859 and 
SAP 865 only 
Adenosine 2-aminoethanol D- trehalose a- acetyl 
neuraminic acid 
Cellobiose  
Inosine Laminarin D-L- a glycerol 
phosphate 
b- methyl-D- 
galactoside 
 
 a-keto-butyric acid Maltose Butyric acid  
  b- methyl-D-glucoside L- ornithine  
  Maltotriose   
  L- alanine   
  Methyl-pyruvate   
  Inulin   
  Mannan   
  Salicin   
Table 3. 5 Metabolic variation between three isolates of Brachyspira pilosicoli. This table shows the 
different carbon sources utilised by each B. pilosicoli isolate and the carbon sources shared by two out 
of three B. pilosicoli isolates to demonstrate the metabolic variation between isolates after 48 hours of 
anaerobic culture at 37°C using optical density at 540nm wavelength to capture the reduction of the 
tetrazolium dye and subsequent colour change, indicative of cellular respiration. 
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able to identify B. pilosicoli and B. intermedia. There were no specific primers sequences 
available for the detection for B. alvinipulli or B. innocens and therefore these isolates could 
not be detected using PCR in these studies. Primer sequences have been developed to identify 
the non-pathogenic Brachyspira species, B. innocens and B. murdochii, but cannot distinguish 
between them (Atyeo et al., 1999) which made them unsuitable for these studies. 
Furthermore, due to the poor understanding of B. alvinipulli and the paucity of genomic data, 
primer design has not previously been attempted. This confirmed the need to use whole 
genome sequencing for species identification. 
Using the data summarised in Table 3.1, seven Brachyspira isolates were selected for whole-
genome sequencing (excluding B. alvinipulli ATCC 51933 as the genome sequence was 
available), these isolates were those that were most likely to have been identified using 
biochemistry, PCR or a combination of both as this increased the likelihood of obtaining 
isolates from all four of the species implicated in poultry infection. The isolates sent for whole-
genome sequencing are listed in Table 3.1 and were B2904 and SAP 859, which were 
presumptive B. pilosicoli, SAP 865 and SAP 943 which were presumptive B. alvinipulli, SAP 891 
and SAP 919 which were presumptive B. intermedia and SAP 924 and SAP 927 which were 
presumptive B. innocens. The genome sequence for B. alvinipulli ATCC 51933 was already 
publicly available on Genbank. 
 
3.2.2.2 Whole genome sequencing and phylogenetics 
 
An overview of the whole genome sequence data processing and analysis can be seen in 
Figure 3.5. In brief, raw sequence reads were assembled de novo using the Shovill pipeline, a 
genome assembler for Illumina whole genome sequence data 
(https://github.com/tseemann/shovill). The quality of these assemblies was assessed using 
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Quast v2 (Gurevich et al., 2013), a summary of these data are presented in Table 3.7. All of 
the sequences presented in this table were of sufficient quality for annotation and 
phylogenetic analysis, as indicated by the high N50 values and low L50 values which described 
the quality of assembled contigs. 
The Brachyspira genomes ranged in size from 2.54 - 3.49 Mbps, with a GC content ranging 
from 26.9-28.1%. B. pilosicoli isolates had the smallest genome size, ranging from 2.57- 2.75 
Mbps, B. alvinipulli and B. intermedia had the largest genome size at 3.42 and 3.49 Mbps, 
respectively and B. innocens had a genome size of ranging from 3.15- 3.20 Mbps (this will be 
further discussed in Chapter 4). The number of coding sequences varied with the genome 
size, with B. pilosicoli having the lowest number and B. alvinipulli and B. intermedia having 
the highest numbers. Overall, the GC content (%) and the number of tRNAs (38 or 39) were 
consistent across all eight Brachyspira isolates.  
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Figure 3. 5 Summary of whole genome sequence data processing and analysis. Raw sequence reads 
from each Brachyspira isolate were assembled de novo using Shovill and all available Genbank 
sequences were downloaded. Assembly statistics were generated for all Brachyspira sequences using 
Quast to ensure the sequences were of sufficient quality for further analysis. Sequences of good 
quality were annotated using Prokka, followed by core genome SNP analysis. Phylogenetic 
dendrograms of these data were generated using Figtree, which allowed the accurate speciation of 
each Brachyspira isolates.
Raw sequence reads 
.fastq.gz files 
 
Sequences assembled 
using Shovill 
 
Contigs for each isolate 
.fna files 
 
Genbank sequences 
of all publicly 
available Brachyspira 
 
Quast analysis of 
sequences to check quality  
 
Core genome SNP or FFPry 
analysis of sequences 
 
Phylogenetic dendrogram 
visualised using Figtree 
 
Species identification of all 
Brachyspira isolates 
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Brachyspira Isolate Size (bp) 
 
GC 
content 
(%) 
Number of 
coding 
sequences 
Number of 
tRNAs 
Number of 
Contigs 
Largest 
Contig 
N50* L50** 
B. alvinipulli ATCC 
51933 
3420763 
 
26.9 3209 39 22 
 
582949 
 
342358 
 
4 
 
B. innocens SAP 924 3150198 
 
27.8 2725 39 95 
 
379134 
 
66364 
 
13 
 
B. innocens SAP 927 3203920 
 
28.1 2816 39 139 
 
171035 
 
51776 
 
20 
 
B. innocens SAP 943 3200075 
 
27.8 2811 39 72 
 
361958 
 
102553 
 
11 
 
B. intermedia SAP 
919 
3493658 
 
27.4 3005 38 144 
 
217871 
 
80677 
 
15 
 
B. pilosicoli B2904 2765477 
 
27.0 2658 38 1 
 
2765477 
 
2765477 
 
1 
 
B. pilosicoli SAP 859 2542553 
 
28.1 2288 38 13 
 
637327 
 
409203 
 
3 
 
B. pilosicoli SAP 865 2545332 
 
28.1 2252 38 22 
 
698261 
 
637106 
 
2 
 
Table 3. 6 The size of the genomes in base pairs (bp), GC content (%), number of coding sequences, number of RNAs, number of contigs, 
largest contig, the N50 value and the L50 value for each of the Brachyspira genomes. Data for the assembly statistics were generated from 
Prokka and the data for the assembly quality were generated from Quast. 
* N50 value is defined as the minimum contig length required to cover 50% of the genome, i.e. half of the contigs are equal to or larger than 
the N50 contig size. The larger the N50 value, the higher the quality of the assembly. 
** L50 value is defined as the number of contigs required to account for 50% of the genome. The lower the L50 value, the higher the quality 
of the assembly.  
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To observe the genetic diversity amongst Brachyspira isolates and to speciate each of the 
isolates selected for these studies, phylogenetics were employed using parSNP to analyse the 
core genome single nucleotide polymorphisms (SNPs) of all available Brachyspira genomes. 
This included forty genomes downloaded from Genbank, thirteen B. pilosicoli and one B. 
murdochii genomes sequenced in a collaborative project (Figure 3.6) and seven genomes 
sequenced during these studies. B. pilosicoli B2904 was sequenced in these studies to ensure 
that the isolate was identical to the isolate used by Mappley et al. (2012) as it was used as a 
control strain. B. alvinipulli ATCC 51933 was used in phenotypic assays and genome analysis 
but was not sent for sequencing as the genome sequence was publicly available. The 
phylogenetic dendrogram, which can be seen in Figure 3.6, illustrated distinct clusters of well 
characterised Brachyspira species, namely B. hyodysenteriae and B. pilosicoli. Clusters of B. 
intermedia and B. suanatina, B. hampsonii and the non-pathogenic species B. innocens and B. 
murdochii could also be identified despite the small numbers of available genome sequences.  
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Figure 3. 6 A phylogenetic 
dendrogram illustrating the 
phylogenetic relationships within the 
Brachyspira genus. Sixty-one 
Brachyspira genomes were clustered 
according to the core genome single 
nucleotide polymorphisms (SNPs) 
using parSNP (Treangen et al., 2014). 
Isolates highlighted in red were those 
presented in these studies, isolates 
highlighted in blue were those from a 
collaborative project and those 
highlighted in black were downloaded 
from GenBank.  
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Following phylogenetic analysis, it was possible to confidently determine the species of each 
of the novel Brachyspira isolates used in these studies. To summarise: B2904, SAP 859 and 
SAP 865 were identified as B. pilosicoli, SAP 919 was identified as B. intermedia and SAP 924, 
927 and 943 were identified as B. innocens. These isolates were selected for further studies 
presented in Chapters 5, 6 and 7, in addition to B. alvinipulli ATCC 51933 to ensure all species 
of Brachyspira implicated in avian intestinal spirochaetosis were considered. Presumptive B. 
intermedia SAP 891 was determined to be a mixed culture which contain both low GC contigs, 
characteristic of Brachyspira, and high GC contigs. Therefore, this isolate was excluded from 
any further analysis.  
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3.3 Discussion  
 
These studies focussed on phenotypically and genotypically characterising a panel of eight 
avian Brachyspira isolates for subsequent study into the pathobiology of this organism, and 
how Lactobacillus probiotics may be able to mitigate avian intestinal spirochaetosis caused 
by Brachyspira species. It was essential to select and characterise isolates that represented 
all species implicated in avian intestinal spirochaetosis, including B. alvinipulli, B. intermedia, 
B. pilosicoli and B. innocens. Although B. innocens is currently identified as non-pathogenic, it 
has been associated with significantly reduced egg production in free range flocks and was 
therefore utilised in these studies (Burch et al., 2009). 
A combination of Gram staining, Warthin-Starry staining and dark field microscopy identified 
the morphology and phenotype of the cells: Gram negative staining and their characteristic 
“corkscrew-like motility” (Naresh and Hampson, 2010). Until recently biochemistry was the 
primary method used to speciate Brachyspira isolates (Fellström and Gunnarsson, 1995; 
Hommez et al., 1998). These methods were only able to identify 46% of the Brachyspira 
isolates. Similar results were reported by Feberwee et al (2008), where less than 50% of 
isolates were identifiable with biochemistry alone. The biochemical profiling methods 
developed by Fellström and Gunnarsson (1995) grouped Brachyspira species in order to 
differentiate them. B. intermedia isolates were placed in group II because they were indole 
positive. B. pilosicoli isolates were placed in group IV because they were hippurate positive 
and indole negative. Importantly, B. pilosicoli and B. alvinipulli isolates could only be 
distinguished in the ability to metabolise b-glucosidase, where B. pilosicoli was negative and 
B. alvinipulli was positive, although B. alvinipulli has not been officially grouped biochemically. 
B. innocens isolates were placed in group III, which is sub-sectioned into IIIa, IIIb and IIIc. 
Groups IIIb and IIIc contained B. innocens, but vary in their a-glucosidase activity, indicating 
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metabolic variation within the B. innocens species. Traditionally, B. innocens could be 
distinguished from B. murdochii, in group IIIa by the ability to metabolise a-galactosidase  
(Hommez et al., 1998), however biochemically, B. innocens SAP 943 was classified as group 
IIIa. Biochemical testing developed by Fellström and Gunnarsson (1995) was determined 
using porcine isolates which have been shown, in some cases, to be distinct from avian 
isolates (Atyeo et al., 1999). This may, in part contribute to the fact that some of the avian 
Brachyspira isolates used here appear to have ‘atypical’ metabolic capabilities. 
Understanding the growth kinetics of each Brachyspira isolate was essential to begin to 
consider mitigation strategies to improve poultry welfare. Brachyspira are fastidious, slow 
growing organisms as seen in Figure 3.2; this considered, probiotics could be a suitable 
mitigation strategy as they are fast growing, less fastidious organisms. Many Lactobacillus 
species grow to high densities in 16-24 hours and Brachyspira reaches log phase after 
approximately 25 hours of growth, therefore it may be possible that Lactobacillus could exert 
their inhibitory effects against Brachyspira to prevent exponential growth.  
Antimicrobial resistance is a growing concern with many bacterial pathogens including 
Brachyspira. The emergence of antimicrobial resistance in Brachyspira has been noted in 
several studies, with the highest resistance observed to macrolide antibiotics such as tylosin 
and lincosamide antibiotics such as lincomycin. Resistance to tiamulin is also increasing but 
still remains one of the most effective antibiotics used to treat Brachyspira infections 
(Karlsson et al., 2004; Burch, 2005; Hampson et al., 2006; Pringle et al., 2006).  
The antibiotic resistance profiles of eight Brachyspira isolates presented in Table 3.2 showed 
that the majority of isolates were sensitive to all antibiotics tested, with B. pilosicoli SAP 865 
and B. alvinipulli ATCC 51933 showing decreased sensitivity to chlortetracycline. It is 
important to note that clinical breakpoints are yet to be formally defined for Brachyspira 
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isolates and thus it is not possible to officially specify that an isolate as clinically sensitive or 
resistant to an antibiotic (Mirajkar et al., 2016). Many break-point values for common 
antimicrobials such as tiamulin, tylosin and lincomycin have been proposed as a way of 
bridging this gap in knowledge, with break-point determination based on both agar dilution 
and broth microdilution methods (Duhamel et al., 1998; Burch, 2005; Pringle et al., 2012; 
Hellman et al., 2014). The general consensus for the broth microdilution method was that an 
MIC of < 0.25 mg/L deemed a Brachyspira isolate sensitive to tiamulin, an MIC of < 16 mg/L 
deemed a Brachyspira isolate sensitive to tylosin and an MIC of < 50 mg/L deemed a 
Brachyspira isolates sensitive to lincomycin (Burch, 2005; Pringle et al., 2012; Hellman et al., 
2014). These values have therefore been used in the studies presented here to determine the 
sensitives of all eight isolates to the antibiotics tested. The only available proposed break-
points for chlortetracycline were determined using the agar dilution method, whereby an MIC 
of < 4 mg/L deemed a Brachyspira isolate sensitive to chlortetracycline (Brooke et al., 2003; 
Hampson et al., 2006). On average, the MIC values from the broth microdilution method were 
reported as one dilution lower than that of the agar dilution method, and therefore an MIC 
of < 2 mg/L was used to interpret the sensitivity of each Brachyspira isolate to 
chlortetracycline (Rohde et al., 2004).  
Although Brachyspira are sensitive to a number of antimicrobials, the bacteriostatic 
antibiotics tiamulin and tylosin are the most effective and widely used, with their mode of 
action targeting bacterial protein synthesis. Widespread resistance to tylosin has been 
identified which may be partially attributed to the use of tylosin as an antibiotic growth 
promoter in the swine industry (Kim et al., 2016). Resistance to tylosin has been linked to two 
mutations on the 23S rRNA gene whereby a transversion from an A to a T in position 2058 or 
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a transversion from an A to a C or a transition from an A to a G in position 2059 are associated 
with tylosin resistance (Karlsson et al., 2004).  
Many Brachyspira isolates are still susceptible to tiamulin, which correlates with the results 
presented in this study. Epidemiological studies have estimated that 10-15% of isolates tested 
were identified as resistant between 1990 and 2010 (Pringle et al., 2012) and more recent 
studies have also estimated that approximately 9% of Brachyspira isolates tested were 
resistant to tiamulin (Mirajkar et al., 2016). Resistance to tiamulin has been associated with 
point mutations in the domain V of the 23S rRNA gene and the ribosomal protein L3 gene. 
These genes are in close proximity to the peptidyl transferase centre which is the binding site 
of tiamulin thus, mutations in this binding site and in neighbouring proteins may affect the 
efficacy of tiamulin  (Pringle et al., 2004; Hidalgo et al., 2011). Considering the decreasing 
susceptibly to commonly used antibiotics and the removal of antibiotic growth promoters, it 
is imperative that control strategies are implemented to promote intestinal health and 
prevent disease. The use of probiotics may be able to decrease the need for antibiotic use in 
poultry, thus decreasing the selective pressure on pathogens such as Brachyspira, in addition 
to potentially promoting a healthy intestinal microflora and improving overall health and 
welfare of poultry. 
There is a significant lack of understanding of Brachyspira metabolism, only recently have high 
throughput methods been used to investigate the carbon metabolism of Brachyspira isolates 
using Biolog technology (Mappley et al., 2012). Previous characterisation of Brachyspira 
isolates has been conducted by supplementing media with sugars such as fructose, maltose, 
mannose and sucrose, to name a few, in order to determine the metabolic capabilities of 
different species. These methods were established in the late 1980s and 1990s and were 
limited to a relatively small number of sugars (Stanton and Lebo, 1988; Trott et al., 1996; 
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Stanton et al., 1998). More recently, with the availability of whole genome sequences, 
metabolic modelling has been used to infer the metabolic capabilities of Brachyspira but little 
phenotypic testing has been reported (Wanchanthuek et al., 2010). Therefore, the use of the 
Biolog Phenotypic MicroarrayTM technology has the ability to screen many more carbon 
sources, which could not only help to improve the identification of Brachyspira isolates but 
could also improve the understanding the metabolic capabilities of these organisms. 
Biolog PMTM technology was used as a further phenotypic characterisation method for the 
panel of eight Brachyspira isolates presented in these studies. It was apparent that more 
comprehensive phenotypic testing with a much greater number of Brachyspira isolates is 
required to identify carbon sources unique to each species with the aim of improving current 
biochemical testing methods. 
The results of this study indicated that all Brachyspira isolates utilised a number of carbon 
sources involved in glycolysis which therefore plays a major role in energy production for this 
organism, these included glucose, glucose-6-phosphate, fructose-6-phosphate, fructose and 
galactose. Metabolic modelling, following whole genome sequencing, has also indicated that 
glycolysis is the backbone of energy productive for Brachyspira species (Wanchanthuek et al., 
2010). Glucose-6-phosphate and fructose-6-phosphate are also important constituents of the 
pentose phosphate pathway which is important for biosynthetic production of fatty acids and 
nucleotides. B. pilosicoli, B. murdochii and B. hyodysenteriae were found to have a complete 
set of genes for the pentose phosphate pathway including genes such as ribulose-5-
phosphate epimerase and isomerase, to convert glucose-6-phosphate to ribulose-5-
phosphate, a major constituent of this pathway (Bellgard et al., 2009; Wanchanthuek et al., 
2010). Lactobacillus species are also able to metabolise many of these carbon sources using 
similar pathways, therefore this could be evidence that potential probiotic isolates could 
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directly compete with Brachyspira for available nutrients (Saulnier et al., 2011). Brachyspira 
isolates were unable to metabolise many of the intermediates involved in the tricarboxylic 
acid cycle (TCA) such as malic acid, fumaric acid and succinic acid, as a result of having an 
incomplete set of genes for this metabolic pathway. Thus, suggesting that ATP is generated 
through the fermentation of sugars. This can be observed with other spirochaetes such as 
Borrelia burgdorferi (Lackum and Stevenson, 2005) and Treponema pallidum (Bellgard et al., 
2009). 
B. pilosicoli isolates metabolised more carbon sources than other Brachyspira isolates on the 
PM1 and PM2 plates, and this more extensive metabolic capacity may contribute to the ability 
to infect a wide host range, including pigs, poultry, humans, horses and dogs (Trott et al., 
1996). This versatility may have contributed to the success of B. pilosicoli as an intestinal 
pathogen.  
It was not possible to attribute unique carbon source utilisation to a specific species of 
Brachyspira for a several reasons. Firstly, only one isolate of B. alvinipulli and B. intermedia 
was used thus these data may not be representative of each species due to the notable 
metabolic variations described in other species (Mappley, 2012). Additionally B. innocens and 
B. piloscioli isolates exhibited variation within each species. For example, inosine was utilised 
soley by B. pilosicoli B2904 in these studies. When this was compared to data from Mappley 
et al (2012) it was observed that B. pilosicoli 95/1000 and WesB could also utilise inosine, 
whereas B. pilosicoli SAP 859 and 865 did not. Of these five B. pilosicoli isolates only SAP 865 
was able to utilise inulin, trehalose, b- methyl-D-glucosidase, methyl pyruvate and mannan, 
suggesting that SAP 865 may be an atypical isolate of B. piloscioli. However, more isolates 
would need to be tested in future studies to generate typical phenotypes for each Brachyspira 
species. Similarly carbon sources that were specific to B. innocens were only representative 
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of one isolate and in the absence of data from more isolates, it was not possible to select 
carbon sources that would be suitable targets for differential diagnoses of Brachyspira.  
The Biolog data in these studies largely agreed with the data published by Mappley et al 
(2012), however there were discrepancies with 47 carbon sources. This could be attributed 
to the modifications of methods used in these studies whereby Biolog plates were prepared 
and incubated in an anaerobic cabinet for 48 hours instead of being incubated as specified by 
Biolog. According to the manufacturer, anaerobic gas can auto-reduce the tetrazolium dye 
after 48 hours of incubation, and therefore the duration of this experiment was limited. 
Mappley et al (2012) incubated plates for 120 hours, which may have resulted in the 
respiration on more carbon sources by Brachyspira. Initial descriptions of B. pilosicoli (Trott 
et al., 1996), B. intermedia (Stanton et al., 1997), B. innocens (Ochiai et al., 1997) and B. 
alvinipulli (Stanton et al., 1998) characterised metabolic profiles for a relatively small number 
of carbon sources. These also largely match the data presented in these studies, however it 
was apparent that once multiple isolates from each species were characterised, more carbon 
sources could be utilised than originally identified. For example, B. intermedia, B. innocens 
and B. pilosicoli were reported as not being able to metabolise L-rhamnose, however all 
isolates in the studies presented here were able to utilise this carbon source, this is further 
evidence to suggest that there are metabolic variations between Brachyspira isolates within 
the same species, as previously observed.  
With this in mind, future work could focus in applying this phenotypic assay to a wider range 
of Brachyspira isolates in order to build metabolic profiles for each species implicated in avian 
intestinal spirochaetosis. The use of this rapid, high throughput method may then have the 
ability to improve current diagnostic methods, especially for avian isolates which are overall, 
less well characterised than porcine isolates. 
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Genotypic characterisation of Brachyspira isolates was used to correctly identify all isolates. 
It was evident from Table 3.1 that biochemistry results alone, were highly variable and did 
not always correspond to the species identified by PCR. It has been noted that in addition to 
phenotypic variations between avian and porcine isolates, there are also genotypic variations 
whereby species-specific primers designed for B. intermedia and B. pilosicoli were able to 
identify 100% of porcine isolates, but only 40% and 85% of avian isolates, respectively (Atyeo 
et al., 1999). The species-specific PCR primers used in these studies correctly identified three 
of the four B. pilosicoli isolates tested and both of the B. intermedia isolates tested, although 
following whole genome sequencing one of these was identified as mixed with B. innocens, 
highlighting the need for further investigation into the design of B. innocens species-specific 
primers. This may also highlight the need to review B. pilosicoli PCR primers in future studies 
as they were initially developed using human Brachyspira isolates (Park et al., 1995; Mikosza 
et al., 2001) and thus the diversity observed between porcine and avian isolates may also 
apply with human isolates. Additionally, the need for PCR primers to identify all Brachyspira 
isolates implicated in poultry disease is apparent. However, due to the paucity of information 
about the B. alvinipulli species and the absence of genome data, this is not possible. 
Differential PCR based methods have been developed to distinguish avian Brachyspira species 
using the nox gene instead of the 16S or 23S rRNA genes because, although well conserved in 
the Brachyspira genus with approximately 86% sequence identity among isolates, they are 
less well conserved than the 16S or 23S rRNA genes which show a maximum sequence 
divergence of 2% and 3% respectively, therefore there is a greater likelihood of species 
specificity (Atyeo et al., 1999). These PCRs have been developed to distinguish pathogenic 
species of Brachyspira from non-pathogenic species and therefore can detect the presence 
of B. innocens and B. murdochii but cannot distinguish between them.  
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Considering the difficulty in identifying the panel of Brachyspira isolates presented in Table 
3.1, seven isolates were sent for whole genome sequencing for definitive identification to 
inform isolate section for further studies presented in Chapters 5, 6 and 7. Using 
phylogenetics it was shown that both isolates SAP 865 and SAP 943 were not B. alvinipulli, 
but belonged to B. pilosicoli and B. innocens, respectively, further highlighting the need to 
fully characterise B. alvinipulli. 
The genome sequence of each Brachyspira isolates detailed in Table 3.6 showed that each 
isolate had a genome size of between 2.54- 3.49 Mbp with a GC content (%) of between 26.9-
28.1%. These data were representative of the Brachyspira genus, with B. pilosicoli having the 
smallest, but most variable genome size when compared to any other species (Wanchanthuek 
et al., 2010; Håfström et al., 2011; Mappley et al., 2012; Lin et al., 2013; Black et al., 2015). In 
studies presented here, the B. pilosicoli genome size ranged from 2.54- 2.76 Mbp but are 
known to be as large as 2.88 Mbp in the example of B. pilosicoli WesB (Mappley et al., 2012), 
however B. hyodysenteriae have a more stable genome size ranging from 3.01- 3.1 Mbp, with 
the majority of isolates approximately 3.03 Mbp (Black et al., 2015). This may be as a result 
of B. pilosicoli having undergone increased genome evolution as a result of the ability to infect 
a wide host range, whereas pigs are the primary host for B. hyodysenteriae, although there 
have been reports of this organism colonising of poultry in close proximity to pig units, in 
addition to be isolated from rheas in the USA (Jensen et al., 1996; Thomson et al., 2007). 
In summary, this chapter described the identification and characterisation of eight 
Brachyspira isolates, including all species implicated in avian intestinal spirochaetosis. A 
combination of phenotypic and genotypic methods were utilised to ensure the accurate 
identification of isolates, including biochemical testing, PCR and whole genome sequencing. 
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Combining these techniques was imperative to the accurate identification of all Brachyspira 
isolates, which were used in subsequent studies presented in this thesis. 
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Chapter 4: Comparative genomics of Brachyspira species implicated in 
intestinal spirochaetosis  
 
4.1 Introduction  
 
There is a paucity of data relating to both the physiology and genomics of Brachyspira species. 
This lack of knowledge may be, in part due to the small number of isolates that have 
undergone whole genome sequencing. Furthermore, there are Brachyspira species, such as 
B. aalborgi, that have yet to have their genome sequences determined. There have been very 
few comparative genomics studies conducted on the Brachyspira genus, however as whole 
genome sequencing is becoming more economic and readily accessible, the understanding of 
Brachyspira biology and evolution will no doubt improve significantly.  
Previous comparative genomics studies have focussed on comparing Brachyspira isolates 
within one species, in particular B. hyodysenteriae (Black et al., 2015) and B. pilosicoli 
(Mappley et al., 2012), as these are the most well characterised Brachyspira species. These 
studies have found that B. hyodysenteriae is a relatively conserved species and highly adapted 
to cause disease in pigs (Bellgard et al., 2009; Black et al., 2015), whereas B. pilosicoli is a 
diverse species, capable of causing disease in a wide host range (Mappley et al., 2012). 
Additionally, a study that compared one isolate of B. hyodysenteriae, B. pilosicoli and B. 
murdochii indicated the diversity between these species, although the interpretation of these 
data are limited as analysis was conducted with single isolates from each species 
(Wanchanthuek et al., 2010). Finally, more recently genome features from other Brachyspira 
species, such as B. intermedia and B. innocens  have been investigated, however pangenome 
analysis has been limited to a small number of publicly available sequences and therefore, 
comparisons must be treated as preliminary (Hampson and Wang, 2017).  
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The studies presented in this chapter follow on from the results presented in Chapter 3, 
where whole genome sequencing was used to confirm the species of Brachyspira isolates 
used in subsequent studies. A comparative genomics approach was used to compare 
Brachyspira species implicated in both avian, human and porcine disease. These comparisons 
build upon published data by using more sequences from B. pilosicoli, B. innocens and B. 
intermedia (Bellgard et al., 2009; Wanchanthuek et al., 2010; Mappley et al., 2014; Hampson 
and Wang, 2017). Additionally, key virulence genes such as methyl-accepting chemotaxis 
protein (MCP)  genes and chemotaxis genes (che) were investigated to determine any key 
differences between Brachyspira species which may give insight into the host range or 
pathogenicity. 
Therefore, the aims and objectives of this chapter were: 
• To determine the genome sequences of a panel of Brachyspira species implicated in 
avian intestinal spirochaetosis.  
• To use a pangenome approach to compare all available Brachyspira whole genome 
sequences, including those determined in this study. Comparative genomics was 
completed by splitting species in to three comparable groups: “B. hyodysenteriae”, “B. 
pilosicoli” and “Other” (comprising of all other Brachyspira species). 
• To use the output from the comparative studies to select target genes of interest to 
highlight similarities/ differences between Brachyspira species. 
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4.2 Results  
 
4.2.1 Genome size comparisons between Brachyspira species 
 
The phylogenetic tree presented in Chapter 3 (also shown below) demonstrated evolutionary 
divergence between B. hyodysenteriae and B. pilosicoli, with other species such as B. 
alvinipulli, B. innocens, B. intermedia and B. murdochii positioned between them. As 
mentioned, the phylogenetic relationships between species of the Brachyspira genus have 
not been extensively investigated, most likely due to the lack of available genome sequences. 
More recently, Hampson and Wang (2017) took a similar approach to the studies presented 
here and compared all publicly available Brachyspira genome sequences.  However, in the 
studies presented here nineteen  B. pilosicoli genomes were included, compared to three in 
previously published studies (Mappley et al., 2012). Furthermore, novel B. innocens, B. 
intermedia and B. murdochii sequences were included. 
For the purpose of these analyses, fifty-six genomes from the analysis presented in Chapter 3 
were split in to three groups: “B. hyodysenteriae”, “B. pilosicoli” and “Other”, the latter 
containing the genome sequences of all other available Brachyspira species. This grouping 
was necessary to ensure that Brachyspira species with only one or two available genome 
sequences were not excluded from analysis at this early stage in the studies. It must be noted 
that four genomes were removed from this analysis due to poor sequence quality as 
determined by Quast (three B. hampsonii and one B. pilosicoli), additionally, the B. pilosicoli 
B2904 genome was present twice, and one version was removed (Appendix II) 
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Figure 3. 6a A phylogenetic dendrogram 
illustrating the phylogenetic relationships 
within the Brachyspira genus. Sixty-one 
Brachyspira genomes were clustered 
according to the core genome single 
nucleotide polymorphisms (SNPs) using 
parSNP (Treangen et al., 2014). Isolates 
highlighted in red were those presented 
in these studies, isolates highlighted in 
blue were those from a collaborative 
project and those highlighted in black 
were downloaded from GenBank.  
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Comparisons of Brachyspira genome size and number of coding sequences showed that these 
varied considerably between different Brachyspira species, as shown in Table 4.1 and Figure 
4.1. From the genome information presented in Table 4.1 it can be seen that B. intermedia 
has the largest genome size, between 3.33 and 3.49 Mbps, although it is important to note 
that there were only two available genomes for comparison. Notably, B. pilosicoli had on 
average the smallest genome size, but also represented the largest range in genome sizes, 
ranging from 2.43 to 2.75 Mbps, with an average of 2.64 Mbps. B. hyodysenteriae had an 
average genome size of 3.06 Mbps with a range between 2.99 and 3.19 Mbps.  
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Species Number of genomes Genome Size (Mbp) 
(standard deviation) 
Assembly status Source 
B. alvinipulli  1 3.42  Complete NCBI 
B. hampsonii * 2 3.16-3.18 (0.08) 4 complete, 1 scaffold NCBI 
B. hyodysenteriae 25 2.99-3.19 (0.05) 3 complete, 18 scaffold, 4 contigs NCBI 
B. innocens 4 3.15-3.28 (0.05) Contigs 1 NCBI, 3 this study 
B. intermedia  2 3.33-3.49 (0.13) 1 complete, 1 contigs 1 NCBI, 1 this study 
B. murdochii 2 3.14-3.24 (0.07) 1 complete, 1 contigs NCBI 
B. pilosicoli ** 19 2.43-2.76 (0.09) 3 complete, 1 scaffold, 17 contigs 4 NCBI, 17 this study 
B. suanatina  1 3.25 Contigs NCBI 
Table 4. 1 Available Brachyspira whole genome sequences used in the pangenome analysis are presented here. These sequences were either 
obtained from GenBank, NCBI or sequenced for the purpose of the studies presented here. The number of genomes per species are detailed, 
in addition to the assembly status and the source of the sequences. 
* three B. hampsonii sequences were removed from the pangenome analysis due to poor quality genome sequences (30446, 30599 and NSH-24) 
** two B. pilosicoli sequences were removed from the pangenome analysis because: (a) there were duplicate B2904 genomes and (b) the 
sequence for WesB was poor quality.  
 
Figure 4. 1 Comparisons of the genome size (A) and the number of coding sequences (B) between different species in the Brachyspira genus. The 
size of Brachyspira genomes range from approximately 2.43- 3.49 Mbps depending on the species, with B. pilosicoli having overall the smallest 
genomes and B. alvinipulli and B. intermedia appearing to have some of the largest. The number of coding sequences is consistent with genome 
size, with B. pilosicoli having some of the lowest numbers of coding sequences and B. alvinipulli and B. intermedia having some of the highest. 
The genomes are separated into groups on the x axis, the first group showing B. hyodysenteriae, and second group showing the “Other” group 
of Brachyspira species and the third group showing B. pilosicoli sequences.* three B. hampsonii sequences were removed from the pangenome 
analysis due to poor quality genome sequences (30446, 30599 and NSH-24) 
** two B. pilosicoli sequences were removed from the pangenome analysis because: (a) there were duplicate B2904 genomes and (b) the 
sequence for WesB was poor quality.  
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Figure 4. 1 Comparisons of the genome size (A) and the number of coding sequences (B) between different species in the Brachyspira genus. The size 
of Brachyspira genomes range from approximately 2.43- 3.49 Mbps depending on the species, with B. pilosicoli having overall the smallest genomes 
and B. alvinipulli and B. intermedia appearing to have some of the largest. The number of coding sequences is consistent with genome size, with B. 
pilosicoli having some of the lowest numbers of coding sequences and B. alvinipulli and B. intermedia having some of the highest. The genomes are 
separated into groups on the x axis, the first group showing B. hyodysenteriae, and second group showing the “Other” group of Brachyspira species and 
the third group showing B. pilosicoli sequences.  
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4.2.2 Pangenome analysis of Brachyspira species  
 
A pangenome approach was used to compare all fifty-six Brachyspira genomes detailed in 
Table 4.1. All newly sequenced genomes were assembled using Shovill 
(https://github.com/tseemann/shovill), annotated using Prokka (Seemann, 2014) and 
subjected to Roary analysis (Page et al., 2015). A Quast analysis was completed for all 
available genomes to ensure they were of suitable quality for the pangenome analysis using 
the criteria discussed in Chapter 3 (Gurevich et al., 2013). The workflow is detailed in Figure 
4.2, which builds upon the results presented in Chapter 3. Roary is a pangenome pipeline that 
allows for the comparison of annotated genomes. Coding sequences are converted into 
protein sequences and all comparisons are performed with BLASTP with a defined percentage 
sequence identity. A sequence identity cut off of 80% was used, as demonstrated in Figure 
4.3. To identify the optimal cut off, the number of unique BLAST hits were plotted against the 
percentage BLAST cut off. The rationale behind selecting a suitable cut off was to identify the 
point at which the number of unique hits plateaued. This was at approximately 90%, however 
because multiple species of Brachyspira were being compared, an 80% cut off was used to 
ensure that comparisons were not overly stringent. 
The Roary analysis produced a presence/absence gene matrix for each annotated gene in all 
selected Brachyspira isolates. This analysis was conducted with paralog clustering enabled, 
which ensured that paralogous genes were not split into separate groups, thus correcting for 
high allelic variation within the genomes (van Vliet, 2017). 
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Figure 4. 2 Summary of sequence data processing and analysis for the comparative genomics. Raw 
sequence reads from each Brachyspira isolate used in these studies, were assembles de novo using 
Shovill. Publicly available Brachyspira sequences were also obtained from Genbank and assembly 
statistics were generated for all fifty-six genome sequences using Quast to ensure the sequences were of 
sufficient quality for further analysis. Sequences of sufficient quality were annotated using Prokka, 
followed by Roary analysis to determine the presence/absences of each of the genes annotated by 
Prokka. An 80% sequence identity cut-off was used. The genes of interest selected for comparative 
analysis were motility and chemotaxis genes as they are key virulence factors for Brachyspira and showed 
interesting distribution between species.  
 
Figure 4. 3 The effect of the BLAST identity cut off on the number of unique hits within the dataset. The 
cut-off is usually set where the graph begins to tail off, which for Brachyspira is approximately 90%.  
However, because comparisons were being made between species in the genus, a cut-off of 80% was 
chosen, as indicated by the red arrow.Figure 4. 4 Summary of sequence data processing and analysis for 
the comparative genomics. Raw sequence reads from each Brachyspira isolate used in these studies, were 
assembles de novo using Shovill. Publicly available Brachyspira sequences were also obtained from 
Genbank and assembly statistics were generated for all fifty-six genome sequences using Quast to ensure 
the sequences were of sufficient quality for further analysis. Sequences of sufficient quality were 
annotated using Prokka, followed by Roary analysis to determine the presence/absences of each of the 
genes annotated by Prokka. An 80% sequence identity cut-off was used. The genes of interest selected 
for comparative analysis were motility and chemotaxis genes as they are key virulence factors for 
Brachyspira and showed interesting distribution between species.  
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The pangenome analysis, comparing all available Brachyspira genome sequences revealed 
that the core genome of the Brachyspira genus consisted of 1089 genes. There was evidence 
to suggest the divergence of B. pilosicoli from other species of Brachyspira; analysis of the 
accessory genome identified 1423 genes that were unique to B. pilosicoli, only thirty-five 
genes shared with B. hyodysenteriae and 210 genes shared with other species in the genus, 
as shown in Figure 4.4. In contrast, B. hyodysenteriae had 306 unique genes and shared 1329 
genes with the other species of Brachyspira. The group of “Other” Brachyspira had 1502 
unique genes, however this group represented six different species of Brachyspira (B. 
alvinipulli, B. innocens, B. intermedia, B. murdochii, B. hampsonii and B. suanatina), thus 
highlighting that B. pilosicoli isolates are distinct within the Brachyspira genus, demonstrated 
by the 1423 unique genes. 
Figure 4. 3 The effect of the BLAST identity cut off on the number of unique hits within the 
dataset. The cut-off is usually set where the graph begins to tail off, which for Brachyspira 
is approximately 90%.  However, because comparisons were being made between species 
in the genus, a cut-off of 80% was chosen, as indicated by the red arrow.  
 
 
Figure 4. 5 The effect of the BLAST identity cut off on the number of unique hits within the 
dataset. The cut-off is usually set where the graph begins to tail off, which for Brachyspira 
is approximately 90%.  However, because comparisons were being made between species 
in the genus, a cut-off of 80% was chosen, as indicated by the red arrow.  
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The Brachyspira pangenome can also be visualised as a presence/ absence matrix generated 
by Roary, as shown in Figure 4.5. These data clearly show that B. pilosicoli was genetically 
distinct from all other species of Brachyspira that have currently been sequenced. As 
illustrated in Figures 4.4 and 4.5, B. hyodysenteriae and the “Other” species of Brachyspira 
share a significant proportion of genes, although B. hyodysenteriae has its own, smaller set of 
unique genes. Conversely, B. pilosicoli only shares a small number of genes with the “Other” 
Brachyspira species and B. hyodysenteriae yet has a large proportion of unique genes.
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Figure 4. 4  A Venn diagram of the unique and shared genes between the three groups of 
Brachyspira used in these studies: B. pilosicoli, B. hyodysenteriae and “Other”, which contained 
B. alvinipulli, B. intermedia, B. hampsonii, B. murdochii, B. suanatina and B. innocens. Each circle 
represents the number of genes in each group and the overlapping regions represent the 
number of genes shared by the respective species. 
 
Figure 4. 7  A Venn diagram of the unique and shared genes between the three groups of 
Brachyspira used in these studies: B. pilosicoli, B. hyodysenteriae and “Other”, which contained 
B. alvinipulli, B. intermedia, B. hampsonii, B. murdochii, B. suanatina and B. innocens. Each circle 
represents the number of genes in each group and the overlapping regions represent the 
number of genes shared by the respective species. 
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Figure 4. 5 Identification of genes present in the Brachyspira pangenome. The genomes were ordered according to the SNP phylogenetic tree, with dark blue 
indicating the presence of a gene and white indicating the absence of a gene. Genes were firstly ordered according to the core genes, followed by the genes shared 
between B. hyodysenteriae (red) and the “Other” Brachyspira species (yellow), genes present in only B. hyodysenteriae isolates and genes present only in B. 
pilosicoli isolates (blue). A small set of genes also appeared to be specific to the non-pathogenic species B. innocens and B. intermedia. The overview of genes was 
identified using Roary, based on an 80% BLAST identity cut-off, with paralog clustering enabled. These data highlight that B. pilosicoli is evolutionarily divergent 
from other species of Brachyspira and that it has its own unique accessory genome, sharing very few genes with other species of Brachyspira. B. hyodysenteriae 
and the “Other” Brachyspira species are more closely related to one another than to B. pilosicoli.  
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As a result of the diversity observed within B. pilosicoli isolates, analysis was conducted to 
investigate the pangenome of this species, and that of B. hyodysenteriae as a comparison. B. 
pilosicoli and B. hyodysenteriae had a similar pangenome size, with B. pilosicoli consisting of 
3705 genes and B. hyodysenteriae consisting of 3401 genes, as illustrated in Figure 4.6. 
However, B. pilosicoli core genes (95-100% of genomes contained these genes) represented 
only 47% of the pangenome, with 1749 genes, whereas B. hyodysenteriae core genes 
represented 70% of the pangenome, with 2385 genes. B. pilosicoli also have a larger 
proportion of cloud genes (15-95% of genomes contained these genes) and shell genes (less 
than 15% of genomes contained these genes) compared to B. hyodysenteriae, with 944 cloud 
genes compared to 632 genes, respectively and 1012 shell genes compared to 384 genes, 
respectively. 
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Figure 4. 6 Pangenome analysis of (A) B. pilosicoli and (B) B. hyodysenteriae. The genes were identified using Roary with an 80% identity cut-off, with paralog 
clustering enabled. The size of the pangenomes were similar when comparing B. pilosicoli and B. hyodysenteriae, however the core genome (genes present 
in 95-100% of the genome sequences) was distinctly different between the two species. B. pilosicoli had a much larger accessory genome, consisting of 
cloud genes (genes present in 15-95% of the genome sequences) and shell genes (genes present in less than 15% of the genome sequences), when compared 
to B. hyodysenteriae. 
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4.2.3 Distribution of chemotaxis genes in Brachyspira species  
 
An initial analysis of the annotation of the genes showing differential distribution in the three 
groups suggested an overrepresentation of genes associated with motility and chemotaxis. 
Therefore, these genes were further investigated using a comparative genomics approach. 
Motility and chemotaxis are key virulence factors for Brachyspira and contribute to the 
pathogenicity associated with this genus, as discussed in Chapter 1. Therefore, the hypothesis 
was that proteins such as methyl-accepting chemotaxis proteins (MCP) and chemotaxis 
proteins (Che), involved in directed motility and chemotaxis towards specific chemical stimuli 
differ between species of Brachyspira, which may make an important contribution to the 
ability to infect different hosts and host tissues.  
The different MCP and Che proteins annotated within the genome sequences of isolates 
selected for analysis are shown in Figure 4.7. There were a high number of MCP genes present 
within the Brachyspira pangenome compared to other gastrointestinal pathogens such as E. 
coli (which has four well characterised MCPs) and Campylobacter (which has at least ten 
MCPs) (Liu and Parales, 2008; Li et al., 2014).  Approximately fifteen MCP genes were found 
uniquely in B. pilosicoli and approximately forty different MCP proteins were present within 
the B. hyodysenteriae pangenome, with many of these were shared with other species of 
Brachyspira, but not with B. pilosicoli. Therefore, B. pilosicoli appeared to have its own set of 
unique MCP genes which made this species distinct from other Brachyspira species. 
Additionally, Figure 4.7 suggested that there may be some MCPs that were predominantly 
present in B. innocens isolates, however more genome sequences would need to be analysed 
in order to strengthen these data as this was based on only four genome sequences. 
In contrast, the chemotaxis protein machinery appeared to be well conserved between all 
Brachyspira species whereby all of the key che genes, for example cheA, cheY and cheX, were 
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present in multiple copies and were mostly shared between species, although B. pilosicoli was 
missing some copies of genes. 
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Figure 4. 7 Distribution of methyl-accepting proteins (MCPs) and chemotaxis proteins. The genes encoding these 
proteins were identified from the Roary analysis with an 80% cut-off identity with paralogue clustering enabled. 
The red highlights the genes present in B. hyodysenteriae, the blue highlights the genes present in B. pilosicoli and 
the yellow highlights the genes present in B. innocens (although a small number of genomes were used). There 
were distinct groups of MCPs unique to B. pilosicoli, however B. hyodysenteriae appeared to share some of the 
same MCPs with other species of Brachyspira. The chemotaxis proteins were similar within the genus, with B. 
pilosicoli and the “Other” species of Brachyspira appearing to have few copies of genes compared to B. 
hyodysenteriae.  
 
 
 
Figure 4. 18 Distribution of methyl-accepting proteins (MCPs) and chemotaxis proteins. The genes encoding these 
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As a result of discovering the distinct sets of MCPs in the genus a more detailed investigation 
of DNA sequences was conducted. B. pilosicoli B2904 and B. hyodysenteriae WA1 genomes 
were downloaded from Genbank as representative genomes and a database of all of the MCP 
genes was created. B. pilosicoli B2904 contained fifteen MCP genes and B. hyodysenteriae 
WA1 contained thirty-nine genes. This database was created in ABRicate 
(https://github.com/tseemann/abricate) and all available B. pilosicoli and B. hyodysenteriae 
genome sequences were screened for the fifty-four MCP genes in that database. In the 
interest of comparing pathogenic species with non-pathogenic species of Brachyspira to 
investigate if MCPs may relate to pathogenicity, B. innocens and B. murdochii sequences were 
also screened for the presence of these MCP genes as this may potentially provide an insight 
in to genes that may contribute to pathogenicity.  
The analysis presented in Figure 4.8, highlighted, once again how distinct the 
presence/absence of MCP genes was between different species. For example, B. pilosicoli did 
not share any MCP genes with either B. hyodysenteriae, B. innocens or B. murdochii. 
Interestingly, the fifteen MCP genes are shared between all B. pilosicoli in the analysis, except 
B. pilosicoli SAP 772, which lacked two of the fifteen MCP genes, which matched its position 
as an outgroup within B. pilosicoli in the phylogenetic tree shown in (Figure 3.6). Not all of the 
B. hyodysenteriae isolates contained all thirty-nine MCP genes that were present in B. 
hyodysenteriae WA1, however between thirty-four and thirty-eight genes were found in the 
B. hyodysenteriae isolates analysed. Interestingly, B. innocens and B. murdochii shared 
between thirteen and sixteen of these genes with B. hyodysenteriae but none with B. 
pilosicoli, despite occupying some of the same hosts. The MCP genes identified in the B. 
innocens and B. murdochii genome analysis highlighted that MCP genes are shared by these 
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non-pathogenic species, but also by B. hyodysenteriae, therefore may not directly result in 
pathogenicity.  
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Figure 4. 8 Distribution of the genes encoding methyl-accepting proteins present in B. pilosicoli, B. 
hyodysenteriae, B. innocens and B. murdochii genome sequences. A list of MCP genes was obtained 
from the complete genome sequences of B. pilosicoli B2904 and B. hyodysenteriae WA1, which were 
used as example genomes because they were complete and previous analysis suggested that they 
contained a high proportion of MCP genes identified during the Roary analysis. An ABRicate database 
was generated and the genes present in the B. pilosicoli, B. hyodysenteriae, B. innocens and B. murdochii 
were screened against this database using a 75% cut-off. Blue indicates presence of a gene and white 
indicates absence of a gene. These data demonstrated once again that B. pilosicoli had distinct MCP 
genes from other species of Brachyspira and that non-pathogenic species of Brachyspira shared some 
MCP genes with the pathogenic B. hyodysenteriae but that the presence of certain MCP genes was 
unique to the non-pathogenic isolates and could easily be distinguished from B. hyodysenteriae.  
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To explore the sequence similarity between the different MCPs in B. pilosicoli and B. 
hyodysenteriae, the sequences were translated into protein sequences and aligned using 
COBALT (Constraint-based Multiple Alignment Tool) 
(https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi) to investigate areas of sequences 
homology. The sequences of B. pilosicoli MCPs appeared to be highly conserved between 
alignment position 805 and 871, as shown in red in Figure 4.9. On analysis of this region using 
the Conserved Domains tool on NCBI 
(https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) it appeared that this region was a 
signalling domain thought to be responsible for transducing a signal to CheA. The areas 
highlighted in blue are less well conserved sequences, of which there are several, but protein 
function could not be assigned to these regions using the Conserved Domains database 
indicating that the MCPs present in B. pilosicoli are distinct from one another. Similarly, B. 
hyodysenteriae MCP sequences showed a small region of conserved sequence at the 
approximate alignment positions of 790 and 803, which were also shared with the sequences 
of B. pilosicoli MCPs (Figure 4.10), although protein function could not be assigned.  These 
data demonstrated that the Brachyspira MCPs do have some sequences homology, but that 
they are also distinct both within a species and between different species in the genus.  
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Figure 4. 9 Alignment of fifteen B. pilosicoli methyl-accepting protein sequences. The alignment was 
performed using COBALT whereby red indicated areas of highly conserved residues, blue indicated 
areas of less conserved residues and grey indicated regions with no homology or gaps in the protein 
sequence. The horizontal scale represents the amino acid alignment position. B. pilosicoli MCPs showed 
significant homology in residues between alignment position 805 and 871, however there were less 
homologous residues which make these MCPs distinct from one another.  
 
Figure 4. 22 Alignment of fifteen B. pilosicoli methyl-accepting protein sequences. The alignment was 
Figure 4. 10 Alignment of thirty-nine B. hyodysenteriae methyl-accepting protein sequences. The 
alignment was performed using COBALT whereby the red indicated areas of highly conserved residues, 
blue indicated areas of less conserved residues and grey indicated regions of no homology or gaps in the 
protein sequence. The horizontal scale represents the amino acid alignment position.  B. hyodysenteriae 
MCPs showed significant homology in residues between alignment position 790 and 803, however had 
more regions with low homology, suggesting there was diversity in the MCPs.  
  
 
Figure 4. 20 Alignment of fifteen B. pilosicoli methyl-accepting protein sequences. The alignment was 
performed using COBALT whereby red indicated areas of highly conserved residues, blue indicated areas 
of less conserved residues and grey indicated regions with no homology or gaps in the protein sequence. 
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4.3 Discussion  
 
The studies presented in this chapter have used a comparative genomics approach to 
compare all available Brachyspira whole genome sequences, including those available on 
Genbank and those generated in this thesis. The data presented builds on other comparative 
genomics studies that make genetic comparisons within one species of Brachyspira (Bellgard 
et al., 2009; Mappley et al., 2012) or interspecies comparisons with a small number of 
different Brachyspira species (Wanchanthuek et al., 2010; Håfström et al., 2011). The strength 
of the comparisons made in this chapter arises from having fifteen novel B. pilosicoli genome 
sequences available for analysis. Furthermore, the studies presented here have provided 
additional genome sequences for B. intermedia, B. innocens and B. murdochii. This overall 
contributed significantly more data to the limited data currently available in the public 
domain.  
Genome sizes of Brachyspira isolates varied depending on the species of Brachyspira. B. 
pilosicoli had the smallest genome size and yet is able to infect the largest host range. This 
had previously been proposed to be as a result of B. pilosicoli undergoing a high degree of 
reductive evolution (Håfström et al. 2011; Mappley et al., 2012) and thus it has been 
suggested that B. pilosicoli may be an older pathogen than other Brachyspira species such as 
B. hyodysenteriae (Håfström et al., 2011).  Reductive genome evolution may have reduced 
the gene redundancy observed in species such as B. hyodysenteriae, furthermore the 
selection of different gene sets may have resulted in the ability to more effectively colonise 
the desired niche. For example, B. pilosicoli and B. aalborgi have the unique ability to form 
end on attachments to enterocytes which may enhance the colonisation and pathogen 
survival in the large intestine. Furthermore, other spirochaete species such as Leptospira have 
undergone net loss of genes during evolutionary divergence to become intermediate and 
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pathogenic species (Xu et al., 2016). The genetic divergence of B. pilosicoli may have been as 
result of a similar process, thus suggesting that gene loss is a result of spirochaetes adapting 
to their ecological niche and may have contributed to the reduced genome size of B. pilosicoli. 
In addition to a reduction in genome size, the selection of differing gene sets is likely to have 
occurred to contribute to the genetic diversity of B. pilosicoli, as exemplified by the unique 
set of MCP genes. 
It is likely that Brachyspira species originally infected multiple hosts, but that B. 
hyodysenteriae later specialised to colonise the porcine host. Despite B. hyodysenteriae 
having a larger genome size compared to B. pilosicoli, it is smaller than other Brachyspira 
species capable of infecting multiple hosts, such as B. alvinipulli and B. intermedia. This could 
be as a result of host specialisation and subsequent loss of genes that were not required for 
the colonisation of the porcine gastrointestinal tract.  
A pangenome analysis of Brachyspira species revealed that the core genome contained 
approximately 1089 genes; a previous study, comparing B. pilosicoli 95/1000, B. murdochii 
56-160T and B. hyodysenteriae WA1 reported a core genome of 1087 genes, thus validating 
the data presented here (Wanchanthuek et al., 2010). Interestingly, in these studies, B. 
pilosicoli shared relatively few genes with B. hyodysenteriae (35 genes) and the “Other” 
Brachyspira species (210 genes), further supporting the evolutionary divergence of this 
species. Another study suggested that B. pilosicoli and B. hyodysenteriae shared 
approximately 592 genes of their accessory genome (Wanchanthuek et al., 2010). However, 
this was limited to the comparison of one genome from each species thus giving an inaccurate 
representation and demonstrating the importance of analysing a larger number of genome 
sequences for accurate interpretation of pangenome analyses. In the data presented here, B. 
hyodysenteriae and the “Other” species of Brachyspira shared 1329 genes, suggesting that 
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these species are more closely related to one another than B. pilosicoli. This concurred with 
previous reports that B. hyodysenteriae was more closely related to B. intermedia and B. 
murdochii (Håfström et al., 2011).  
On closer analysis of the individual B. pilosicoli and B. hyodysenteriae pangenomes, it was 
evident that B. hyodysenteriae had a larger core genome, with 70% of the pangenome 
consisting of core genes. This is likely to be associated with this species being host restricted 
and infecting only the porcine host (Harris et al., 1972; Hampson et al., 2006). B. pilosicoli had 
a smaller core genome, with 47% of the pangenome consisting of core genes and 53% 
consisting of accessory genes. This may be as a result of infecting a wider host range and 
therefore being exposed to a wider gene pool which could be exchanged with B. pilosicoli 
through horizontal gene transfer or bacteriophage infection for example. Furthermore, a 
large accessory genome may aid in adaptation and colonisation of different hosts.  
B. pilosicoli had previously been reported to have a core genome of 2132 gene, based on the 
analysis of three genome sequences (Mappley et al., 2012). The studies presented here 
indicated a slightly smaller core genome of 1749 genes, from the analysis of nineteen 
genomes. This relatively small proportion of core genes, in addition to allowing the infection 
of multiple hosts, may also be responsible for the varied disease status and pathology 
associated with both natural and experimental infections with B. pilosicoli (Mappley et al., 
2014). 
Comparisons of the Brachyspira genome sequences revealed significant differences in the 
genes responsible for coding methyl-accepting proteins (MCPs), however chemotaxis 
proteins (Che) were generally well conserved. Thus, suggesting that the MCPs responsible for 
detecting different chemotactic signals differ between species. However, the process of 
directed motility using chemotaxis machinery (Che proteins) is similar in all species within the 
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genus. MCPs are essential for Brachyspira responses to chemotactic signals to facilitate 
directed movement of the bacterial cells. In order to colonise the large intestine, Brachyspira 
must gain close proximity to the intestinal epithelium, facilitated by chemotaxis to 
compounds such as mucins (Naresh and Hampson, 2010). There were distinct differences in 
both the number of MCPs and also the distribution between different species of Brachyspira. 
B. pilosicoli had a small number of MCPs (approximately fifteen) compared to B. 
hyodysenteriae (between forty and fifty). As previously mentioned, B. pilosicoli have the 
ability to attach to the enterocytes to form a pseudo-brush border, whereas B. hyodysenteriae 
colonise the crypts of the enterocytes, but also the lumen of the colon, which may result in 
having to detect an increased number of chemotactic signals, hence the large number of 
MCPs. Interestingly, B. pilosicoli did not share any MCPs with any other species of Brachyspira 
investigated. Further studies with B. aalborgi may be able to investigate whether these MCPs 
are specific to B. pilosicoli or if they are potentially specific to Brachyspira species that can 
attach to epithelial cells, or indeed those that can infect humans. Conversely, B. 
hyodysenteriae shared a number of MCPs with the “Other” Brachyspira species, in addition 
to having a unique set of MCPs. This suggests further evidence for B. pilosicoli being more 
evolutionarily divergent for other species in the genus and highlights some key differences in 
key Brachyspira virulence factors (Bellgard et al., 2009; Wanchanthuek et al., 2010). Previous 
comparisons of Brachyspira species revealed that B. pilosicoli genes code for McpA and McpB, 
but not for McpC, despite McpC being detected in the genomes of other Brachyspira species. 
McpA is responsible for taxis towards glucose, a methyl glucose, McpB is responsible for taxis 
towards asparagine, aspartate, glutamine and histidine and McpC is responsible to taxis 
towards cysteine, proline, threonine, glycine, serine, lysine, valine and arginine. This may 
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result in B. pilosicoli not being chemotactic to amino acids such as serine which are known to 
be potent chemoattractants for other species such as B. hyodysenteriae (Muller et al., 1997). 
The large number of MCPs present in the B. hyodysenteriae pangenome analysis may be 
associated with the need to transduce multiple chemotactic signals in the ever-changing 
environment of the colonic lumen. Furthermore, a large number of genes could suggest 
redundancy in the system, whereby Brachyspira and other spirochaetes can rapidly adapt to 
their changing environment. Other spirochaetes such as T. pallidum and B. burgdorferi also 
possess multiple MCPs, suggesting it is commonplace amongst spirochaetes (Bellgard et al., 
2009).  
A comparison was made between B. pilosicoli, B. hyodysenteriae and the non-pathogenic 
species B. innocens and B. murdochii in order to compare the presence/absence of MCP 
genes. This may begin to elucidate if there is an association between MCP genes and 
pathogenicity. It was evident that although B. innocens and B. murdochii share some MCP 
genes with B. hyodysenteriae, many present in this pathogen were absent in the non-
pathogenic species. This could suggest that MCPs are related to pathogenicity, with certain 
MCPs facilitating chemotactic responses to allow B. hyodysenteriae to effectively colonise its 
ecological niche and subsequently cause disease. It could be likely that this chemotactic 
response is not present in non-pathogenic species of Brachyspira due to the absence of 
specific MCPs, which prevents disease following infection. In previous studies, B. 
hyodysenteriae have been shown to be chemotactic towards a variety of mucin components, 
likely to be due to the large number of genes encoding MCPs (Kennedy and Yancey, 1996), 
however no such studies have been conducted with non-pathogenic species of Brachyspira. 
Therefore, the next logical step to further investigating if MCPs contribute to the 
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pathogenicity of different Brachyspira species would be to investigate chemotaxis of B. 
innocens and B. murdochii in vitro.  
Overall, this chapter provides further evidence that B. pilosicoli is evolutionarily distinct from 
other Brachyspira species. The process of reductive evolution may have resulted in a smaller 
genome size following the ability to infect a wide range of hosts. This may have resulted in 
the loss of redundant genes and the retaining of only genes essential for survival and 
pathogenesis.  Pangenome analysis suggested that B. pilosicoli shared few genes with other 
species of Brachyspira, suggesting early evolutionary divergence from other species in the 
genus. B. hyodysenteriae are more closely related to the other species of Brachyspira and 
shared similar MCPs which were distinct from B. pilosicoli. Additionally, these studies 
provided evidence that MCPs contribute to pathogenicity as non-pathogenic species shared 
some, but not all MCPs with B. hyodysenteriae, suggesting that these MCPs may be essential 
for chemotaxis in these species, but may not be directly related to pathogenicity. These 
studies were a starting point for the investigation of chemotaxis genes in Brachyspira species, 
however further in vitro and in silico studies will be required to fully elucidate their roles in 
the pathobiology of Brachyspira.  
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Chapter 5: The characterisation of Lactobacillus species as potential 
probiotic candidates for the control of avian intestinal spirochaetosis 
 
5.1 Introduction 
 
Since the ban of antibiotic growth promoters in livestock in the EU in 2006, the necessity for 
alternatives has become of paramount importance, Lactobacillus probiotics are one such 
alternative. Probiotics are defined as “live micro-organisms that confer health benefits to the 
host when administered in adequate quantities” (FAO/WHO, 2002) and there is increasing 
evidence that probiotics can promote good gut health based on the principle that a healthy 
intestinal microbiota protects against disease (Rantala and Nurmi, 1973; Fuller, 1989; Collins 
et al., 2009). 
It is well documented that probiotic bacteria can inhibit a range of poultry pathogens such as 
Campylobacter jejuni, Salmonella and E. coli (La Ragione and Woodward, 2003; Resta-Lenert 
and Barrett, 2003; Wolfenden et al., 2007; Santini et al., 2010; Olnood et al., 2015). More 
recently, studies have demonstrated the potential for Lactobacillus isolates to antagonise 
Brachyspira both in vitro and in vivo  (Mappley et al., 2011; Mappley et al., 2013), however 
the exact mechanisms of action have yet to be elucidated.  
Therefore, this chapter aimed to isolate and characterise a number of avian Lactobacillus 
isolates as potential probiotics for the control of avian intestinal spirochaetosis. A range of 
appropriate tools were utilised to characterise these isolates in accordance to The European 
Food Safety Authority guidelines (EFSA et al., 2017). These included antimicrobial resistance 
testing, bile and acid tolerance, 16S rRNA sequencing and whole genome sequencing to 
phenotypically and genotypically characterise the panel of potential probiotics. This ensured 
that any probiotics met the safety criteria for use in animal nutrition. Furthermore, these 
Lactobacillus isolates were tested to ascertain the inhibitory potential against a panel of 
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Brachyspira isolates, with the intention of selecting potential probiotic candidates for further 
investigation in Chapters 6 and 7.  
Therefore, the aims and objectives of this chapter were: 
• To isolate a panel of Lactobacillus isolates from the faeces of healthy, free-range 
chickens. 
• To create phenotypic and genotypic profiles of each isolate in accordance to the EFSA 
guidelines to ensure selected probiotic candidates would be suitable as commercial 
animal feed supplements. 
• To determine the inhibitory ability of each Lactobacillus isolate against the panel of 
eight Brachyspira isolates characterised in Chapter 3. 
• To select an appropriate number of probiotic candidates suitable for further study. 
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5.2  Results 
 
5.2.1 Isolation and identification of potential probiotics  
 
A total of fifty lactic acid bacteria were isolated from healthy free-range laying hens. These 
fifty isolates were initially subjected to Gram stains, catalase tests and each isolate was 
cultured on MRS agar under both aerobic and anaerobic conditions, and in broth at 37°C to 
ensure sufficient growth for subsequent experiments. Of the fifty isolates tested, seventeen 
were catalase negative, Gram positive rods with a strong growth phenotype under both 
aerobic and anaerobic conditions, on both agar and in broth. Therefore, these seventeen 
isolates, shown in (Table 5.1) were further characterised as potential probiotics because of 
their presumptive Lactobacillus identification and their robustness and versatility as indicated 
by the growth studies.  
 
5.2.2 Genotypic characterisation of Lactobacillus isolates 
 
These seventeen presumptive Lactobacillus isolates were initially speciated using 16S rRNA 
sequencing (Table 5.1). It was noted that the majority of isolates identified were either L. 
crispatus, L. reuteri or L. salivarius; the most abundant Lactobacillus isolates in the chicken 
gastrointestinal tract (Abbas Hilmi et al., 2007). Following the identification of these isolates 
one isolate, L. agilis SAP 2014 was removed from further study as it was not an approved 
species for animal feed supplements according to the EFSA guidelines (European Food Safety 
Authority, 2015). 
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Table 5. 1 A summary of the biochemistry, 16S rRNA sequencing and whole genome sequencing 
results for all Lactobacillus isolates characterised in these studies. Isolates were further characterised 
in accordance to probiotic guidelines. At this early stage of characterisation, eleven isolates met these 
criteria and were sent for whole genome sequencing to confirm their species and investigate potential 
for antimicrobial resistance and virulence genes and predict bacteriocin gene clusters. 
Lactobacillus 
Species 
 
Isolate 
Name 
Catalase 16S rRNA 
sequencing 
identification  
Whole Genome 
Sequencing 
identification 
L. agilis SAP 2104 - L. agilis - 
L. crispatus SAP 2105 - L. crispatus L. crispatus 
L. crispatus SAP 2106 - L. crispatus L. crispatus 
L. crispatus SAP 2107 - L. crispatus L. crispatus 
L. crispatus SAP 2109 - L. crispatus - 
L. crispatus SAP 2110 - L. crispatus - 
L. crispatus SAP 2111 - L. crispatus - 
L. mucosae SAP 2102 - L. mucosae - 
L. reuteri SAP 2108 - L. reuteri L. reuteri 
L. reuteri SAP 2114 - L. reuteri L. reuteri 
L. reuteri SAP 2115 - L. reuteri L. reuteri 
L. salivarius SAP 2103 - L. salivarius L. salivarius 
L. salivarius SAP 2112 - L. salivarius - 
L. salivarius SAP 2113 - L. salivarius L. salivarius 
L. salivarius SAP 2116 - L. salivarius L. salivarius 
L. salivarius SAP 2117 - L. salivarius L. salivarius 
L. salivarius SAP 2118 - L. salivarius Poor sequence 
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5.2.2.1 Whole genome sequencing for characterisation of potential probiotics 
 
The most recent edition of the EFSA guidelines stipulated that whole genome sequencing 
should be used for the ‘unequivocal taxonomic identification of the strain, as well as for 
characterisation of the strain regarding their potential “functional traits of concern” (EFSA et 
al., 2017). Therefore, whole genome sequencing was employed to confirm the identity of 
each Lactobacillus isolate and interrogate the genomes for possible traits of concern. Five 
isolates L. crispatus SAP 2109, 2110 2111, L. mucosae SAP 2102 and L. salivarius SAP 2112 
were not sent for sequencing due to poor quality and yield of DNA following multiple 
attempts at DNA extraction. Hence, these five isolates were subsequently removed from 
further studies. The eleven remaining isolates were sent for whole genome sequencing using 
Illimina MiSeq or HighSeq technology, conducted at MicrobesNG, University of Birmingham. 
A summary of the sequence data is shown in Table 5.2. 
The whole genome sequences were processed using the same methods illustrated in Figure 
3.5. The only difference was that the 2x250bp paired end sequence reads were processed 
and assembled into contiguous sequences using the SPAdes 3.10 genome assembler 
(Bankevich et al., 2012). Following assembly, Quast v2  analysis (Gurevich et al., 2013) was 
used to ensure the sequences were of sufficient quality for further analysis, as shown in Table  
5.2.  All of these sequences, except for L.  salivarius SAP 2118 (which was subsequently 
removed) were of sufficient quality to be annotated using Prokka, subsequent phylogenetic 
analysis was conducted using the core genome SNPs to speciate each of the potential 
probiotic candidates presented in Table 5.1. It was worth noting that the results from the 16S 
rRNA sequencing were concurrent with the identification of all isolates using whole genome 
sequencing.  
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Lactobacillus genomes ranged from 2.0-2.2 Mbp in size, with a GC content ranging from 32.5- 
38.6%, the L. reuteri isolates had the smallest genomes and the highest GC content. The 
number of coding sequences and RNAs were similar amongst all isolates and are 
representative of the L. crispatus, L. reuteri and L. salivarius species (Table 5.2) (Frese et al., 
2011; Lee et al., 2017; Ojala et al., 2014).  
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Lactobacillus Isolate Size (bp) 
 
GC 
content 
(%) 
Number of 
coding 
sequences 
Number of 
RNAs 
Number of 
Contigs 
Largest 
Contig 
N50* L50** 
L. crispatus SAP 2105 2110158 
 
32.62 
 
2042 86 36 
 
345434 
 
137660 
 
5 
 
L. crispatus SAP 2106 2023727 36.83 2025 73 36 554180 
 
131824 
 
4 
 
L. crispatus SAP 2107 2228254 
 
36.68 2227 73 40 
 
554181 
 
140039 
 
5 
 
L. reuteri SAP 2108 2042049 
 
38.57 
 
2014 74 81 
 
144585 
 
68674 
 
11 
 
L. reuteri SAP 2114 2040448 
 
38.57 
 
2008 73 73 
 
121930 
 
68674 11 
 
L. reuteri SAP 2115 2054410 
 
38.58 
 
2020 89 72 
 
122758 
 
68766 
 
11 
 
L. salivarius SAP 2103 2110631 
 
32.62 
 
2042 86 38 
 
400788 
 
137103 
 
5 
 
L. salivarius SAP 2113 2108064 
 
32.59 
 
2047 80 37 
 
359028 
 
157700 5 
L. salivarius SAP 2116 2113188 
 
32.63 
 
2043 81 51 
 
359220 
 
137658 
 
5 
L. salivarius SAP 2117 2111031 32.61 2045 80 35 358986 
 
137658 
 
5 
* N50 value is defined as the minimum contig length required to cover 50% of the genome, i.e. half of the contigs are equal to or larger than 
the N50 contig size. The larger the N50 value, the higher the quality of the assembly. 
** L50 value is defined as the number of contigs required to account for 50% of the genome. The lower the L50 value, the higher the quality 
of the assembly.  
  
Table 5. 2 The size of the genomes in base pairs (bp), GC content (%), number of coding sequences, number of RNAs, number of contigs, largest 
contig, the N50 value and the L50 value for each of the Lactobacillus genomes. Data for the assembly statistics were generated from Prokka and 
the data for the assembly quality were generated from Quast. 
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Following assembly and annotation, additional screening of the Lactobacillus genomes was 
undertaken to identify any potential virulence factors, plasmids and antimicrobial resistance 
genes that may have been present in these genomes. This was undertaken using ABRicate 
software which used a combination of databases, including CARD, ARG-ANNOT, Resfinder, 
the virulence factor database and Plasmidfinder to identify any of these traits that may make 
them unsuitable as probiotics, as seen in Table 5.3 (https://github.com/tseemann/abricate). 
Of the ten Lactobacillus isolates, 50% carried the tetM and ermB genes, which may confer 
resistance to tetracycline and macrolide antibiotics such as erythromycin and 20% of the 
isolates carried the tetW gene, which may also confer resistance to tetracycline. 30% of the 
isolates, all of which were L. reuteri, carried no resistance genes. None of the isolates 
characterised harboured any potential known virulence genes or plasmids which may have 
deemed them unsuitable for probiotic use. Overall, it was clear that L. reuteri isolates were 
more suitable as potential probiotic candidates due to absence of any antimicrobial resistance 
genes, plasmids or virulence factors. All L. salivarius isolates demonstrated the presence of 
genes conferring resistance to tetracycline and macrolide antibiotics, which needed to be 
tested in order to confirm the phenotype.   
Additional online tools such as Bagel 4 (http://bagel4.molgenrug.nl/) and Anti-SMASH 
(https://antismash.secondarymetabolites.org/#!/start) were utilised to predict potential 
bacteriocin and secondary metabolite gene clusters present in the genome sequences. The 
secretion of these inhibitory metabolites may contribute to the inhibition of intestinal 
pathogens such as Brachyspira and thus enhance the probiotic action of the Lactobacillus 
isolates.  These tools were used in combination to enable the identification of all known 
potential bacteriocin gene clusters and protein sequences, these were then screened using 
BLAST, to confirm their identification. 
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Species Isolate Name Predicted 
antimicrobial 
resistance 
genes a 
Predicted 
antibiotic 
resistance  
Virulence 
genes b 
Plasmids c 
L. salivarius SAP 2103 tetM, ermB Tetracycline, 
Macrolide 
None None 
L. crispatus SAP 2105 tetM, ermB Tetracycline, 
Macrolide 
None None 
L. crispatus SAP 2106 tetW Tetracycline None None 
L. crispatus SAP 2107 tetW Tetracycline None None 
L. reuteri SAP 2108 None None None None 
L. salivarius SAP 2113 tetM, ermB Tetracycline, 
Macrolide 
None None 
L. reuteri SAP 2114 None None None None 
L. reuteri SAP 2115 None None None None 
L. salivarius SAP 2116 tetM, ermB Tetracycline, 
Macrolide 
None None 
L. salivarius  SAP 2117 tetM, ermB Tetracycline, 
Macrolide 
None None 
a AMR genes were predicted using ABRicate which used the CARD, ARG-ANNOT and Resfinder 
databases to predict AMR genes. 
b Virulence genes were predicted using ABRicate which used the Virulence Factor Database (VFBD) 
to known predict virulence factors. 
c Plasmids were predicted using ABRicate which used the PlasmidFinder database to predict known 
plasmids. 
 
Table 5. 3 Summary of results generated by ABRicate to investigate the potential antimicrobial 
resistance genes, virulence genes and plasmids present in all of the Lactobacillus genomes. These data 
show that 70% of the Lactobacillus isolate harbour antimicrobial resistance genes that confer 
resistance to tetracycline or macrolide antibiotics, or a combination of both. The L. reuteri isolates did 
not appear to have any antimicrobial resistance genes, potentially making them more suitable 
probiotics.  
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Anti-SMASH produced limited results, as shown in Table 5.4. This database was only able to 
detect the presence of potential salivaricin gene clusters in L. salivarius isolates. Salivaricin is 
a class I bacteriocin and is classified as a lantibiotic with bactericidal properties (Barbour et 
al., 2016). Class I bacteriocins are small, often heat stable peptides that contain the non-
proteogenic amino acids lanthionine and b-methyllanthionine, which form covalent bridges 
between amino acids resulting in internal ring motifs. 
 
 
 
 
Bagel 4 identified the presence of predicted enterolysin A and helveticin J bacteriocin gene 
clusters in addition to an unnamed class II bacteriocin, as shown in Table 5.5. Putative gene 
clusters for enterolysin A were present in all of the Lactobacillus isolates as previously 
observed by Chung et al (2018) and helveticin J gene clusters were identified in all L. crispatus 
isolates. Enterolysin A and helveticin J are class III bacteriocins, these are large (> 30kDa), heat 
Table 5. 4 Summary of the secondary metabolite gene clusters predicted by Anti-SMASH. This 
database was able to predict the presence of salivaricin gene clusters in L. salivarius genome 
sequences but did not predict any other gene clusters in other species of Lactobacillus.   
Species Isolate Name Predicted secondary metabolite gene clusters  
L. salivarius SAP 2103 Salivaricin 
L. crispatus SAP 2105 None 
L. crispatus SAP 2106 None 
L. crispatus SAP 2107 None 
L. reuteri SAP 2108 None 
L. salivarius SAP 2113 Salivaricin 
L. reuteri SAP 2114 None 
L. reuteri SAP 2115 None 
L. salivarius SAP 2116 Salivaricin 
L. salivarius  SAP 2117 Salivaricin 
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labile proteins that are subdivided into bacteriolytic enzymes such as enterolysin A which 
cause lysis of cell walls or non-lytic proteins such as helveticin J (Yang et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-SMASH and Bagel 4 were used together to ensure that all possible putative gene clusters 
were identified from the Lactobacillus genome sequences. It was noted during these analyses 
that the core protein sequences for salivaricin (produced by Anti-SMASH) and bacteriocin 
class II (produced by Bagel 4) were 100% homologous (Appendix III), and thus these may be 
the same genes with a different annotation, as shown in Figure 5.1. Interestingly, Anti-SMASH 
identified the putative bacteriocin gene as salivaricin (a class I bacteriocin) but Bagel 4 
Species Isolate Name Predicted bacteriocin gene clusters 
L. salivarius SAP 2103 Enterolysin A Class III 
Bacteriocin Class II 
L. crispatus SAP 2105 Enterolysin A Class III 
Bacteriocin Class II 
L. crispatus SAP 2106 Enterolysin A Class III 
Helveticin J 
L. crispatus SAP 2107 Enterolysin A Class III 
Helveticin J 
L. reuteri SAP 2108 Enterolysin A Class III 
L. salivarius SAP 2113 Enterolysin A Class III 
Bacteriocin Class II 
L. reuteri SAP 2114 Enterolysin A Class III 
L. reuteri SAP 2115 Enterolysin A Class III 
L. salivarius SAP 2116 Enterolysin A Class III 
Bacteriocin Class II 
L. salivarius  SAP 2117 Enterolysin A Class III 
Bacteriocin Class II 
Table 5. 5 Summary of the bacteriocin gene clusters predicted by Bagel 4. This database was able 
to predict class IIc bacteriocins, these bacteriocins are small (5-10 kDa), heat stable peptides which 
are not subject to extensive post translational modifications. It was also able to detect class III 
bacteriocins, these are larger ( > 30kDa), heat stable proteins which are split into two groups. 
Group A are bacteriolytic proteins such as enterolysin A and Group B are non-lytic such as helveticin 
J. 
 
 
 
Table 4. 3 Summary of the bacteriocin gene clusters predicted by Bagel 4. This database was able 
to predict class IIc bacteriocins, these bacteriocins are small (5-10 kDa), heat stable peptides which 
are not subject to extensive post translational modifications. It was also able to detect class III 
bacteriocins, these are larger ( > 30kDa), heat stable proteins which are split into two groups. 
Group A are bacteriolytic proteins such as Enterolysin A and Group B are non-lytic such as 
Helveticin J. 
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identified it as a class II bacteriocin, indicating the need for more complete bacteriocin 
databases.  
All Lactobacillus isolates tested had putative bacteriocin gene clusters present in the genome. 
The L. reuteri isolates only had one predicted cluster for enterolysin A, whereas the L. 
salivarius and L. crispatus genomes contained clusters for salivaricin, the class II bacteriocin 
and helveticin J, respectively. Further studies presented in Chapter 6 explored the inhibition 
of metabolites in the Lactobacillus cell free supernatant to attempt to determine the role of 
these bacteriocins against Brachyspira. 
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16/05/2018 https://antismash.secondarymetabolites.org/upload/bacteria-b72e08b6-4c6a-4b25-83c5-1f2b1da72fb9/svg/knownclusterblast1_all.svg
https://antismash.secondarymetabolites.org/upload/bacteria-b72e08b6-4c6a-4b25-83c5-1f2b1da72fb9/svg/knownclusterblast1_all.svg 1/1
Query sequence
BGC0000624: Salivaricin CRL1328 alpha peptide / salivaricin CRL1328 beta... (50% of genes show similarity)
16/05/2018 https://antismash.secondarymetabolites.org/upload/bacteria-b72e08b6-4c6a-4b25-83c5-1f2b1da72fb9/svg/knownclusterblast1_all.svg
https://antismash.secondarymetabolites.org/upload/bacteria-b72e08b6-4c6a-4b25-83c5-1f2b1da72fb9/svg/knownclusterblast1_all.svg 1/1
Query sequence
BGC0000624: Salivaricin CRL1328 alpha peptide / salivaricin CRL1328 beta... (50% of genes show similarity)
MMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAGTVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
Figure 5. 1 Aligned outputs from Anti-SMASH and Bagel 4 to show a predicted bacteriocin gene clusters for L. salivarius SAP 2116. (A) Shows 
the output from Anti-SMASH, the query sequence is aligned to the known Salivaricin gene cluster which shows that 50% of the genes are 
similar. (B) Shows the output from Bagel 4 which identified a potential gene cluster for a type II bacteriocin. It is evident from this figure 
that both Anti-SMASH and Bagel 4 can identify some similar putative gene clusters, however they are annotated differently, which is why 
it is beneficial to use both pipelines. (C) Shows the protein sequence of the protein identified as the core peptide of the bacteriocin gene 
cluster. This sequence was highlighted by both Anti-SMASH and Bagel 4 and identified as bacteriocin from L. salivarius using BLAST but did 
not elude to the identification of this bacteriocin. 
 
A 
 
B 
 
C 
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5.2.2.2 Phylogenetics 
 
Phylogenetics using the whole genome sequences confirmed the identity of the panel of 
Lactobacillus isolates. All sequences from the three species highly abundant in the chicken 
gastrointestinal tract, L. crispatus, L. reuteri and L. salivarius, were downloaded from 
Genbank. Following this, parSNP analysis was employed to analyse the core genome single 
nucleotide polymorphisms (SNPs) of all available Lactobacillus sequences to create the 
phylogenetic dendrograms seen in Figures 5.2, 5.3 and 5.4.  
The phylogenetic dendrograms clearly showed that each of the Lactobacillus isolates 
presented in these studies, belonged to the correct species as identified by the 16S rRNA 
sequencing. The data showed high levels of genetic similarity within each species from the 
isolates characterised here, this was as a result of isolates being isolated from one flock of 
hens. However, these were later tested for their inhibition against Brachyspira and each 
exhibited a different phenotype, thus suggesting that they were not identical isolates. 
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Figure 5. 2  A phylogenetic dendrogram 
illustrating the phylogenetic 
relationships within the Lactobacillus 
crispatus species. Fifty-five L. crispatus 
genomes were clustered according to 
the core genome SNPs using parSNP 
(Treangen et al., 2014). Isolates 
highlighted in red were those 
presented in these studies, isolates in 
black were downloaded from 
Genbank. This dendrogram shows that 
the two isolates presented in these 
studies were L. crispatus.  
  
 
Figure 4. 31 A phylogenetic 
dendrogram illustrating the 
phylogenetic relationships within the 
Lactobacillus crispatus species. Fifty-
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Figure 5. 3 A phylogenetic dendrogram 
illustrating the phylogenetic relationships 
within the Lactobacillus salivarius species. 
Seventy-nine L. salivarius genomes were 
clustered according to the core genome SNPs 
using parSNP (Treangen et al., 2014). Isolates 
highlighted in red were those presented in 
these studies, isolates in black were 
downloaded from Genbank. This dendrogram 
shows that the five isolates presented in these 
studies were L. salivarius.  
 
 
 
Figure 4. 37 A phylogenetic dendrogram 
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 Lactobacillus salivarius KLA004   
 Lactobacillus salivarius KLW008   
 Lactobacillus salivarius KLW002   
 Lactobacillus salivarius KLW009   
 Lactobacillus salivarius KLW005   
 Lactobacillus salivarius KLW001   
 Lactobacillus salivarius KLF004   
 Lactobacillus salivarius KLF002   
 Lactobacillus salivarius KLF003   
 Lactobacillus salivarius KLW004   
 Lactobacillus salivarius KLW003   
 Lactobacillus salivarius KLF007   
 Lactobacillus salivarius KLW006   
 Lactobacillus salivarius KLW010   
 Lactobacillus salivarius KLW007   
 Lactobacillus salivarius KLF005   
 Lactobacillus salivarius JCM 1230   
 Lactobacillus salivarius cp400   
 Lactobacillus salivarius ZLS006   
 Lactobacillus salivarius NIAS840   
 Lactobacillus salivarius GJ-24   
 Lactobacillus salivarius CICC 23174   
 Lactobacillus salivarius CCuG44481   
 Lactobacillus salivarius SMXD51   
 Lactobacillus salivarius An63   
 Lactobacillus salivarius An128   
 Lactobacillus salivarius An84   
 Lactobacillus salivarius SAP 2117 
 Lactobacillus salivarius SAP 2116   
 Lactobacillus salivarius SAP 2103   
 Lactobacillus salivarius SAP 2113   
 Lactobacillus salivarius SAP 2105   
 Lactobacillus salivarius SGL 03   
 Lactobacillus salivarius JCM1046   
 Lactobacillus salivarius NCIMB8817   
 Lactobacillus salivarius JCM 1047   
 Lactobacillus salivarius LMG 14477   
 Lactobacillus salivarius LMG 14476   
 Lactobacillus salivarius NCIMB702343 UNK 
 Lactobacillus salivarius AH4231   
 Lactobacillus salivarius AH43324   
 Lactobacillus salivarius AH4331   
 Lactobacillus salivarius ACS-116-V-Col5a   
 Lactobacillus salivarius 866 LSAL   
 Lactobacillus salivarius CCuG45735   
 Lactobacillus salivarius CCuG47826   
 Lactobacillus salivarius CCuG47825   
 Lactobacillus salivarius L21   
 Lactobacillus salivarius Ren   
 Lactobacillus salivarius 01M14315   
 Lactobacillus salivarius JCM 1040   
 Lactobacillus salivarius AH43348   
 Lactobacillus salivarius UCC118   
 Lactobacillus salivarius NCIMB8818   
 Lactobacillus salivarius 609 LSAL   
 Lactobacillus salivarius JCM 1044   
 Lactobacillus salivarius CCuG2753OB   
 Lactobacillus salivarius JCM 1042   
 Lactobacillus salivarius NCIMB8816   
 Lactobacillus salivarius CCuG38008   
 Lactobacillus salivarius CECT 5713   
 Lactobacillus salivarius 778 LSAL   
 Lactobacillus salivarius DSM 20554   
 Lactobacillus salivarius BCRC 12574   
 Lactobacillus salivarius DSM 20492   
 Lactobacillus salivarius BCRC 14759   
 Lactobacillus salivarius DSM 20555   
 Lactobacillus salivarius ATCC 11741   
 Lactobacillus salivarius gul2 UNK 
 Lactobacillus salivarius gul1 UNK 
 Lactobacillus salivarius JCM 1045   
 Lactobacillus salivarius L28   
 Lactobacillus salivarius LPM01   
 Lactobacillus salivarius CCuG47171   
0.050 
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Figure 5. 4 A phylogenetic dendrogram 
illustrating the phylogenetic relationships 
within the Lactobacillus reuteri species. Ninety- 
five L. reuteri genomes were clustered 
according to the core genome SNPs using 
parSNP (Treangen et al., 2014). Isolates 
highlighted in red were those presented in 
these studies, isolates in black were 
downloaded from Genbank. This dendrogram 
shows that the three isolates presented in 
these studies were L. reuteri.  
 
 
 
 
Figure 4. 38 A phylogenetic dendrogram 
 Lactobacillus reuteri 114q   
 Lactobacillus reuteri 114g   
 Lactobacillus reuteri 601f   
 Lactobacillus reuteri 601g   
 Lactobacillus reuteri 601l   
 Lactobacillus reuteri 609i   
 Lactobacillus reuteri 609e   
 Lactobacillus reuteri 107k   
 Lactobacillus reuteri 107j   
 Lactobacillus reuteri 107e   
 Lactobacillus reuteri 114h   
 Lactobacillus reuteri 105k   
 Lactobacillus reuteri 105i   
 Lactobacillus reuteri 105c   
 Lactobacillus reuteri 105d   
 Lactobacillus reuteri 105n   
 Lactobacillus reuteri 105o   
 Lactobacillus reuteri 105w   
 Lactobacillus reuteri 609l   
 Lactobacillus reuteri 609d   
 Lactobacillus reuteri 117w   
 Lactobacillus reuteri 117n   
 Lactobacillus reuteri 111f   
 Lactobacillus reuteri 117r   
 Lactobacillus reuteri 111b   
 Lactobacillus reuteri 105p   
 Lactobacillus reuteri 111l   
 Lactobacillus reuteri 103b   
 Lactobacillus reuteri 103v   
 Lactobacillus reuteri 103o   
 Lactobacillus reuteri 111v   
 Lactobacillus reuteri 103p   
 Lactobacillus reuteri mlc3   
 Lactobacillus reuteri LTH2584   
 Lactobacillus reuteri TMW1-656   
 Lactobacillus reuteri TMW1-112   
 Lactobacillus reuteri 100-23   
 Lactobacillus reuteri KLR2001   
 Lactobacillus reuteri KLR3003   
 Lactobacillus reuteri KLR3002   
 Lactobacillus reuteri KLR2004   
 Lactobacillus reuteri KLR2006   
 Lactobacillus reuteri pg-3b   
 Lactobacillus reuteri ZLR003   
 Lactobacillus reuteri CECT8605   
 Lactobacillus reuteri 121   
 Lactobacillus reuteri ATCC 53608   
 Lactobacillus reuteri UBA625   
 Lactobacillus reuteri lp167-67   
 Lactobacillus reuteri KLR1004   
 Lactobacillus reuteri KLR3005   
 Lactobacillus reuteri KLR4001   
 Lactobacillus reuteri KLR2007   
 Lactobacillus reuteri KLR2008   
 Lactobacillus reuteri KLR3004   
 Lactobacillus reuteri KLR2002   
 Lactobacillus reuteri KLR2003   
 Lactobacillus reuteri KLR1001   
 Lactobacillus reuteri I5007   
 Lactobacillus reuteri KLR3006   
 Lactobacillus reuteri KLR1002   
 Lactobacillus reuteri SAP 2114   
 Lactobacillus reuteri SAP 2108   
 Lactobacillus reuteri SAP 2115   
 Lactobacillus reuteri MD IIE-43   
 Lactobacillus reuteri CSF8   
 Lactobacillus reuteri An166   
 Lactobacillus reuteri An71   
 Lactobacillus reuteri JCM 1081   
 Lactobacillus reuteri CF48-3A   
 Lactobacillus reuteri SD2112   
 Lactobacillus reuteri M27U15   
 Lactobacillus reuteri MM34-4A   
 Lactobacillus reuteri RC-14   
 Lactobacillus reuteri 1366   
 Lactobacillus reuteri 20-2   
 Lactobacillus reuteri 3c6   
 Lactobacillus reuteri 482 46   
 Lactobacillus reuteri 480 44   
 Lactobacillus reuteri 482 54   
 Lactobacillus reuteri 484 32   
 Lactobacillus reuteri 484 39   
 Lactobacillus reuteri TD1   
 Lactobacillus reuteri LR0   
 Lactobacillus reuteri lpuph   
 Lactobacillus reuteri P43   
 Lactobacillus reuteri LTH5448   
 Lactobacillus reuteri I49   
 Lactobacillus reuteri DSM 20016   
 Lactobacillus reuteri CRL 1098   
 Lactobacillus reuteri JCM 1112   
 Lactobacillus reuteri MM4-1A   
 Lactobacillus reuteri MM2-3   
 Lactobacillus reuteri IRT   
 Lactobacillus reuteri HI24   0.050 
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5.2.3 Screening Lactobacillus isolates as potential probiotics 
 
In addition to confirming the identification of Lactobacillus isolates using phenotypic and 
genotypic tests as described previously, candidate probiotics needed to be screened for their 
inhibition against Brachyspira in order to ascertain their potential success as an intervention 
for avian intestinal spirochaetosis. The most inhibitory Lactobacillus isolates underwent 
further characterisation to determine antimicrobial resistance profiles in line with EFSA 
guidelines, in addition to confirming resistance phenotypes informed by whole genome 
sequencing. Further bile salt and acid tolerance tests were conducted to predict the likelihood 
of isolate survival through the avian gastrointestinal tract.  
 
5.2.3.1 Initial screening Lactobacillus isolates for inhibitory effects against Brachyspira  
 
The panel of ten Lactobacillus isolates that met the preliminary selection criteria and for 
which a genome sequences was now available (Table 5.1) were screened for their inhibitory 
activity against five of the Brachyspira isolates which had the ability to grown sufficiently in 
broth. The CFS of each Lactobacillus isolate used in these studies was obtained as described 
in Chapter 2. The pH of each CFS after culture ranged from pH 3.8 to 4.5, depending on the 
Lactobacillus isolate, therefore the pH of each CFS was adjusted to pH 3.8 and 4.5 to 
investigate the upper and lower pH within this range. To explore inhibition at a neutral pH 
the CFS was also adjusted to pH 7.2 and MRS broth controls were pH adjusted to either pH 
3.8, 4.5 or 7.2.  
The inhibition of Brachyspira was dependent on the isolate of Lactobacillus used and it was 
important to note that there was not one Lactobacillus isolate that was inhibitory against all 
Brachyspira isolates. There was evidence of both pH-dependent and pH-independent 
mechanisms of inhibition, observable in Table 5.6. These mechanisms will be explored further 
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in Chapter 6; however, it was observed that there was a significant difference between the 
growth of Brachyspira when the broth was supplemented with MRS at pH 3.8 compared to 
MRS at pH 7.2 thus indicating this pathogen’s sensitivity to acid (p £ 0.05).  
The pH-independent mechanism was explored here in order to determine which Lactobacillus 
isolates had the greatest inhibitory potential against Brachyspira, thus the p values in Table 
5.6 correspond to the differences of the CFS and its pH matched control. Of the three different 
pH values tested, CFS at pH 3.8 had the greatest inhibitory effect against Brachyspira. B. 
pilosicoli SAP 865 was the most tolerant to the Lactobacillus CFS at pH 3.8 and growth was 
significantly reduced (p value £  0.05) by only two of the ten Lactobacillus CFSs tested. B. 
pilosicoli B2904 and B. intermedia SAP 919 were the most susceptible to the different CFSs, 
with between five and six different Lactobacillus isolates significantly (p value £  0.05) 
reducing growth. B. innocens SAP 493 was also significantly susceptible to four different CFSs 
at pH 3.8 (p value £  0.05). Overall this indicated that Brachyspira isolates were susceptible to 
low pH Lactobacillus CFS. There were very few observable differences between the growth of 
Brachyspira supplemented with CFS at pH 4.5 and the pH matched control, with only B. 
pilosicoli SAP 859 and B. innocens SAP 943 showing significant decreases in growth. At pH 7.2, 
however, there appeared to be an increase in the number of Lactobacillus isolates capable of 
significantly reducing the growth of some isolates of Brachyspira. B. pilosicoli B2904 was more 
susceptible to the pH 7.2 CFS with six Lactobacillus isolates significantly reducing growth (p 
value£  0.01). B. pilosicoli SAP 865 and B. innocens SAP 943 were inhibited by approximately 
the same number of CFSs, however the Lactobacillus isolates responsible for this inhibition 
were different. On the other hand, B. intermedia SAP 919 and B. pilosicoli SAP 859 were 
inhibited by fewer Lactobacillus isolates at a neutral pH. 
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Of the ten Lactobacillus isolates tested, four were selected as potential probiotics for further 
exploration into the mechanisms of inhibition against Brachyspira in vitro and in vivo, 
described in Chapters 6 and 7. The isolates selected were L. reuteri SAP 2114 and 2115 and L. 
salivarius SAP 2116 and 2117. The primary criteria for selecting these isolates was their 
inhibitory activity against the Brachyspira isolates tested, as shown in Table 5.6. These four 
isolates were overall the most inhibitory against Brachyspira at the different pH values. L. 
reuteri SAP 2114 significantly inhibited B. pilosicoli B2904 (p£ 0.001) and SAP 859, B. 
intermedia SAP 919 (p £ 0.05) at pH 3.8 and B. pilosicoli SAP 859 (p £ 0.0001) and B. innocens 
SAP 934 (p £ 0.001) at pH 4.5. L. reuteri SAP 2115 demonstrated the greatest inhibitory effects 
against Brachyspira, significantly inhibiting B. pilosicoli B2904 (p £ 0.001) and SAP 859 (p £ 
0.05), B. intermedia SAP 919 (p £ 0.05) and B. innocens SAP 943 (p £ 0.005) at pH 3.8, B. 
pilosicoli SAP 859 (p £ 0.005) at pH 4.5 and B. pilosicoli B2904 (p £ 0.005), B. intermedia SAP 
919 (p £ 0.05) and B. innocens SAP 943 (p £ 0.05) at pH 7.2.  L. salivarius SAP 2116 significantly 
inhibited B. pilosicoli B2904 (p £ 0.0001) and B. innocens SAP 943 (p £ 0.05) at pH 3.8 and B. 
pilosicoli SAP 859 (p £ 0.005) at pH 4.5. Although this Lactobacillus isolate did not inhibit 
Brachyspira as significantly as other isolates, it was one of the four that inhibited Brachyspira 
at pH 4.5 and was therefore selected for further characterisation. L. salivarius SAP 2117 
demonstrated the greatest inhibitory ability against Brachyspira compared to all other L. 
salivarius isolates tested and significantly inhibited B. pilosicoli B2904 (p £ 0.005) and SAP 859 
(p £ 0.05) and B. innocens SAP 943 (p £ 0.005) at pH 3.8, B. pilosicoli SAP 859 (p £ 0.005) at 
pH 4.5 and B. pilosicoli B2904 (p £ 0.005) and SAP 859 (p £ 0.05) at pH 7.2. 
Following the selection of the most inhibitory Lactobacillus isolates against Brachyspira, it was 
important to consider the EFSA guidelines (EFSA et al., 2017) and investigate the antimicrobial 
resistance profiles of these four isolates. Screening of the L. reuteri whole genome sequences 
 167 
for potential antimicrobial resistance (AMR) genes revealed that these isolates did not 
harbour any of the AMR genes, however the L. salivarius isolates potentially harboured tetM 
and ermB which potentially conferred resistance to tetracycline and erythromycin. Therefore, 
MIC testing was employed to determine if the AMR genotype conferred phenotypic 
resistance to these antibiotics.  
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Table 5. 6 Initial screening of Lactobacillus cell free supernatant (CFS) for inhibition against 
Brachyspira. The area under the curve was calculated for each of the Brachyspira growth curves 
supplemented with different CFS, using GraphPad Prism 7. Significant inhibition of Brachyspira growth 
are highlighted in green whereby the p value was £ 0.05. Significant increases in Brachyspira growth 
are highlighted in orange. The area under the curve values were compared to the pH matched MRS 
control using a one- way ANOVA to determine significant inhibition of Brachyspira independent of pH. 
A pH dependent mechanism of inhibition was also noted when comparing growth of Brachyspira at 
pH 3.8 and 7.2. The p values presented were used to determine the inhibitory capability of each 
Lactobacillus CFS against each Brachyspira isolate. It was evident that this inhibition was dependent 
on the isolate of Brachyspira, the isolate of Lactobacillus and the pH of the CFS, therefore only the 
most inhibitory Lactobacillus isolates were selected for further study. These isolates were L. reuteri 
SAP 2114 and 2115 and L. salivarius 2116 and 2117. These experiments were performed with five 
biological replicates, each with three technical replicates. 
     MRS 3.8 vs  MRS 7.2 0.0001 0.0272 0.3387 0.0042 0.0001
     MRS   vs.      SAP 2103 CFS  0.9999 0.166 0.0349 0.0008 0.0714
     MRS   vs.      SAP 2105 CFS  0.9996 0.166 0.9931 0.0137 0.7573
     MRS   vs.      SAP 2106 CFS  0.9996 0.166 0.9996 0.0008 0.7573
     MRS   vs.      SAP 2107 CFS  0.0011 0.0004 0.0172 0.6399 0.9991
     MRS   vs.      SAP 2108 CFS  0.9996 0.166 0.5742 0.6399 0.0039
     MRS   vs.      SAP 2113 CFS  0.1922 0.0004 0.6474 0.0008 0.7573
     MRS   vs.      SAP 2114 CFS  0.0001 0.2607 0.7107 0.05 0.1267
     MRS   vs.      SAP 2115 CFS  0.0011 0.0265 0.999 0.0289 0.004
     MRS   vs.      SAP 2116 CFS  0.0001 0.1135 0.999 0.986 0.0188
     MRS   vs.      SAP 2117 CFS  0.0055 0.0071 0.999 0.7272 0.0042
     MRS   vs.      SAP 2103 CFS  0.9853 0.116 0.6035 0.9995 0.7506
     MRS   vs.      SAP 2105 CFS  0.9997 0.4531 0.9999 0.9944 0.9999
     MRS   vs.      SAP 2106 CFS  0.1048 0.572 0.6035 0.1563 0.9999
     MRS   vs.      SAP 2107 CFS  0.8237 0.4531 0.6035 0.9991 0.9999
     MRS   vs.      SAP 2108 CFS  0.8034 0.9999 0.9999 0.9996 0.6693
     MRS   vs.      SAP 2113 CFS  0.9988 0.4531 0.9999 0.9943 0.9999
     MRS   vs.      SAP 2114 CFS  0.9996 0.0001 0.6035 0.7067 0.0009
     MRS   vs.      SAP 2115 CFS  0.5 0.0026 0.9999 0.9997 0.9999
     MRS   vs.      SAP 2116 CFS  0.782 0.003 0.7043 0.0999 0.9999
     MRS   vs.      SAP 2117 CFS  0.9873 0.0026 0.6035 0.9994 0.0999
     MRS   vs.      SAP 2103 CFS  0.0001 0.2132 0.8748 0.9999 0.9999
     MRS   vs.      SAP 2105 CFS  0.1948 0.9999 0.9224 0.1322 0.0476
     MRS   vs.      SAP 2106 CFS  0.0063 0.9179 0.0001 0.0791 0.0186
     MRS   vs.      SAP 2107 CFS  0.9999 0.2696 0.4356 0.1727 0.0636
     MRS   vs.      SAP 2108 CFS  0.0016 0.9987 0.9997 0.0014 0.0008
     MRS   vs.      SAP 2113 CFS  0.0016 0.011 0.4356 0.5984 0.7985
     MRS   vs.      SAP 2114 CFS  0.1617 0.999 0.4356 0.9932 0.9999
     MRS   vs.      SAP 2115 CFS  0.0016 0.6864 0.4356 0.0262 0.05
     MRS   vs.      SAP 2116 CFS  0.99 0.9597 0.456 0.999 0.8865
     MRS   vs.      SAP 2117 CFS  0.0016 0.05 0.4356 0.8587 0.9731
B. intermedia  SAP 919 B. innocens SAP 943
P- Value ≤ 0.05
pH 4.5
pH 7.2
pH 3.8
B. pilosicoli  B2904 B. pilosicoli  SAP 859 B. pilosicoli SAP 865
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5.2.3.2 Antimicrobial sensitivity testing of Lactobacillus  
 
The European Food Safety Authority (EFSA) (European Food Safety Authority, 2012) stipulates 
that in order for an organism to be considered as a potential feed additive, the antimicrobial 
resistance profiles for ampicillin, chloramphenicol, clindamycin, erythromycin,  gentamicin, 
kanamycin, streptomycin, tetracycline and vancomycin need to be determined in order to 
assess the risk of transference of AMR genes. Notably, some Lactobacillus isolates are innately 
resistant to vancomycin and thus there is no risk of transmitting this resistance. The MICs for 
the four selected potential probiotic candidates, L. reuteri SAP 2114, L. reuteri SAP 2115, L. 
salivarius SAP 2116 and L. salivarius SAP 2117 were tested using the broth microdilution 
method and the results are summarised in Table 5.7. MIC values were interpreted according 
to the EFSA guidelines, using the FEEDAP official MIC cut-off values detailed in brackets in 
Figure 5.7 (EFSA et al., 2017). 
L. reuteri SAP 2114 and 2115 were the most suitable probiotic candidates because firstly, all 
of the MIC values obtained were at or below the cut-off concentrations stipulated by the EFSA 
guidelines, and secondly, they did not harbour potential antimicrobial resistance genes. The 
L. salivarius isolates SAP 2116 and 2117 had MIC values higher than stated in the guidelines 
for erythromycin, kanamycin, streptomycin and tetracycline. These isolates were therefore 
less suitable as probiotic candidates, however remained in further studies to characterise the 
mechanisms of inhibition due to their inhibitory activity against Brachyspira as detailed in 
Table 5.6 
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Lactobacillus 
Species 
Strain 
Name 
MIC µg/ml  
Ampicillin 
 
Chloramphenicol  
 
Clindamycin  
 
Erythromycin 
 
Gentamicin 
 
Kanamycin 
 
Streptomycin 
 
Tetracycline 
 
Vancomycin 
L. reuteri SAP 
2114 
2 
(2) 
4 
(4) 
< 0.0062 
(1) 
       0.25 
         (1) 
        2 
       (8) 
32 
(64) 
32 
(64) 
32 
(16) 
R 
(n.r) 
L. reuteri SAP 
2115 
        1 
       (2) 
4 
(4) 
< 0.0062 
(1) 
 0.125 
(1) 
1 
(8) 
16 
(64) 
16 
(64) 
4 
(16) 
R 
(n.r) 
L. salivarius SAP 
2116 
2 
(4) 
4 
(4) 
0.25 
(1) 
8 
(1) 
       16 
      (16) 
256 
(64) 
128 
(64) 
128 
(8) 
R 
(n.r) 
L. salivarius  SAP 
2117 
2 
(4) 
             4 
            (4) 
0.125 
(1) 
          4 
         (1) 
16 
(16) 
256 
(64) 
128 
(64) 
128 
(8) 
R 
(n.r) 
E. faecalis  NCTC 
12697 
1 
(1) 
             4 
            (4) 
8 
(8) 
4 
(4) 
8 
(8) 
128 
(1024) 
256 
(1024) 
8 
(16) 
2 
(2) 
Table 5. 7 Minimum inhibitory concentration (MIC) of the antibiotics ampicillin, chloramphenicol, clindamycin, erythromycin, gentamicin, kanamycin, streptomycin, 
tetracycline and vancomycin determined by broth microdilution against the four selected Lactobacillus isolates, L. reuteri SAP 2114 and 2115 and L. salivarius SAP 
2116 and 2117. E. faecalis NCTC 12697 was used as a control strain to ensure correct antibiotic concentrations were used (Andrews, 2001). The experiment was 
performed with three biological replicates, each with three technical replicates. The accepted break-points for L. reuteri, L. salivarius and E. faecalis are presented 
in brackets underneath the recorded MIC.  
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5.2.3.3 Acid tolerance  
 
In order to promote successful passage through the gastrointestinal tract, any potential 
probiotics must be tolerant to acid. The gizzard is the most acidic section of the avian 
gastrointestinal tract, with a pH between 1.9 and 4.5 (Sivihus, 2014). Therefore, it was 
important to ascertain the survival of each of the selected Lactobacillus isolates at pH 1.9 to 
ensure that they could theoretically survive passage through the gizzard.  
At pH 1.9 a significant reduction (p £ 0.05) in numbers of all four Lactobacillus isolates were 
observed after 3 hours of incubation (Jin et al., 1998) (Table 5.8). The numbers of both L. 
salivarius isolates were below the limit of detection after incubation at pH 1.9.  However, a 
~1-1.5 log reduction in bacterial survival was observed for both L. reuteri isolates which 
indicated that these isolates were tolerant to acidic conditions, despite the reduction in cell 
numbers. No significant differences in numbers of Lactobacillus were observed with isolates 
incubated for 3 hours in PBS at pH 7.2.  
  
Lactobacillus Species 
 
pH 1.9 
(CFU/ml) 
 pH 7.2 
(CFU/ml) 
 0 hours             3 hours  0 hours             3 hours 
L. reuteri SAP 2114 1.65x108 
(7.64x106) 
1.28x107 * 
(9.43x106) 
1.70x108 
(8.01x106) 
1.10x108 
(6.08x107) 
L. reuteri SAP 2115 1.08x108 
(6.00x107) 
6.78x106 * 
(2.90x106) 
1.28x108 
(5.67x106) 
1.63x108 
(6.05x107) 
L. salivarius SAP 2116 3.3 x107 
(7.01x106) 
0 * 
(0) 
3.6 x107 
(6.72x106) 
2.52x107 
(5.48x106) 
L. salivarius SAP 2117 3.27x107 
(3.27x107) 
0 * 
(0) 
3.0x107 
(2.89x106) 
2.98x107 
(9.50x106) 
Table 5. 8 Survival of four potential probiotic strains, L. reuteri SAP 2114 and 2115 and L. salivarius 
SAP 2116 and 2117, in acidic conditions following three hours of incubation in PBS at pH 1.9 and 7.2. 
The data represent the mean of three biological replicates, each with three technical replicates, a 
significant reduction in CFU/ml is indicated by an Asterix (*) (p value < 0.05). Standard deviation is 
shown in brackets.  
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5.2.3.4 Bile salt tolerance  
 
The four probiotic candidates were also assessed for their ability to tolerate oxgall (bovine 
bile) and two constituents of poultry bile, taurocholic acid and sodium 
taurochenodeoxycholate (Yeh and Hwang, 2001). Despite these probiotics being intended for 
use in poultry, the sensitivity to oxgall was tested to assess the feasibility for use in other 
livestock species such as cattle. 
Overall, the L. reuteri isolates were more tolerant to the bile salts, compared to L. salivarius. 
Using the method developed by Chateau et al. (1994), it could be observed that L. reuteri SAP 
2114 and SAP 2115 were resistant to 0.3% taurocholic acid as the difference in lag time 
compared to the control was zero hours, as seen in Table 5.9. Interestingly, the growth of L. 
reuteri SAP 2115 was improved by 1% taurocholic acid whereby the lag time was one hour 
shorter compared to control. The log phase of growth was also an important consideration 
when analysing these data. For example, Figure 5.5A suggested that despite the difference in 
the lag phase of 1% sodium taurochenodeoxycholate being two hours when compared to 
control (therefore sensitive to this bile salt in accordance to Chateau et al. (1994)), it was 
evident that this bile salt improved the growth of L. reuteri SAP 2114 significantly (p value £ 
0.001). Similarly, 1% taurocholic acid and 0.3% sodium taurochenodeoxycholate significantly 
increased the overall growth (p value £ 0.01) of L. reuteri SAP 2114 and 2115 (Figure 5.5A and 
B). Therefore, it was important to consider both the lag and log phase when analysing these 
data to determine tolerance to bile salts, especially for the more tolerant Lactobacillus 
isolates. L. salivarius isolates were significantly less tolerant to bile salts, where oxgall and 
taurochenodeoxycholate inhibited the growth of SAP 2116 (Figure 5.5C) and SAP 2117 (Figure 
5.5D) at both 1% and 0.3% (p value £ 0.001). L. salivarius SAP 2116 was sensitive and 2117 
was tolerant to 0.3% taurocholic acid indicated by Table 5.9 and the methods described by 
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Chateau et al. (1994), however it was observed from Figure 5.5C and D that, although there 
was a significant decrease in Lactobacillus growth (p value £ 0.001), these isolates still grew 
sufficiently to be weakly tolerant to the bile salt. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 5 Tolerance of (A) L. reuteri SAP 2114, (B) L. reuteri SAP 2115, (C) L. salivarius SAP 2116 and (D) L. 
salivarius SAP 2117 to poultry and bovine bile salts. Taurocholic acid was tested at 1% (purple) and 0.3% (orange) 
(w/v) in MRS, sodium taurochenodeoxycholate was tested at 1% (black) and 0.3% (brown) (w/v) in MRS and 
oxgall was tested at 1% (red) and 0.3% (green) (w/v) in MRS. The growth of each Lactobacillus isolate under 
these experimental conditions was compared to growth in MRS alone (blue) using area under the curve analysis, 
followed by a one-way ANOVA with Dunnett’s multiple comparison (*, p £ 0.05; **, p £ 0.01; ***, p £ 0.001; 
****, p £ 0.0001). L. reuteri isolates were more tolerant to the poultry bile salts compared to L. salivarius and it 
is evident that none of the isolates were tolerate to oxgall at either 1% or 0.3% (w/v). Growth was measured for 
18 hours using optical density (OD600) and the data presented were means of three biological replicates, each 
with three technical replicates. 
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- 0.3 OD600 not reached 
Bile Salt Product    Lag time (hours)   
 L. reuteri 
SAP 2114 
Difference 
in lag time 
compared 
to control 
L. reuteri 
SAP 2115 
Difference 
in lag time 
compared 
to control 
L. salivarius 
SAP 2116 
Difference 
in lag time 
compared 
to control 
L. salivarius 
SAP 2117 
Difference 
in lag time 
compared 
to control 
Control 4.25 ± 
0.25 
 5.0 ± 1  5.5 ± 0.25  8 ± 1  
1% oxgall  - - - - - - - - 
0.3% oxgall 14.14 ± 2 9.89 - - - - - - 
1% taurocholic acid 5.75 ± 0.5 1.5 4.0 ± 2 -1 17.25 ± 3 11.75 - - 
0.3% taurocholic acid 4.25 ± 0.5 0 5.0 ± 1 0 7.75 ± 2 2.25 8.5 ± 1.5 0.5 
1% sodium 
taurochenodeoxycholate 
6.25 ± 
0.25 
2 15.50 ± 
1.5 
10.50 - - - - 
0.3% sodium 
taurochenodeoxycholate 
6.50 ± 
0.25 
2.25 8.25 ± 1 3.35 - - - - 
Table 5. 9 Lag time of L. reuteri SAP 2114 and 2115 and L. salivarius 2116 and 2117 as a measure of tolerance to the poultry bile salts taurocholic acid and 
sodium taurochenodeoxycholate and the bovine bile salt oxgall. MRS media was supplemented with 1% or 0.3% (w/v) of each bile salt and growth was 
measured by optical density for 18 hours. The lag time was defined as the time taken for each culture to reach an OD600 of 0.3 (Chateau et al., 1994). Data 
are presented as means with standard deviation of three biological replicates, each with three technical replicates. The difference in lag time between the 
media supplemented with bile salts and the control were calculated to determine the tolerance of each Lactobacillus isolate. Tolerance was defined Chateau 
wehereby a delay in growth of less than 15 minutes between the test and control determined an isolate to be resistant to bile salts, between 15 and 40 
minutes determined an isolate to be tolerant, between 40 and minutes determined an isolate to be weakly tolerant and greater than 60 minutes determined 
an isolate to be sensitive to bile salts.  
 
 175 
5.3 Discussion 
 
The studies presented here focussed on the isolation and characterisation of Lactobacillus 
isolates as potential poultry probiotics capable of inhibiting Brachyspira, the causative agent 
of avian intestinal spirochaetosis.  
A panel of Lactobacillus isolates were isolated from the faeces of healthy, free-range hens. 
The isolates were preliminarily characterised using staining, biochemical testing and 16S rRNA 
sequencing to ensure they fulfilled the basic Lactobacillus probiotic criteria defined by EFSA 
(EFSA et al., 2017). These guidelines have been implemented to ensure the safety of potential 
probiotics that are designed as animal feed supplements. Furthermore, Lactobacillus species 
categorised under these guidelines have excellent safety records, and detrimental effects 
produced following ingestion are rare (Gueimonde et al., 2013). 
Although there are undefined probiotic products on the market for the poultry industry, such 
as Aviguardâ (Collins et al., 2009), to identify probiotic products that target Brachyspira, the 
bacterial isolate needs to be well characterised and have proven efficacy against this 
pathogen. Another consideration for a potential probiotic is that it can effectively colonise 
the gastrointestinal tract of the target host and not cause disease (Klaenhammer and Kullen, 
1999). This is why all potential probiotics in these studies were isolated from the faeces of 
healthy chickens, as this suggested that the isolates could colonise the gastrointestinal tract 
without causing disease. However, in vitro testing such as cytotoxicity in gastrointestinal cell 
lines and in vivo testing in chickens would be required to confirm this.  
More recently, as whole genome sequencing has become more readily available, EFSA have 
stipulated that whole genome sequencing is to be used for the ‘unequivocal taxonomic 
identification’ of each potential probiotic isolate intended for animal consumption, therefore 
the selected Lactobacillus isolates were sent for whole genome sequencing. In terms of 
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probiotic characterisation, genome sequencing is the gold standard and has many advantages 
especially in the identification of an organism and the ability to screen for negative gene traits. 
The sequencing used in these studies confirmed the species of each isolate and allowed for 
preliminary comparisons with other published genome sequences to ensure these isolate 
were representative of the species within the Lactobacillus genus (Yun et al., 2009; Frese et 
al., 2011; Ojala et al., 2014; Lee et al., 2017).  Additionally, screening for negative gene traits 
such as antimicrobial resistance genes, virulence genes and plasmids was highly 
advantageous as the detection of these putative genes led to targeted phenotypic assays, 
such as MICs. These assays determined if the presence of an AMR gene conferred phenotypic 
resistance in vitro.  
ABRicate software identified the presence of three antimicrobial resistance genes, tetM, tetW 
and ermB as shown in Table 5.3. All L. salivarius isolates harboured both tetM and ermB, 
indicating resistance to tetracycline and erythromycin. L. crispatus isolates harboured all 
three genes and L. reuteri lacked any of these antimicrobial resistance genes, thus L. reuteri 
isolates were the most suitable for probiotic selection. If an isolate harboured any 
antimicrobial resistance genes, there needed to be proof that these were not transposable to 
other bacteria. However, the tetM and ermB genes have been previously shown to be present 
on plasmids and other mobile genetic elements which can not only be transferred between 
Lactobacillus isolates, but also to other lactic acid bacteria such as Enterococcus faecalis and 
Lactococcus lactis (Gevers et al., 2003).  Therefore, this would render any isolates harbouring 
these genes unsuitable as commercial probiotics, however this did not limit their usefulness 
when exploring the mechanisms of probiotic action against Brachyspira.  
Resistance to tetracycline and erythromycin is most widely detected in Lactobacillus isolates, 
potentially resulting from the wide use of these antibiotics in animals, both as therapeutic 
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agents and growth promoters (Comunian et al., 2010). The genes responsible for these 
resistances are most frequently identified as tetM, tetW and ermB; these genes have been 
associated with conjugative transposons on both chromosomes and plasmids (Roberts, 2008). 
The tetracycline resistance genes, tetM and tetW encode ribosomal protection proteins that 
interfere with the tetracycline binding to the ribosome to prevent the inhibitory effect on 
translation (Xi et al., 2009). The macrolide resistance gene ermB, results in the methylation of 
the ribosomal binding site of the antibiotic, rendering it infective (Desjardins et al., 2004).  
Therefore, Lactobacillus isolates harbouring these genes pose the risk of transferring these 
resistance genes to other bacteria in the gastrointestinal tract.  
Importantly, many lactobacilli, including L. crispatus, L. reuteri and L. salivarius are intrinsically 
resistant to vancomycin and transfer of this resistance has not been observed (Tynkkynen et 
al., 1998). Vancomycin resistance is well characterised in lactic acid bacteria; vancomycin acts 
on the peptidoglycan precursors on the cell wall side of the cytoplasmic membrane and binds 
to D-alanine/D-alanine terminus of the pentapeptide, preventing polymerisation of 
peptidoglycan precursors. In many Lactobacillus species the terminal D-alanine is replaced 
with D-lactate or D-serine, preventing vancomycin binding and conferring resistance innately 
(Gueimonde et al., 2013). 
As previously mentioned, following the identification of putative AMR genes, the MICs for 
nine different antibiotics were tested in accordance to the EFSA guidelines. L. reuteri isolates 
showed the most suitability as probiotic candidates due to the absence of genotypic and 
phenotypic antimicrobial resistance. However, L. salivarius isolates were resistant to four of 
the antibiotics tested: kanamycin, streptomycin, tetracycline and erythromycin, resulting in 
these isolates being less suitable as probiotic candidates. It has long been recognised that the 
use of antibiotic growth promoters in the livestock industry has resulted in the increased 
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incidence of antimicrobial resistance in bacteria isolated from poultry (Gast and Stephens., 
1988). Therefore, the high incidence of antimicrobial resistance was unsurprising and 
highlighted the importance of genotypically and phenotypically screening potential probiotics 
for resistance to antibiotics of both human and veterinary importance.  
Screening of genome sequences was not solely used to screen for negative gene traits but 
was also important in identifying positive traits such as the presence of putative bacteriocin 
genes. Bacteriocins are antibacterial peptides produced by bacteria such as Lactobacillus 
which are inhibitory against other closely related bacteria. These peptides are ribosomally 
synthesised and primarily inhibit bacteria through pore formation or inhibition of cell wall 
synthesis in target cells. However, they have been shown to have activity against Gram 
negative bacteria, especially those that have had their outer membrane permeabilised 
(Cotter et al., 2005; Messaoudi et al., 2013). Studies have indicated that chickens fed on a diet 
containing a bacteriocin derived from L. salivarius had lower counts of C. jejuni following 
challenge, compared to chickens that were fed diets that did not contain the bacteriocin 
(Stern et al., 2006). Therefore, bacteriocins may contribute to the inhibition of Brachyspira in 
the studies presented here (this was further explored in Chapter 6).  
Sixty-six different bacteriocins have been identified in the Lactobacillus genus and studies 
have shown that Lactobacillus isolates of human and animal origin encode for twice as many 
bacteriocin genes compared to those from other sources (Collins et al., 2017). The pipelines 
used in these studies were therefore able to screen for and predict a range of bacteriocin 
peptides. Lactobacillus isolates that encode several bacteriocin genes may have a competitive 
advantage against other bacteria in the gastrointestinal tract as a result of having the ability 
to kill isolates competing for the same niche. However, it is important to note that these 
predicted genes may not translate to functional bacteriocins due to gene mutations. 
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Therefore, phenotypic assays were required to confirm their presence (discussed in Chapter 
6).  
Salivaricin,  a class I lantibiotic, and class II bacteriocins are small, heat stable peptides thought 
to inhibit Gram positive cell wall biosynthesis, thus killing target cells (Barbour et al., 2016). 
Enterolysin A and helveticin J are bacteriolysins (formally known as class III bacteriocins). 
Bacteriolysins are large molecular weight, heat-labile proteins which are sub-divided into two 
groups: group A which are bacteriolytic enzymes that will kill the target cell through bacterial 
cell wall lysis (Enterolysin A) (Khan et al., 2013) and group B which are non-lytic, bacteriostatic 
proteins (Helveticin J) (Yang et al., 2014). These bacteriolysins appear to be abundantly 
present in the different isolates presented here and across other species of Lactobacillus 
(Chung et al., 2018). Many of the known functions of bacteriocins relate to inhibition of 
closely related Gram positive species, however inhibition of C. jejuni and Salmonella 
Typhimurium have been observed in in vivo and in vivo models (Natrajan and Sheldon, 2000; 
Stern et al., 2006) and therefore may play a role in Brachyspira inhibition, this will be further 
explored in Chapter 6. 
In order for Lactobacillus isolates to be considered as potential probiotics, there must be 
evidence health benefits to the host. Therefore, the ten isolates presented in these studies 
were screened for their inhibitory capabilities against Brachyspira in vitro. It is well 
documented that Lactobacillus inhibition is strain specific and therefore it was important to 
determine which isolates of Lactobacillus would be effective against which isolates of 
Brachyspira which were characterised in Chapter 3 (Ouwehand et al., 2002; Mappley et al., 
2011; Campana, et al., 2017). These studies showed a wide range of activity against 
Brachyspira at different pH, as shown in Table 5.6. Using these data, it was possible to select 
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four Lactobacillus isolates that were the most inhibitory against Brachyspira, these were L. 
reuteri SAP 2114 and 2115 and L. salivarius 2116 and 2117. 
The gizzard and duodenum of the avian gastrointestinal tract are harsh environments that 
probiotic bacteria must survive in order to reach the large intestine and caeca. As previously 
mentioned the pH of the gizzard is between 1.9 and 4.5 and in the duodenum, bacteria are 
exposed to bile acids, therefore it was advantageous to test probiotic tolerance to low pH and 
presence of bile to infer in vivo survival (Svihus, 2014). A 3-hour incubation was used in these 
experiments, although it is unlikely that Lactobacillus isolates would be exposed to these 
adverse conditions for this period of time. Feed is estimated to remain in the chicken’s gizzard 
for 30-60 minutes, after which it is mixed with the pancreatic and bile secretions for less than 
five minutes before the pH begins to rise rapidly to approximately pH 6 to allow digestion in 
the small intestine to occur (Svihus, 2014). Although this was designed to be a rapid screen 
for acid and bile salt tolerance, it may have been more appropriate to complete a time course 
experiment to investigate the Lactobacillus viable counts at one and two hours post exposure 
to these adverse conditions. Furthermore, it would have been advantageous to test 
Lactobacillus survival in the presence of chicken gizzard contents, although logistically this 
was not possible in the studies presented here, it is an important future consideration for 
subsequent studies as this will reflect more closely, the real environment of the poultry 
gastrointestinal tract. 
Of the four isolates tested, the L. reuteri isolates were more tolerant to a pH of 1.9 and to the 
presence of bile salts, compared to the L. salivarius isolates. The data here were consistent 
with the study by Heravi et al. (2011) whereby it was suggested that L. reuteri isolates were 
more tolerant to low pH than L. salivarius isolates. This may be as a result of several 
mechanisms designed to ensure Lactobacillus can survive unfavourable environments. Such 
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mechanisms include the accumulation of protective compounds such as compatible solutes 
for example glycine betaine, which act as osmoprotectants to protect against extreme 
osmotic stress (Sheehan et al., 2006). Additionally, the presence of glutamate decarboxylases 
which convert glutamate to GABA and are also known the contribute to the acid tolerance of 
E. coli, Listeria monocytogenes, Lactococcus lactis and L. reuteri as this process consumes the 
H+ protons that contribute to acidity (Su et al., 2011). Therefore, the varying acid tolerance 
and bile salt tolerance may be as a result of genes involved in one or more of these 
mechanisms, these would need further exploration in future studies. 
To summarise, a panel of Lactobacillus isolates were isolated and characterised to determine 
their suitability as probiotic candidates. The characterisation methods were informed by the 
EFSA guidelines which clearly outline the EU requirements for probiotics intended as animal 
feed supplements. Furthermore, candidates had to demonstrate inhibition against 
Brachyspira species. Four Lactobacillus probiotic candidates: L. reuteri SAP 2114 and SAP 2115 
and L. salivarius SAP 2116 and 2117 were selected to explore the mechanisms of Brachyspira 
inhibition. Overall, the L. reuteri isolates were more suitable as probiotic candidates due to 
their tolerance to bile salts and acid, furthermore, they did not harbour any negative gene 
traits, such as antimicrobial resistance genes. L. reuteri SAP 2115 and L. salivarius SAP 2117 
were the most inhibitory against Brachyspira in the studies presented here. Therefore, all four 
isolates will be further explored in subsequent chapters to begin to elucidate a mechanism of 
Brachyspira inhibition by Lactobacillus probiotics.  
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Chapter 6: Investigating the ability of Lactobacillus to inhibit 
Brachyspira species implicated in avian intestinal spirochaetosis 
 
6.1 Introduction  
 
The prevalence of Brachyspira in laying hens is estimated to be as high as 90% in free range 
hens and 76% in caged hens (Burch, 2010). Despite attempts to control disease, as mentioned 
in Chapter 1, the incidence of disease continues to rise. Furthermore, in the UK tiamulin is the 
only licenced antibiotic for the treatment of avian intestinal spirochaetosis. Therefore, 
antimicrobial resistance is an emerging concern as increasing numbers of Brachyspira isolates 
are becoming less sensitive to tiamulin and other antibiotics used worldwide (Herbst et al., 
2017). As a result, alternative control strategies are urgently required to promote animal 
health and to reduce the need for antibiotics. Probiotics are one such intervention that have 
shown inhibitory effects against Brachyspira in vitro (Bernardeau et al., 2009; Mappley et al., 
2011) and the ability to reduce symptoms and Brachyspira colonisation in vivo (Mappley et 
al., 2013). 
Probiotics are widely used in the livestock industry (Collins et al., 2009) and the mechanisms 
underlying their activity appear to be multifactorial. These mechanisms include production of 
acids, bacteriocins and other inhibitory metabolites, in addition to modulation of the immune 
system and causing competition for nutrients and binding sites to prevent colonisation of a 
pathogen (Collins et al., 2009; Campana et al., 2017). However, exact mechanisms of action 
have not been fully elucidated for Brachyspira and may differ depending on the probiotic 
strain, animal host and the pathogen.  
The aim of this chapter was to determine the potential inhibitory mechanisms of action of the 
Lactobacillus isolates characterised in Chapter 5 against the Brachyspira isolates 
characterised in Chapter 3. Preliminary data from Chapter 5 resulted in the characterisation 
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and selection of four probiotic candidates that demonstrated inhibition against Brachyspira: 
L. reuteri SAP 2114 and 2115 and L. salivarius SAP 2116 and 2117. However, the mechanisms 
of inhibition were unknown and required further exploration. Additionally, with the 
commercial potential of these potential probiotics in mind, the inhibition of other common 
pathogens, namely E. coli and Salmonella Typhimurium were tested to explore the ability of 
these Lactobacillus isolates to inhibit a wide range of avian pathogens.  
The aims and objectives of this chapter were: 
• To investigate the Lactobacillus pH dependent and independent mechanisms of 
Brachyspira inhibition. 
• To use NMR analysis to identify metabolites present in the cell free supernatant (CFS) 
of the Lactobacillus isolates which may be responsible for inhibition of Brachyspira 
growth. 
• To investigate how physical interactions between Lactobacillus and Brachyspira may 
impact Brachyspira viability in vitro. 
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6.2 Results  
 
6.2.1 Identifying pH dependent inhibition of Brachyspira 
 
The cell free supernatants (CFS) from L. reuteri SAP 2114 and 2115 and L. salivarius 2116 and 
2117 were approximately pH 3.8 after 18 hours of anaerobic culture in MRS broth at 37°C. To 
differentiate between pH effects and other mechanisms of inhibition, the inhibition assays 
were performed with CFS at pH 3.8 and CFS neutralised to pH 7.2 
To initially determine the pH dependent mechanism of inhibition, Brachyspira were cultured 
in brain heart infusion (BHI) broth supplemented with 10% (v/v) MRS at pH 3.8 and MRS at 
pH 7.2. A pH dependent mechanism of inhibition was observed for all of the Brachyspira 
isolates tested, except for B. pilosicoli SAP 865, as shown in Figure 6.1. The growth of B. 
pilosicoli B2904 and SAP 859, B. intermedia SAP 919 and B. innocens SAP 924 was significantly 
reduced when BHI broth was supplemented with MRS at pH 3.8 compared to MRS at pH 7.2 
(p value £ 0.0001). B. innocens SAP 927 and SAP 943 and B. alvinipulli ATCC 51933 were also 
susceptible to a pH 3.8, but to a lesser extent than other Brachyspira isolates (p value £ 0.05). 
Interestingly, B. pilosicoli SAP 865 was tolerant pH 3.8 as observed in Figure 6.1C, whereby 
there was no significant difference in bacterial growth when the media was supplemented 
with MRS at pH 3.8 compared to pH 7.2.  
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Figure 6. 1 Growth curves of A: B. pilosicoli B2904, 
B: B. pilosicoli SAP 859 C: B. pilosicoli SAP 865 D: B. 
intermedia SAP 919 E: B. alvinipulli ATCC 51933 F: 
B. innocens SAP 943 B3445, G: B. innocens SAP 924 
in BHI+10% serum, supplemented with 10% (v/v) 
MRS broth with pH adjusted to 3.8 (blue) and 7.2 
(red), to investigate the impact of pH on the 
growth of Brachyspira. Growth was monitored 
over 120 hours of anaerobic incubation at 37°C. 
Optical density readings were taken at 620nm 
every ˜10 hours. These data represent an average 
of five biological replicates, each with three 
technical replicates. Significance, if any, is shown 
for pH dependent growth between control groups 
* p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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6.2.2 Identifying pH independent inhibition of Brachyspira 
 
To determine the presence of a pH independent mechanism of inhibition (in addition to the 
pH dependent mechanism), Brachyspira were cultured in BHI broth supplemented with 10% 
(v/v) cell free supernatant at either pH 3.8 or pH 7.2 and growth was compared with the pH 
matched control (MRS at pH 3.8 or pH 7.2). The extent of pH independent inhibition was 
dependent on both the isolate of Lactobacillus and the isolate of Brachyspira it was tested 
against, as shown in Figure 6.2 and Table 6.1.  
B. pilosicoli isolates displayed a range of susceptibilities to Lactobacillus cell free supernatant 
independent of pH as shown in Figure 6.2A-C and Table 6.1. B. pilosicoli B2904 was inhibited 
by all CFSs from each isolate of Lactobacillus (p value £  0.0001), however the growth of B. 
pilosicoli SAP 859 and 865 was not significantly inhibited by a pH independent mechanism 
with the exception of SAP 859 which was inhibited by L. salivarius SAP 2116 (p value £  
0.0001). 
B. intermedia SAP 919 was also inhibited by all Lactobacillus isolates independent of pH (p 
value  £ 0.0001) (Figure 6.2D and Table 6.1). Additionally, L. reuteri SAP 2114 and 2115 were 
significantly more inhibitory at pH 3.8 than the L. salivarius isolates (p value £ 0.0001). L. 
reuteri SAP 2115 was also significantly more inhibitory than L. salivarius SAP 2116 (p value 
0.0004) and SAP 2117 (p value 0.015) at pH 7.2, demonstrating clear phenotypic differences 
between the L. reuteri isolates.  
The growth of B. alvinipulli ATCC 51933 was significantly reduced by the CFS from L. reuteri 
SAP 2115 and L. salivarius SAP 2116 at pH 3.8, compared to the pH matched controls (p value 
£ 0.05) (Figure 6.2E and Table 6.1). However, CFS at pH 7.2 did not significantly affect growth. 
The growth of B. innocens SAP 943 and SAP 924 was significantly inhibited by all Lactobacillus 
CFSs at pH 3.8 compared to the pH matched control (p value £ 0.0001). B. innocens SAP 943 
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and SAP 924 were also significantly inhibited by L. reuteri SAP 2115 at pH 7.2, compared to 
control (p value 0.0004, £ 0.0001, respectively). Additionally, B. innocens SAP 924 was 
significantly inhibited by L. reuteri SAP 2114 and SAP 2115 and L. salivarius SAP 2117 at both 
pH 3.8 and pH 7.2 (p value £ 0.005). B. innocens SAP 927 was not included in these 
experiments because this isolate did not grow sufficiently in broth. 
Overall, L. reuteri SAP 2115 was the most effective Lactobacillus isolate of the panel tested 
because it had the greatest inhibitory effects against multiple Brachyspira isolates (Table 6.1). 
There was a highly variable tolerance to the CFS amongst Brachyspira isolates and no specific 
Lactobacillus isolate was effective against one species of Brachyspira. B. pilosicoli B2904, B. 
intermedia SAP 919 and B. innocens SAP 924 and SAP 943 were the most susceptible to 
Lactobacillus CFS, whereas B. pilosicoli SAP 859 and 865 and B. alvinipulli ATCC 51933 were 
mostly tolerant to the CFS. Thus, demonstrating the need to test a range of Lactobacillus 
against a range of Brachyspira.  
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Figure 6. 2 Growth curves of A: B. pilosicoli B2904, B: B. 
pilosicoli SAP 859 C: B. pilosicoli SAP 865 D: B. intermedia 
SAP 919 E: B. alvinipulli ATCC 51933 F: B. innocens SAP 
943 and G: B. innocens SAP 924, in BIH broth+ 10% 
serum, supplemented with 10% (v/v) CFS from L. reuteri 
SAP 2114 pH 3.8 (green) and pH 7.2 (purple), L. reuteri 
SAP 2115 pH 3.8 (orange) and pH 7.2 (black), L. salivarius 
SAP 2116 pH 3.8 (brown) and 7.2 (dark blue) and L. 
salivarius SAP 2117 pH 3.8 (dark purple) and pH 7.2 
(dark red). These growth curves were compared to pH 
matched MRS controls at pH 3.8 (blue) and pH 7.2 (red). 
Growth was monitored over 120 hours of anaerobic 
incubation at 37°C. Optical density readings were taken 
at 620nm every ˜10 hours. These data represent an 
average of five biological replicates, each with three 
technical replicates. Significance, if any, is shown for pH 
dependent growth between control groups * p ≤ 0.05; 
** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001.  
*** 
**** 
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6.2.3 Investigating the mechanism of pH independent inhibition of Brachyspira  
 
To explore the pH independent mechanisms of inhibition presented in these studies in more 
detail, Lactobacillus cell free supernatants were treated with trypsin or heat inactivated to 
denature any proteins that may have been responsible for Brachyspira inhibition. The 
hypothesis was that proteins, such as those identified in Chapter 5 may contribute to the 
inhibition of Brachyspira. Both trypsin and heat treatment were used to ensure the removal 
of heat stable proteins such as class I and class II bacteriocins and heat labile proteins such as 
bacteriolysins as identified in Tables 5.4 and 5.5 in Chapter 5. The data from these 
experiments are summarised in Figure 6.3, Appendix IV and Tables 6.2 and 6.3. 
Trypsin treatment of the L. reuteri SAP 2114 only had an impact on Brachyspira inhibition at 
pH 3.8. The inhibition of B. pilosicoli B2904, B. intermedia SAP 919 and B. innocens SAP 924 
was significantly reduced with this treatment (p value £ 0.0001, £ 0.0001 and 0.0445, 
respectively). Heat treatment of this CFS increased to inhibition of all Brachyspira isolates 
Table 6. 1 P values for the Brachyspira CFS inhibition assays presented in Figure 5.2. The area under the 
curve was calculated for each of the Brachyspira growth curves supplemented with the CFS from each of 
the four probiotic candidates at either pH 3.8 or pH 7.2. Statistical significance was calculated using a one-
way ANOVA and data were highlighted in green if the p value was £ 0.05 and highlighted in red if the p 
value was > 0.05. 
 
     MRS   vs.      SAP 2114 CFS  0.0001 0.9865 0.7107 0.0001 0.4054 0.0002 0.0001
     MRS   vs.      SAP 2115 CFS  0.0001 0.7829 0.999 0.0001 0.0419 0.0001 0.0001
     MRS   vs.      SAP 2116 CFS  0.0001 0.0001 0.999 0.0001 0.0035 0.0001 0.0001
     MRS   vs.      SAP 2117 CFS  0.0001 0.2341 0.999 0.0001 0.1687 0.0001 0.0001
     MRS   vs.      SAP 2114 CFS  0.0001 0.9995 0.4356 0.0001 0.1731 >0.9999 0.0053
     MRS   vs.      SAP 2115 CFS  0.0001 0.2607 0.4356 0.0001 0.0951 0.0004 0.0001
     MRS   vs.      SAP 2116 CFS  0.0001 0.9824 0.456 0.0001 0.3186 >0.9999 0.222
     MRS   vs.      SAP 2117 CFS  0.0001 >0.9999 0.4356 0.0001 0.9983 0.0654 0.0004
B. innocens 
SAP 924
pH 7.2
pH 3.8
P- Value ≤ 0.05
 B. pilosicoli 
B2904
B. pilosicoli 
SAP 859
B. pilosicoli 
SAP 865
B. intermedia 
SAP 919
B. innocens 
SAP 943
B. alvinipulli 
ATCC 51933
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except for B. intermedia SAP 919, where the inhibition was significantly reduced (p value 
0.0065).  
The trypsin treatment of L. reuteri SAP 2115 had an impact on Brachyspira inhibition at both 
pH 3.8 and 7.2; the inhibition of B. intermedia SAP 919 was significantly reduced at both pH 
3.8 (p value £ 0.0001) and 7.2 (p value £ 0.0001), in addition to the inhibition of B. innocens 
SAP 943 being reduced at pH 7.2 (p value 0.0282). Interestingly, heat treatment of L. reuteri 
SAP 2115 CFS increased the inhibition of all Brachyspira isolates whereby the growth of each 
isolate was below the limit of detection.  
Treatment of L. salivarius SAP 2116 with trypsin resulted in decreased inhibition of B. pilosicoli 
SAP 859 and B. innocens SAP 924 at pH 3.8 (p value 0.0039 and 0.0002, respectively), however 
this treatment had no effect on CFS at pH 7.2. Heat treatment of this CFS did not have any 
impact on the inhibition of any Brachyspira isolates tested.  
Neither trypsin or heat treatment of L. salivarius SAP 2117 had a significant impact on the 
inhibition of Brachyspira isolates at pH 3.8. However, at pH 7.2 trypsin treatment significantly 
reduced the inhibition of B. intermedia SAP 919 and B. innocens SAP 943 and 924 (p value 
0.0214, £ 0.00001 and 0.0052, respectively). Heat treatment of the CFS significantly reduced 
the inhibition of B. pilosicoli B2904, B. intermedia SAP 919 and B. innocens SAP 943 and 924 
(0.003, £ 0.0001, 0.0027 and £ 0.0001, respectively). 
It is important to note that B. pilosicoli SAP 865 was not tested in these assays due to there 
being no evidence of pH independent inhibition. 
To summarise, these studies were used to determine whether the mechanism of Brachyspira 
inhibition by Lactobacillus CFS was in part, attributed to proteinaceous compounds such as 
bacteriocins. Putative bacteriocin genes were identified following whole genome sequence 
analysis, however the presence of these genes was not necessarily indicative of translated 
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protein. Therefore, denaturation of these potential proteins using trypsin and heat treatment 
was used to further investigate the inhibition of Brachyspira. It was evident from these data 
that the effect of these treatments on the Lactobacillus CFS was very much dependent on the 
isolate of Lactobacillus and the target Brachyspira isolate. Overall, trypsin treatment of L. 
reuteri CFSs resulted in reduced Brachyspira inhibition, suggesting the inhibitory role of 
bacteriocins. However, heat treatment increased Brachyspira inhibition. Trypsin treatment of 
L. salivarius SAP 2116 decreased Brachyspira inhibition, but heat treatment had no effect, 
suggesting that heat stable bacteriocins may contribute to inhibition. Treatment of L. 
salivarius SAP 2117 CFS had no effect on Brachyspira inhibition, therefore proteins did not 
play a role in inhibition by this isolate. Therefore, the hypothesis was that this inhibition could 
be attributed to non-protein metabolites produced by the Lactobacillus isolates. Thus, NMR 
analysis was employed to identify metabolites in the cell free supernatant of the four 
Lactobacillus isolates to determine which, if any, may be responsible for Brachyspira 
inhibition.  
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Figure 6. 3 Growth curves of B. pilosicoli B2904 supplemented with A: L. reuteri SAP 2114 CFS at pH 3.8 B: L. reuteri SAP 
2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS at pH 3.8 E: L. reuteri SAP 2114 
CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 CFS at pH 7.2 H: L. salivarius SAP 2117 CFS at 
pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated with trypsin or heat treated to denature potential 
antimicrobial proteins produced by each Lactobacillus isolate. MRS (blue), MRS trypsin treated (red), MRS heat treated 
(green), CFS (purple), CFS trypsin treated (orange) and CFS heat treated (black). Growth was monitored over 120 hours 
of anaerobic incubation at 37°C. Optical density readings were taken at 620nm every ˜10 hours. These data represent an 
average of five biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** ≤ 0.01, *** ≤ 
0.0005, **** ≤ 0.0001.  
 
** 
**** 
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Table 6. 2 P values for the Brachyspira inhibition assays where Lactobacillus CFS was treated with 
trypsin prior to utilisation in these assays. The area under the curve was calculated for each of the 
growth curves shown in Figure 6.3 and Appendix IV and growth of Brachyspira was compared 
between the untreated CFS and the CFS treated with trypsin to determine if denaturation of proteins 
impacted Brachyspira growth. Statistical significance was calculated using a one-way ANOVA and 
data were highlighted in green if the p value was £ 0.05 and highlighted in red if it was > 0.05. 
 
Table 6. 3 P values for the Brachyspira inhibition assays where Lactobacillus CFS was heat treated 
prior to utilisation in these assays. The area under the curve was calculated for each of the growth 
curves shown in Figure 6.3 and Appendix IV and growth of Brachyspira was compared between the 
untreated CFS and the heat treated CFS to determine if denaturation of proteins impacted 
Brachyspira growth. Statistical significance was calculated using a one-way ANOVA and data were 
highlighted in green if the p value was £ 0.05 and highlighted in red if it was > 0.05. 
 
 
Trypsin Treated
SAP 2114 SAP 2115 SAP 2116 SAP 2117
B. pilosicoli B2904 0.0001 0.9965 0.4261 0.4575
B. pilosicoli  SAP 859 0.6728 0.832 0.0039 0.9875
B intermedia SAP 919 0.0001 0.0001 0.8124 0.597
B. alvinipulli ATCC 51933 0.9946 0.986 0.0938 0.887
B. innocens SAP 943 0.0524 0.3638 0.8582 0.1473
B. innocens SAP 924 0.0455 0.672 0.0002 0.4661
B. pilosicoli B2904 0.968 0.9999 0.9476 0.0854
B. pilosicoli  SAP 859 0.2887 0.8276 0.9906 0.9999
B intermedia SAP 919 0.999 0.0001 0.2824 0.0214
B. alvinipulli ATCC 51933 0.053 0.999 0.997 0.9909
B. innocens SAP 943 0.4222 0.0282 0.9939 0.0001
B. innocens SAP 924 0.999 0.9538 0.999 0.0052
P value < 0.05
pH 3.8
pH 7.2
Heat Treated
SAP 2114 SAP 2115 SAP 2116 SAP 2117
B. pilosicoli B2904 0.0001 0.0001 0.9329 0.4641
B. pilosicoli  SAP 859 0.0021 0.0001 0.3006 0.9999
B intermedia SAP 919 0.0065 0.0001 0.0776 0.996
B. alvinipulli ATCC 51933 0.0092 0.0001 0.0978 0.99
B. innocens SAP 943 0.7062 0.0001 0.2479 0.0999
B. innocens SAP 924 0.0001 0.0001 0.5591 0.9938
B. pilosicoli B2904 0.1095 0.3733 0.998 0.003
B. pilosicoli  SAP 859 0.7972 0.9853 0.999 0.9974
B intermedia SAP 919 0.999 0.9856 0.298 0.0001
B. alvinipulli ATCC 51933 0.9718 0.857 0.992 0.9579
B. innocens SAP 943 0.9486 0.0009 0.9529 0.0027
B. innocens SAP 924 0.5656 0.999 0.3113 0.0001
P value < 0.05
pH 3.8
pH 7.2
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6.2.4 NMR 
 
The data presented in section 6.2.3 suggested that a pH independent mechanism, other than 
bacteriocin production in the CFS may have also been responsible for Brachyspira inhibition. 
Therefore, this mechanism was further explored using a metabolomic approach to investigate 
the metabolites present in Lactobacillus cell free supernatant which may have contributed to 
Brachyspira inhibition.  
A nuclear magnetic resonance (1H- NMR) based approach was employed to determine the 
small metabolites present in the cell free supernatants of the ten Lactobacillus isolates 
presented in Chapter 5, following 18 hours of anaerobic culture at 37°C. This was coupled 
with multivariant analysis to determine if taxonomic differences and antimicrobial activity 
against Brachyspira could be predicted from the Lactobacillus metabolic profiles.  
From this analysis, six metabolites were clearly identified in adequate quantities as illustrated 
in the NMR spectra presented in Figure 6.6. The most abundant metabolites were acetate, 
which appeared as a singlet peak at 1.91, lactate, which appeared as a quartet peak at 4.11 
and a doublet peak at 1.33 and ethanol, which appeared as two quartet peaks at 3.6 and 1.2. 
The abundance of these metabolites was expected due to the fermentative metabolic 
pathways utilised by these bacteria (Caplice and Fitzgerald, 1999). Lactobacillus species can 
be homofermentative or heterofermentative and this could be easily identified from the 
spectra shown in Figure 6.6. Homofermentative Lactobacillus species such as L. salivarius and 
L. crispatus fermented sugars to produce only lactic acid and heterofermentative 
Lactobacillus species such as L. reuteri fermented sugars to produce lactic acid and ethanol, 
these metabolic pathways are illustrated in Figure 6.4. Other metabolites, identified in smaller 
quantities were succinate, which appeared as a singlet peak at 2.41 and acetoin, which 
appeared as a singlet peak at 2.2. These metabolic pathways are illustrated in Figure 6.5, 
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whereby pyruvate is metabolised in several different pathways to produce succinate and 
acetoin, in addition to acetate, lactic acid and ethanol.  
 
 
 
 
 
 
 
 
 
Figure 6. 4 The pathways by which glucose is metabolised by Lactobacillus. Homofermenters such L. 
salivarius and L. crispatus produce lactic acid as a major product of glucose fermentation. These 
species use the glycolysis pathway to generate two moles of lactate per mole of glucose. 
Heterofermenters such as L. reuteri produce one mole of lactate, ethanol and CO2 per mole of 
glucose via the pentose phosphate pathway. These two groups of Lactobacillus can be easily 
distinguished using NMR as L. reuteri produced high concentrations of ethanol (Caplice and 
Fitzgerald, 1999). 
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The observable differences between the metabolic profiles of the Lactobacillus isolates were 
not necessarily in the types of metabolites produced, as these are fairly consistent within the 
isolates tested, but in the differing concentrations in which these metabolites were produced. 
This was demonstrated in Figure 6.6, where six spectra are overlaid to illustrate that inhibition 
of Brachyspira may be correlated to the concentration of metabolites produced by different 
Lactobacillus isolates. These six spectra were from the CFS of L. reuteri SAP 2114 and 2115, L. 
salivarius SAP 2116 and 2116, L. crispatus SAP 2107 and the MRS media. As previously 
discussed, these L. reuteri and L. salivarius isolates were shown to be the most inhibitory 
against Brachyspira out of the panel of Lactobacillus isolates tested. Conversely the L. 
Figure 6. 5 The metabolic pathways of Lactobacillus, highlighting the pathways involved in  
the production of lactate, acetate, ethanol, acetoin and succinate (Tsuji et al., 2013). 
 
Glucose 
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crispatus SAP 2107 isolate was shown to be the poorest inhibitor of Brachyspira, as indicated 
in Table 5.6. On comparing these two phenotypes, it could be noted that these differences in 
inhibition may be, in part, attributed to the concentrations of the metabolites produced. For 
example, L. crispatus SAP 2107 produced a lactate concentration of 10mM, the lowest 
concentration of all of the isolates tested and no acetoin or succinate. L. reuteri SAP 2114 
produced one of the highest concentrations of acetate, 38.50mM and the highest succinate 
concentration, 1.23mM. The lactate production by this isolate was the lowest of the isolates 
selected as potential probiotics at a concentration of 24mM, however this was still nearly 2.5x 
higher than the concentration produced by L. crispatus SAP 2107, the poor inhibitor of 
Brachyspira.  
L. reuteri SAP 2115 was previously shown to be the best inhibitor of Brachyspira and produced 
the highest concentration of acetate of all isolates tested, 39.33mM. This isolate also 
produced one of the highest concentrations of lactate of all of the isolates tested, 27.67mM 
and the highest concentration of ethanol of the L. reuteri isolates tested, 70.67mM. This 
isolate did not produce any detectable succinate or acetoin.  
L. salivarius SAP 2116 produced the lowest concentration of acetate, 25mM but produced 
one of the highest concentrations of lactate, 26mM, of all isolates selected at potential 
probiotic candidates. Low concentrations of succinate, 0.59mM and acetoin, 1.5mM were 
also detected. L. salivarius SAP 2117 was the most inhibitory of the L. salivarius isolates tested 
and produced a high acetate concentration, 29.67mM and the highest lactate concentration 
of all isolates tested, 28mM. Additionally, this isolate produced the highest concentration of 
acetoin, 2.07mM and a small amount of succinate, 0.63mM.  
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Glucose was the most abundant, detectible carbon source present in the MRS media, shown 
in yellow in Figure 6.6. On the NMR spectra, glucose appeared as fourteen separate peaks 
between 3.2 and 5.2 and each Lactobacillus isolate was shown to utilise glucose, indicated by 
a depletion in concentration after 18 hours of culture. Glucose utilisation varied depending 
on the isolate of Lactobacillus and low levels of glucose utilisation often resulted in lower 
concentrations of metabolite production. Interestingly, L. reuteri SAP 2115 CFS had the most 
inhibitory effects against Brachyspira and was also one of the highest utilisers of glucose in 
the panel of isolates tested. L. crispatus SAP 2107 CFS (shown in Table 6.4 and illustrated in 
Figure 6.6) was one of the weakest inhibitors of Brachyspira at a low pH and was also one of 
the poorest utilisers of glucose compared to all of the Lactobacillus isolates tested.  
Acetate Lactate Ethanol Glucose Acetoin Succinate
Lactobacillus species Isolate number
L. crispatus SAP 2107 26.00 10.00 0.00 46.67 0.00 0.00
L. reuteri SAP 2114 38.50 24.00 48.5 26.50 0.00 1.23
L. reuteri SAP 2115 39.33 27.67 70.67 21.00 0.00 0.00
L. salivarius SAP 2116 25.00 26.00 0.00 31.00 1.50 0.59
L. salivarius SAP 2117 29.67 28.00 0.00 40.33 2.07 0.63
Metabolite concentration (mM)
Table 6. 4 The concentrations of the key metabolites determined using NMR analysis. The key metabolites 
identified were acetate, lactate, ethanol, acetoin, succinate and glucose. These concentrations were 
calculated using Chenomx and are presented as averages of three biological replicates for the four potential 
probiotics selected in Chapter 4; L. reuteri SAP 2114 and 2115 and L. salivarius SAP 2116 and 2117. These 
values were compared to a Lactobacillus isolate unable to inhibit Brachyspira; L. crispatus SAP 2017. 
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Figure 6. 6 H
1 
Nuclear magnetic resonance (NMR) spectra of Lactobacillus metabolites. The cell free supernatants from all Lactobacillus isolates underwent 
NMR analysis to determine metabolite production following 18 hours of anaerobic culture at 37°C. As an example, six spectra are presented (overlaid) above: 
the four Lactobacillus isolates selected as potential probiotic candidates: L. reuteri SAP 2114 (blue), L. reuteri SAP 2115 (purple), L. salivarius SAP 2116 (green) 
and L. salivarius SAP 2117 (red). In addition to one lactobacilli that was unable to inhibit Brachyspira: L. crispatus SAP 2017 (teal) and the MRS media control 
(yellow). The metabolites lactate, acetate, ethanol, succinate and acetoin are highlighted as potential metabolites that contributed to Brachyspira inhibition. 
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Having identified the metabolites present in the Lactobacillus cell free supernatant using 
NMR, principle component analysis was conducted with samples from each of the ten 
Lactobacillus isolates fully characterised in Chapter 5. Recent studies have used NMR to 
measure the taxonomic differences between Lactobacillus isolates and to predict their 
antimicrobial activity against pathogens (Parolin et al., 2015; Nardini et al., 2016). This 
approach was applied in the studies presented here to determine if the metabolic profiles of 
Lactobacillus isolates could be used to predict inhibition of Brachyspira.  
The first principle component (PC1) and the second principle component (PC2) accounted for 
58% of the total variance of the investigated samples, as shown in Figure 6.7. This multivariant 
analysis showed an interesting correlation which has been previously reported in 
Lactobacillus species (Parolin et al., 2015; Nardini et al., 2016). The metabolome correlated 
with the taxonomy; this was illustrated by the separation of the different Lactobacillus species 
in PC1, which explained 38% of the variance. The clearest separation could be observed with 
the L. crispatus isolates, which were high in PC1, with the exception of SAP 2105. This showed 
variance from L. reuteri and L. salivarius which were low in PC1. Some separation between L. 
reuteri and L. salivarius was demonstrated, but not sufficiently to distinguish between the 
species. Parolin et al. (2015) also reported that the variance in PC2 correlated with the 
inhibition of the pathogens, however in the studies presented here, there was insufficient 
data to support this hypothesis, although there was some separation in PC2 according to the 
Brachyspira inhibition. For example, L. salivarius SAP 2116 and 2117 were low in PC2 and L. 
crispatus SAP 2107 was high in PC2, thus suggesting that those isolates high in PC2 may be 
less inhibitory. However, L. reuteri SAP 2115, the most inhibitory isolate, was in the middle of 
PC2, suggesting that the principle component analysis was able to separate good and bad 
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inhibitors of Brachyspira but not able to separate the extent of inhibition in the good 
inhibitors. 
Following the principle component analysis, a colour plot was generated to identify the 
metabolites responsible for the variance observed in PC1, as seen in Figure 6.8. It was evident 
that there were two key differences between the cluster of L. reuteri and L. salivarius (both 
low in PC1) and L. crispatus (high in PC1). The first difference was in the production of lactate, 
whereby L. reuteri and L. salivarius isolates produced significantly more lactate than L. 
crispatus. The exception to this was L. crispatus 2105; two of the three biological replicates 
clustered with the majority of the L. salivarius isolates, however one replicate clustered with 
the remaining L. crispatus isolates. This highlights the need for more biological replicates to 
strengthen these data; it is proposed that at least six replicates it optimal. The second 
difference was in the glucose utilisation, whereby L. reuteri and L. salivarius isolates utilised 
more glucose than L. crispatus isolates. Therefore suggesting, as previously mentioned, that 
isolates capable of utilising more glucose were more inhibitory towards Brachyspira. 
Furthermore, the utilisation of glucose is directly linked to the production of lactate, thus the 
more glucose consumed, the higher the lactate concentration. However, when analysing the 
raw data, it was clear that other factors, such as acetate production may play a role in 
Brachyspira inhibition. Although the production of ethanol was associated with isolates low 
in PC1, this metabolite was not significant in highlighting the difference in PC1. This is most 
likely because isolates low in PC1 were both L. reuteri and L. salivarius and only L. reuteri 
isolates produce ethanol as discussed earlier in the chapter.  
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Figure 6. 7 PCA score plot for Lactobacillus cell free supernatant samples. The plot shows the distribution of eleven isolates from three species of Lactobacillus, 
five isolates of L. salivarius (orange), three isolates of L. crispatus (yellow) and three isolates of L. reuteri (blue) in principle component 1 (PC1) and principle 
component 2 (PC2). These two principle components account for 58% of the total variance between the metabolite spectra, with PC1 totally 38% of the 
variance and PC2 totalling 20% of the variance. These data show three biological replicates of all of the Lactobacillus CFSs tested. 
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Figure 6. 8 Associated metabolites of the principle component 1 (PC1). PC1 accounted for the most variance between the metabolic profiles of the Lactobacillus 
isolates, there were two clear clusters of isolates in PC1, the L. reuteri/L. salivarius cluster, which was low in PC1 and the L. crispatus cluster, which was high in 
PC1. The metabolites associated with this variance were identified as lactate, associated with the L. reuteri/L. salivarius cluster (indicated by the downwards 
peaks) and glucose, associated with the L. crispatus cluster (indicated by the upwards peaks). Other peaks, identified in blue were indicative of ethanol and 
acetate, however these differences were not significant.  
Glucose 
 
Lactate 
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6.2.5 Lactobacillus antagonise the viability and growth of Brachyspira 
 
In addition to investigating the effects of cell free supernatant and the secreted metabolites 
by Lactobacillus isolates, the effects of Lactobacillus cells on the viability and growth of 
Brachyspira were also determined using the ‘spot test’ method described by Bernardeau et 
al. (2009). Unlike the data presented by Bernadeau et al. (2009), there were no differences 
between the viability of Brachyspira when co-cultured with Lactobacillus for 4 hours and 24 
hours, therefore the results for 4 hours were presented in Figure 6.9.  
As predicted, the results from the ‘spot test’ assay showed that the inhibition of Brachyspira 
was dependent on the isolate of Lactobacillus tested. The L. reuteri isolates SAP 2114 and 
2115 were the most inhibitory against all Brachyspira isolates, significantly inhibiting seven of 
the eight Brachyspira isolates when viable cells were used (B. pilosicoli B2904 p value 0.0003, 
B. pilosicoli SAP 865, p value £0.0001, B. intermedia SAP 919, p value 0.0006, B. alvinipulli 
ATCC 51933, p value £ 0.0001 and B. innocens SAP 924, SAP 927 and SAP 943, p value £ 
0.0001). Co- culture with viable L. reuteri SAP 2114 and 2115 isolates prevented the growth 
of B. pilosicoli SAP 865, B. alvinipulli ATCC 51933 and B. innocens SAP 924, SAP 927 and SAP 
943. Therefore, it was evident that live L. reuteri isolates were able to inhibit all Brachyspira 
species implicated in poultry infection, but not all isolates within a species, as B. pilosicoli SAP 
859 was not inhibited by any Lactobacillus isolate. Furthermore, heat-inactivated L. reuteri 
SAP 2114 and SAP 2115 were able to significantly inhibit six of the eight Brachyspira isolates, 
namely B. pilosicoli B2904 (p value 0.039) and SAP 865 (p value £ 0.0001), B. alvinipulli ATCC 
51933 (p value £ 0.0001) and B. innocens SAP 943, SAP 924 and SAP 927 (p value £ 0.0001). 
Of the L. salivarius isolates, only SAP 2117 significantly inhibited B. pilosicoli B2904, both when 
the cells were viable (p value 0.0072) and heat-inactivated (p value 0.0314). This 
demonstrated that physical interactions between L. salivarius and Brachyspira species were 
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not as inhibitory as with L. reuteri and that once again the L. reuteri isolates were more 
inhibitory against Brachyspira and therefore, have the potential to be the most suitable 
probiotic candidates for an intervention against avian intestinal spirochaetosis. 
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Figure 6. 9 The effect of live and heat inactivated Lactobacillus isolates on the viability of A: B. 
pilosicoli B2904, B: B. pilosicoli SAP 859, C: B. pilosicoli SAP 865, D: B. intermedia SAP 919, E: B. 
alvinipulli ATCC 51933, F: B. innocens SAP 943, G: B. innocens SAP 924 and H: B. innocens SAP 927 
after four hours of co-incubation with L. reuteri SAP 2114 live cells (red) or heat inactivated cells 
(green), L. reuteri SAP 2115 live cells (purple) or heat inactivated cells (orange), L. salivarius SAP 
2116 live cells (black) or heat inactivated cells (brown) and L. salivarius SAP 2117 live cells (dark 
blue) or heat inactivated cells (dark purple). Brachyspira culture with PBS was used as a control 
(blue). These data are an average of five biological replicates, each with three technical replicates. 
Significance, if any was determined by a one-way ANOVA and is shown for the reduction of 
Brachyspira viability compared to culture with PBS alone, * p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** 
≤ 0.0001. 
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6.2.6 Efficacy of probiotic candidates against other avian pathogens 
 
The four probiotic candidates presented in these studies were shown to be inhibitory against 
Brachyspira, however in addition their efficacy against Salmonella and E. coli was determined 
to assess these probiotic candidates as multi-purpose probiotics.  
As observed with Brachyspira, there was a pH dependent mechanism of Salmonella and E. 
coli inhibition, whereby MRS or CFS at pH 3.8 was significantly more inhibitory that at pH 7.2 
(p value £ 0.001), as shown in Figure 6.10. Salmonella Typhimurium SAP 16 was both highly 
susceptible to low pH and the CFSs of all four Lactobacillus isolates (p value £ 0.001). Unlike 
for Brachyspira, L. reuteri SAP 2115 was the least effective against Salmonella Typhimurium 
SAP 16 and L. reuteri SAP 2114 and L. salivarius SAP 2116 and SAP 2117 were significantly 
more effective than SAP 2115 at pH 3.8 (p value £ 0.001).  
E. coli isolates had a range of susceptibilities to the different Lactobacillus CFSs, however were 
all significantly inhibited by low pH (p value £ 0.001). E. coli A2 was the most tolerant of the 
E. coli isolates tested, with only L. reuteri SAP 2114 and L. salivarius SAP 2117 significantly 
inhibiting this isolate at pH 3.8 (p value £ 0.001). E. coli B1 was significantly inhibited by the 
L. salivarius isolates SAP 2116 and 2117 at both pH 3.8 and pH 7.2 (p value £ 0.001). E. coli B3 
was the most susceptible isolate tested and was significantly inhibited by the CFS of L. reuteri 
SAP 2115 and L. salivarius SAP 2116 and 2117 at both pH 3.8 and pH 7.2 (p value £ 0.001). 
The data presented here also demonstrate significant phenotypic differences between all of 
the Lactobacillus isolates tested both within and between species (p value £ 0.001). 
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Figure 6. 10 Growth curves of A: Salmonella Typhimurium SAP 16, B: E. coli A2 (APEC; serogroup O1), C: E. coli 
B1 (APEC; serogroup O78) and D: E. coli B3 (APEC; serogroup O2) in nutrient broth, supplemented with 10% 
(v/v) CFS from L. reuteri SAP 2114 pH 3.8 (green) and pH 7.2 (purple), L. reuteri SAP 2115 pH 3.8 (orange) and 
pH 7.2 (black), L. salivarius SAP 2116 pH 3.8 (brown) and pH 7.2 (dark blue) and L. salivarius SAP 2117 pH 3.8 
(dark purple) and pH 7.2 (dark red). Control wells were supplemented with MRS pH 3.8 (blue) and MRS pH 7.2 
(red). Growth was monitored over 18 hours of aerobic culture at 37°C. Optical density readings were taken at 
600nm every 15 minutes. These data represent an average of three biological replicates, each with three 
technical replicates. Significance, if any, is shown for the pH independent growth between control and test 
groups* p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001.  
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6.3 Discussion 
 
The studies presented in this chapter focussed on beginning to identify the mechanisms by 
which potential Lactobacillus probiotics may exert inhibitory effects against Brachyspira 
species. The mechanisms underlying the activity of Lactobacillus probiotics against pathogens 
such as Brachyspira appeared to be multifactorial and included the production of 
antimicrobial metabolites and bacteriocins, in addition to physical interactions with 
pathogen, as explored in this chapter (Campana et al., 2017).  
A pH dependent mechanism of Brachyspira inhibition was first described by Mappley et al 
(2011) whereby the growth of Brachyspira was significantly reduced when growth media was 
supplemented with MRS broth and CFS at pH 3.8 compared with a pH of 7.2. The same 
mechanism has been described in the studies presented here, whereby the majority of 
Brachyspira isolates grew significantly better when media was supplemented with MRS broth 
and CFS adjusted to pH 7.2 compared to pH 3.8 (p value £ 0.05).  B. pilosicoli B2904 and SAP 
859, B. intermedia SAP 919 and B. innocens SAP 924 were the most highly susceptible to a low 
pH (p value £ 0.0001), suggesting that Lactobacillus probiotics may exert the greatest 
inhibitory effects on those Brachyspira isolates that are most susceptible to acidic conditions. 
Moreover, acidic conditions have been shown to induce a stress response in Brachyspira 
isolates, demonstrated by the formation of spherical bodies and damage to the cell 
membrane (Bernardeau et al., 2009). 
The L. reuteri isolates tested here demonstrated a greater inhibitory effect against 
Brachyspira species, compared to L. salivarius isolates. This was further evidence to support 
that probiotic activity of Lactobacillus isolates can be dependent on the properties of both 
the probiotic bacteria and the strain of the pathogen tested (Wine et al., 2009; Mappley et 
al., 2011; Campana et al., 2017).  
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In addition to a pH dependent mechanism of inhibition of Brachyspira, it was evident that 
there was also a pH independent mechanism of inhibition. This was demonstrated by a 
significant decrease in Brachyspira growth (p value £ 0.05) compared to the pH matched 
control. One of the most important considerations for the selection of probiotic bacteria is 
the protection against bacterial pathogens in the gastrointestinal tract of the host (Šušković 
et al., 2010). The role of antimicrobial compounds such a proteins and metabolites are crucial 
to the characterisation of probiotic bacteria. Thus, elucidating these pH independent 
mechanisms and improving the understanding of how probiotics exert their activity against 
pathogens is becoming of increasing importance. Therefore, one of the key objectives of this 
chapter was to explore the mechanisms involved in this inhibition and this was achieved using 
two different approaches. The first was to investigate the potential influence of proteins in 
the CFS of the Lactobacillus isolates. Whole genome sequence analysis of the panel of 
Lactobacillus isolates identified several putative bacteriocin gene clusters, as observed in 
Tables 5.4 and 5.5. Three classes of bacteriocins were identified from this analysis, one class 
I bacteriocin, one class II bacteriocin and two bacteriolysins (formally class III bacteriocins). As 
previously mentioned in Chapter 5, class I and II bacteriocins, are heat stable peptides and 
bacteriolysins such as enterolysin A and helveticin J, are heat labile proteins (Khan et al., 2013; 
Yang et al., 2014; Barbour et al., 2016). Therefore, two approaches to denature these proteins 
were used, firstly to trypsin treat the CFSs (Gopal et al., 2001) to denature any potential heat 
stable proteins and secondly to heat treat the CFS to denature any potential heat labile 
proteins. These treatments had varying effects on the inhibitory ability of the CFS against 
Brachyspira, suggesting that both secreted proteins and metabolites may be important in 
pathogen inhibition. Furthermore, demonstrating that there were multiple isolate specific 
activities contributing to Brachyspira inhibition. For example, the trypsin treatment of L. 
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reuteri SAP 2114 cell free supernatant at pH 3.8 reduced the inhibitory effect against three of 
the Brachyspira isolates tested, B. pilosicoli B2904, B. intermedia SAP 919 and B. innocens SAP 
924. Thus, suggesting that proteinaceous antimicrobial metabolites may have been secreted 
from L. reuteri SAP 2114 and were contributing to the inhibition of these Brachyspira isolates. 
Interestingly, heat treatment of L. reuteri SAP 2114 increased the inhibition of B. pilosicoli 
B2904 and B. innocens SAP 924 and showed a small, non-significant reduction in inhibition of 
B. intermedia SAP 919. Therefore, it may be suggested that the inhibition of these three 
Brachyspira isolates may be, in part, attributed to the production of a heat stable bacteriocin 
(Collins et al., 2017) that was denatured during trypsin treatment. However, whole genome 
sequence analysis did not identify any of these potential bacteriocins in L. reuteri SAP 2114. 
This highlights the importance of combining both phenotypic and genotypic testing as these 
in silico analysis databases may be incomplete or may not be able to identify all gene present 
from contiguous genome assemblies.  A study by Gopal et al. (2001) also demonstrated a 
species-specific reduction in antimicrobial activity against E. coli following trypsin treatment 
which corresponds to the data in the studies presented here. Trypsin treatment of L. reuteri 
SAP 2115 at pH 3.8 only significantly reduced the inhibition of B. intermedia SAP 919, 
demonstrating that L. reuteri SAP 2114 and 2115 have slightly different mechanisms of action 
against different Brachyspira isolates. Interestingly, L. reuteri SAP 2115 was the most 
inhibitory of the four potential probiotics tested in these studies, this significant inhibition of 
multiple Brachyspira isolates is therefore unlikely to solely be as a result of bacteriocin 
production by this Lactobacillus isolate. The heat treatment of L. reuteri SAP 2115 CFS at pH 
3.8 prevented the growth of all of the Brachyspira isolates tested. This is a surprising result 
that has not been reported in the literature, and furthermore many studies have stated that 
heat treating Lactobacillus CFS has no difference on its antimicrobial activity (Forestier et al., 
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2001; Mariam et al., 2014). Technical failure which, given the repeats done, is an unlikely 
explanation and so it must be surmised that heating may have changed the conformation of 
a metabolite present in the CFS, resulting in increased inhibitory activity. It is known there are 
many bacterial toxins that require processing to be effective. Cleavage of a precursor 
molecule can generate active toxins in the case of toxins such as Pseudomonas exotoxin A 
and Shiga-like toxins (Gordon and Leppla, 1994). However, the production of toxins from 
Lactobacillus species is not well documented and it seems counterintuitive that Lactobacillus 
isolates would produce a product that requires such dramatic processing to be effective. It is 
possible that a conformational change induced by heating ‘accidentally’ created a more toxic 
product. Heat treated MRS at pH 3.8 did not demonstrate enhanced activity against 
Brachyspira compared to the untreated, pH matched control, therefore that rules out heat 
treatment potentially changing the pH of the CFS and thus resulting in increased inhibition.  
Trypsin and heat treatment of L. salivarius SAP 2116 CFS at pH 3.8 reduced the inhibition of 
two of the Brachyspira isolates tested, B. pilosicoli SAP 859 and B. innocens SAP 924, CFS 
treatment had no effect on the other Brachyspira isolates tested. This suggested that other 
secreted metabolites may play a more significant role in the inhibition attributed to this 
Lactobacillus. However, these results suggest the presence of both heat stable and heat labile 
proteins, as identified in Chapter 5. The in-silico analysis of the L. salivarius SAP 2116 genome 
using Bagel 4 and Anti-SMASH identified both putative class II bacteriocins and enterolysin A. 
As previously stated, class II bacteriocins are heat stable and thus trypsin treatment, but not 
heat treatment, could denature them. Bacteriolysins are heat labile and thus heat treatment 
and trypsin treatment may denature these proteins. Therefore, there was evidence that both 
class II bacteriocins and bacteriolysins may be contributing to Brachyspira inhibition with L. 
salivarius SAP 2116 CFS. Although many bacteriocins are known to have activity against other 
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Gram positive or closely related bacteria, there is evidence to suggest they can affect more 
divergently related Gram negative bacteria (Cotter et al., 2005; Messaoudi et al., 2013). 
Bacteriocins have been shown most often to contribute to the inhibition of Gram negative 
bacteria when the outer membrane has been permeabilised (Cotter et al., 2005), this may be 
an important mechanism of Brachyspira inhibition because the CFS of Lactobacillus has been 
shown to cause damage to Brachyspira cell membranes (Bernardeau et al., 2009). 
Furthermore, lactic acid has been shown to be a potent membrane permeabiliser in E. coli 
(Alakomi et al., 2000) and thus this mechanism may apply to Brachyspira, although further 
tests would be needed to confirm this. The inhibition of Brachyspira at pH 3.8 by L. salivarius 
SAP 2117 CFS was not affected by either trypsin or heat treatment, thus it was hypothesised 
that the inhibition may be solely attributed to production of other inhibitory metabolites.  
The trypsin and heat treatment of the CFS at pH 3.8 in many incidences, significantly reduced 
the inhibition of Brachyspira, but the same was not observed at pH 7.2. This was further 
evidence for the activity of bacteriocins as a mechanism of Brachyspira inhibition as they are 
known to have a higher activity at a lower pH range (Houlihan et al.,2004). Thus, if the 
bacteriocins had been denatured the effect on Brachyspira inhibition may be more prominent 
at pH 3.8 compared to pH 7.2. 
The inhibitory effects of the L. reuteri isolates tested in these studies were more affected by 
trypsin and heat treatment than the L. salivarius isolates, suggesting that the inhibition by 
these L. reuteri isolates may be multifactorial, whereas L. salivarius inhibition may be more 
primarily associated with the secretion of non-protein metabolites.    
Therefore, the second approach to investigate the mechanisms by which Lactobacillus CFS 
inhibit Brachyspira was to identify the metabolites secreted by each isolate following 18 hours 
of anaerobic culture. The NMR analysis identified several key metabolites, such as acetate 
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and lactate, known to lower the pH of the CFS and other inhibitory compounds such as 
ethanol, succinate and acetoin, with proposed antibacterial activity (Šušković et al., 2010). 
Organic acid production by Lactobacillus species is a direct result of glucose metabolism 
either by glycolysis for homofermenters or by the pentose phosphate pathway for 
heterofermenters (Caplice and Fitzgerald, 1999). Therefore, increased glucose utilisation 
results in increased acid production, thus increasing the inhibition of susceptible pathogens 
such as Brachyspira (Bernardeau et al., 2009). The data presented here demonstrated this, 
whereby L. reuteri SAP 2115 utilised the most glucose, which subsequently generated the 
highest concentrations of acetic acid and lactic acid, in addition to high concentration of 
ethanol, resulting in the greatest inhibition of Brachyspira.  
Acetoin has been reported as a potential antimicrobial compound produced by Lactobacillus 
and is documented to have activity against Gram negative bacteria (Collins et al., 2009a; 
Šušković et al., 2010). This metabolite is formed when acetaldehyde condenses with a 
molecule of pyruvate to form 2-acetolactate, subsequently acetoin is formed by the 
decarboxylation of the 2-acetolactate.  
The final metabolite produced in sufficient quantities to be detected by NMR was succinate. 
Succinate is produced by some Lactobacillus isolates via an incomplete TCA cycle (Tsuji et al., 
2013) and while it has no known antimicrobial activity against pathogens, short chain fatty 
acids including succinate have been shown to produce up to 15% of the energy requirements 
in humans and up to 30% in pigs (Rinttila and Apajalahti, 2013). This could be of great 
importance to the productivity and feed conversion of livestock such as poultry and pigs. 
Furthermore, short chain fatty acids are weak acids and represent a potential acid stress on 
sensitive pathogens due to their high concentration and the low pH already established by 
lactic acid. Uncharged protonated weak acids are diffusible across cell membranes, 
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potentially lowering the internal pH of a bacterial cell, resulting in cell death (Ricke, 2003; 
Bearson et al., 2006).  
Principle component analysis was used to analyse and compare the metabolome of 
Lactobacillus isolates. Principle component 1 (PC1) and principle component 2 (PC2) 
accounted for 58% of the total variance in the investigated samples. The first component, 
which accounted for 38% of the total variance, was found to be mainly influenced by the 
taxonomy of the Lactobacillus isolates, these findings are in agreement with Parolin et al. 
(2015) and Nardini et al. (2016). Parolin et al. (2015) and Nardini et al. (2016) also reported 
the second component to be mainly influenced by the activity against Candida and Chlamydia, 
respectively. Although there was a suggestion of this in the data presented here, the 
distribution of the data do not show a strong link to anti-Brachyspira activity in the second 
component. However, the first component showed some clustering of isolates that were 
highly inhibitory against Brachyspira from those that poorly inhibited Brachyspira. L. reuteri 
and L. salivarius isolates clustered low in PC1 and were associated with good Brachyspira 
inhibition whereas L. crispatus isolates clustered high in PC1 and were associated with poor 
Brachyspira inhibition. In order to visualise the metabolites responsible for these differences, 
a colour plot was generated and illustrated that these key differences were primarily as a 
result of lactate and un-utilised glucose in the samples.  
The utilisation of glucose and production of organic acids are metabolically interrelated and 
represent defensive strategies against pathogens such as Brachyspira (Caplice and Fitzgerald, 
1999). Therefore, isolates that were unable to utilise high concentrations of glucose 
adequately, such as L. crispatus SAP 2107, were unsuitable as probiotics for several reasons. 
Firstly, they may not be commercially viable as they may not grow in sufficient quantities. 
Secondly, a low utilisation of glucose could lead to poor production of organic acids. Finally, 
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poor glucose utilisation could be linked to increased glucose concentrations in the 
gastrointestinal tract, thus potentially promoting the growth of undesirable bacteria. This 
could be important in Brachyspira infection as these bacteria utilise glucose for metabolic 
processes as indicated in Chapter 3.  
High levels of glucose utilisation have been linked to Lactobacillus isolates with the greatest 
inhibition of pathogens. Nardini et al. (2016) supplemented the CFS of high glucose utilising 
Lactobacillus with glucose to ‘reset the sugar consumption’, which resulted in a significant 
increase in C. trachomatis infectivity. Suggesting that glucose depletion in the CFS may result 
in pathogen inhibition in vivo. Of the isolates selected for characterisation as potential 
probiotics, L. reuteri SAP 2114 and 2115 and L. salivarius SAP 2116 were high utilisers of 
glucose and subsequently produced high concentrations of organic acids. L. salivarius SAP 
2117 was a poor utiliser of glucose, yet produced sufficient concentrations of organic acids, 
this was the proposed primary mechanism of inhibition, as previous studies deemed protein 
denaturation to be ineffective at reducing inhibition.  
Another proposed mechanism by which probiotics exert their inhibitory effects is by physical 
interactions with the pathogen. This mechanism could prove to be of great importance 
against Brachyspira in vivo because motility and chemotaxis are important virulence factors 
for this organism (Naresh and Hampson, 2010). In order to colonise and attach to colonic 
enterocytes, Brachyspira, in particular B. pilosicoli, need to penetrate and move through the 
mucus layer. The cork-screw like motility of Brachyspira allows them to move through highly 
viscous substances such as mucus (Chunhao Li et al., 2000) and chemotaxis towards mucin 
allows the bacteria to target desired colonisation sites. Lactobacillus have been shown to 
physically interact with B. pilosicoli, B. innocens and B. hyodysenteriae and cause 
coaggregation of bacteria. This interaction has been demonstrated to directly reduce the 
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motility of Brachyspira species, both when Lactobacillus cells are viable and heat inactivated 
(Bernardeau et al., 2009; Mappley et al., 2011). The results presented in this study show 
similar results whereby many Brachyspira isolates were inhibited by both viable and heat 
inactivated L. reuteri isolates. However, L. salivarius isolates had very little effect on the 
viability of Brachyspira. In most incidences, where Brachyspira viability was reduced by live 
Lactobacillus cell, heat inactivated cells also caused inhibition, suggesting that this effect was 
not as a result of competition for nutrients or production of antimicrobial compounds and 
was likely to be as a result of the passive coaggregation of Brachyspira and Lactobacillus as 
previously demonstrated (Bernardeau et al., 2009). Despite this, it was evident that some B. 
pilosicoli isolates may be tolerant of this mechanism of inhibition. For example, B. pilosicoli 
SAP 859 was the only isolate tested that was unaffected by co-culture with Lactobacillus 
isolates, suggesting that this mechanism is not universally inhibitory. 
Finally, it is well documented that probiotics are very much strain specific in their activity and 
the pathogens that they inhibit. With this in mind, it was interesting to determine if the 
potential probiotics characterised in Chapter 5 could be inhibitory against pathogens other 
than Brachyspira. It is widely reported that probiotics have activity against other avian 
pathogens such as E. coli and Salmonella (Rantala and Nurmi, 1973; Resta-Lenert and Barrett, 
2003; La Ragione and Woodward, 2003), therefore L. reuteri SAP 2114 and 2115 and L. 
salivarius SAP 2116 and 2117 were tested against these species to determine if they had a 
broad spectrum of inhibition. Once again, all isolates tested had both pH dependent and pH 
independent mechanisms of inhibition with Salmonella Typhimurium SAP 16 being the most 
susceptible to all Lactobacillus isolates at a low pH compare to E. coli. This may be as a result 
of E. coli having greater acid tolerance as it can inhabit the gastrointestinal tract as a 
commensal. Overall, it was evident that all Lactobacillus isolates tested significantly inhibited 
 218 
both E. coli and Salmonella isolates and thus they have the potential against a range of poultry 
pathogens. It is important to note that inhibition was once again dependent on the isolate of 
Lactobacillus, and therefore an appropriate isolate, or combination of isolates would need to 
be selected for prophylactic use based on the desired target pathogens.  
To summarise, the mechanisms underlying the activity of Lactobacillus isolates against 
Brachyspira and other avian pathogens appeared to be multifactorial and included the 
production of antimicrobial compounds such as lactic acid and potential bacteriocin proteins. 
Furthermore, Lactobacillus isolates can coaggregate with Brachyspira, potentially interfering 
with two of its key virulence factors (Li et al., 2000; Bernardeau et al., 2009; Naresh and 
Hampson, 2010). In these studies, L. reuteri isolates appear to be the most effective, with 
evidence to suggest all three of these mechanisms were involved in Brachyspira inhibition in 
vitro, moreover, they were effective against other known avian pathogens, making them the 
most suitable probiotic candidates.  
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Chapter 7: Investigating the immune response to Brachyspira in tissue 
culture and the protective effective of Lactobacillus in a Brachyspira 
infection model using Galleria mellonella. 
 
7.1 Introduction  
 
There is a significant lack of understanding regarding the stimulation of the innate avian 
immune response to Brachyspira infection (Hampson, 2018).  However, severe inflammatory 
symptoms have been reported following infection including: typhlitis and necrotic 
inflammation of the large intestine (Buckles et al., 1997; Nemes et al., 2006). The 
inflammatory immune responses that result in these severe clinical manifestations are poorly 
understood. However, it is reported that the innate immune response is the first line of 
defence against Brachyspira once they reach the lower gastrointestinal tract. Histological 
analysis of human Brachyspira infections demonstrate infiltration of macrophages into the 
lamina propria in response to infection, and detection of Brachyspira within macrophages 
demonstrate these cells play a significant role in response to infection  (Antonakopoulos et 
al, 1982; Padmanabhan et al., 1996). Furthermore, evidence from porcine infections suggests 
that neutrophils have a role in the inflammatory immune response to Brachyspira, a possibly 
significant role given that these cells are the predominant cell found in Brachyspira infected 
tissue (Costa et al., 2014). To date there is no evidence that suggests Brachyspira can survive 
and replicate within immune cells.  
There is a growing body of evidence documenting the immunomodulatory properties of 
probiotics in the innate immune system, with a number of studies demonstrating their ability 
to modulate the immune system by both upregulating immune responses, proposed to help 
fight infection, and downregulating immune responses, proposed to help prevent 
inflammation in vitro (Haller et al., 2000; Zhang et al., 2005; Ma et al., 2011). This is an 
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important balancing act to ensure that the pathogen is cleared by the immune system with a 
sufficient inflammatory response, but that this response does not result in extensive 
pathology to the host (Vanderpool et al., 2008). Moreover, recent probiotic studies using 
Galleria mellonella have suggested immunomodulatory properties of Lactobacillus and 
subsequent protection from pathogens (Rossoni et al., 2017; Scalfaro et al., 2017).  
This chapter aimed to characterise the host innate immune responses to Brachyspira using 
an avian in vitro model of infection to investigate the macrophage response to infection, 
additionally the ability of Lactobacillus to alter these immune responses was investigated. An 
in vivo model of infection (Galleria mellonella) was used as a rapid screen for Brachyspira 
virulence and to investigate how a probiotic intervention may be able to protect from the 
morbidity and mortality associated with Brachyspira infection in the context of a functional 
immune system. 
The aims and objectives of this chapter were: 
• To establish an in vitro HD11 avian macrophage model for studying Brachyspira 
infection and to characterise the macrophage cytokine responses to all species 
implicated in avian intestinal spirochaetosis. 
• To investigate how the cytokine gene expression is affected by exposing the HD11 cells 
to Lactobacillus prior to Brachyspira infection.  
• To establish an in vivo G. mellonella infection model for Brachyspira infection and to 
characterise the morbidity and mortality in response to all species implicated in avian 
intestinal spirochaetosis. 
• To investigate how the morbidity and mortality associated with Brachyspira infection 
are affected when G. mellonella are infected with Lactobacillus prior to infection with 
Brachyspira. 
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7.2 Results 
 
7.2.1 HD11 avian macrophage cytokine responses to Brachyspira 
 
The cytokine response to Brachyspira was characterised for one isolate of B. alvinipulli, B. 
intermedia, B. innocens and B. pilosicoli, as shown in Figure 7.1. When compared to the 
control, infection with B. pilosicoli SAP 859 resulted in the greatest expression of all of the 
cytokines tested, in particular IFNg (Figure 7.1E). B. intermedia SAP 919 elicited the lowest 
expression of IL1b, IL10 and IFNg, showing no significant difference from the control and B. 
alvinipulli elicited the lowest expression of IL6 and IL8. B. innocens, which is currently thought 
to be non-pathogenic, elicited similar cytokine expression as those species considered to be 
pathogenic in poultry, including the second largest IFNg response. The responses to the 
different species of Brachyspira were largely similar, except for in a few incidences. For 
example, the IFNg expression in response to B. innocens SAP 924 was significantly higher 
compared to B. intermedia SAP 919 (p value 0.0215). Additionally, the IFNg expression in 
response to B. pilosicoli SAP 859 was significantly greater than that of B. intermedia SAP 919 
(p value £ 0.0001), B. alvinipulli ATCC 51933 (p value £ 0.0001) and B. innocens SAP 924 (p 
value 0.0009).  
Brachyspira that had not entered the macrophages survived for the duration of the 
experiment, as determined by culture of the tissue culture media following the three-hour 
infection. By contrast, they did not survive within the macrophages, as determined using a 
gentamicin protection assay. This suggested that in this model, macrophages were capable of 
killing internalised Brachyspira, although electron microscopy should be used to confirm this. 
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7.2.2 HD11 avian macrophage cytokine responses to Lactobacillus 
 
Probiotic bacteria are generally recognised as safe (GRAS) and are used very widely (Mattia 
and Merker, 2008; EFSA et al., 2017). However, these bacteria are also recognised by the 
immune system and as one aim of this study was to exploit certain Lactobacillus isolates as 
possible control agents against Brachyspira, therefore, it was important to characterise the 
immune response to Lactobacillus in this model. L. reuteri SAP 2115 was selected for study in 
this model because it was significantly more inhibitory against a range of Brachyspira in vitro 
than other isolates tested and L. salivarius SAP 2117 was selected because it was the most 
inhibitory of the L. salivarius isolates against Brachyspira.  
By comparison to the responses elicited by Brachyspira isolates, L. reuteri SAP 2115 elicited 
similar expression of IL1b, IL8 and IL10 whereas the expression of IL6 was lower, but not 
significantly. The expression of IFNg was significantly lower compared to that of B. pilosicoli 
SAP 859 (p value £ 0.0001), B. alvinipulli ATCC 51933 (p value £ 0.0014) and B. innocens SAP 
924 (p value £ 0.0001). L. salivarius SAP 2117 elicited a similar expression of IL8 to 
Brachyspira, however the expression of IL1b, IL6 IL10 and IFNg were significantly lower. For 
example, the IL1b response to L. salivarius SAP 2117 was significantly lower compared to B. 
pilosicoli SAP 859 (p value 0.0115), B. alvinipulli ATCC 51933 (p value 0.0194) and B. innocens 
SAP 924 (p value 0.0487). Furthermore, the expression of IL10 was significantly lower than B. 
pilosicoli SAP 859 (p value 0.0168) and finally the IFNg response was significantly lower than 
B. pilosicoli SAP 859 (p value £ 0.0001), B. alvinipulli ATCC 51933 (p value 0.0103) and B. 
innocens SAP 924 (p value 0.0004) (Table 7.1). These data show that there were key 
differences in the cytokine gene expression between pathogenic bacteria such as Brachyspira 
and probiotic bacteria such as Lactobacillus. In addition, there were differences in gene 
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expression between Lactobacillus, which may demonstrate the need to carefully select 
probiotic strains dependent on their immunomodulatory abilities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
Re
la
tiv
e 
No
rm
al
is
ed
 E
xp
re
ss
io
n
PBS 
B3445
B3078 
ATCC 
B3450
471a
482b0
1
2
3
4
5
6
Re
la
tiv
e 
No
rm
al
is
ed
 E
xp
re
ss
io
n
PBS 
B3445
B3078 
ATCC 
B3450
471a
482b
0
1
2
3
4
5
6
Re
la
tiv
e 
No
rm
al
is
ed
 E
xp
re
ss
io
n
PBS 
B3445
B3078 
ATCC 
B3450
471a
482b0
1
2
3
4
5
6
Re
la
tiv
e 
No
rm
al
is
ed
 E
xp
re
ss
io
n
ATCC 
PBS 
B3445
B3078 
B3450
471a
482b
0
1
2
3
4
5
6
Re
la
tiv
e 
No
rm
al
is
ed
 E
xp
re
ss
io
n
PBS 
B3445
B3078 
ATCC 
B3450
471a
482b
A 
 
B 
 
C 
 
D 
 
E 
 
Figure 7. 1 Expression of cytokine transcripts from HD11 avian macrophages 4-hours post infection with 
Brachyspira species. A: Expression of IL1b B: Expression of IL6 C: Expression of IL8 D: Expression of IL10 and E: 
Expression of IFNg. The bars represent the following infections: blue- mock infection with PBS, green- infection 
with B. intermedia SAP 919, purple- infection with B. pilosicoli SAP 859, orange- infection with B. alvinipulli ATCC 
51933, black- infection with B. innocens SAP 924, brown- infection with L. reuteri SAP 2115 and dark blue- 
infection with L. salivarius SAP 2117. Data are representative of three biological replicates each with three 
technical replicates. Mean values and SEM are displayed. P values are presented in Table 7.1. Significance, if any, 
is shown between infection with PBS, compared to Brachyspira infection * p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, 
**** ≤ 0.0001. 
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7.2.3 HD11 avian macrophage cytokine responses to Brachyspira following pre-exposure to 
Lactobacillus  
 
In the experiments presented here, pre-exposure of HD11 cells to Lactobacillus resulted in a 
marked effect on subsequent cytokine responses to Brachyspira infection. The most 
significant reductions in cytokine expression were observed in the expression of IFNg (Figure 
7.2E). Infecting the HD11 cells with both L. reuteri SAP 2115 and L. salivarius SAP 2117 
significantly reduced the IFNg expression in response to B. pilosicoli SAP 859, B. alvinipulli 
ATCC 51933 and B. innocens SAP 924 (p value £ 0.0001). The IFNg response to B. intermedia 
SAP 919 was also reduced, however not significantly (p value 0.177 and > 0.99, respectively). 
L. reuteri SAP 2115 was able to reduce the expression of IFNg to a greater extent than L. 
salivarius SAP 2117. The IL6 response to B. pilosicoli SAP 859 was also significantly reduced by 
the pre-exposure to both L. reuteri SAP 2115 and L. salivarius SAP 2117 (p value £ 0.0005) 
(Figure 7.2B). Furthermore, this response was significantly reduced to B. innocens SAP 924 
after prior infection with L. salivarius SAP 2117 (p value £ 0.05). The overall gene expression 
of IL6 was reduced when cells were infected with both Lactobacillus isolates prior to infection 
with Brachyspira, despite no significance being observed. The expression of IL8 was 
Table 7. 1 P values for the comparison of cytokine expression between all Brachyspira isolates and the 
control infection with PBS. Expression of IL1b, IL6, IL8, IL10 and IFNg were compared between 
Brachyspira isolates using a one-way ANOVA to investigate the HD11 cell responses to different 
Brachyspira species. P values are presented whereby values highlighted in green were ≤ 0.05 and those 
highlight in red were > 0.05. 
IL1β IL6 IL8 IL10 IFNγ
B. intermedia  SAP 919 0.3902 0.691 0.4844 0.4007 0.3536
B. pilosicoli  SAP 859 0.0004 0.1768 0.2486 0.0042 0.0001
B. alvinipulli  ATCC 51933 0.0004 0.9445 0.8986 0.0413 0.0018
B. innocens  SAP 924 0.0011 0.6156 0.5127 0.128 0.0001
L. reuteri  SAP 2115 0.006 0.8812 0.5395 0.0451 >0.9999
L. salivarius  SAP 2117 0.9351 0.8834 0.5755 >0.9999 >0.9999
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predominantly unaffected by Lactobacillus pre-exposure, although gene expression in 
response to B. pilosicoli SAP 859, the strongest inducer of IL8 expression was significantly 
reduced by L. reuteri SAP 2115 (p value £ 0.05) (Figure 7.2C). The response to IL10 gene 
expression was similar to that of IL6, there was an overall decrease in expression as a result 
of pre-exposure to both Lactobacillus isolates (Figure 7.2D). However, significance was only 
observed when cells infected with B. pilosicoli were pre-exposed to L. salivarius SAP 2117. L. 
salivarius SAP 2117 was not able to induce a high level of IL10 expression, compared to L. 
reuteri SAP 2115, but was still able to modulate the cytokine response in response to 
Brachyspira infection. As previously mentioned, immunomodulation can be the up or 
downregulation of an immune response. In the studies presented here, IL6, IL10 and IFNg are 
significantly downregulated in response to Brachyspira, following exposure to Lactobacillus. 
However, IL1b was significantly upregulated in response to infection with B. intermedia SAP 
919 (p value £ 0.005) (Figure 7.2A). An increase in IL1b expression in response to B. pilosicoli 
SAP 859 was also observed after exposure to L. salivarius SAP 2117, however this was not 
significant (p value 0.330). The expression of IL1b in response to B. alvinipulli ATCC 51933 and 
B. innocens SAP 924 remained largely unchanged.  
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Figure 7. 2 Expression of cytokine transcripts from HD11 avian macrophage cells after pre-treatment with either 
L. reuteri SAP 2115 or L. salivarius SAP 2117 for 30 minutes prior to infection with Brachyspira species for 4 
hours. A: Expression of IL1b B: Expression of IL6 C: Expression of IL8 D: Expression of IL10 and E: Expression of 
IFNg. The bars represent the following infections: blue- mock infection with PBS, green- infection with B. 
intermedia SAP 919, purple- infection with B. pilosicoli SAP 859, orange- infection with B. alvinipulli ATCC 51933, 
black- infection with B. innocens SAP 924, brown- infection with L. reuteri SAP 2115, dark blue- infection with 
L. salivarius SAP 2117, dark purple- infection with L. reuteri SAP 2115 followed by B. intermedia SAP 919, dark 
red- infection with L. salivarius SAP 2117 followed by B. intermedia SAP 919, dark green- infection with L. reuteri 
SAP 2115 followed by B. pilosicoli SAP 859, peach- infection with L. salivarius SAP 2117 followed by B. pilosicoli 
SAP 859, light green- infections with L. reuteri SAP 2115 followed by B. alvinipulli ATCC 51933, light blue- 
infection with L. salivarius SAP 2117 followed by B. alvinipulli ATCC 51933, lilac- infection with L. reuteri SAP 
2115 followed by B. innocens SAP 924 and grey- infection with L. salivarius SAP 2117 followed by B. innocens 
SAP 2117. Data are representative of three biological replicates each with three technical replicates. Mean 
values and SEM are displayed. Significance, if any, is shown between infection with Brachyspira alone, 
compared to Lactobacillus pre-treatment * p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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7.2.4 Developing a Galleria mellonella model to study Brachyspira infection 
 
The Galleria mellonella (greater wax moth) larvae insect model has been previously used to 
assess the infection of a number of pathogenic bacteria including, Campylobacter jejuni and 
E. coli (Senior et al., 2011; Alghoribi et al., 2014; Mehat et al., 2018). This model has a number 
of advantages in that G. mellonella possess haemocytes that have been likened to mammalian 
neutrophils and neutrophils are considered analogous to heterophils (Montali, 1988; Brooks 
et al., 1996). Therefore, G. mellonella haemocytes may respond to Brachyspira in a similar 
way to avian heterophils.  
The first stage in developing a model to study Brachyspira infection was to determine the 
dose of Brachyspira that would show a gradual increase in G. mellonella mortality over time. 
Three different doses of Brachyspira were selected; 1 x 105, 1 x 106 and 1 x 107 CFU/ larvae 
and the mortality in response to these bacterial doses are shown in Figure 7.3. It was evident 
from these experiments that the different Brachyspira doses had a distinct effect on the 
mortality of the larvae. Doses of 1 x 105 and 1 x 106 CFU/larvae did not result in gradual 
increases in mortality over 168 hours for any isolate except for B. innocens SAP 924 (Figure 
IL1β IL6 IL8 IL10 IFNγ
SAP 919 vs. SAP 919+ SAP 2115 0.7595 0.3624 >0.9999 0.9986 0.1775
SAP 919 vs. SAP 919+ SAP 2117 0.0043 0.1838 0.996 0.9581 >0.9999
SAP 859 vs. SAP 859 + SAP 2115 >0.9999 0.0002 0.0134 0.058 0.0001
SAP 859 vs. SAP 859 + SAP 2117 0.3306 0.0001 0.2753 0.0313 0.0001
ATCC 51933 vs. ATTC 51933+ SAP 2115 >0.9999 0.9952 >0.9999 0.5417 0.0004
ATCC 51933 vs. ATCC 51933 + SAP 2117 >0.9999 0.8751 0.9992 0.1432 0.2524
SAP 924 vs. SAP 924 + SAP 2115 >0.9999 0.1038 0.972 0.7293 0.0001
SAP 924 vs. SAP 924 + SAP 2117 0.999 0.019 0.9997 0.4152 0.0001
Table 7. 2 A summary of the P values to compare the cytokine responses from HD11 cells infected 
with Brachyspira alone, compared to cells pre-treated with different Lactobacillus isolates. 
Significance was determined using a one-way ANOVA with a p value of ≤ 0.05 indicating a significant 
difference (highlighted in green) and a p value of > 0.05 indicating no significant difference 
(highlighted in red). 
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7.3E), which was shown to have the highest mortality when infected with low doses of 
Brachyspira.  Therefore, a dose of 1 x 107 CFU/ larvae was selected because in all isolates 
tested there was a gradual increase in mortality over time. Furthermore, a time point of 120 
hours as selected as the time course for this experiment because the majority of mortality 
occurred in this time frame. From this preliminary data, it was clear that each Brachyspira 
isolate resulted in distinct mortality profiles in the larvae and that despite B. innocens being 
proposed as non-pathogenic in the avian host, it was indeed pathogenic in this host.  
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Figure 7. 3 Galleria mellonella percent survival after infection with multiple doses of Brachyspira species. A: 
Infection with B. pilosicoli B2904, B: Infection with B. pilosicoli SAP 859, C: Infection with B. intermedia SAP 919, 
D: Infection with B. innocens SAP 943 and E: Infection with B. innocens SAP 924. Blue lines represent infection 
with 1x105 CFU/ larvae of Brachyspira, red lines represent infection with 1x106 CFU/ larvae of Brachyspira and 
green lines represent infection with 1x107 CFU/ larvae of Brachyspira. Data are representative of three 
biological replicates each with 10 larvae per infection group. Mortality scores were recorded every 24 hours for 
168 hours of incubation at 37°C. 
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7.2.5 Galleria mellonella infection model 
 
Following on from the preliminary studies, all eight Brachyspira isolates were screened using 
the G. mellonella model at a dose of 1 x 107 CFU/ larvae, as shown in Figure 7.4. G. mellonella 
that were not injected and those that were injected with PBS showed 100% survival and no 
associated morbidity, as seen in Figure 7.4A and Figure 7.4B. Each Brachyspira isolate 
significantly reduced the survival of G. mellonella larvae, but to varying degrees (p value < 
0.0001). Additionally, each Brachyspira isolate significantly increased the melanisation score 
of the larvae, also to varying degrees (p value < 0.0001). 
Of the three B. pilosicoli isolates, infection with SAP 859 and SAP 865 resulted in the highest 
survival rates, 78% and 83% respectively and the lowest melanisation scores, 23 and 19, 
respectively. Whereas, B. pilosicoli B2904 had one of the lowest survival rates of all of the 
isolates tested, 60% and one of the highest melanisation scores, 31. Additionally, of the three 
B. innocens isolates tested, SAP 943 resulted in the lowest survival rate, 45% and highest 
morbidity score of all isolates tested, 34. B. innocens SAP 924 and SAP 927 were less virulent 
to the G. mellonella larvae and resulted in a survival rate of 55% and 62% and melanisation 
scores or 29 and 27, respectively. B. intermedia SAP 919 was the second most virulent isolate 
in this model with a survival rate of 48% and a melanisation score of 32. B. alvinipulli ATCC 
51933 elicited similar responses to B. pilosicoli SAP 859, with a survival rate of 77% and a 
melanisation score of 23. Overall, it was not possible to correlate the survival rate and 
melanisation scores to a particular species of Brachyspira. As observed in previous assays, 
each isolate exhibited unique characteristics that could not be correlated to a particular 
species of Brachyspira.  
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Figure 7. 4 Galleria mellonella A: percent survival and B: morbidity scores following infection with 107 CFU/ 
larvae of B. pilosicoli B2904 (blue), B. pilosicoli SAP 859 (red), B. pilosicoli SAP 865 (green), B. alvinipulli ATCC 
51933 (purple), B. intermedia SAP 919 (orange), B. innocens SAP 943 (black), B. innocens SAP 924 (brown) and 
B. innocens SAP 927 (dark blue). Control larvae were injected with sterile PBS (dark purple) to control for 
injection technique and non-injected controls (dark red) were used to control for the rate of larval pupation 
for the 120-hour duration of incubation at 37°C. The percent survival and morbidity scores were calculated 
from five biological replicates, each with 10 larvae per experimental condition. Scores were recorded every 
24 hours. Significance, if any, is shown between infection with Brachyspira, compared to the PBS control 
infection * p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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In addition to observing the morbidity and mortality associated with Brachyspira infection in 
G. mellonella larvae, attempts to culture Brachyspira from the haemolymph of the larvae 
were conducted to determine the duration of survival of Brachyspira within the larvae. One 
isolate from each species of Brachyspira was selected for these studies; B. pilosicoli SAP 859, 
B. intermedia SAP 919, B. alvinipulli ATCC 51933 and B. innocens SAP 924. These isolates were 
selected due to range of morbidity and mortality observed in Figure 7.4, in order to determine 
if probiotic interventions would be suitable for Brachyspira infections of differing virulence. 
These data were summarised as qualitative data in Table 7.3 due to the difficulty and 
inaccuracy of counting individual colonies of Brachyspira. It was evident that Brachyspira 
remained viable in the G. mellonella haemolymph for up to 48 hours post infection for B. 
pilosicoli SAP 859 and B. alvinipulli ATCC 51933 and up to 24 hours post infection for B. 
intermedia SAP 919 and B. innocens SAP 924. Interestingly, the associated morbidity and 
mortality following Brachyspira infection continued to increase after the bacteria were no 
longer viable in the haemolymph. Following four hours of infection, the numbers of all 
Brachyspira isolates began to decrease until approximately 24-48 hours post infection, after 
which viable Brachyspira were below the limits of detection.  
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Histopathology was also conducted to investigate the immune responses and pathology 
associated with Brachyspira infection in this model and to determine where Brachyspira 
localised in the larvae. Histopathology scores assessed the bacteria in the gut, the 
inflammatory bodies and the clusters of haemocytes circulating within the larvae, as shown 
in Table 7.4. These scores can be seen in detail in Section 2.4, however in brief, a score of 0 
corresponds to no bacteria in the gut,  inflammatory bodies or haemocyte clusters, a score of 
1 corresponds to a very small number of bacteria, inflammatory bodies and haemocytes 
clusters, a score of 2A corresponds to a small number bacteria, inflammatory bodies and 
haemocytes clusters, a score of 2B corresponds to a moderate number bacteria, inflammatory 
bodies and haemocytes clusters and a score of 3 corresponds to an abundance of bacteria, 
inflammatory bodies and haemocytes clusters.  
The inflammatory/ melanin bodies developed rapidly post infection and were observed in 
very low numbers immediately after infection with each Brachyspira species. Within two 
hours of infection, there were small numbers of inflammatory/ melanin bodies in response 
Time 
(hours) 
B. pilosicoli 
SAP 859 
B. intermedia 
SAP 919 
B. alvinipulli 
ATCC 51933 
B. innocens 
SAP 924 
0 +++ +++ +++ ++ 
1 +++ +++ +++ ++ 
2 ++ +++ +++ ++ 
4 + ++ + + 
6 + ++ + + 
24 + + + + 
48 + - + - 
72 - - - - 
96 - - - - 
120 - - - - 
Table 7. 3 Qualitative summary of Brachyspira species cultured from the haemolymph of 
the Galleria mellonella larvae. Haemolymph from three larvae was pooled at each of the 
time points, cultured on to FABA and incubated anaerobically at 37°C for 3-5 days.  
+++ strong Brachyspira growth, ++ intermediate Brachyspira growth, + weak Brachyspira 
growth and – no Brachyspira growth. 
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to all Brachyspira isolates. This concurred with the observable colour change (melanisation) 
of the larvae within two hours post infection. Between 48 and 96 hours the numbers of 
inflammatory/melanin bodies increased to a moderate number, depending on the species of 
Brachyspira. Overall, these scores were similar following infection with each species of 
Brachyspira tested. 
The numbers of bacteria in the gut of the G. mellonella increased over the duration of these 
experiments following infection with B. pilosicoli SAP 859, B. intermedia SAP 919 and B. 
alvinipulli ATCC 51933.  However, no bacteria were observed in the gut following infection 
with B. innocens SAP 924. Importantly, these bacteria were not identified as Brachyspira, but 
as Gram positive cocci, likely to be Enterococci as these are known to colonise the 
gastrointestinal tracts of G. mellonella. Infection with B. pilosicoli SAP 859 resulted in the 
highest numbers of bacteria in the gut. The clustering of haemocytes occurred later on in the 
infection process compared to the development of inflammatory bodies. Small clusters of 
haemocytes appeared 24 hours after infection with B. pilosicoli SAP 859, B. intermedia SAP 
919 and B. innocens SAP 924, whereas only very small numbers of haemocytes were observed 
after 48 hours of B. alvinipulli ATCC 51933 infection. Overall, the histological analysis showed 
the development of a cellular immune response over time, however there were no 
histological indicators that correlated with the morbidity or mortality scores associated with 
infection by different Brachyspira species. For example, B. pilosicoli SAP 859 was the least 
virulent of the isolates selected in this model yet showed some of the highest scores for 
bacteria in the gut, inflammatory/ melanin bodies and haemocyte clusters.  
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Time 
(hours)
Bacteria in gut 
(cocci)
Inflammatory/ 
melanin bodies
Clusters of 
haemocytes 
0 1 1 0
1 1 1 0
2 1 2a 1
4 2a 2a 1
6 2a 2a 1
24 1 2a 2a
48 1 2a 2a
72 1 2b 2a
96 2a 2b 2b
120 2a 3 2b
0 0 1 0
1 0 1 0
2 0 2a 1
4 1 2a 1
6 2a 2a 1
24 1 2a 2a
48 1 2b 2a
72 1 2b 2a
96 1 2b 2a
120 1 2b 2a
0 1 1 0
1 0 1 0
2 0 2a 0
4 1 2a 0
6 0 2a 0
24 1 2a 0
48 1 2b 1
72 1 2a 1
96 2a 2b 1
120 0 2b 1
0 0 1 0
1 0 2a 0
2 0 1 1
4 0 2a 1
6 0 2a 1
24 0 2a 2a
48 0 2a 2a
72 0 2a 2a
96 0 2b 2b
120 0 2b 2b
B. pilosicoli 
SAP 859
B. intermedia 
SAP 919
B. alvinipulli 
ATCC 51933
B. innocens 
SAP 924
Table 7. 4 Histology scores from infection with different Brachyspira species. This scoring system scored the 
presence of bacteria in the gut, the inflammatory/ melanin bodies and the clusters of haemocytes observed 
in the larvae after infection with B. pilosicoli SAP 859, B. intermedia SAP 919, B. alvinipulli ATCC 51933 and B. 
innocens SAP 924. A score of 0 denotes no sign of infection, a score of 1 denotes minimal signs of infection 
with very small numbers of the descriptors below, a score of 2A denotes a mild infection with small numbers 
of the descriptors below, a score of 2B denotes moderate infection, with moderate numbers of the descriptors 
below and a score of 3 denotes severe infection with high numbers of the descriptors below. 
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Haematoxylin and Eosin (H&E) staining of histology sections at 24-hour intervals for 120 hours 
showed the development of an immune response in the G. mellonella larvae. This was 
characterised by the infiltration of haemocytes in the haemolymph and the early 
development of inflammatory nodules at 24 hours post infection (Figure 7.5C), numerous 
pigmented bodies and clotted haemolymph at 48 hours (Figure 7.5D), increased pigmented 
bodies and increasing haemocyte circulation at 72 hours (Figure 7.5E), development of 
pigmented bodies throughout the larvae at 96 hours and 120 hours (Figures 7.5F and G). 
Control sections that were not infected with Brachyspira showed no signs of infection, 
although there were some circulating haemocytes in the haemolymph (Figures 7.5A and B). 
There was clear evidence that Brachyspira induced an immune response in this model over 
the course of 120 hours.  Therefore, the G. mellonella model was deemed suitable for the 
study of Brachyspira infection. 
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Figure 7. 5 Haematoxylin and eosin staining of Galleria 
mellonella sagittal sections infected with B. pilosicoli 
SAP 859 at a dose of 107 CFU/ larvae. A: Larvae injected 
with sterile PBS after 24 hours (scale bar 100µm), B: 
Larvae injected with sterile PBS after 48 hours (scale bar 
100µm), C: 24 hours post infection (scale bar 100µm), 
D: 48 hours post infection (scale bar 50µm), E: 72 hours 
post infection (scale bar 50µm), F: 96 hours post 
infection (scale bar 2µm) and G: 120 hours post 
infection (scale bar 2µm). Larvae were incubated at 
37°C for the duration of the experiment, with three 
individual larvae fixed in formalin every 24 hours. 
Structures are annotated as follows: a: adipose tissue, 
c: cuticle, ge: gut epithelium, gl: gut lumen, h: 
haemolymph, hc: haemocytes, ht: haemolymph clotted, 
in/pb: inflammatory nodule/ pigmented body, m: 
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The H&E staining was unable to detect Brachyspira in the larvae, this was most likely due to 
poor uptake of the stain by the bacteria, this was also notable for Gram stains. Therefore, 
silver stains were conducted on a small number of slides due to its specificity for spirochaetes, 
as mentioned in Chapter 3. The sliver stains, shown in Figure 7.6, show that in addition to 
circulating in the haemolymph, Brachyspira are located in the muscle of the larvae. Moreover, 
these bacteria showed classic spirochaete morphology, exemplified by their long spiral shape 
devoid of spherical bodies. 
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Figure 7. 6 Warthin- Starry stained sagittal sections 
of Galleria mellonella infected with B. pilosicoli SAP 
859 at a dose of 107 CFU/ larvae. A: 0 hours post 
infection, B: 4 hours post infection, C: 24 hours 
post infection. Scale bars 100µm Larvae were 
incubated at 37°C for the duration of the 
experiment, with three individual larvae fixed in 
formalin every 24 hours. The primary location of 
the Brachyspira appeared to be localised in the 
muscle. 
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7.2.6 Developing a G. mellonella model to study probiotics as an intervention against 
Brachyspira infection  
 
Having determined the G. mellonella model as a model to study the Brachyspira infection, it 
was important to determine whether a probiotic intervention may be able to protect the 
larvae from this pathogen.  
Initially, the effects of each of the four Lactobacillus isolates was tested to determine the dose 
of Lactobacillus that would not induce mortality or any associated morbidity in the larvae. A 
range of doses from 1 x 105 to 1 x 102 CFU/ larvae were tested, as shown in Figure 7.7. These 
data showed that infections with Lactobacillus at doses of 1 x 102, 1 x 103 and 1 x 104 CFU/ 
larvae resulted in 90 to 100% survival in the larvae, whereas infection with 1 x 105 induced 
significant mortality in the larvae (p value < 0.0001), most likely due to bacterial load and 
rapid replication of Lactobacillus. Morbidity scores were zero throughout these experiments. 
As a result of these preliminary experiments, a dose of 1 x 104 CFU/ larvae was selected as 
this was the highest dose of injectable Lactobacillus that did not induce significant mortality 
in this model. Previous probiotic experiments in G. mellonella have utilised a range of 
Lactobacillus species and doses against a range of pathogens including Candida albicans, 
Salmonella Typhimurium, E. coli, Staphylococcus aureus and Listeria monocytogenes (Grounta 
et al., 2016; Rossoni et al., 2017; Scalfaro et al., 2017). Thus, emphasising the requirement to 
optimise Lactobacillus doses and species for the designated pathogen.  
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7.2.7 Lactobacillus probiotics as an intervention against Brachyspira in the G. mellonella     
model  
 
To assess the ability of the four probiotic candidates selected in Chapter 5 to protect against 
Brachyspira infection in this model, G. mellonella were initially infected with Lactobacillus, 
followed by infection with Brachyspira.  
It was evident that a one-hour pre-treatment with Lactobacillus afforded some protection for 
larvae prior to Brachyspira infection, compared to the controls injected with PBS, as shown in 
Figure 7. 7 Galleria mellonella survival after infection with between 102 and 105 CFU/ larvae of A: L. reuteri 
SAP 2114, B: L. reuteri SAP 2115, C: L. salivarius SAP 2116 and D: L. salivarius SAP 2217. The green lines 
represent infection with 102 CFU/ larvae, the red lines represent infection with 103 CFU/ larvae, the blue 
lines represent infection with 104 CFU/larvae and the purple lines represent infection with 105 CFU/ larvae. 
Data are representative of three biological replicates each with 10 larvae per infection group. Mortality 
scores were recorded every 24 hours for 168 hours of incubation at 37°C. Significance, if any, is shown 
between infection with different Lactobacillus doses, compared to the PBS control infection * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001.  
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Figure 7.8. As demonstrated in assays described in Chapters 5 and 6, the protective effects of 
the chosen probiotics were dependent on the isolate of Lactobacillus and the isolate of 
Brachyspira. Lactobacillus infection prior to infection with B. pilosicoli SAP 859 (Figure 7.8A) 
did not have any significant protective effects on the G. mellonella larvae, however L. reuteri 
SAP 2114 demonstrated a small protective effect. Larvae infected with L. reuteri SAP 2114 
and L. salivarius SAP 2117 were significantly protected from mortality associated with 
infection with B. intermedia SAP 919 (p value £ 0.0001) (Figure 7.8B). Whereas, L. reuteri SAP 
2115 and L. salivarius SAP 2116 did not elicit any protection against B. intermedia SAP 919, in 
fact L. salivarius SAP 2116 slightly decreased the survival rate of the larvae. Despite this, L. 
salivarius SAP 2116 was the only Lactobacillus isolate to significantly protect the larvae from 
infection with B. alvinipulli ATCC 51933 (p value £ 0.00332). L. reuteri SAP 2115 and L. 
salivarius SAP 2117 demonstrated the ability to protect larvae after 72 hours and increase 
their overall survival. L. reuteri SAP 2114 decreased the survival rate compared to the PBS 
control (Figure 7.8C). Infections with L. salivarius SAP 2116 and SAP 2117 were able to 
significantly improve the survival of larvae infected with B. innocens SAP 924 (p value £ 
0.0332, £ 0.0021, respectively) compared to the control. L. reuteri SAP 2115 also conferred 
protection against B. innocens SAP 924, although this was not significant (Figure 7.8D). The 
larvae infected with Lactobacillus showed no significant mortality compared to the PBS 
control. Furthermore, there were no observable differences in the morbidity scores when 
larvae were infected with any of the Lactobacillus isolates prior to Brachyspira infection. 
It is worth noting that G. mellonella were also injected with Lactobacillus CFS from all four 
probiotic candidates prior to Brachyspira infection. Despite the CFS alone not causing any 
associated morbidity or mortality, co-infection with Brachyspira resulted in 100% mortality 
within 48 hours post infection, thus the CFS could not protect the larvae.  
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Figure 7. 8 Galleria mellonella percent survival following a one-hour pre-infection with 104 CFU/ larvae of 
Lactobacillus, before infection with Brachyspira species at a dose of 107 CFU/ larvae. A: Infection with B. 
pilosicoli SAP 859, B: infection with B. intermedia SAP 919, C: infection with B. alvinipulli ATCC 51933, D: 
infection with B. innocens SAP 924 and E: infection with Lactobacillus isolates. The blue lines represent the 
control infection of PBS followed by Brachyspira infection, the red lines represent infection with L. reuteri SAP 
2114 followed by Brachyspira infection, the green lines represent infection with L. reuteri SAP 2115 followed 
by Brachyspira infection, the purple lines represent infection with L. salivarius SAP 2116 followed by 
Brachyspira infection and the orange lines represent infection with L. salivarius SAP 2117 followed by 
Brachyspira infection. Percent survival was calculated from five biological replicates, each with 16 larvae per 
experimental condition. Scores were recorded every 24 hours. Significance, if any, is shown between infection 
with Lactobacillus followed by Brachyspira infection and injection with sterile PBS followed by Brachyspira 
infection * p ≤ 0.05; ** ≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001.  
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7.3 Discussion  
 
The studies presented in this chapter focussed on improving the understanding of the innate 
immune responses to Brachyspira infection using both in vitro and in vivo models.  The data 
generated here from the in vitro HD11 avian macrophage studies indicated that Brachyspira 
elicited immune responses in cells of the innate immune system and that pre-exposure to 
Lactobacillus probiotics were able to alter these responses. 
To further study the pathobiology of Brachyspira infections and probiotics an in vivo G. 
mellonella infection model was developed in order to ascertain the virulence of each 
Brachyspira isolate in the context of a functional immune system and investigate whether 
pre-exposure to Lactobacillus could protect the larvae from the morbidity and mortality 
associated with infection, given the immunomodulatory properties already observed in the 
HD11 cells.  
Host immune responses against Brachyspira species are poorly understood (Hampson, 2018). 
There has been no significant research conducted to determine the innate immune responses 
to Brachyspira, although the adaptive immune response is known to generate antibodies 
against Brachyspira in low levels (Hampson, 2018). Therefore, the studies presented here 
characterised the macrophage response to Brachyspira in vitro using HD11 avian 
macrophages in culture. The HD11 cell line is a macrophage-like cell line created by 
transforming chicken haematopoietic cells with the avian myelocytomatosis type MC29 virus 
(Beug et al., 1979).  
Infections with Brachyspira in both humans and animals have been associated with the 
infiltration of immune cells such as macrophages in the lamina propria, which lies just under 
the mucosal epithelium (Antonakopoulos et al, 1982; Padmanabhan et al., 1996; Duhamel, 
2001; Hampson, 2017), demonstrating the importance of macrophages in defence against 
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Brachyspira. Brachyspira have shown the ability to cause chronic caecal and colonic 
inflammation as a result of invading the lamina propria (Duhamel, 2001). Therefore, 
understanding the macrophage response to infection and investigating mitigation strategies 
may improve treatment and control of avian intestinal spirochaetosis.  
In order to determine the immune responses to Brachyspira species, the production of a 
selection of pro- and anti-inflammatory cytokines were measured. After four hours of 
infection all Brachyspira isolates were capable of inducing expression of the pro-inflammatory 
cytokines IL1b, IL6, IL8 and IFNg and the anti-inflammatory cytokine IL10. Both pathogenic 
and non-pathogenic Brachyspira elicited similar cytokine responses from the HD11 cells. B. 
innocens is often regarded as a commensal bacteria as no clinical disease has been associated 
with infection, similarly C. jejuni is considered as a commensal bacteria in the avian hosts, 
however studies have shown that Campylobacter were also capable of eliciting immune 
responses in HD11 cells (Smith et al., 2005). B. pilosicoli SAP 859 elicited the greatest cytokine 
responses, in particular the IFNg response, which was significantly higher than other isolates. 
The differences in immune response may be as a result of the response to lipooligosaccharide 
(LOS) on the outer membrane of Brachyspira. LOS have been shown to be antigenically 
distinct both between species and within species of Brachyspira (Lee and Hampson, 1999), 
thus may have an impact on the subsequent immune response. LOS activates toll-like 
receptor 4 (TLR4) which is expressed on a number of immune cells, including macrophages. 
This activation produces a pro-inflammatory response and may be, in part attributed to the 
differences in the pro-inflammatory responses induced by the different species of Brachyspira 
(both pathogenic and non-pathogenic) (John et al., 2017).  
A gentamicin protection assay was utilised to determine whether Brachyspira could survive 
intracellularly. As previously mentioned, Brachyspira have been located within macrophages 
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using microscopy techniques but no reports of intracellular replication or survival have been 
made (Antonakopoulos et al., 1982). The assay utilised in these studies demonstrated that 
Brachyspira do not survive within the HD11 cells, however remained viable when cultured 
from the tissue culture media following three hours of infection. Following this, a fluorescent 
oxidative burst assay was performed in an attempt to measure phagocytic activity of the 
macrophages in response to Brachyspira in order to further characterise the immune 
response to this pathogen. However, control experiments containing Brachyspira alone 
resulted in higher background fluorescence than a co-culture with the pathogen and HD11, 
and thus this assay did not give accurate results. This may have been as a result of the 
Brachyspira nox gene activity in the presence of oxygen. This gene aids in the conversion of 
oxygen to water via a superoxide intermediate which would oxidise the fluorescent dye in 
this experiment, resulting in this assay being an unsuitable method to measure oxidative burst 
(Hajjar et al., 2017). 
Immunomodulation is one of many proposed mechanisms of probiotic action. Probiotic 
bacteria are known to stimulate the immune responses in the gastrointestinal tract without 
causing disease and are hypothesised to prime the immune system, but also to modulate 
responses to control the production of cytokines and chemokines (Haller et al., 2000). The 
cytokine responses to L. reuteri SAP 2115 and L. salivarius SAP 2117 were investigated as 
these two probiotic candidates were the most successful of their species throughout all 
experiments conducted in Chapters 5 and 6. It was initially important to establish the cytokine 
response elicited by these selected Lactobacillus isolates. Both isolates were able to induce 
the expression of both pro- and anti-inflammatory cytokines, except for IFNg which is a potent 
pro-inflammatory cytokine (Tau and Rothman, 1999). L. salivarius SAP 2117 was unable to 
induce the expression of IL10, an anti-inflammatory cytokine capable of preventing 
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inflammation and restoring homeostasis during infection (Iyer and Cheng, 2012). Whereas, L. 
reuteri SAP 2115 was able to induce significantly higher levels of IL10 expression, thus 
suggesting that this probiotic candidate may be more suitable because IL10 expression may 
play a significant role in controlling immune responses as a result of Brachyspira infection. 
However, this would need to be shown in an appropriate animal model. Increased IL10 
production has been associated with the decreased expression of proinflammatory cytokines 
such as IFNg (de Moreno de Leblanc et al., 2011) and these studies have suggested that IFNg 
is the most expressed pro-inflammatory cytokine (of those tested here) in Brachyspira 
infection. Therefore, Lactobacillus isolates that induce the expression of IL10 may be more 
favourable as probiotic candidates to mitigate avian intestinal spirochaetosis because they 
have the potential to reduce the inflammatory response, thus may contribute to reducing the 
severity of the disease. 
The experiments conducted in these studies suggested evidence of alterations in cytokine 
expression following probiotic pre-treatment as many of the cytokine responses were 
significantly altered when the HD11 cells were pre-exposed to either L. reuteri SAP 2115 or L. 
salivarius SAP 2117. As previously highlighted, the IFNg response appears to be of significant 
importance in Brachyspira inflammation as this was the most highly expressed cytokine, 
especially in response to B. pilosicoli SAP 859. The infection of HD11 cells with Lactobacillus 
prior to Brachyspira infection reduced the expression of IFNg  in response to all Brachyspira 
species. IFNg signalling is mediated through the Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) pathway which is known to be inactivated by some 
isolates of Lactobacillus in response to infection (Lee et al., 2010; Llewellyn and Foey, 2017). 
L. acidophilus and L. plantarum isolates have been shown to activate STAT1 and STAT3 and 
inactivate JAK2, which is essential for IFNg signalling (Llewellyn and Foey, 2017). The 
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expression of IL6 following pre-exposure to Lactobacillus was also reduced in response to 
Brachyspira. In addition to the inhibition of the JAK/STAT pathways, Lactobacillus probiotics 
have also been shown to attenuate the NFkB and ERK pathways which are responsible for the 
production of pro-inflammatory IL6, therefore, reducing its expression. (Lee et al., 2010; 
Llewellyn and Foey, 2017). The expression of IL1b and IL8 remained largely unchanged after 
pre-exposure to Lactobacillus. The expression of these cytokines has been linked to NFkB and 
p38 MAPK pathways (Takanashi et al., 2013) and therefore the Lactobacillus isolates used in 
these studies may have been ineffective against the branches of these pathways involved in 
IL1b  and IL8 production. As with all experiments conducted thus far, the impact on cytokine 
gene expression was dependent on both the Brachyspira and Lactobacillus isolates, as 
previously observed by Llewellyn and Foey (2017). Probiotic bacteria have been known to 
induce the expression of suppressor of cytokine signalling (SOCS) genes. These proteins are 
known to be inhibitory regulators of the JAK/STAT pathway and TLR4 mediated cytokine 
responses (Dimitriou et al., 2008), thus downregulating the expression of pro-inflammatory 
cytokines. SOCS genes, in particular SOCS3 is known to be inducible by IL10. The anti-
inflammatory response is initiated by the phosphorylation of STAT3 which inhibits the 
production of pro-inflammatory cytokines using the JAK/STAT pathway, this in turn 
upregulates the gene expression of SOCS genes. In human macrophages, L. rhamnosus GG 
was shown to increase the phosphorylation of STAT3 and increase the expression of SOCS3, 
which was proposed to be a mechanism of immune modulation in human health (Latvala et 
al., 2011). It is important to note that much of this research has been conducted in human or 
murine models both in vitro and in vivo and thus it can only be speculated that similar 
responses occur in the avian host.  
 248 
These studies have demonstrated that there is careful regulation of the innate immune 
system in response to infection. Lactobacillus isolates downregulated the expression of pro-
inflammatory cytokines which in vivo may prevent a severe pro-inflammatory response. They 
also resulted in an overall downregulation of IL10 which may be fundamental in controlling 
the immune response to ensure there is enough of a response to clear infection, but that it is 
not dampened so significantly that the infection can proliferate. It is imperative to repeat the 
studies described in whole animal in vivo studies to test the hypotheses derived by studies in 
in vitro tissue culture albeit HD11 cells are chicken derived.  
The Galleria mellonella infection model has been previously shown to be a powerful and 
effective infection model for a number of pathogens such as Campylobacter jejuni, E. coil and 
Candida albicans (Brennan et al., 2002; Senior et al., 2011; Alghoribi et al., 2014). 
Furthermore, this model has proven useful in investigating antibiotic and probiotic 
interventions to treat and prevent disease (Benthall et al., 2015; Scalfaro et al., 2017). This 
infection model is becoming a more popular alternative to mammalian and avian models of 
infection due to the simplicity and reliability, in addition to being an inexpensive tool that is 
more ethically accepted. The G. mellonella model is useful for studying infection in the 
context of a functional immune system, although no studies of Brachyspira infection have 
been conducted in this model. G. mellonella are capable of innate immune responses, these 
responses consist of two parts (Tsai et al., 2016). The first is the cellular immune response, 
mediated by immune cells know as haemocytes, which are present in the haemolymph of the 
insects (Ramarao et al., 2012). The second is the humoral immune response, which is 
mediated by molecules such as melanin. Haemocytes are capable of phagocytosis and can 
produce small antimicrobial peptides. These cells are functionally analogous to mammalian 
neutrophils, which are analogous to avian heterophils (Brooks et al., 1996); therefore, this 
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model may be able to give an insight to Brachyspira infection in both mammalian and avian 
hosts. The humoral immune response can be measured as the production of melanin results 
in a visible colour change in the larvae. Melanin encapsulates pathogens at the site of 
infection, which is followed by the coagulation of haemolymph (Tsai et al., 2016). 
In order to begin to develop a Brachyspira infection model using G. mellonella larvae, all eight 
Brachyspira isolates used throughout the studies presented here were injected into the larvae 
to assess their virulence in this model. Pathogens such as C. jejuni and C. albicans have been 
well researched in this model and has been used to identify virulence trends in isolates 
(Brennan et al., 2002; Champion et al., 2010; Mehat et al., 2018). Therefore, similar 
approaches for Brachyspira infection were undertaken. Interestingly, the virulence observed 
in the G. mellonella had some key differences to that of avian infection, namely that B. 
innocens resulted in the highest mortality in this model, however this species is proposed to 
be non-pathogenic in the avian host (Mappley et al., 2014). Although B. innocens is deemed 
non-pathogenic in the avian host, there has been some evidence that this species of 
Brachyspira is linked to poor egg production in flocks, especially in free-range hens (Burch et 
al., 2009) and thus may be causing disease in chickens. B. innocens was capable of eliciting 
pro-inflammatory responses in HD11 cells also, showing that it does cause an immune 
response comparable to that of pathogenic species. In chickens, disease caused B. alvinipulli, 
B. intermedia and B. pilosicoli manifests as similar clinical symptoms, but can range in severity, 
therefore, the range of morbidity and mortality associated with these isolates in the G. 
mellonella model may show some similarities to avian infection. However, many more 
isolates of Brachyspira would need to be screened using this model in order to reach a 
conclusion, furthermore, the virulence of these Brachyspira isolates would need to be 
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determined in a chicken host to be able to confirm the similarity of the avian and the insect 
host.  
Brachyspira remain viable in the G. mellonella haemolymph for between 24 and 48 hours post 
infection, suggesting that the cellular and humoral immune responses in these larvae are 
capable of killing this pathogen. Notably, for many of the isolates tested, the highest mortality 
rates were observed within the first 48 hours of infection. This could be associated with the 
infiltration of increasing numbers haemocytes and development of inflammatory/ melanin 
bodies to clear the infection. This can be observed in the histology scoring and also in the H&E 
stains which showed the increasing numbers of haemocytes at 24 hours and the development 
of pigmented bodies at 48 hours post infection. It is also important, however to consider that 
Brachyspira are fastidious anaerobes and thus bacterial numbers may also be declining due 
to lack of nutrients and presence of oxygen.  
In the avian host, Brachyspira are primarily found in the caeca and large intestine, however 
they have been known to enter the bloodstream and cause systemic infection and as a result 
have been found in the spleen and liver of infected birds (Mappley et al., 2013). The G. 
mellonella infection model is a systemic infection model as the bacteria are injected directly 
into the haemolymph. Sliver staining of G. mellonella tissue sections showed that the 
Brachyspira were primarily located in the muscle tissue and no spirochaetes were observed 
in the gut. Silver stains were conducted at 0, 4 and 24 hours post infection to observe where 
the bacteria were localised in this model, ideally more time points would have been stained 
in order to qualitatively monitor Brachyspira, however financial constraints limited this. The 
silver stains of B. pilosicoli SAP 859 suggested that the bacterial cells were healthy as they 
displayed a long spirochaete morphology; Brachyspira are known to form spherical bodies 
and become more cocci in shape in response to stress (Wood et al., 2006; Bernardeau et al., 
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2009). It is also worth noting that the muscle of birds following Brachyspira infection has not 
been extensively investigated for the presence of Brachyspira, although one study found that 
chicken carcasses were contaminated with Brachyspira (Verlinden et al., 2012).  Therefore, 
the localisation of these bacteria in the Galleria mellonella model may inform avian infection 
studies in future in vivo testing as this may be a possible route of zoonotic infection. 
Brachyspira were not found in the gastrointestinal tracts of the larvae with H&E, Gram or 
Silver staining. However, there were increased numbers of Gram positive cocci in the gut, as 
noted during the histology scoring. Enterococcus faecalis is known to be a commensal of the 
gut of G. mellonella larvae (Jarosz, 1979) and therefore, it could be suggested that an infection 
with Brachyspira could have compromised the immune system, thus allowing the 
proliferation of E. faecalis.  
This model of G. mellonella infection was systemic in nature, and although it proved to be a 
useful model to assess the virulence of different isolates, avian intestinal spirochaetosis is 
primarily a gastrointestinal disease, despite there being some evidence of systemic infection. 
Interestingly, analogies have been found between the epithelial cells of the larvae’s midgut 
and the intestinal cells of the mammalian digestive system (Ramarao et al., 2012) and 
therefore may prove to be a useful gut model in future studies. However previous studies 
have demonstrated that the ingestion of foodborne pathogens such as L. monocytogenes and 
P. aeruginosa does not induce mortality in this model (Fedhila et al., 2010). Other drawbacks 
would include the technical difficulties of feeding the larvae and that exact infection doses 
would be difficult to obtain (Tsai et al., 2016).  
G. mellonella were determined as a suitable model for Brachyspira infection, therefore 
Lactobacillus probiotics were investigated as a suitable intervention for the mortality and 
morbidity associated with pathogen infection. Previous studies using Lactobacillus in G. 
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mellonella have tested several doses of these bacteria and their ability to protect against the 
chosen pathogen, ranging from 102 to 109 CFU/ larvae, with mortality associated with higher 
doses of Lactobacillus (Grounta et al., 2016; Rossoni et al., 2017; Scalfaro et al., 2017). In the 
studies presented here, a range of 102 to 105 CFU/ larvae were tested with only 105 CFU/ml 
causing any associated mortality, therefore a dose of 104 CFU/ml was selected as this was the 
highest dose of Lactobacillus that did not result in any associated morbidity and mortality.  
As with the assays presented in Chapter 6, the effects of the different Lactobacillus isolates 
were very much specific on both the isolate of Lactobacillus and the isolate of Brachyspira.  
B. intermedia SAP 919 was the most sensitive to probiotic intervention whereby L. reuteri SAP 
2114 and L. salivarius SAP 2117 were able to protect the larvae against Brachyspira infection. 
L. salivarius SAP 2116 was able to protect against infection with both B. alvinipulli ATCC 51933 
and B. innocens SAP 924, in addition to L. salivarius SAP 2117 being able to protect against B. 
innocens SAP 924 infection. Previous studies have also demonstrated that pre-treatment with 
Lactobacillus could protect against C. albicans, L. monocytogenes and S. aureus (Grounta et 
al., 2016; Rossoni et al., 2017; Scalfaro et al., 2017). It has been proposed by Rossoni et al. 
(2017) and Scalfaro et al. (2017) that pre-treatment with Lactobacillus may be able to prime 
the immune system by increasing the numbers of haemocytes in the haemolymph, thus when 
the larvae are challenged with C. albicans the infection can be rapidly addressed, however 
this was not investigated in these studies. Additionally, physical interactions between 
Brachyspira and Lactobacillus could have resulted in the protective effect observed in the 
larvae, as observed the co-culture experiments in Chapter 6 and in tissue culture experiments 
conducted by Mappley et al. (2011). Finally, studies presented earlier in Chapter 6 
demonstrated that the Lactobacillus isolates used in these studies were able to produce 
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antimicrobial compounds that were shown to inhibit Brachyspira species, therefore these 
may be contributing to the protective effect following Brachyspira infection.  
Interestingly, L. reuteri SAP 2115, which was the most successful inhibitor of Brachyspira in 
the in vitro experiments presented in Chapter 6 did not demonstrate any significant 
protection of G. mellonella larvae in this model. Suggesting that multiple mechanisms 
interplay in the protective effects of probiotics and that not all probiotics elicit effects by the 
same mechanisms. Throughout the studies presented in Chapter 6, B. pilosicoli SAP 859 was 
one of the most tolerant isolates to probiotic intervention and the same trends in data were 
seen in these studies whereby probiotic intervention did not protect the larvae from infection 
with B. pilosicoli SAP 859.  
Notably, this model was utilised to characterise the G. mellonella response to Brachyspira 
with the intention of optimising this alternative in vivo model which could be used to 
potentially explore isolate virulence and probiotic protection in the context of a functional 
immune system. It would be important to validate these results in a more realistic in vivo 
chicken model, however the G. mellonella model provided useful preliminary data. 
Further studies with a larger number of probiotics and a larger number of Brachyspira isolates 
are needed to validate the G. mellonella model to conclude if Lactobacillus probiotics would 
be a suitable intervention in this model, however these experiments have made progress 
towards this aim. It is important to note that the reproducibility of results between batches 
of G. mellonella purchased from live food stores can be poor, which may have accounted for 
the variability in results between biological replicates. To overcome this, future studies would 
be conducted with TruLarvÔ as these G. mellonella larvae are standardised by age and weight 
and come from a breeding colony devoid of hormone or antimicrobials, thus improving the 
reproducibility of experiments.  
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In summary, this chapter described the investigation of innate immune response to 
Brachyspira and Lactobacillus using two models of infection and demonstrated that pre-
infection with Lactobacillus was able to significantly alter the immune responses to 
Brachyspira species. Probiotic bacteria have been well documented to be involved in many 
immunomodulatory processes, involving many pathways to control pro-inflammatory 
immune responses. Further studies are required to determine the exact mechanisms of 
protection elicited in these experiments.  However, significant progress has been made in 
understanding the innate immune response to Brachyspira infection and how Lactobacillus 
probiotics may be able to mitigate disease. 
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Chapter 8: Final discussion and future perspectives  
 
8.1 Summary of results, limitations and discussion 
 
Brachyspira species pose a significant economic burden in the UK and globally and yet remain 
poorly understood. Therefore, this study aimed to gain greater understanding of those 
Brachyspira species associated with economic impacts in the poultry industry and to 
investigate mitigation strategies to ease this burden and improve poultry health and welfare. 
The studies presented here aimed to characterise and thereby improve the understanding of 
Brachyspira species implicated in avian intestinal spirochaetosis, with the genome studies 
presenting the largest number of Brachyspira whole genome sequences to date, to highlight 
the genetic variance between species in the genus. They also aimed to investigate probiotic 
interventions and their mechanisms of action. It was shown that probiotics have the potential 
to mitigate Brachyspira infection by several mechanisms including acid production, the 
activity of bacteriocins and other inhibitory metabolites independent of pH and co-
aggregation of Brachyspira. Furthermore, the data generated in this study were the first 
reports on the immune interactions of Brachyspira with HD11 cells in a tissue culture model 
and the development of a Galleria mellonella model to investigate Brachyspira infection and 
potential probiotic interventions.  
 
8.1.1 Phenotypic characterisation of Brachyspira 
 
Traditional phenotypic methods of identification were employed (Fellström and Gunnarsson, 
1995) but these were unable to identify many of the isolates tested possibly because the tests 
used were developed for Brachyspira isolates of porcine origin which have been shown and 
confirmed here to be phenotypically distinct from poultry isolates (Atyeo et al., 1999; 
Feberwee et al., 2008).  
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Current phenotypic methods proved ineffective when identifying Brachyspira species isolated 
from poultry in the studies presented here. Therefore, as a continuation of the work 
published by Mappley et al. (2012), Biolog technology was utilised with the aim of identifying 
metabolic capabilities unique to each species of Brachyspira that could be targeted for the 
differential diagnosis of species responsible for poultry disease. Thirty-nine carbon sources 
were utilised by all Brachyspira isolates, many of these associated with glycolysis and the 
pentose phosphate pathway; metabolic pathways previously mapped in genome studies 
(Bellgard et al., 2009; Wanchanthuek et al., 2010). Unfortunately, Biolog data analysis did not 
reveal any unique metabolic targets that could distinguish Brachyspira species which is likely 
to be a result of the small number of isolates tested and the metabolic diversity observed 
within different species. A greater understanding of the metabolic pathways and this diversity 
could be achieved by investigating more isolates of each species, in addition to combining 
these data with the genotypic data available for each isolate. B. pilosicoli isolates were 
capable of respiring on sixty-six carbon sources on the PM1 and PM2 Biolog plates, whereas 
the other species were capable respiring on between fifty-seven and fifty-nine carbon 
sources. This may be related to the larger host range of B. pilosicoli, whereby utilising more 
carbon sources may provide adaptability for different ecological niches.  
Interestingly, the pangenome analysis of B. pilosicoli demonstrated the genotypic diversity 
within this species, with 53% of the pangenome consisting of accessory genes and only 47% 
consisting of core genes. This is not characteristic of Brachyspira species because the B. 
hyodysenteriae core consisted of 70% of the genes. These findings highlight the plasticity of 
the B. pilosicoli genome, which reflects the metabolic diversity observed in phenotypic 
studies. Further work could identify the metabolic genes within the accessory genome to 
potentially explain the phenotypic differences observed between isolates of B. pilosicoli to 
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confirm this hypothesis. Also, there is a need to understand what metabolic genes are present 
and active or present but redundant through accumulation of mutations. Similarly, if present 
but inactive, would certain environments select revertants as this too contributes to dynamic 
plasticity of the phenotype and as yet nothing is known of this. Phenotypic analysis clearly 
has limitations and requires a more detailed genotypic approach to support them and answer 
some of the questions arising. 
 
8.1.2 Genotypic characterisation of Brachyspira 
 
Whole genome sequencing has proved to be a  very useful tool, not only for the identification 
of Brachyspira (discussed in Chapter 3), but also for  improving the understanding of the genus 
(Bellgard et al., 2009; Pati et al., 2010; Wanchanthuek et al., 2010; Mappley et al., 2012). The 
studies presented here have contributed fifteen novel B. pilosicoli genomes to the five 
available on Genbank, making the comparative genomics more robust than previous studies 
(Wanchanthuek et al., 2010; Mappley et al., 2012). In order to make more accurate 
comparisons additional genome sequences from B. alvinipulli, B. innocens and B. intermedia 
are required. Comparison of all available genome sequences (Chapter 4) revealed that B. 
pilosicoli isolates were distinct from other species of Brachyspira and also that this species 
had a larger accessory genome (53% of the genes) compared to other species such as B. 
hyodysenteriae (30% of the genes). This may account for B. pilosicoli being the only species 
that is capable of infecting human, porcine and avian species (Trott et al., 1996), in addition 
to being able to form end-on attachments to the intestinal epithelium (Trampel et al., 1994; 
Muniappa et al., 1996). B. aalborgi is the only other species capable of this, however no 
genome sequences are available for this species and thus this interaction cannot be further 
investigated (Mappley et al., 2014). Novel comparisons between B. pilosicoli, B. 
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hyodysenteriae and the “Other” Brachyspira species, including B. alvinipulli, B. intermedia, B. 
innocens, B. hampsonii, B. murdochii and B. suanatina suggested that B. hyodysenteriae and 
the “Other” species of Brachyspira shared more genes with one another (1329 genes) than 
with B. pilosicoli which shared 210 genes with the “Other” species and only thirty-five genes 
with B. hyodysenteriae. This was the first pangenome analysis highlighting the differences 
between the species, as previous studies have only used one isolate from each species, which 
is not representative of the intra-species diversity (Wanchanthuek et al., 2010).  
 
8.1.3 Lactobacillus as a probiotic intervention against Brachyspira 
 
Four Lactobacillus isolates (Chapter 5) were selected for further investigation primarily due 
to their ability to inhibit multiple Brachyspira species, in addition to their suitability as 
commercial products as described in the EFSA guidelines (EFSA et al., 2017). L. reuteri isolates 
are likely to be suitable probiotic candidates for commercialisation, as also suggested by 
Mappley et al. (2011; 2013), because of their greater inhibition of Brachyspira, the absence 
of antimicrobial resistance genes and tolerance to bile salts and acid, in addition to showing 
the greatest immunomodulatory potential in the HD11 avian macrophage assays. L. salivarius 
isolates were used in these studies as a comparison between hetero- and homofermentative 
Lactobacillus but were shown to be less inhibitory than L. reuteri. Recently, in vitro studies 
have investigated the effects of probiotics as intervention strategies for Brachyspira infection 
for both porcine and avian species of Brachyspira. Inhibition has been proposed to be as a 
result of several mechanisms, including acid production (primarily attributed to lactic acid), 
hydrogen peroxide production and production of other antimicrobial compounds such as 
bacteriocins (Bernardeau et al., 2009; Klose et al., 2009, 2010; Mappley et al., 2011). 
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The inhibitory ability of organic acids produced by lactic acid bacteria such as Lactobacillus  is 
well established (Collins et al., 2009).  The studies presented here suggested that acid 
production by the Lactobacillus isolates contributed significantly to the inhibition of 
Brachyspira. Lactobacillus cell free supernatant and MRS media were significantly more 
inhibitory at pH 3.8 compared to pH 7.2; this was observed for all Brachyspira isolates except 
for B. pilosicoli SAP 865, which appeared to be acid tolerant, therefore making it unsuitable 
for probiotic intervention. If time permitted an analysis of acid tolerance response genes in 
this isolate would have been of interest in investigating this unusual phenotype. Additional 
studies could utilise SEM to identify spherical bodies or evidence of cell membrane disruption 
to confirm the acid stress responses previously identified in Brachyspira isolates (Bernardeau 
et al., 2009). Furthermore, NMR analysis showed that the most inhibitory Lactobacillus 
isolates produced the highest concentrations of organic acids, subsequently consuming the 
highest concentrations of glucose. Lactobacillus isolates that consume more glucose may be 
more inhibitory against Brachyspira in vivo as there would be greater competition for this 
essential nutrient.  
The production of antimicrobial peptides was also investigated in these studies using 
techniques to denature proteins present in the Lactobacillus cell free supernatant. These 
studies suggested that L. reuteri isolates produced heat stable bacteriocins as trypsin 
treatment of the cell free supernatant significantly reduced the inhibition of a number of 
Brachyspira isolates. L. salivarius SAP 2117 produced heat labile bacteriocins as heat 
treatment of the cell free supernatant reduced the inhibition of Brachyspira isolates. 
Bacteriocin activity was generally greater at pH 3.8, supporting the hypothesis that acid may 
permeabilise the cell membrane and enhance the activity of bacteriocins (Cotter et al., 2005). 
Conversely, the peptides produced by L. salivarius SAP 2117 were more effective at pH 7.2, 
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suggesting that bacteriocins can inhibit Gram negative bacteria independent of pH. Future 
work would aim to identify these proteins and characterise their efficacy against Brachyspira 
in more detail. Physical interactions between Brachyspira and potential Lactobacillus 
probiotics have shown that co-aggregation is an important mechanism of inhibition, both in 
simple in vitro assays (Bernardeau et al., 2009) and in tissue culture models (Mappley et al., 
2011). This co-aggregation impairs the pathogen’s motility, as previously discussed, motility 
is regarded as a key virulence factor of Brachyspira and is vital for its survival and colonisation 
in the large intestine. The L. reuteri isolates selected for these studies showed the ability to 
impair Brachyspira viability following co-culture with viable and heat inactivated cells 
suggesting that this effect was not as a result of competition for nutrients or production of 
antimicrobial compounds and was likely to be as a result of the passive coaggregation of 
Brachyspira and Lactobacillus as previously demonstrated (Bernardeau et al., 2009). Some B. 
pilosicoli isolates were tolerant of this mechanism of inhibition, for example B. pilosicoli SAP 
859 was unaffected by co-culture with Lactobacillus isolates, suggesting that this mechanism 
is not universally applicable to all Brachyspira. L. salivarius isolates were not effective in these 
studies, demonstrating that the ability to co-aggregate with Brachyspira is isolate specific. The 
results from this study are limited as the culture conditions do not represent those of the 
gastrointestinal tract, however these preliminary results could be confirmed using an in vitro 
intestinal cell line which may be a closer representation of the bacterial interactions at the 
epithelium.  In addition to the mechanisms mentioned above, Lactobacillus species are robust 
and grow rapidly, compared to the slow growing, fastidious nature of Brachyspira species. 
This therefore makes Lactobacillus probiotics ideal candidates to mitigate Brachyspira as they 
have the potential to outcompete Brachyspira in the large intestine (Mappley et al., 2013).  
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The HD11 avian macrophage cell line has been used to explore the innate immune response 
to a number of avian pathogens including, Salmonella species and Campylobacter jejuni in 
order to explore host-pathogen interactions (Kaiser et al., 2000; Smith et al., 2005). 
Therefore, the initial aim of the studies presented here was to develop a novel tissue culture 
model using HD11 cells to investigate the in vitro macrophage response to Brachyspira and 
Lactobacillus species. Subsequently, the immunomodulatory properties of the Lactobacillus 
isolates were investigated by pre-treating the cells with the probiotic candidates prior to 
infection with Brachyspira. Brachyspira species demonstrated the ability to induce both pro- 
and anti-inflammatory cytokine responses in the HD11 cells with the greatest level of 
expression observed in IFNg. IL1b and IL10 expression were also significantly upregulated 
compared to the control, however no significant differences were observed in IL6 or IL8 
expression. A similar study to investigate the macrophage response to C. jejuni demonstrated 
the induction of pro-inflammatory cytokines such as IL1b, IL6 and IL8 from these cells, 
however IFNg and IL10 responses were not significantly different from the control infection 
(Smith et al., 2005).  L. reuteri SAP 2115 significantly upregulated IL1b and IL10, with the 
upregulation of IL10 potentially contributing to the control of the pro-inflammatory immune 
response. L. salivarius SAP 2117 did not induce significant changes in cytokine expression 
compared to the control, suggesting that this isolate may not be as effective at modulating 
the immune response as L. reuteri SAP 2115. 
Studies where cells were pre-treated with Lactobacillus prior to infection with Brachyspira 
suggested that these potential probiotics could not only directly inhibit Brachyspira, as 
demonstrated in Chapters 5 and 6, but could also modulate the innate immune response 
following infection with this pathogen. As previously mentioned, Brachyspira species induced 
the expression of several pro-inflammatory cytokines from the HD11 macrophages, with the 
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most marked effect on the expression of IFNg. This cytokine is important in both the innate 
and adaptive immune responses. It is an important activator of macrophages and also a 
potent activator of Class II major histocompatibility complex (MHC) expression on an antigen 
presenting cell which presents antigens to T cells (Holling et al., 2004). When HD11 cells were 
pre-treated with Lactobacillus isolates before challenge with Brachyspira, the IFNg response 
from the HD11 cells was significantly reduced. Thus, demonstrating the ability of Lactobacillus 
to modulate the immune response and reduce the pro-inflammatory cytokine expression. 
This modulation is hypothesised to be via the JAK/STAT pathway which mediates IFNg 
signalling, which is known to be inhibited by some isolates of Lactobacillus (Lee et al., 2010; 
Llewellyn and Foey, 2017). Lactobacillus isolates, including L. acidophilus and L. plantarum 
activate STAT1 and STAT3 and inactivate JAK2 inhibiting the production of pro-inflammatory 
cytokines via the JAK/STAT pathway. This has been proposed to be a key anti-inflammatory 
mechanism of probiotics which may prove useful in the mitigation of H. pylori infection, 
although in vivo experiments are required to test this hypothesis (Lee et al., 2010). Further 
investigation of inflammatory markers in an experimental chicken model may help to quantify 
the protective response against Brachyspira in vivo. The study by Mappley et al. (2013) 
showed reduced inflammation in birds treated with the probiotic, although this was 
attributed to reduced Brachyspira numbers as immune responses were not considered in this 
study.  
The Galleria mellonella model has been used increasingly to assess the virulence of pathogens 
including Campylobacter and E. coli, and has been used to identify a number of virulence 
determinants in pathogens such as C. jejuni (Champion et al., 2010; Senior et al., 2011; 
Alghoribi et al., 2014; Mehat et al., 2018). Therefore, the aim of this study was to determine 
if this model would be suitable for the study of Brachyspira and possible probiotic 
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interventions. Recent studies have suggested that the pre-treatment of G. mellonella larvae 
with probiotics can modulate the immune system by increasing the numbers of circulating 
haemocytes and protecting the larvae from mortality associated with pathogen infection (de 
Oliveira et al., 2017; Ribeiro et al., 2017; Rossoni et al., 2017). The study presented here 
demonstrated that protection by Lactobacillus species was not only dependent on the isolate 
of Lactobacillus, but also by the isolate of Brachyspira the larvae were infected with. For 
example, L. salivarius SAP 2117 had a significant protective effect against B. intermedia SAP 
919 and B. innocens SAP 924 but not against the other Brachyspira isolates. Interestingly, the 
L. reuteri isolates were the most inhibitory against Brachyspira isolates in the in vitro 
experiments however, in the G. mellonella model, they showed little or no protection. 
Conversely, L. salivarius isolates were the least inhibitory against Brachyspira isolates in vitro 
but were able to protect larvae. The associated immune responses require further 
investigation and these findings emphasise the need for a more representative model of 
infection. That said, this model provides a number of advantages over mammalian and avian 
models; there are few ethical considerations, the model is easily manipulated and inexpensive 
and the larvae are capable of a cellular immune response comparable to that of mammalian 
neutrophils and avian heterophils (Montali, 1988; Brooks et al., 1996). However, there are a 
number of considerations and limitations with this model, primarily it is not representative of 
mammalian or avian infection as it does not resemble to route of infection or provide the 
optimal ecological niche for Brachyspira. This was not the intention for this model as the aim 
was to explore its suitability as a model for Brachyspira infection in the context of a functional 
immune system and to investigate the protective effects of potential probiotics. Results from 
this model did, however, raise some questions regarding Brachyspira infection in chickens 
which would require further investigation. For example, Brachyspira were located in the 
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muscle tissue of the G. mellonella larvae, therefore it would be important to determine if this 
occurs in chickens. Interestingly, there have been reports of chicken carcass contamination 
with Brachyspira (Verlinden et al., 2012), however this could also be as a result of faecal 
contamination. 
Additionally, this model requires further validation through testing an increased number of 
Brachyspira isolates from all known species. Unfortunately, this was not possible in the 
studies reported here due to the limited number of Brachyspira isolates available in the SAP 
collection at Surrey University. The data produced demonstrated that no correlation between 
Brachyspira species and morbidity and mortality scores were observed, this may be as a result 
of the small numbers of isolates initially used in these studies. Alternatively, as revealed by 
the pangenome analysis of B. pilosicoli, the accessory genome for these species constitutes 
approximately 53% of its genes which therefore may result in the varied virulence observed 
in both the G. mellonella model and experimental infection models with B. pilosicoli, as 
previously discussed. 
Overall, this thesis has aimed to explore the potential for novel probiotics to mitigate avian 
intestinal spirochaetosis caused by Brachyspira species. This was achieved by characterising 
a panel of Brachyspira isolates and a panel of Lactobacillus isolates in order to explore the 
mechanisms by which probiotics may exert their effects. A number of mechanisms 
contributed to the inhibition of Brachyspira and it was evident that inhibition was 
multifaceted and depended on the isolate of Lactobacillus tested and the susceptibility of the 
Brachyspira isolate. On reflection, each of these assays were performed at 37°C, the optimal 
temperature for mammals, despite avian species having an internal temperature of 42°C. This 
was a limitation because antimicrobial metabolite production may differ at 42°C compared 
to 37°C. Therefore, future work would focus on optimising assays at the optimal avian 
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temperature. For the studies described here, 37°C was utilised as all previous protocols 
utilised this temperature for the growth of Brachyspira; this organism was difficult to grow 
during initial isolation and therefore, once this protocol was optimised at 37°C this was used 
throughout all assays presented here. Additionally, from a commercial perspective, 
antimicrobial metabolites such as bacteriocins could be produced and purified at 37°C in vitro 
and then added as feed supplements to poultry diets. Therefore, the use of 37°C for the 
growth of Lactobacillus in these studies may be advantageous.  
An alternative approach would be to consider testing a multi-species probiotic product. The 
four probiotics used throughout these studies have demonstrated a range of different 
inhibitory abilities, via a range of mechanisms. Therefore, suggesting that a mixed species 
probiotic may be a more suitable mitigation strategy because several mechanisms of action 
would be involved in Brachyspira inhibition. These isolates also demonstrated inhibition 
against E. coli and Salmonella isolates and thus it would be important to consider these 
Lactobacillus isolates for several pathogens infecting poultry, however in vivo confirmation of 
these findings is essential. 
 
8.2 Conclusion 
 
In conclusion, the studies presented here have demonstrated that novel Lactobacillus 
candidates were suitable as potential probiotic intervention strategies against Brachyspira 
species implicated in poultry disease. Lactobacillus isolates used in the studies showed the 
ability to exert their inhibitory effects via several different mechanisms: (i) the production of 
organic acids such as lactic acid (ii) the production of inhibitory metabolites, independent of 
pH (iii) the secretion of bacteriocins and bacteriolysins (iv) the physical interactions with 
Brachyspira to impair motility and (v) modulation of the immune response to Brachyspira 
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infection. It is important to note that there was not one probiotic candidate that was effective 
against all Brachyspira isolates or that inhibited Brachyspira via all of the mechanisms 
described. L. reuteri SAP 2115 was overall the most successful probiotic candidate. However, 
investigating a multispecies probiotic may be a more suitable approach for further studies. 
 
8.3 Future perspectives  
The results presented in this thesis provide the foundation for further investigation in a 
number of key areas:  
(1) Additional isolates from each of the species implicated in avian intestinal 
spirochaetosis require whole genome sequencing in order to conduct more in-depth 
comparative genomics. The studies presented here added fifteen novel B. pilosicoli 
genomes to the analysis which allowed direct comparisons with the twenty-five 
available B. hyodysenteriae genomes. Additionally, these studies contributed one B. 
intermedia genome and three B. innocens genomes for comparative analysis.  
However, this was not sufficient to compare these individual species, thus they were 
grouped which limited the comparisons that could be made. Furthermore, an 
increased number of genome sequences for non-pathogenic Brachyspira would allow 
for comparisons between pathogenic and non-pathogenic species which be an 
important advancement in the knowledge of this genus.  
(2) Lactobacillus cell free supernatants require further interrogation in order to purify and 
identify inhibitory proteins. Screening whole genome sequences for putative 
bacteriocin genes identified several that may be inhibitory against Brachyspira 
species. Additionally, trypsin and heat treatment of cell free supernatants from certain 
Lactobacillus isolates decreased the inhibition of Brachyspira. Therefore, protein 
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precipitation and fractionation could be used to isolate the proteins present in the cell 
free supernatant and these could be tested against Brachyspira to determine 
inhibition. 
(3) The G. mellonella infection model needs further validation with an increased number 
of Brachyspira isolates from all species. Additionally, the mechanism of probiotic 
protection in this model requires further characterisation. For example, haemocyte 
counts would be conducted to support the theory that immunomodulation by 
Lactobacillus contributes to the protection against Brachyspira. Histopathology of 
infection with Lactobacillus alone and in combination with Brachyspira needs to be 
analysed and compared with that of Brachyspira infection alone. It would also be 
important to determine the location of Lactobacillus and whether they co-aggregate 
with Brachyspira in this model.  
(4) The findings of this thesis should be validated in an in vivo chicken model and in 
particular the results from the in vitro HD11 tissue culture and the in vivo Galleria 
mellonella model. An experimental chicken model such as that published by Mappley 
et al., 2013 would validate if the probiotic candidates characterised in these studies 
would have a protective effect in the desired host.  
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Carbon Source PM1
Neg control 0 0 0 0 0 0 0 0
L- Arabinose 0.62193333 0.82995 0.7591 0.84463333 0.87433333 0.85176667 0.81513333 0.78701111
N-Acetyl-D-glucosamine 0.21293333 0.26695 0.2896 0.1017 0.16463333 0.03083333 0.04026667 0.01155556
D- Saccharic Acid -0.0079333 -0.0015 -0.01025 0.00653333 -0.0074 0.00986667 0.00393333 0.00081111
Succinic Acid -0.0082667 0.00165 -0.01055 0.00446667 -0.0017 0.007 0.00406667 0.00195556
D- Galactose 0.39813333 0.6524 0.7053 0.58403333 0.56306667 0.76503333 0.63486667 0.64202222
L- Aspartic Acid -0.0069333 0.0014 -0.0007 0.0017 -0.0054667 0.0013 0.00323333 0.00084444
L- Proline 0.0028 0.00085 -0.0121 -0.0014667 -0.0067 0.00106667 0.0061 0.00293333
D- Alanine 0.01406667 -0.00345 -0.01495 0.00066667 -0.0053667 0.00063333 0.00323333 -0.0006889
D- Trehalose -0.0007333 0.0062 -0.0018 0.1047 0.1542 0.00113333 0.0056 0.0013
D- Mannose 0.42693333 0.7299 0.71855 0.5275 0.55223333 0.714 0.70043333 0.65344444
Dulcitol 0.06306667 0.0018 -0.0144 0.03376667 -0.0067 -0.0101667 0.00276667 0.00252222
D-Serine -0.0026333 -0.00485 0.03305 -0.0023667 -0.0069 0.0034 0.0059 -0.0007667
D- Sorbitol -0.0065 -0.00225 -0.0106 -0.0059333 0.09283333 -0.0020667 0.0051 -0.0007667
Glycerol 0.15256667 -0.0016 -0.0045 -0.003 -0.0047667 0.00773333 0.00873333 0.00504444
L- Fuctose 0.30753333 0.31715 0.47415 0.3664 0.5218 0.6088 0.56013333 0.48344444
D- Glucuromic Acid 0.6736 0.4602 0.5852 0.5423 0.5992 0.70936667 0.65496667 0.61788889
D- Gluconic Acid -0.0028 -0.00285 -0.01505 0.00393333 -0.0048333 0.00176667 0.00253333 0.00051111
D,L-a-Glycerol-Phosphate 0.03996667 0.05725 0.03115 0.22826667 0.16673333 0.17133333 0.44226667 0.14792222
D-Xylose 0.64953333 0.8524 0.7652 0.8409 0.87376667 0.84483333 0.85766667 0.80648889
L- Lactic Acid 0.24823333 -0.0016 0.0031 -0.0016 -0.0054667 0.00243333 0.00563333 0.00254444
Formic Acid -0.0031 0.01665 0.00435 0.0036 -0.0056 0.00773333 0.0061 0.00023333
D-Mannitol 0.06586667 0.00635 -0.0137 0.00146667 0.0267 -0.0022667 0.00466667 -4.444E-05
D- Gluamic Acid 0.2025 -0.00645 -0.00385 -0.0005333 0.00056667 -0.0079 0.00716667 0.00682222
D- Glucose-6-Phosphate 0.28086667 0.5174 0.5017 0.38796667 0.4464 0.52036667 0.448 0.408
D- Galactonic Acid-y-Lactone 0.1142 0.0891 0.0955 0.1384 0.09633333 0.1454 0.15516667 0.15025556
D, L-Malic Acid 0.00086667 0.00115 -0.0002 0.00603333 -0.0008 0.00246667 0.00686667 0.00315556
D-Ribose 0.91806667 0.7422 0.5364 0.7208 0.8796 0.82143333 0.73836667 0.71392222
Tween 20 -0.0132333 -0.0319 -0.052 -0.0197667 -0.0323667 -0.0338667 -0.0191 -0.0187667
L- Rhamnose 0.54293333 0.7179 0.72445 0.7142 0.7495 0.82706667 0.77576667 0.75548889
D- Fructose 0.4549 0.5525 0.68415 0.52696667 0.62296667 0.75106667 0.7452 0.68256667
Acetic Acid 0.05576667 -0.004 -0.0066 0.00133333 -0.0033333 -0.0007 0.01076667 0.00272222
a-D-Glucose 0.27066667 0.55425 0.62435 0.2099 0.3766 0.60703333 0.38053333 0.32891111
Maltose 0.2271 0.00655 -0.00085 0.11563333 0.20893333 0.00906667 0.01176667 0.00388889
D- Melibiose 0.26146667 0.17535 0.44905 0.2289 0.34656667 0.46393333 0.28756667 0.22525556
Thymidine 0.24326667 0.001 -0.0087 -0.0036333 -0.0080333 -0.0138667 0.00513333 -0.0003889
L- Asparagine -0.0044667 -0.00395 -0.0065 0.00233333 -0.0039 -0.0016 0.00646667 0.00098889
D-Aspartic Acid -0.0040667 -0.0053 -0.00655 0.004 -0.0089667 0.01406667 0.0062 0.00113333
D- Glucosaminic Acid -0.0026 0.003 0.0029 0.0021 0.02803333 0.00286667 0.01563333 0.00661111
1,2- Propanediol 0.23913333 0.0002 -0.00015 0.00526667 -0.0032667 0.01476667 0.0107 0.00453333
Tween 40 -0.012 -0.02945 -0.0399 -0.0157333 -0.0289 -0.0264333 -0.0103 -0.0120667
a-Keto-Glutaric Acid 0.31523333 0.00285 0.00055 0.05616667 0.01986667 0.0184 0.01993333 0.01117778
a-Keto- Butyric Acid 0.26896667 0.0628 0.1174 0.29276667 0.09846667 0.08296667 0.0636 0.10096667
a-Methyl-D0 Galactoside 0.00076667 0.0094 0.01225 0.0057 0.01166667 0.0123 0.01586667 0.00575556
a-D-Lactose 0.26036667 0.3641 0.2673 0.19866667 0.1753 0.298 0.18163333 0.06094444
Lactoulose 0.1729 0.15665 0.29005 0.21716667 0.22456667 0.1279 0.30453333 0.12117778
Sucrose -0.0025333 0.00975 0.0129 0.01583333 0.01483333 -0.0015333 0.01353333 0.00334444
Uridine -0.0066667 0.0705 0.0049 -0.0024333 -0.0011333 -0.0135333 0.0155 0.00536667
L- Glutamine -0.0056 0.0026 0.0188 -0.0030667 -0.0058 0.00223333 0.00933333 0.00174444
m-Tartaric Acid -0.0036667 -0.00655 -0.0018 0.00563333 -0.0060333 -0.0009333 0.01203333 0.00251111
D-Glucose-1-Phosphate -0.0035667 0.0086 -0.0042 0.00803333 -0.0025667 0.01376667 0.01106667 0.00598889
D- Fructose-6-Phosphate 0.35986667 0.54165 0.644 0.59096667 0.5278 0.6575 0.65016667 0.58465556
Tween 80 0.26903333 -0.0269 -0.0387 -0.0191667 -0.0259667 -0.0247333 -0.0084667 -0.0111889
a-Hydroxy Glutatic Acid-y-
Lactone 0.00323333 -0.00065 -0.0084 0.01456667 -0.0029333 0.02163333 0.0166 0.00733333
a-Hydroxy Butyric Acid -0.0021333 -0.0042 -0.0105 0.00526667 -0.0061333 0.01466667 0.01486667 0.01105556
B-Methyl-D-Glucoside 0.00433333 -0.0002 -0.005 0.2196 0.0508 0.10096667 0.19953333 0.06631111
Adinitol -0.0009333 -0.00675 -0.0206 0.02263333 -0.0057667 0.00333333 0.01016667 0.00235556
Maltotriose 0.25926667 0.0176 0.0936 0.2402 0.21546667 0.06403333 0.0516 0.01736667
2- Deoxy Adenosine 0.0155 -0.00255 -0.01545 0.00013333 -0.0084333 -0.0006 0.00866667 -0.0003778
Adenosine 0.28293333 0.4727 0.02245 -0.0012333 -0.0028667 -0.0089 0.00766667 0.00145556
Glycyl-:-Aspartic Acid 0.00073333 -0.00025 0.0019 0.00096667 -0.0001333 0.00753333 0.0047 0.0024
Citric Acid -0.0095667 -0.006 0.00065 -0.0058333 -0.0036667 -0.0054 0.0039 -0.0012333
m-Inositol -0.0005667 -0.0024 -0.00295 0.0025 -0.0117333 -0.0007667 0.0072 0.00053333
D- Threonine -0.0019 -0.00935 -0.01165 0.00206667 -0.0088333 0.00806667 0.01053333 0.00231111
B. innocens 
SAP 943
B. alvinipulli 
ATCC 51933
B. pilosicoli 
B2904
B. pilosicoli 
SAP 859
B. pilosicoli 
SAP 865
B. 
intermedia 
SAP 919
B. innocens 
SAP 924
B. innocens 
SAP 927
Table 9. 1 48-hour end point utilisation of carbon sources of PM1 and PM2 plates for 8 isolates of 
Brachyspira using the Biolog Phenotypic MicroarrayTM (PM) technology. The extent of respiration 
is colour-coded whereby dark purple indicates high levels of respiration on a carbon source, purple 
indicates moderate levels of respiration on a carbon source, pale purple indicates low levels of 
respiration on a carbon source and white indicates no respiration on a carbon source.  
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Fumaric Acid 0.05036667 5E-05 -0.0085 0.00543333 0.004 0.0052 0.01216667 0.00422222
Bromo Succinic Acid 0.00313333 0.0018 0.00635 0.02113333 0.00983333 0.0109 0.00706667 0.00565556
Propionic Acid 0.00096667 -0.00125 -0.0095 0.00716667 0.0018 0.00583333 0.0057 0.0029
Mucic Acid 0.00106667 -0.0026 -0.00915 0.00883333 -0.0112667 0.0089 0.00843333 0.00217778
Glycolic Acid 0.14993333 -0.0064 -0.01485 0.007 -0.0047333 0.00546667 0.0151 0.00623333
Glyoxylic Acid 0.1644 0.15045 0.16565 0.27713333 0.13423333 0.2155 0.29016667 0.16792222
D- Cellobiose 0.25966667 0.0691 0.11065 0.246 0.2112 0.13523333 0.044 0.017
Inosine -0.0039333 0.17085 -0.0067 -0.0005 -0.0084667 -0.0051667 0.0029 -0.0021
Glycyl- Glutamic Acid -0.0040667 0.005 0.0176 0.00043333 -0.0021333 0.0057 0.00456667 0.00122222
Tricarballylic Acid -0.0062333 -0.00425 -0.00915 -0.0031333 -0.0107667 0.00213333 0.00266667 0.00545556
L- Serine -0.0076667 -0.0083 -0.01775 0.00356667 -0.0098667 -0.0026333 0.00646667 -0.0004444
L- Threonine -0.0041333 -0.0063 -0.0172 -0.0041 -0.0078333 -0.0031 0.01116667 0.00292222
L- Alanine 0.01233333 -0.0037 -0.0137 0.21716667 -0.0087333 -0.0001333 0.00853333 0.00251111
L- Alanyl-Glycine 0.00046667 -0.0059 -0.0052 0.00633333 -0.0052333 0.01093333 0.00983333 0.01077778
Acetoacetic Acid 0.01206667 0.0814 0.0954 0.02123333 0.0402 0.0601 0.07353333 0.05667778
N- Acetyl-B-D-Mannosamine 0.22203333 0.0035 0.01575 0.0855 0.2155 0.01336667 0.00523333 0.00367778
Mono Methly Succinate -0.0008333 0.0037 -0.00935 0.00426667 -0.0043667 0.00166667 0.01186667 0.00348889
Methyl Pyruvate 0.2178 0.01305 -0.01225 0.15456667 0.04513333 0.28286667 0.23843333 0.08361111
D- Malic Acid -0.0055667 -0.00085 -0.0102 -0.0034333 -0.0076 0.0099 0.00613333 0.00221111
L- Malic Acid -0.0092333 5E-05 -0.00695 -0.0039 -0.0090333 -0.0126333 0.00363333 -0.0001556
Glycy- L -Proline -0.0076667 0.0369 0.05475 -0.0012667 0.01243333 -0.0021667 0.0014 -0.0024667
p-Hydroxy Phenyl Acetic Acid -0.003 0.0024 -0.0027 0.00093333 -0.0048 0.00126667 0.0084 0.0044
m-HydroyPhenyl Acetic Acid -0.0014 0.004 0.00445 0.00366667 -0.0030333 -0.0015667 0.00873333 0.00281111
Tyramine -0.0013 0.0031 0.034 0.01573333 0.00023333 0.01193333 0.0156 0.0115
D- Psicose 0.48013333 0.7883 0.7716 0.63973333 0.73103333 0.736 0.67186667 0.74225556
L- Lyxose 0.5868 0.5363 0.41325 0.6683 0.71096667 0.70013333 0.70043333 0.59871111
Glucuronamide 0.5134 0.72975 0.71145 0.72486667 0.7136 0.80546667 0.74646667 0.74148889
Pyruvic Acid 0.23033333 0.31985 0.5735 0.3541 0.09853333 0.43433333 0.2908 0.16366667
L- Galactonic Acid-y- Lactone 0.50976667 0.70305 0.6555 0.42653333 0.50753333 0.6194 0.47196667 0.48778889
D- Galacturonic Acid 0.2938 0.36635 0.4825 0.37676667 0.4611 0.5745 0.43316667 0.43522222
Phenylethyl-amine 0.0141 0.007 -0.01255 0.01756667 -0.0008333 0.02046667 0.01163333 0.00787778
2- Aminoethanol -0.0026333 0.0383 0.10655 0.00923333 -0.0068667 0.00363333 0.00486667 0.00382222
Carbon Source PM2
Neg Control -0.0041 0.0142 -0.00435 0.00853333 0.0096 0.00676667 0.0077 0.0032
Chondrionitin Sulfate C 0.00263333 0.02 0.01485 0.02196667 0.007 0.01133333 0.01206667 0.00918889
a-Cyclodextrin -0.0072 0.0027 -0.02285 0.0031 0.18253333 0.25506667 0.0733 0.0259
B- Cyclodextrin -0.0015333 0.0171 -0.0157 -0.0003 0.05306667 0.00273333 0.00606667 0.00288889
y- Cyclodextrin 0.00236667 0.00285 -0.01825 0.00636667 0.02143333 0.0189 0.04193333 0.01591111
Dextrin 0.30306667 0.43515 0.40645 0.3095 0.3942 0.46803333 0.42976667 0.26792222
Gelatin 0.00123333 0.00385 0.0004 0.00826667 0.01163333 0.00836667 0.0084 0.00306667
Glycogen 0.00876667 0.0132 0.0041 0.02253333 0.01313333 0.01813333 0.02143333 0.01267778
Inulin 0.04693333 0.0279 0.02755 0.1428 0.03916667 0.03053333 0.04346667 0.02535556
Laminarin 0.08736667 0.1047 0.32065 0.07976667 0.20406667 0.23466667 0.15326667 0.05315556
Mannan 0.01496667 0.01105 0.00365 0.12606667 0.02893333 0.01563333 0.0159 0.00863333
Pectin 0.35686667 0.4377 0.47225 0.3449 0.35703333 0.47603333 0.41423333 0.25634444
N- Acetyl-D-Galactosamine -0.0046333 0.0053 -0.0107 0.00893333 0.0039 0.02116667 0.00213333 -8.889E-05
A-Acetly-Neuraminic Acid 0.00683333 0.19515 0.2532 0.01123333 0.01263333 0.00363333 0.00603333 0.00367778
B-D-Allose 0.63073333 0.48785 0.5351 0.63866667 0.65423333 0.69596667 0.66753333 0.59457778
Amygdalin 0.00106667 0.0045 0.0032 0.03453333 0.1926 0.03396667 0.0093 0.00603333
D-Arabinose 0.8803 0.84385 0.79765 0.86176667 0.88923333 1.02913333 0.85976667 0.82035556
D-Arabitol 0.0034 0.00355 -0.0091 0.0417 0.01206667 0.02086667 0.01546667 0.00872222
L- Arabitol 0.00036667 0.0003 -0.01435 0.02173333 -0.0028667 0.0105 0.00953333 0.00107778
Arbutin 0.08363333 0.0376 0.0472 0.0875 0.05786667 0.105 0.10263333 0.08107778
2- Deoxy-D- Ribose 0.80123333 0.7587 0.7222 0.79606667 0.8427 0.84046667 0.8148 0.7802
i- Erythritol 0.00293333 0.00105 -0.013 0.0297 0.00226667 0.08276667 0.01416667 0.00375556
D-Fucose 0.37696667 0.5291 0.5007 0.40983333 0.4026 0.56026667 0.48213333 0.33204444
3-0-B-D-Galacto-pyranosyl-D-
Arabinose 0.6311 0.796 0.72295 0.6082 0.62386667 0.70133333 0.66043333 0.60747778
Gentiobiose 0.36343333 0.4865 0.46205 0.30106667 0.31816667 0.4064 0.3678 0.22893333
L- Glucose 0.3257 0.186 0.23885 0.3114 0.37233333 0.4491 0.39766667 0.25565556
Lactitol 0.0025 0.06965 0.00815 0.01483333 0.14133333 0.1846 0.26833333 0.09067778
D- Melezitose 0.00886667 0.0012 -0.00735 0.01466667 0.01313333 0.0124 0.0137 0.00626667
Maltitol 0.00566667 0.00295 -0.0086 0.01113333 0.0088 0.0136 0.01396667 0.00658889
a-Methyl-D-Glucoside 0.0087 0.00765 0.0047 0.0173 0.00026667 0.03016667 0.01666667 0.00752222
B-Methyl-D-Galactoside 0.00396667 0.23815 0.11045 0.0195 0.19443333 0.27883333 0.1773 0.059
3- Methyl Glucose 0.4208 0.4201 0.4254 0.4329 0.42073333 0.55706667 0.4697 0.29973333
B-Methyl-D- Glucuronic Acid 0.00226667 -0.00125 -0.00535 0.0302 0.01323333 0.01313333 0.01653333 0.00611111
a-Methyl-D-Mannoside 0.00266667 0.00365 -0.0076 0.01143333 0.00213333 0.16126667 0.0173 0.00716667
B-Methyl-D-Xyloside -0.0009667 0.0042 -0.0034 0.02013333 0.00566667 0.19223333 0.055 0.01786667
B. alvinipulli 
ATCC 51933
B. pilosicoli 
B2904
B. pilosicoli 
SAP 859
B. pilosicoli 
SAP 865
B. 
intermedia 
SAP 919
B. innocens 
SAP 924
B. innocens 
SAP 927
B. innocens 
SAP 943
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Palatinose 0.75626667 0.77155 0.71565 0.73426667 0.65846667 0.81496667 0.7703 0.74213333
D-Raffinose -0.0050333 0.117 0.09545 0.03126667 0.00743333 0.01203333 0.00783333 0.00267778
Salicin 0.25246667 0.00705 -0.0055 0.1145 0.15983333 0.17026667 0.16533333 0.05741111
Sedoheptulosan 0.00246667 0.00095 -0.0101 0.01166667 0.0043 0.01056667 0.01166667 0.00712222
L-Sorbose 0.76043333 0.68695 0.7037 0.7581 0.70943333 0.80286667 0.7735 0.7392
Stachyose 0.00496667 0.00445 -1E-04 0.0128 0.01156667 0.0224 0.0411 0.0165
D- Tagatose 0.86543333 0.84605 0.8064 0.8676 0.74216667 0.9248 0.8821 0.8452
Turanose 0.44073333 0.3008 0.2935 0.34566667 0.3603 0.5037 0.4771 0.29326667
Xylitol 0.00273333 -0.00225 -0.00775 0.0145 -0.0016667 0.01673333 0.01913333 0.00567778
N-Acetyl-D-Glucosaminitol -0.0021333 0.00125 -0.0101 0.0099 -0.0001333 0.0101 0.0091 0.00376667
y-Amino Butyric Acid 0.002 -1E-04 -0.0074 0.01153333 -0.0038 0.0106 0.01463333 0.00447778
B- Amini Valeric Acid -0.0026 0.0021 -0.01755 0.00613333 -0.0031667 0.01036667 0.01346667 0.00588889
Butyric Acid 0.0259 0.6031 0.70845 -0.0001667 0.19776667 0.29856667 0.2465 0.08163333
Capric Acid -0.0043667 -0.01005 -0.03865 -0.0031 -0.0223 -0.0196 -0.0071333 -0.0065444
Caproic Acid -0.0057333 0.0023 -0.00305 0.00756667 -0.0052 0.0068 0.01006667 0.00548889
Citraconic Acid 0.00103333 -0.00255 -0.01165 0.01256667 0.00803333 0.008 0.011 0.00466667
Citramalic Acid 0.00096667 -0.0006 -0.0101 0.01256667 -0.0070333 0.01053333 0.0109 0.00366667
D- Glucosamine 0.8518 0.7957 0.74845 0.84303333 0.71573333 0.9299 0.87813333 0.82651111
2-Hydroxy Benzoic Acid 0.0002 0.00265 -0.0094 0.0157 0.01206667 0.0105 0.01543333 0.00584444
4- Hydroxy Benzoic Acid 0.00373333 0.0016 -0.00565 0.03906667 0.00816667 0.0193 0.01556667 0.00685556
B- Hydroxy Butyric Acid -0.0005 0.00045 -0.0076 0.0097 0.2322 0.0175 0.01466667 0.01235556
y-Hydroxy Butyric Acid 0.00126667 -0.00255 -0.0162 0.0125 0.00573333 0.00476667 0.00923333 0.00281111
a-Keto-Valeric Acid 0.0937 0.1323 0.1565 0.23876667 0.11613333 0.4229 0.1811 0.16003333
Itaconic Acid 0.03703333 0.0174 -0.0098 0.0451 0.01636667 0.01656667 0.0384 0.0334
5-Keto-D-Gluconic Acid 0.81756667 0.7784 0.6755 0.84176667 0.77786667 0.85766667 0.82013333 0.79877778
D-Lactic Acid Methly Ester 0.0097 0.0072 -0.0062 0.02083333 0.00776667 0.018 0.01453333 0.01297778
Malonic Acid -0.0088667 -0.0045 0.002 -0.0033333 -0.0088333 0.00256667 0.0042 -1E-04
Melibionic Acid 0.00806667 0.0071 0.0061 0.02063333 0.0274 0.0239 0.0232 0.02383333
Oxaclic Acid 0.003 -0.002 -0.0026 0.01063333 0.0057 0.01126667 0.0113 0.00566667
Oxalomalic Acid 0.24603333 0.1977 0.1991 0.38716667 0.19903333 0.4281 0.2243 0.19576667
Quinic Acid 0.00056667 0.00125 -0.0087 0.01583333 -0.0033667 0.0156 0.01176667 0.00342222
D-Ribono-1,4-Lactone 0.01203333 0.00175 -0.0147 0.02116667 -0.0023 0.00873333 0.01466667 0.00868889
Sebacic Acid 0.00216667 0.0054 -0.00595 0.02333333 0.0066 0.01566667 0.0115 0.0059
Sorbic Acid 0.59163333 0.4928 0.48155 0.6022 0.5044 0.6841 0.6091 0.55886667
Succinamic Acid 0.00086667 0.00595 -0.0129 0.0175 0.00146667 0.00266667 0.012 0.00523333
D-Tartaric Acid -0.0017 0.005 -0.02165 0.01516667 -0.0073 -0.0013 0.0051 0.00156667
L- Tartaric Acid -0.0031 0.00205 -0.00695 0.01073333 -0.0059333 0.00163333 0.00853333 -0.0008222
Acetamide -0.0004667 0.0039 -0.01455 0.00963333 0.00786667 0.0118 0.00756667 0.00188889
L-Alaninamide -0.0041667 0.00025 -0.0007 0.0046 -0.0042 0.00433333 0.00133333 0.00074444
N-Acetyl-L-Glutamic Acid -0.0043 0.0064 -0.00525 0.00416667 0.00323333 0.00803333 0.00633333 0.00414444
L- Arginine -0.0003667 0.0016 0.00335 0.00696667 -0.0133 0.00213333 0.01023333 0.00357778
Glycine -0.0013333 0.003 -0.0212 0.0164 0.0022 0.00366667 0.00616667 0.00248889
L- Histidine 0.0022 0.00475 -0.01575 0.08326667 0.00423333 0.00546667 0.01506667 0.00965556
L. Homoserine -0.0065667 0.0021 -0.01595 0.00953333 -0.0098667 0.00506667 0.01073333 0.00427778
Hydroxy-L-Proline -0.0047667 0.00515 -0.00845 0.01076667 -0.0076 0.00556667 0.0098 0.0049
L- Isoleucine 0.00193333 0.00785 -0.0138 0.0102 -0.0010667 0.00486667 0.0085 0.00343333
L- Leucine -0.0034667 0.0044 0.01595 0.00763333 -0.0015 0.0018 0.0079 0.0047
L- Lysine 0.02163333 0.01155 0.021 0.01876667 0.00293333 -0.0019333 0.0078 0.00166667
L- Methionine -0.0037667 0.00545 0.03705 0.01253333 -0.0090667 0.0018 0.0056 0.00366667
L- Ornithine 0.03326667 0.163 0.1895 0.07893333 0.02076667 0.00443333 0.00946667 0.00468889
L- Phenylalanine -0.0024333 0.0384 0.004 0.0269 0.0008 0.00863333 0.00506667 0.00135556
L- Pyroglutamic Acid -0.0022 0.0093 0 0.02183333 0.00413333 0.0052 0.00373333 0.00107778
L- Valine -0.0037 0.02355 0.0219 0.00803333 -0.0087333 0.00853333 0.00563333 0.00057778
D,L- Carnitine -0.0071333 0.00785 -0.0076 0.0012 -3.333E-05 0.00116667 0.00443333 0.00111111
Sec-Butylamine -0.0091333 -0.0157 -0.02295 -0.0062333 -0.0088667 -0.0068333 0.00046667 -0.0039778
D,L- Octopamine 0.04246667 0.1334 0.1954 0.13536667 0.0244 0.02706667 0.01746667 0.00678889
Putrescine 0.00536667 0.135 0.0985 0.10456667 0.03383333 0.1224 0.03383333 0.01534444
Dihydroxy Acetone 0.65043333 0.46055 0.418 0.63586667 0.6846 0.73386667 0.6569 0.53883333
2,3- Butanediol -0.0015333 0.0767 0.01685 0.0037 -0.0024 0.0017 0.0033 0.00186667
2,3- Butone 0.06543333 0.03505 0.02325 0.06123333 0.05346667 0.0431 0.04796667 0.03828889
3-Hydroxy-2- Butanone 0.00066667 0.03095 -0.01165 0.0101 0.0006 0.00563333 0.00303333 0.00101111
Total carbon sources utilised
59 66 57 57
30
Percentage of carbon 
sources utilised 31.0526316 34.73684211 30
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Table 9. 2 Genome assembly statistics for all Brachyspira whole genome sequences used in the 
comparative genomic studies and exclusion criteria for the five genomes removed from these studies. 
  
Assembly # contigs Largest contig Total length N50 L50 # N's per 100 kbp reason for exclusion excluded
Balvp001_ATCC51933 22 582949 3420763 342358 4 256.84
Bhamp002_30446 4 1924647 3037350 1924647 1 595.88 very large number of N inserted x
Bhamp003_30599 612 34622 2943158 7864 111 0.07 very low N50, poor quality genome sequencing x
Bhamp004_NSH-16 77 224477 3161271 88495 13 0
Bhamp005_NSH-24 178 103774 2969002 29547 29 0 low N50, poor quality genome sequencing x
Bhamp006_P280-1 16 953127 3186631 690165 2 0.25
Bhyod007_865 105 320136 3009507 111249 9 16.61
Bhyod008_ATCC27164 2 3041447 3074045 3041447 1 0
Bhyod009_B204 113 245629 3045413 86825 11 118.57 large number of N inserted
Bhyod010_B6933 90 215281 3056944 124108 9 124.05 large number of N inserted
Bhyod011_B78 94 419366 3056178 154115 7 14.4
Bhyod012_B8044 165 191659 3018724 71132 14 1.33
Bhyod013_BH718 2 2998332 3034648 2998332 1 0
Bhyod014_FM88-90 118 303456 2993625 170197 6 0.77
Bhyod015_FMV89-3323 111 367772 3167038 142819 6 11.05
Bhyod016_G21 85 325507 3113349 122169 8 17.34
Bhyod017_G44 135 237607 3002616 98426 11 18.98
Bhyod018_JR1 427 417478 3173932 99212 9 11.03
Bhyod019_JR2 474 266428 3193448 115365 10 38.64
Bhyod020_JR3 446 179915 3158623 60136 19 18.24
Bhyod021_NSW15 158 153661 3020963 71065 16 11.92
Bhyod022_NSW5 155 380148 3023934 75956 11 7.61
Bhyod023_NX 143 196673 3013691 78384 11 72.54 large number of N inserted
Bhyod024_Q17 129 249263 3019999 80615 13 15.23
Bhyod025_ST190 71 321703 3059185 155275 7 11.44
Bhyod026_ST195 94 390917 3082158 148037 7 15.57
Bhyod027_ST210 90 470364 3055385 151603 7 17.67
Bhyod028_ST265 209 342883 3108081 57007 14 1.29
Bhyod029_VIC2 79 239727 3023965 124009 9 17.53
Bhyod030_WA100 187 316037 3130163 77247 13 11.5
Bhyod031_WA1 2 3000694 3036634 3000694 1 0
Binno032_B3453 139 171035 3203920 51776 20 0
Binno033_B3650 95 379134 3150198 66364 13 0
Binno034_B3652 72 361958 3200075 102553 11 0
Binno035_ATCC29796 130 168341 3281611 52799 20 0
Bintm036_B3445 144 217871 3493658 80677 15 0
Bintm037_PWS-A 2 3304788 3308048 3304788 1 0
Bmurd038_B-11 32 889148 3144515 720165 2 0
Bmurd039_DSM12563 1 3241804 3241804 3241804 1 0
Bpilo040_B-04 6 2342853 2598894 2342853 1 0
Bpilo041_B-06 71 435730 2764670 185117 6 0
Bpilo042_B-14 30 680182 2435627 170846 4 0
Bpilo043_B2903 13 1226659 2756759 732242 2 0
Bpilo044_B2904 74 198373 2739777 84986 11 0 duplicate x
Bpilo045_B2905 10 1778376 2546415 1778376 1 0
Bpilo046_B2953 69 319509 2729767 120589 7 0
Bpilo047_B3078 13 637327 2542553 409203 3 0
Bpilo048_B3084 22 698261 2545332 637106 2 0
Bpilo049_B-31 8 1144602 2588278 522457 2 0
Bpilo050_B3420 54 290230 2696933 150269 6 0
Bpilo051_B3424 84 316261 2767941 101345 8 0
Bpilo052_B3451 16 933847 2639689 809962 2 0
Bpilo053_B3545 116 148079 2631575 50006 17 0
Bpilo054_B-37 5 1651971 2590466 1651971 1 0
Bpilo055_B-67 10 1112538 2549350 1037582 2 0
Bpilo056_95-1000 1 2586443 2586443 2586443 1 0
Bpilo057_B2904 1 2765477 2765477 2765477 1 0.54
Bpilo058_P43-6-78 1 2555556 2555556 2555556 1 0
Bpilo059_SP16 59 198665 2703361 106143 10 0.44
Bpilo060_WesB 1 2889522 2889522 2889522 1 1026.71 very large number of N inserted x
Bsuan061_BRSU_AN4859-03 34 2243936 3258009 2243936 1 0.55
 299 
Appendix III (Chapter 5) 
 
Species Isolate 
Name 
Predicted 
secondary 
metabolite gene 
clusters  
Protein Sequence BLAST sequence homology 
L. salivarius SAP 2103 Salivaricin MMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRG 
GMAGTVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
Multispecies bacteriocin 
(Lactobacillus) (100%) 
L. crispatus SAP 2105 None   
L. crispatus SAP 2106 None   
L. crispatus SAP 2107 None   
L. reuteri SAP 2108 None   
L. salivarius SAP 2113 Salivaricin MMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRG 
GMAGTVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
Multispecies bacteriocin 
(Lactobacillus) (100%) 
L. reuteri SAP 2114 None   
L. reuteri SAP 2115 None   
L. salivarius SAP 2116 Salivaricin MMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRG 
GMAGTVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
Multispecies bacteriocin 
(Lactobacillus) (100%) 
L. salivarius  SAP 2117 Salivaricin MMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGG Multispecies bacteriocin 
(Lactobacillus) (100%) 
Table 9. 3 Protein sequences and BLAST sequence homology for the putative bacteriocin genes identified by the Anti-SMASH bacteriocin 
mining pipeline. 
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MAGTVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH  
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Species Isolate Name Predicted 
bacteriocin gene 
clusters 
Protein Sequence BLAST sequence homology 
 
L. salivarius SAP 2103 Enterolysin A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteriocin Class IIc 
VYLVKIRNGDETTVIHGTKNNTLGDAKVSMTVSAASSFTFIIYPNNTGYF 
KLREWTTYIDVTQSGKYIFRGRVIAVNPKHNEDGTFYKEITCESAMAYLN 
DSILSWEKVDKKPADFFVELINEHNKQMGDASKQFKIAENSVTNNTNNL 
YCYVEDGISILEEMKTDLLQNEDLGGEISIDYRNDGNYISWTRDKKVKGQ 
QVIKLAKNLKTLSAKPDISKICSVLYPFGATKEVPVDQKNDEKTNEVSTPRI 
NISSVNNGKNYIEDPELIKAIGRVSNTKTWENIKEPKNLLAKAQEYLKTM 
RNYRIAYELDAVDLQPLGLAVDSFECGNYYHVINPVINVDEWLRLVGVTI 
DLNKPLESTLTVGDQVKRLVDYSMDNIQTERNLRRLAAEQQVLKHQNN 
MLIDENNQLKQTIIKLWNDILSKQESNDSSGSAWNWPFKPPATIRFDGA 
QLFGVNPGGEFRPNGFHDGLDFGSVNWPGSEVKAIHDGTVTLKGAMD 
GLGNYFVTNGDGFNIVYQEAFGSASDIRVNIGDHVKVGDVVGIRTTDHL 
HVGVTKHDFNAALGSAFSNNGTWLDPKKLIEDGLKNNMGTTQPVNGD 
WGPVIRNAATKMKVNISDNDVNRIKALIANESGGNQTVTQQVWDQN 
MAAGTPAQGLLQYVPSTFNAYAVDGHRNIKSGFDQLLAFFNNSTWSSD 
ISLHGWGPNGSKRFDKIPA 
MIIMMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAG 
TVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
M23 peptidase (Lactobacillus 
salivarius) (65%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multispecies bacteriocin (Lactobacillus) 
(100%) 
L. crispatus SAP 2105 Enterolysin A Class III 
 
 
 
 
 
 
 
 
 
 
 
 
VYLVKIRNGDETTVIHGTKNNTLGDAKVSMTVSAASSFTFIIYPNNTGYF 
KLREWTTYIDVTQSGKYIFRGRVIAVNPKHNEDGTFYKEITCESAMAYLN 
DSILSWEKVDKKPADFFVELINEHNKQMGDASKQFKIAENSVTNNTNNL 
YCYVEDGISILEEMKTDLLQNEDLGGEISIDYRNDGNYISWTRDKKVKGQ 
QVIKLAKNLKTLSAKPDISKICSVLYPFGATKEVPVDQKNDEKTNEVSTPRI 
NISSVNNGKNYIEDPELIKAIGRVSNTKTWENIKEPKNLLAKAQEYLKTM 
RNYRIAYELDAVDLQPLGLAVDSFECGNYYHVINPVINVDEWLRLVGVTI 
DLNKPLESTLTVGDQVKRLVDYSMDNIQTERNLRRLAAEQQVLKHQNN 
MLIDENNQLKQTIIKLWNDILSKQESNDSSGSAWNWPFKPPATIRFDGA 
QLFGVNPGGEFRPNGFHDGLDFGSVNWPGSEVKAIHDGTVTLKGAMD 
GLGNYFVTNGDGFNIVYQEAFGSASDIRVNIGDHVKVGDVVGIRTTDHL 
HVGVTKHDFNAALGSAFSNNGTWLDPKKLIEDGLKNNMGTTQPVNGD 
WGPVIRNAATKMKVNISDNDVNRIKALIANESGGNQTVTQQVWDQN 
M23 peptidase (Lactobacillus 
salivarius) (65%) 
 
 
 
 
 
 
 
 
 
Table 9. 4 Protein sequences and BLAST sequence homology for the putative bacteriocin genes identified by the Bagel 4 bacteriocin mining pipeline. 
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Bacteriocin Class IIc 
 
 
MAAGTPAQGLLQYVPSTFNAYAVDGHRNIKSGFDQLLAFFNNSTWSSD 
ISLHGWGPNGSKRFDKIPA 
MIIMMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAG 
TVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
 
 
Multispecies bacteriocin (Lactobacillus) 
(100%) 
 
L. crispatus SAP 2106 Enterolysin A Class III 
 
 
 
 
Helveticin J 
MKFRKLIISLLGTALLTSSVGLSTTTASADTLDDSQNTTEVQPKNLKWAYP 
FKANKKNGVRPMYNAQTFGITNYMRSTTPPSYFHDGWDFGFSEVGHS 
NVYAIHQGTVKKVAYGNGLGWFIWVISPDNYVEVYQEGFNKKKDIYVK 
TGQKIKLGQKIGKLTGSHLHLGVTQTNKDYINKYGFPCKNWNVNNGTW 
LNPIEVIKSNLKK 
MVKNITPELVYRLNGMHHVVAQVGAVIDNHIFALQLLHSAHDVLVYRK 
HEGLTKNVDYSEPHLVMTGFGHTQTWVPANDKDEYFVGAKPNSGNW 
TTQIARVKYPRLLPERYTSNTQLPRLSHLNRATDVPYDGHNHLHRVEASV 
SPNGKYFMIAAIWDDDSGHFALYDLNEVNQKLDENGTTNTPITDLHCLS 
AFHIDNFDHPSVAPSEEAPQMIDSVQGYAIDDDKNIYISNQLSPKIDHAT 
GEVTTWSRKIVKFPWGETNPENWQVAMIDGIDLPDRYSEVESIHVQAP 
DDIYLTVAYHQKYVKDGEFKLRTLENQIFHISDLG 
M23 peptidase (Lactobacillus crispatus) 
(99%) 
 
 
 
Bacteriocin (Lactobacillus crispatus) 
(96%) 
 
L. crispatus SAP 2107 Enterolysin A Class III 
 
 
 
Helveticin J 
MKFRKLIISLLGTALLTSSVGLSTTTASADTLDDSQNTTEVQPKNLKWAYP 
FKANKKNGVRPMYNAQTFGITNYMRSTTPPSYFHDGWDFGFSEVGHS 
NVYAIHQGTVKKVAYGNGLGWFIWVISPDNYVEVYQEGFNKKKDIYVK 
TGQKIKLGQKIGKLTGSHLHLGVTQTNKDYINKYGFPCKNWNVNNGTW 
LNPIEVIKSNLKK 
MVKNITPELVYRLNGMHHVVAQVGAVIDNHIFALQLLHSAHDVLVYRK 
HEGLTKNVDYSEPHLVMTGFGHTQTWVPANDKDEYFVGAKPNSGNW 
TTQIARVKYPRLLPERYTSNTQLPRLSHLNRATDVPYDGHNHLHRVEASV 
SPNGKYFMIAAIWDDDSGHFALYDLNEVNQKLDENGTTNTPITDLHCLS 
AFHIDNFDHPSVAPSEEAPQMIDSVQGYAIDDDKNIYISNQLSPKIDHAT 
GEVTTWSRKIVKFPWGETNPENWQVAMIDGIDLPDRYSEVESIHVQAP 
DDIYLTVAYHQKYVKDGEFKLRTLENQIFHISDLG 
M23 peptidase (Lactobacillus crispatus) 
(99%) 
 
 
 
Bacteriocin (Lactobacillus crispatus) 
(96%) 
L. reuteri SAP 2108 Enterolysin A Class III MEGKLIFKPSHLKSKVLSTLTVCGGALFLLSGNAAADDQTTDVQQPVTP 
QQTTNEQPNASTVDVQTPNTYNGVAVSPQASEATQNTENYNVVPTQ 
GNNQEVQHKEATQPQNPNNYGYLDSVSLSNNELQVSGWQATNQAED 
KPYHYVIAYDNTAKAELGRQQVKNVSRPDVAQAYPDATNADNSGFNST 
IKINTTNEDYTNHSISVISRYSDATNGEGNHVDYWYPAFTFDQGNYAWL 
DDMHTENDQLHVTGWNATNQASNKDYHYVILYNKTKGHELSRQLVDE 
KNSQRPDVQKVYQNVNNATKSGFNVTFDLSKLSFDASDQLQVISRYSD 
M23 peptidase (Lactobacillus reuteri) 
(99%) 
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AQNGEGNRVDFWFAPTSRENQGNLDSANFSNGQLVVNGWHANDASI 
IAPNHFLILFDRTANKQAASLSASQVNRPDVAKAFGAIQTAGKAGFTGT 
FNANVIIPGHEYSLVSRYSTSANGNGDQGHYVDYWFNGLEFNQARYSV 
DSFTQNDKGFHVTGWMASDFAVNRPNAYVILLNNGKEVTRSKVTLTD 
RSDVAAVYPSLYNSRKSGFSTDLIVNPASLTGELSMILRFTGSNDGNSNY 
TDQNTNKYATNAGSFDTVNVSGNQIKVAGWHASTQTAGKDYQFIIVLDR 
NGHELTRQAVNTKDITRNDVQKVYPWLTNSVKS 
GFDTTVSINDQINHKVVRLIHRYSNQANGEGSYVDYYSNPISVYSEFQNE 
NGTTFYYDSRTGAKKTGWVNINNNNYYFDPSTGAMFTGTHTVDGKSY 
DFGNNGVAVENDKWGWPFPNVGEGHFGGAQLFGVNPGGQFRRNGF 
HDGLDFGSIDHPGSEVHAIHGGKVTQIGYTAGLDWYVLVDTGEYLTVY 
QEAFSNKNNIQVQVGQQINTGDVIGRRDTAHVHIGVTRQHNFNIALAN 
SFNNNGTWLNPLDLIRNGSK 
L. salivarius SAP 2113 Enterolysin A Class III 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteriocin Class IIc 
MFQGKILVQGVNRAEKEPLNLFDPKSVQIQWKVNQTWSLQFTAYNDG 
SLAYQMLESEASIFLDNQEYIIKQVADDSSNGLDSIQVTATHVYFEVQKIR 
KYKDYVDPEDKDKQTDVKVLKDNTDSSKSDDSDNAKTDTSEKTEGNTTT 
KVTTKTTDETQQDNQNQVTYSIQDVLEHWLKDNKLGFTYEVIGSFEKKE 
LEELQDGTGADMLSKISDTWSNAIIYPDNRKIRVYSADKFNLNRGNRIDY 
LNNASEIKFSTDSTSLTNMAYCIGGKYSVETTTETTTTTTTTTTSGGWGW 
PFPSVGEGNFMQAQRFGNDGGYRQNGFHEGLDFGSVDHPGRDVHAI 
HGGKVTIKSYMGGLGNYVVISGGGYNVVYQEAFSSPNNIIVNVGDTVK 
VGDVIGYRDTSHLHVGVTKADFNVAVGKSFTNDGTWLDPLELIKNGPS 
DTDTETSSETNSNSNTQEYYYFAPFMYRDEESIKKYGEHPAEPIEDGRFK 
DKSAMIEYVKTKLQPEPSLSIDVTTTTDIKPIAGDVVHVMVKSQDISTNFT 
LTGFTWYPYSYPVDNPTSITLNSNVQNILDYQNSRQKQFNKAISELKSST 
NEAINNSNSFNEFGGNQQLKTWLNDFVGG 
MIIMMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAG 
TVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
M23 peptidase (Lactobacillus 
salivarius) (97%) 
 
 
 
 
 
 
 
 
 
Multispecies bacteriocin (Lactobacillus) 
(100%) 
 
L. reuteri SAP 2114 Enterolysin A Class III MEGKLIFKPSHLKSKVLSTLTVCGGALFLLSGNAAADDQTTDVQQPVTP 
QQTTNEQPNASTVDVQTPNTYNGVAVSPQASEATQNTENYNVVPTQ 
GNNQEVQHKEATQPQNPNNYGYLDSVSLSNNELQVSGWQATNQAED 
KPYHYVIAYDNTAKAELGRQQVKNVSRPDVAQAYPDATNADNSGFNST 
IKINTTNEDYTNHSISVISRYSDATNGEGNHVDYWYPAFTFDQGNYAWL 
DDMHTENDQLHVTGWNATNQASNKDYHYVILYNKTKGHELSRQLVDE 
KNSQRPDVQKVYQNVNNATKSGFNVTFDLSKLSFDASDQLQVISRYSD 
M23 peptidase (Lactobacillus reuteri) 
(99%) 
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AQNGEGNRVDFWFAPTSRENQGNLDSANFSNGQLVVNGWHANDASI 
IAPNHFLILFDRTANKQAASLSASQVNRPDVAKAFGAIQTAGKAGFTGT 
FNANVIIPGHEYSLVSRYSTSANGNGDQGHYVDYWFNGLEFNQARYSV 
DSFTQNDKGFHVTGWMASDFAVNRPNAYVILLNNGKEVTRSKVTLTD 
RSDVAAVYPSLYNSRKSGFSTDLIVNPASLTGELSMI 
LRFTGSNDGNSNYTDQNTNKYATNAGSFDTVNVSGNQIKVAGWHAST 
QTAGKDYQFIIVLDRNGHELTRQAVNTKDITRNDVQKVYPWLTNSVKS 
GFDTTVSINDQINHKVVRLIHRYSNQANGEGSYVDYYSNPISVYSEFQNE 
NGTTFYYDSRTGAKKTGWVNINNNNYYFDPSTGAMFTGTHTVDGKSY 
DFGNNGVAVENDKWGWPFPNVGEGHFGGAQLFGVNPGGQFRRNGF 
HDGLDFGSIDHPGSEVHAIHGGKVTQIGYTAGLDWYVLVDTGEYLTVY 
QEAFSNKNNIQVQVGQQINTGDVIGRRDTAHVHIGVTRQHNFNIALAN 
SFNNNGTWLNPLDLIRNGSK 
L. reuteri SAP 2115 Enterolysin A Class III MEGKLIFKPSHLKSKVLSTLTVCGGALFLLSGNAAADDQTTDVQQPVTP 
QQTTNEQPNASTVDVQTPNTYNGVAVSPQASEATQNTENYNVVPTQ 
GNNQEVQHKEATQPQNPNNYGYLDSVSLSNNELQVSGWQATNQAED 
KPYHYVIAYDNTAKAELGRQQVKNVSRPDVAQAYPDATNADNSGFNST 
IKINTTNEDYTNHSISVISRYSDATNGEGNHVDYWYPAFTFDQGNYAWL 
DDMHTENDQLHVTGWNATNQASNKDYHYVILYNKTKGHELSRQLVDE 
KNSQRPDVQKVYQNVNNATKSGFNVTFDLSKLSFDASDQLQVISRYSD 
AQNGEGNRVDFWFAPTSRENQGNLDSANFSNGQLVVNGWHANDASI 
IAPNHFLILFDRTANKQAASLSASQVNRPDVAKAFGAIQTAGKAGFTGT 
FNANVIIPGHEYSLVSRYSTSANGNGDQGHYVDYWFNGLEFNQARYSV 
DSFTQNDKGFHVTGWMASDFAVNRPNAYVILLNNGKEVTRSKVTLTD 
RSDVAAVYPSLYNSRKSGFSTDLIVNPASLTGELSMILRFTGSNDGNSNY 
TDQNTNKYATNAGSFDTVNVSGNQIKVAGWHASTQTAGKDYQFIIVLD 
RNGHELTRQAVNTKDITRNDVQKVYPWLTNSVKSGFDTTVSINDQINH 
KVVRLIHRYSNQANGEGSYVDYYSNPISVYSEFQNENGTTFYYDSRTGAK 
KTGWVNINNNNYYFDPSTGAMFTGTHTVDGKSYDFGNNGVAVENDK 
WGWPFPNVGEGHFGGAQLFGVNPGGQFRRNGFHDGLDFGSIDHPGS 
EVHAIHGGKVTQIGYTAGLDWYVLVDTGEYLTVYQEAFSNKNNIQVQV 
GQQINTGDVIGRRDTAHVHIGVTRQHNFNIALANSFNNNGTWLNPLDL 
IRNGSK 
M23 peptidase (Lactobacillus reuteri) 
(99%) 
L. salivarius SAP 2116 Enterolysin A Class III 
 
 
VYLVKIRNGDETTVIHGTKNNTLGDAKVSMTVSAASSFTFIIYPNNTGYF 
KLREWTTYIDVTQSGKYIFRGRVIAVNPKHNEDGTFYKEITCESAMAYLN 
DSILSWEKVDKKPADFFVELINEHNKQMGDASKQFKIAENSVTNNTNNL 
M23 peptidase (Lactobacillus 
salivarius) (65%) 
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Bacteriocin Class IIc 
YCYVEDGISILEEMKTDLLQNEDLGGEISIDYRNDGNYISWTRDKKVKGQ 
QVIKLAKNLKTLSAKPDISKICSVLYPFGATKEVPVDQKNDEKTNEVSTPRI 
NISSVNNGKNYIEDPELIKAIGRVSNTKTWENIKEPKNLLAKAQEYLKTM 
RNYRIAYELDAVDLQPLGLAVDSFECGNYYHVINPVINVDEWLRLVGVTI 
DLNKPLESTLTVGDQVKRLVDYSMDNIQTERNLRRLAAEQQVLKHQNN 
MLIDENNQLKQTIIKLWNDILSKQESNDSSGSAWNWPFKPPATIRFDGA 
QLFGVNPGGEFRPNGFHDGLDFGSVNWPGSEVKAIHDGTVTLKGAMD 
GLGNYFVTNGDGFNIVYQEAFGSASDIRVNIGDHVKVGDVVGIRTTDHL 
HVGVTKHDFNAALGSAFSNNGTWLDPKKLIEDGLKNNMGTTQPVNGD 
WGPVIRNAATKMKVNISDNDVNRIKALIANESGGNQTVTQQVWDQN 
MAAGTPAQGLLQYVPSTFNAYAVDGHRNIKSGFDQLLAFFNNSTWSSD 
ISLHGWGPNGSKRFDKIPA 
MIIMMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAG 
TVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
 
 
 
 
 
 
 
 
 
 
 
 
Multispecies bacteriocin (Lactobacillus) 
(100%) 
L. salivarius  SAP 2117 Enterolysin A Class III 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteriocin Class IIc 
MFQGKILVQGVNRAEKEPLNLFDPKSVQIQWKVNQTWSLQFTAYNDG 
SLAYQMLESEASIFLDNQEYIIKQVADDSSNGLDSIQVTATHVYFEVQKIR 
KYKDYVDPEDKDKQTDVKVLKDNTDSSKSDDSDNAKTDTSEKTEGNTTT 
KVTTKTTDETQQDNQNQVTYSIQDVLEHWLKDNKLGFTYEVIGSFEKKE 
LEELQDGTGADMLSKISDTWSNAIIYPDNRKIRVYSADKFNLNRGNRIDY 
LNNASEIKFSTDSTSLTNMAYCIGGKYSVETTTETTTTTTTTTTSGGWGW 
PFPSVGEGNFMQAQRFGNDGGYRQNGFHEGLDFGSVDHPGRDVHAI 
HGGKVTIKSYMGGLGNYVVISGGGYNVVYQEAFSSPNNIIVNVGDTVK 
VGDVIGYRDTSHLHVGVTKADFNVAVGKSFTNDGTWLDPLELIKNGPS 
DTDTETSSETNSNSNTQEYYYFAPFMYRDEESIKKYGEHPAEPIEDGRFK 
DKSAMIEYVKTKLQPEPSLSIDVTTTTDIKPIAGDVVHVMVKSQDISTNFT 
LTGFTWYPYSYPVDNPTSITLNSNVQNILDYQNSRQKQFNKAISELKSST 
NEAINNSNSFNEFGGNQQLKTWLNDFVGG 
MIIMMKEFTVLTECELAKVDGGYTPKNCAIAVGGGMLSGAIRGGMAG 
TVFGVGTGNLAGAFAGAHIGLVAGGLACIGGYLGSH 
M23 peptidase (Lactobacillus 
salivarius) (97%) 
 
 
 
 
 
 
 
 
 
 
 
Multispecies bacteriocin (Lactobacillus) 
(100%) 
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Figure 9. 1 Growth curves of B. intermedia SAP 919 supplemented with A: L. reuteri SAP 2114 CFS at pH 3.8 
B: L. reuteri SAP 2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS at 
pH 3.8 E: L. reuteri SAP 2114 CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 CFS 
at pH 7.2 H: L. salivarius SAP 2117 CFS at pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated with 
trypsin or heat treated to denature potential antimicrobial proteins produced by each Lactobacillus isolate. 
MRS (blue), MRS trypsin treated (red), MRS heat treated (green), CFS (purple), CFS trypsin treated (orange) 
and CFS heat treated (black). Growth was monitored over 120 hours of anaerobic incubation at 37°C. 
Optical density readings were taken at 620nm every ˜10 hours. These data represent an average of five 
biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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Figure 9. 2 Growth curves of B. alvinipulli ATCC 51933 supplemented with A: L. reuteri SAP 2114 CFS at pH 
3.8 B: L. reuteri SAP 2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS 
at pH 3.8 E: L. reuteri SAP 2114 CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 
CFS at pH 7.2 H: L. salivarius SAP 2117 CFS at pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated 
with trypsin or heat treated to denature potential antimicrobial proteins produced by each Lactobacillus 
isolate. MRS (blue), MRS trypsin treated (red), MRS heat treated (green), CFS (purple), CFS trypsin treated 
(orange) and CFS heat treated (black). Growth was monitored over 120 hours of anaerobic incubation at 
37°C. Optical density readings were taken at 620nm every ˜10 hours. These data represent an average of 
five biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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Figure 9. 3 Growth curves of B. pilosicoli SAP 859 supplemented with A: L. reuteri SAP 2114 CFS at pH 3.8 
B: L. reuteri SAP 2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS at 
pH 3.8 E: L. reuteri SAP 2114 CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 CFS 
at pH 7.2 H: L. salivarius SAP 2117 CFS at pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated with 
trypsin or heat treated to denature potential antimicrobial proteins produced by each Lactobacillus isolate. 
MRS (blue), MRS trypsin treated (red), MRS heat treated (green), CFS (purple), CFS trypsin treated (orange) 
and CFS heat treated (black). Growth was monitored over 120 hours of anaerobic incubation at 37°C. 
Optical density readings were taken at 620nm every ˜10 hours. These data represent an average of five 
biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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Figure 9. 4 Growth curves of B. innocens SAP 924 supplemented with A: L. reuteri SAP 2114 CFS at pH 3.8 
B: L. reuteri SAP 2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS at 
pH 3.8 E: L. reuteri SAP 2114 CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 CFS 
at pH 7.2 H: L. salivarius SAP 2117 CFS at pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated with 
trypsin or heat treated to denature potential antimicrobial proteins produced by each Lactobacillus isolate. 
MRS (blue), MRS trypsin treated (red), MRS heat treated (green), CFS (purple), CFS trypsin treated (orange) 
and CFS heat treated (black). Growth was monitored over 120 hours of anaerobic incubation at 37°C. 
Optical density readings were taken at 620nm every ˜10 hours. These data represent an average of five 
biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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Figure 9. 5 Growth curves of B. innocens SAP 943 supplemented with A: L. reuteri SAP 2114 CFS at pH 3.8 
B: L. reuteri SAP 2115 CFS at pH 3.8 C: L. salivarius SAP 2116 CFS at pH 3.8 D: L. salivarius SAP 2117 CFS at 
pH 3.8 E: L. reuteri SAP 2114 CFS at pH 7.2 F: L. reuteri SAP 2115 CFS at pH 7.2  G: L. salivarius SAP 2116 CFS 
at pH 7.2 H: L. salivarius SAP 2117 CFS at pH 7.2 in BIH broth+ 10% serum. Each CFS was either treated with 
trypsin or heat treated to denature potential antimicrobial proteins produced by each Lactobacillus isolate. 
MRS (blue), MRS trypsin treated (red), MRS heat treated (green), CFS (purple), CFS trypsin treated (orange) 
and CFS heat treated (black). Growth was monitored over 120 hours of anaerobic incubation at 37°C. 
Optical density readings were taken at 620nm every ˜10 hours. These data represent an average of five 
biological replicates, each with three technical replicates. Significance, if any, is shown for changes in 
growth when comparing CFS without treatment to CFS with either trypsin or heat treatment * p ≤ 0.05; ** 
≤ 0.01, *** ≤ 0.0005, **** ≤ 0.0001. 
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